<SEC-DOCUMENT>0001140361-23-039544.txt : 20230814
<SEC-HEADER>0001140361-23-039544.hdr.sgml : 20230814
<ACCEPTANCE-DATETIME>20230814131059
ACCESSION NUMBER:		0001140361-23-039544
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230814
DATE AS OF CHANGE:		20230814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PDS Biotechnology Corp
		CENTRAL INDEX KEY:			0001472091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				264231384
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37568
		FILM NUMBER:		231168167

	BUSINESS ADDRESS:	
		STREET 1:		25B VREELAND ROAD
		STREET 2:		SUITE 300
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		800-208-3343

	MAIL ADDRESS:	
		STREET 1:		25B VREELAND ROAD
		STREET 2:		SUITE 300
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Edge Therapeutics, Inc.
		DATE OF NAME CHANGE:	20090911
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>brhc20057346_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:pdsb="http://pdsbiotech.com/20230630" xmlns="http://www.w3.org/1999/xhtml">
<head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_6c009218040741b1b2604e20837dc8c5" contextRef="c20230101to20230630" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_283688b8bdb44a82b3334f054597cf47" contextRef="c20230101to20230630" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_fea2677f23654174bd2b716d11f6ca4a" contextRef="c20230101to20230630">2023</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_bb9b9de8f103407abbefaf2511bcdbe3" contextRef="c20230101to20230630">Q2</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_936c1cad8f4d43548ba0a86bf8099e8a" contextRef="c20230101to20230630">0001472091</ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Fact_f0c3462c2ee44efcb853f792cd6a38ad" contextRef="c20230630_RangeAxis_MinimumMember">P4Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="pdsb-20230630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230101to20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220801to20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230630_DebtInstrumentAxis_TermLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_DebtInstrumentAxis_LoanBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_DebtInstrumentAxis_LoanAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_DebtInstrumentAxis_LoanDMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220831_DebtInstrumentAxis_LoanCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_DebtInstrumentAxis_LoanFMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_DebtInstrumentAxis_LoanEMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_VariableRateAxis_PrimeRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230714_PlanNameAxis_EquityIncentivePlan2014Member_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20141231_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190331_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210617_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230630_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_PlanNameAxis_EquityCompensationPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220517_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220516_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201207_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201208_PlanNameAxis_InducementPlan2019Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230630_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230630_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230630_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>pdsb:Loan</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>pdsb:Lease</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <!-- base href="file:///C:/Users/SayaP/AppData/Local/Temp/PROfile/ftkylt1r.3y5/expand/content/form10q.htm" -->
      <div></div>

      <!-- Licensed to: Broadridge Financial Solutions
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
      <div>
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
        <div>
          <div style="text-align: center; margin-right: 6.6pt; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">UNITED STATES</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; margin-right: 7.7pt; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">SECURITIES AND EXCHANGE COMMISSION</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-size: 12pt; font-weight: bold; font-family: 'Times New Roman';">Washington, D.C. 20549</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-size: 18pt; font-weight: bold; font-family: 'Times New Roman';">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_b59d840e3f5d4a04a4b5f41cf1292907" contextRef="c20230101to20230630">10-Q</ix:nonNumeric></div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">(Mark One)</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="Fact_f6b096a4566e4970b5a0c5c9321a777d" contextRef="c20230101to20230630" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric><br />
                  </span> </td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="font-weight: bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman';">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_2421b349f3234401ac29fb4d54a972fa" contextRef="c20230101to20230630" format="ixt:date-monthname-day-year-en">June 30, 2023</ix:nonNumeric></div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 27pt; vertical-align: top;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_2bc49b0f278f4090873b0e45d74212ae" contextRef="c20230101to20230630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
                  </span> </td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">&#160;<span style="font-weight: bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman';">For the transition period from ____________ to _____________</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; margin-right: 4.4pt;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman';">Commission file number <span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_6576a71ce2c442c1b71d7df756e5c631" contextRef="c20230101to20230630">001-37568</ix:nonNumeric></span></div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 24pt;">
                  <div style="text-align: center; text-indent: -0.9pt; margin-left: 3.75pt; font-weight: bold;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_ba517afd436d482596883e64ced60f82" contextRef="c20230101to20230630">PDS Biotechnology Corp</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">oration</span></div>
                </td>

    <td style="width: 20.4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Exact name of registrant as specified in its charter)</div>
                </td>

    <td style="width: 20.4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_5ef9c1b493104b1e99b101bd8333528c" contextRef="c20230101to20230630" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_3014b5225e5f4c4da6899b0f3e109287" contextRef="c20230101to20230630">26-4231384</ix:nonNumeric><br />
                    </span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(State or other jurisdiction of incorporation or organization)</div>
                </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(IRS Employer Identification No.)</div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_bb88bccb436443fba222c0784bf10065" contextRef="c20230101to20230630">25B Vreeland Road,</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_d172b7d629bf4b61904f0f3ea7cc7e5d" contextRef="c20230101to20230630">Suite 300</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_71b7850c106b4886a5f25e115c184deb" contextRef="c20230101to20230630">Florham Park,</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_70f7652cd5a0452b869e5f3b61b3a9ec" contextRef="c20230101to20230630">NJ</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_beb815aa6ad34874bbc2b1bf41fbf4eb" contextRef="c20230101to20230630">07932</ix:nonNumeric></div>
                </td>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 40%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Address of principal executive offices)</div>
                </td>

    <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_e6a7652a769e4788bfa45b2529405319" contextRef="c20230101to20230630">800</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_90bb7f872a414841bd0261b9fe6c1f43" contextRef="c20230101to20230630">208-3343</ix:nonNumeric></div>
                </td>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 30%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Registrant&#8217;s telephone number)</div>
                </td>

    <td style="width: 35%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 20.42%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>

  <tr>

    <td style="width: 20.42%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 60%; vertical-align: top;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(Former name, former address and former fiscal year, if changed since last report)</div>
                </td>

    <td style="width: 20%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">Securities registered pursuant to Section 12(b) of the Act:</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
                  <div style="font-family: 'Times New Roman';">Title of each class</div>
                </td>

    <td style="width: 2%; vertical-align: bottom; text-align: center; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
                  <div style="font-family: 'Times New Roman';">Trading symbol(s)</div>
                </td>

    <td style="width: 2.19%; vertical-align: bottom; text-align: center; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">Name of each exchange on which registered</div>
                </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top; white-space: nowrap;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_43fac12d95fd4e9c891e9e2d5b229302" contextRef="c20230101to20230630">Common Stock, par value $0.00033 per share</ix:nonNumeric><br />
                    </span> </div>
                </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_71ab8fb2ef9d4599a7c4c6a0c5aa92d5" contextRef="c20230101to20230630">PDSB</ix:nonNumeric><br />
                    </span> </div>
                </td>

    <td style="width: 2.19%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';">The <ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_b6c44aba72494d699c5aeb7083357610" contextRef="c20230101to20230630" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC<br />
                    </span> </div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
            months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_b9bf0882257f41c79dbe2c56f775d526" contextRef="c20230101to20230630">Yes</ix:nonNumeric> &#9746; No &#9744;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section
            232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_bbab0b39097a4452b4e1c436e5236010" contextRef="c20230101to20230630">Yes</ix:nonNumeric>
            &#9746; No &#9744;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
            company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 24.55%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Large accelerated filer &#9744;</div>
                </td>

    <td style="width: 24.55%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Accelerated filer &#9744;</div>
                </td>

    <td style="width: 24.55%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_98e4c1627d4e4d179d64b0ad70359ebd" contextRef="c20230101to20230630" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric> &#9746;</div>
                </td>

    <td style="width: 26.36%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_226e12c63dfb45bdbd7999ec2e807254" contextRef="c20230101to20230630" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 100%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman';">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_b7ca6c4d2ddb42a6a2c955c2860887fd" contextRef="c20230101to20230630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>
                </td>

  </tr>


</table>
          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">&#160;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
            accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify; font-family: 'Times New Roman';">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_5fac3df56a714ca4b442de5ab070ac3d" contextRef="c20230101to20230630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160; No &#9746;</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-align: justify;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman';">The number of shares of the registrant&#8217;s Common Stock, par value $0.00033 per share, outstanding as of August 7, 2023 was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_5c6d9145477c49e49de2765e298fc1e8" contextRef="c20230807" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,868,188</ix:nonFraction>.</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div>
            <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after:always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          </div>

          <!--PROfilePageNumberReset%Num%2%%%--></div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="text-align: left;">
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FORM 10-Q FOR THE QUARTER ENDED <span style="font-size: 10pt;">June 30, 2023</span></div>

      <div style="text-align: left;"><span style="font-family: 'Times New Roman';"><br />
        </span> </div>

      <a id="INDEX"><!--Anchor--></a>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">INDEX</div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br />
        </span> </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Page</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="3">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-weight: bold;">Part I &#8212; <span style="text-decoration: underline;">Financial Information</span></span></div>
              </td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 1.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Financial Statements (Unaudited):</div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#BalanceSheets">Condensed Consolidated Balance Sheets</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3</div>
              </td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#OperationsandComprehensiv">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4</div>
              </td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#StockholdersEquity">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5</div>
              </td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#CashFlows">Condensed Consolidated Statements of Cash Flows</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;6</div>
              </td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#NotestoCondensed">Notes to Condensed Consolidated Financial Statements</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;7</div>
              </td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 2.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ITEM2.">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">17</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 3.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ITEM3">Quantitative and Qualitative Disclosures About Market Risk</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">31</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 4.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ITEM4">Controls and Procedures</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">31<br />
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="3">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a href="#OTHERINFORMATION">Part II &#8212; <span style="text-decoration: underline;"><span style="font-size: 10pt;">Other Information</span></span></a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 1.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#LEGALPROCEEDINGS">Legal Proceedings</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 1A.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#RISKFACTORS">Risk Factors</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 2.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#UNREGISTEREDSALESOFEQUITY">Unregistered Sales of Equity Securities and Use of Proceeds</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 3.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#DEFAULTSUPONSENIORSECURIT">Defaults Upon Senior Securities</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 4.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#MINESAFETYDISCLOSURES">Mine Safety Disclosures</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 5.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ITEM5.">Other Information</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Item 6.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#EXHIBITS">Exhibits</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">32</td>

  </tr>

  <tr>

    <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 9%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#EXHIBITINDEX">EXHIBIT INDEX</a></div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">33</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="2">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a href="#SIGNATURES">SIGNATURES</a></div>
              </td>

    <td style="width: 79%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>

    <td style="width: 8%; vertical-align: top; text-align: center;">34</td>

  </tr>


</table>
        <div> <span style="font-family: 'Times New Roman';"><br />
          </span> </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                </a></div>

            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%3%%%--> </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                    <div style="font-weight: bold;"><span style="font-family: 'Times New Roman';">PART 1. &#160;&#160; <br />
                      </span> </div>
                  </td>

    <td style="align: left; vertical-align: top; width: auto;">
                    <div style="font-weight: bold; font-family: 'Times New Roman';">&#160;FINANCIAL INFORMATION</div>
                  </td>

  </tr>


</table>
          </div>

          <div style="font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                    <div style="text-align: left; font-weight: bold; font-family: 'Times New Roman';">ITEM 1.</div>
                  </td>

    <td style="vertical-align: top; width: auto;">
                    <div style="text-align: left; text-indent: -45pt; margin-left: 45pt; font-weight: bold;"><!--Anchor--><span style="font-family: 'Times New Roman';">FINANCIAL STATEMENTS</span></div>
                  </td>

  </tr>


</table>
          </div>

          <div style="text-align: center;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div style="text-align: center; font-weight: bold;"><!--Anchor--><span style="font-family: 'Times New Roman';">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</span></div>

          <div><span style="font-weight: bold; font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div style="text-align: center; color: rgb(0, 0, 0);"><!--Anchor--><span style="font-weight: bold; font-family: 'Times New Roman';"><!--Anchor-->Condensed Consolidated</span><a id="BalanceSheets"><!--Anchor--></a><span style="font-family: 'Times New Roman';"> <span style="font-weight: bold;">Balance Sheets<!--Anchor--><!--Anchor--></span></span><!--Anchor--></div>

          <div><span style="font-family: 'Times New Roman';"><br />
          </span></div>

          <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;"><span style="font-family: 'Times New Roman';"><br />
                  </span> </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-family: 'Times New Roman';">June 30, 2023</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2022</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">ASSETS</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: &#38;amp;">
                  <div style="text-align: center; font-family: 'Times New Roman';">(unaudited)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Current assets:</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp; width: 76%; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Cash and cash equivalents</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_58cd4bde50064e879484494d9c2b33ff" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,624,991</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_2c5533225ad44d25b51f3b96b8ebdedf" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">73,820,160</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt;"><span style="font-family: 'Times New Roman';">Prepaid expenses and other assets<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_ba5045bb2b1146809daf8b45a5ff6b4d" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,725,958</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_a6f868956f5141c3b6d5dfba703002a3" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,660,230</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Total current assets</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_8e82065c38b4463cb75c905e217dc8bd" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">63,350,949</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_de9ac827d7464354846d0e8450cfce8f" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">76,480,390</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Property and equipment, net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_1610703be8d14131b468dd1feb95d5b8" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">143,600</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_e3123f90e91241e09fb614e4acf21877" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;">
                  <div style="text-align: left; font-size: 10pt; margin-left: 9pt;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Financing lease right-to-use assets</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" id="Fact_ec51644928f342fab65fffab15c9344e" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">220,213</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" id="Fact_79bdfa67c2564faea68c946258c3b0f4" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">374,888</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Operating lease right-to-use asset</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_0d29dcc322e949e597a16135417353e1" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">39,488</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_ed0f77e865224f6eb3cdfd22d83f3d4e" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">152,645</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Total assets</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Assets" id="Fact_4281ffb1886b4fcf81a360ce214507dc" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">63,754,250</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Assets" id="Fact_9e0f5b2a7aae49e0a944cd5525cb1a74" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">77,007,923</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Current liabilities:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Accounts payable</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_46d1f113f7064383b9c0a53ae3c621cb" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,414,905</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: &#38;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_786bc17e06704462a43e5cc423205c58" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,219,287</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Accrued expenses</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_77f4221a3d974b8d89b110b90f8789c8" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,376,325</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_f5980f0733194e649c543011e04d0352" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,313,708</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;">
                  <div style="text-align: left; font-size: 10pt; margin-left: 18pt; font-family: 'Times New Roman';">Financing lease obligation-short term</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" id="Fact_930a97456ab54b1094d86a6ca6b52bbf" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">53,309</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" id="Fact_9065c4fc58de4480a7013244f7452ecb" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,612</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Operating lease obligation-short term</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_0599c00c47a541f4af094db186b378c7" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">59,650</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_b7093cf420664f3e8d411c52ad0fc2f3" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">231,429</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="margin-left: 27pt; font-family: 'Times New Roman';">Total current liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_c9c498fc16054a4aa66ae8b81d8ce318" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,904,189</ix:nonFraction><br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_265b5300de1f4c238f300aa6f6149985" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,821,036</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Noncurrent liabilities:</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 18pt;">Note payable, net of debt discount</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:SecuredLongTermDebt" id="Fact_e79f4575e7a24f05a2aa0ae73e620e02" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">23,254,367</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:SecuredLongTermDebt" id="Fact_b4272ad0792244358be9eed96e8c20d7" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">23,020,844</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 18pt;">Financing lease obligation-long term</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" id="Fact_68f4c5b4c5504fbdad7e92f20176f50c" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">151,505</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" id="Fact_5099de4cb3a24d3389dd6cb3fde33fbc" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">164,013</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total liabilities:</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_ee4953fdccaa4d9f83a899fd467ecb68" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">31,310,061</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_d48a783ef7c34207b4346111c6e48cd0" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33,005,893</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">STOCKHOLDERS&#8217; EQUITY</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman';">Common stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_b8f1e1cec1554bf39aa91bfb5373ba1e" contextRef="c20221231" unitRef="U003" decimals="5" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_afe705407fef4fe3b552a6f1f274f4d7" contextRef="c20230630" unitRef="U003" decimals="5" scale="0" format="ixt:num-dot-decimal">0.00033</ix:nonFraction></ix:nonFraction></span>
                      par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_431de4d30dd64797aa7083104cd64761" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_de047457995d478d92605420094ba417" contextRef="c20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized at <span style="text-indent: 0pt;">June 30, 2023</span> and <span style="text-indent: 0pt;">December 31, 2022</span>,&#160;<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_d79271ee9a174f7b84c41f5392723335" contextRef="c20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_3df64f5fb65b4e51a5b78f5305ebb1e1" contextRef="c20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,868,188</ix:nonFraction></ix:nonFraction></span> shares and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_887dc19dc6b64d18a7175a1a2ae8fd5a" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_f828179e22b349d18d0a45eeef3ba5e7" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,170,317</ix:nonFraction></ix:nonFraction></span><span style="font-family: &#38;amp;"> shares issued and outstanding at <span style="text-indent: 0pt;">June 30, 2023</span> and <span style="text-indent: 0pt;">December 31, 2022</span>, respectively</span></span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_a47bde7256bc458086cdb2556c8d25ed" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,188</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_b828a76b6b95439bbd99e74407b29be2" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,956</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Additional paid-in capital</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_50674871eb3e46a584b9df2dbdafd92d" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">155,187,231</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_d9f9ca9030864b54a06a464ad811e628" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">145,550,491</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Accumulated deficit</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_7f6e65f53dea4969ada42ab21649e6c6" contextRef="c20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">122,753,230</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_e5fa26da84dd45efbe0ac5bc5ebaa25f" contextRef="c20221231" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">101,558,417</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Total stockholders&#8217; equity</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_08b733a4e2414b378a9aed24878392b1" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">32,444,189</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_89d2a3f6b0aa42899a92a6294c698b6d" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">44,002,030</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Total liabilities and stockholders&#8217; equity</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_8b3940b36839447b938cbc07d93e5530" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">63,754,250</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_3180b1082b314039be709c6632793839" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">77,007,923</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>


</table>
          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div style="font-family: 'Times New Roman';">See accompanying notes to the condensed consolidated financial statements.</div>

          <div><span style="font-family: 'Times New Roman';"><br />
          </span></div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">3</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div>
                <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                  </a></div>

              </div>

            </div>

          </div>

          <!--PROfilePageNumberReset%Num%4%%%--> </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</div>

    <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="OperationsandComprehensiv"><!--Anchor--></a><span style="font-family: 'Times New Roman';">Condensed Consolidated Statements of Operations and Comprehensive Loss</span><!--Anchor--><!--Anchor--><!--Anchor--></div>

    <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>

    <div style="text-align: left;"><span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Three Months Ended June 30,</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Six Months Ended June 30,</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2023<br />
              </span> </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2022<br />
              </span> </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2023<br />
              </span> </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2022<br />
              </span> </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating expenses:</div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Research and development expenses</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_8bba540a61a4413faccfea9f3ae4f817" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,004,852</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_fd5627f320894633aa7860de8ca23890" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,761,646</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_60ce88eebee04e13821339f1516a7d49" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,848,538</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_eaa294547e034ac8802375de78cd1af6" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,922,961</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">General and administrative expenses</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_5b78f82529644b048abc0c85b43ae6b2" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,691,321</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_fc09345edcf749d1b39251e3faa13f32" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,331,006</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_e1ac8b1e75134de6be703d1c502e7d8c" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,270,049</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_e4d4eca890a84f02bf8319cba6f1edcb" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,648,913</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total operating expenses</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_9aef51dd433c4069aeff637002eb389b" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,696,173</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_57b4430b66f74d9fb17fe684467c4354" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,092,652</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_96358d707af447a59eed7925afc22495" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,118,587</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_dafa5490aa4641598d8f94925b0d5359" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">15,571,874</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Loss from operations</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_898151dcf1644cd59b775729f9a90292" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">12,696,173</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_5edb96973b724027b45f9390f263a93e" contextRef="c20220401to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">7,092,652</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_3f8e84babafc444d940c15e80df89a8a" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">22,118,587</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_55f1ee071a5947a281a65ebef312bba9" contextRef="c20220101to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">15,571,874</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 52%; background-color: #CCEEFF;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Interest income (expenses), net</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 14.4pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"><span style="font-family: 'Times New Roman';">&#160;Interest income<br />
                  </span> </div>
              </div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_cfd8d9f4cca14b1f8b89dac2662007fa" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">750,654</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_f546e4c345224266b4572bc952e24ad7" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">74,547</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_c72eb3371158441cb3df2babec54eede" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,479,995</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_14a025f188e74c01b7d1ec46d20657d3" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">80,247</ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160; Interest expense</div>
          </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_39b65869a0fc438babeaed2d84f851dd" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">995,397</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestExpense" id="Fact_64688066719f4f7982e9c045fd507b57" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_8ffbd5c0a9fa4f50a7ff8cfde83aeb44" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,962,242</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestExpense" id="Fact_db6c0fb8bd79405faf92eace357936b8" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; font-family: 'Times New Roman';">Interest income (expenses), net</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_48abaa1ffa8c41c7ad6a9669ab79c8e0" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">244,743</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_c71b680948334f36a50bc3ef78b3b47c" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">74,547</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_cf42185cfb204234b631c15914d37691" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">482,247</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" id="Fact_669db3e4ba764a36b50546bf4b19c450" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">80,247</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%;"><span style="font-family: 'Times New Roman';">Loss before income taxes<br />
            </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_d0125977f7354c72ab26334dfd6a5ff2" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">12,940,916</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_1fcabb81db8e481984a93ac606a07e86" contextRef="c20220401to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">7,018,105</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_6abb0fbaac1a460291375d1e75d91d68" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">22,600,834</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_51565e47403d496ba70b5da85c54d24a" contextRef="c20220101to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">15,491,627</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;"><span style="font-family: 'Times New Roman';">Benefit for income taxes <br />
            </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_b33dc11bd3d2422d94f8d0b9f0259d60" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,406,021</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_582d0cdea4724fd5813585c512e8f1a8" contextRef="c20220401to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,198,905</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_1f168ecfd98a491db20df18d14d9e6ab" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,406,021</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_f231c52bc9b241a5b598a08e38540250" contextRef="c20220101to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,198,905</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
            <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net loss and comprehensive loss</div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_377ea27d197048f5942f829f477da39b" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c8e74a3f54754ac39f048f57d5655ce4" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">11,534,895</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_168c4bd943c74e22990b18bddbaea573" contextRef="c20220401to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_26f7a6d1b18248619a757ae546ef3889" contextRef="c20220401to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">5,819,200</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_810abc1986434ae3a3079c95e9cddff9" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_31fde16c696c42ba979f6f8f06f778cd" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">21,194,813</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_9de7ba64ee8e4fa182f316fcfb74a14d" contextRef="c20220101to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_fa688cb517e6427aa1dfb4e6dfc0cdd1" contextRef="c20220101to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">14,292,722</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Per share information:</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net loss per share, basic and diluted</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_843d6131b1344b5abc58409f48041fad" contextRef="c20230401to20230630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_524e9b25a74a44b499d2bf8b8b6e73f6" contextRef="c20230401to20230630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.37</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_00d43245b3ca4deba80dcfa6b75e1d6e" contextRef="c20220401to20220630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_0f2d6c5a0b3f41c2a504bf9a4dd94a10" contextRef="c20220401to20220630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.20</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_01b8a864ef314062b7cb0c77d1e0cff7" contextRef="c20230101to20230630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_4d64c8a7c73f4f298033d85bb655d9e2" contextRef="c20230101to20230630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.69</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman';">$</div>
          </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_33ef74912c5b40c697f7297fd319b8ad" contextRef="c20220101to20220630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_d8e5cb42cc494cb89598ace68a4074a5" contextRef="c20220101to20220630" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.50</ix:nonFraction></ix:nonFraction></div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div style="font-family: 'Times New Roman';">)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
            <div>
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted average common shares outstanding, basic, and diluted</div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_c191ceb8a4e9404c8a7243fc8090441f" contextRef="c20230401to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_185868c66f3d4f17bf5677657b204c94" contextRef="c20230401to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,802,498</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_58fa32f85fbf475f99e3641379dcde87" contextRef="c20220401to20220630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_68db77a33a334551993cf150bb508a98" contextRef="c20220401to20220630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">28,451,579</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_7af4ec41069a445bb2fcfd3f8290a668" contextRef="c20230101to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_89edddddde5a47439dbc98e49215eb5d" contextRef="c20230101to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,616,310</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
            <div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_16be6bf8c60f44d19a8ef1f960cd84c3" contextRef="c20220101to20220630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_dfb97dd9234e4da1961c0bbfecef1e66" contextRef="c20220101to20220630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">28,450,104</ix:nonFraction></ix:nonFraction></div>
            </div>
          </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>


</table>
    <div><span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">See accompanying notes to the condensed consolidated financial statements.</div>

    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageFooter" style="width: 100%;"></div>

      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">4</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div>
          <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
            </a></div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</div>

    <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="StockholdersEquity"><!--Anchor--></a><span style="font-family: 'Times New Roman';">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</span><!--Anchor--><!--Anchor--><!--Anchor--></div>

    <div style="text-align: center;"><span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Common Stock</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-weight: bold; text-align: center;"><span style="font-family: 'Times New Roman';"><br />
              </span> </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-weight: bold; text-align: center;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Shares </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Issued</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Amount</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Paid-in </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Capital</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Accumulated </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Deficit</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Total </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Equity</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">January 1, <span style="text-indent: 0pt;">2022</span></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_a17f18e557ee453eb9b345ee86e10817" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">28,448,612</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6c87cf06e4344f1d9211f5c112e479dc" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,387</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_511f41f42528440ea8325a94861d1ca2" contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">123,904,602</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d34bac104ab2426ea302532f79b45316" contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">60,703,562</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3a31dea4cc304adab1341e91f0accd27" contextRef="c20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">63,210,427</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock based compensation expense</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_8b4457e26a7b4ffebca507e9cdc2c09c" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_b7cc6b9c7ea74b4f994c8650dcaeebdf" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,128,973</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_1b297cf17dbf4fbbb2aaaf7d27b7277a" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_690ed19515384e1c9157b25169bb7314" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,128,973</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">Issuances of common stock, from exercise of stock options</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_b40f15915a074a118366ae28a34dc4df" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,282</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_85dffa3f4df549eb9ab5c8f4d5f53d95" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_3663bb5de7dc4d5292a36e5b9fb7132f" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,487</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_b5033d45247441a2a56c0d7283db88c8" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_9680e474dfb24de897c9bb3db591ef97" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,488</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ff7cc99dd1814c8bb80dff7a88d65f26" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8d587fa7eb16423783d2f39dd1e6e0f2" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_426b3e6a049a42128e770a0f1ad0ffa1" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,473,522</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8f9c7a771886444fae5fbfca75bb2256" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">8,473,522</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance - March 31, <span style="text-indent: 0pt;">2022</span></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_f2b6d1fb9ee8400296441c92c3c97e32" contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">28,450,894</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_86cd78018b2e4add888676bb01f5cb1d" contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,388</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d413b1cf114a40af8421545e281be822" contextRef="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">125,041,062</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_65d0918c4cc84c86a0047b04359965a0" contextRef="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">69,177,084</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c85a1a5e4a554f6a96a46409d5b9e36f" contextRef="c20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">55,873,366</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock based compensation expense</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_b85c7ec911b3480ebf5444cad3d1d0bd" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_1f3370fc68d14f888eb92a8e8abed6a3" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,348,601</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_bb7476561dbe46cd954c1ffa0311a444" contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_bee912fdb9e74e2d800f3a005cd60d64" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,348,601</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Issuances of common stock, from exercise of stock options</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_b5e1bccf07d8419b87791f922445e2ab" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">7,794</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_dc6899b61ec746b4a51cde21f8c57655" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_f369d9748bd44041b7ff93f6b3bab9e2" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,426</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_6ade92214ef94d5ca736adc32e0bff2b" contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_0086ef5ffd6442fa966e61209177fbf4" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,429</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7f502060fb224d63aed8d554784d1dd3" contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e41678e80515408c8bbcf24adfb9ab6a" contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e786e9af6dc547679a1c10fa8746d577" contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">5,819,200</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_449bf0e5bb824f9584f29a3881304880" contextRef="c20220401to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">5,819,200</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance - June 30, 2022</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_3ceef7e34b454135a68b80a937afd5ed" contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">28,458,688</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_5ba641eef356458187afee7cc0b888d3" contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,391</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_db53b31ccb6c419bbba68b32b23752c3" contextRef="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">126,412,089</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b3b0f61b06724ac68b273da4d2c64a72" contextRef="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">74,996,284</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_40e6a6c748d04c0087ac656e02ac8e7d" contextRef="c20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">51,425,196</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div><span style="font-family: 'Times New Roman';"><br />
        </span> </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Common Stock</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" colspan="2"><span style="font-family: 'Times New Roman';"><br />
              </span> </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; font-weight: bold; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Shares </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Issued</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Amount</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional</div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Paid-in </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Capital</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Accumulated </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Deficit</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Total </div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Equity</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">January 1, <span style="text-indent: 0pt;">2023</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_072bee52c106457c86537fd1b853f60e" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,170,317</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d4b889cfacc346acb1a8e5dfe4b8e3b7" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,956</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c22de3d64b7d4909a6392c3016acac01" contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">145,550,491</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e6d4f19c24454031acd521ec311b58e8" contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">101,558,417</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_aca96ffd59e9401394bb5c370ade91da" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">44,002,030</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock based compensation expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_d56e24862104405ba96c470b0c5a507e" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_4d56635128854c1e8cddbd744611499b" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,080,319</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_23dba73f6ee84414871e4385d8fb7c7a" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_03688abcd4da4b7aa2305dea2d82322b" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,080,319</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">Issuances of common stock from the Sales Agreement, net</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_33b829a3541d4a8a86b8158acb78b304" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">553,293</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_4dfa382e0007474085c3b1ad4b320dfb" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">183</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_3a02eb81c3994f40bac63d6a55ce06ff" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,588,339</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_d8b1ee21a0cb42c98450ef64468ea012" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_f150f45c2e50497788e728e25403d1cd" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,588,522</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_94d3fd92b5064269bde0299620830d7c" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a794180720ef4128b5b6d4fc2446190a" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b8147a09fd0442e78e62f4df4ed9d3b0" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">9,659,918</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e157fabb85b745e1932a472cbf7796e5" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">9,659,918</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance - March 31, <span style="text-indent: 0pt;">2023</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_83f27d7992ca4ce38ae96a66f6d63597" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,723,610</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman';">$<br />
              </span> </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4c499ff1726c4752b57aa3059e2d7833" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,139</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman';">$<br />
              </span> </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6ba72e7db42744c2af96276ec0f7f0e9" contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">152,219,149</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman';">$<br />
              </span> </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4821885b92004a529b329ab49377a98f" contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">111,218,335</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman';">$<br />
              </span> </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6d2558224bab4ed88eefcd02275acf18" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">41,010,953</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Stock based compensation expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_55e84919f4d447e6871c51d747267c5b" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_cb691ab584cd41d9bce0e3d5ed1143a4" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,105,538</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_09f20ccd89394565bce47b581e9f910a" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_feba92dd57fa49c381ae4bc87588edd5" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,105,538</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Issuances of common stock, from exercise of stock options</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_c3f1f5b77eee42b68153f8a9b81f8c9e" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,409</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_e3f29555788d42bfbd11cbb5bdc02b5b" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_5a2b037500f143d7b564c24d36e20e01" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,848</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_46135533ea024d04ac7e5bdf3b86a4b9" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_31b62653268744489ffc96efbb9f8674" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,849</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1"><span style="font-family: 'Times New Roman';">Issuance of common stock for consulting agreement<br />
              </span> </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_3859312f726d48fa9d7eb2e3149062fa" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_b63823edd4c241138d8e0b47a9ba4467" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_700abeb320014369be12e25ac7c52879" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">609,967</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_b8d4b89041b5493085ab451c8f15fd4a" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="Fact_d90416ee77fb40cea9aefc58e3e08cf7" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">610,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);" rowspan="1"><span style="font-family: 'Times New Roman';">Issuances of common stock from the Sales Agreement, net<br />
              </span> </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_87750f91fc28447db72e6dd62c898c28" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">43,169</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_0ecd053706b74eff887b7150b5230f3e" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_788e156232d5498eb554053410b36a0d" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">243,729</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_b032526ff8e24b7bb493750f7f156ab8" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_ec0b3ceb66244963a46fc53d91258c69" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">243,743</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f06854d265a5405f98b10984b0e5c414" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_bfd14e1d54624ce1aab7d2dd30f71798" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_25cbc41faaed41c1b338609faac4adbc" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">11,534,895</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6403afe5eab345149fe7550a2a19a897" contextRef="c20230401to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">11,534,895</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Balance - June 30, <span style="text-indent: 0pt;">2023</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_9cce72280d284a9599dc859108110d3b" contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">30,868,188</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_fba67b7742be4d77a97121246f69178f" contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,188</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d5a9819ca3984b069f6b69b6182d72e2" contextRef="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">155,187,231</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1b2529990feb492a92e7726e8e52c909" contextRef="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">122,753,230</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4de60f016f7f4195a01e8f656e3da696" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">32,444,189</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    </div>

    <div><span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">See accompanying notes to the condensed <span style="font-size: 10pt; color: rgb(0, 0, 0);">consolidated</span> financial statements.</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br />
      </span> </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageFooter" style="width: 100%;"></div>

      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">5</span></div>

      <div style="page-break-after:always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div>
          <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
            </a></div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <div style="text-align: center; font-weight: bold;"><!--Anchor--><span style="font-family: 'Times New Roman';">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</span></div>

          <div style="text-align: center;"><span style="font-weight: bold; font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div style="text-align: center; color: rgb(0, 0, 0);"><span style="font-weight: bold; font-family: 'Times New Roman';">Condensed Consolidated</span><a id="CashFlows"><!--Anchor--></a><span style="font-family: 'Times New Roman';"> <span style="font-weight: bold;"><!--Anchor-->Statements






                of
                <!--Anchor-->
                <!--Anchor-->Cash Flows<!--Anchor--></span></span><!--Anchor--></div>

          <div style="text-align: center;"><span style="font-weight: bold; font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">(Unaudited)</div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-family: 'Times New Roman';">Six Months Ended June 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';">2023<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center;"><span style="font-family: 'Times New Roman';">2022<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman';">Cash flows from operating activities:</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Net loss</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6a7648533a9b49c098e30c517170a32f" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">21,194,813</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cb6a798a79b14c6e981627ce1717c772" contextRef="c20220101to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">14,292,722</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman';">Adjustments to reconcile net loss to net cash used in operating activities:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Stock-based compensation expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_07c65ca40c024f07a2f5f91505d5a4c2" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,185,857</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_30aa9a7d593140658171bf7d8ee9126f" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,477,574</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt;">
                      <div style="margin-left: 9pt; text-indent: -9pt;"><span style="font-family: 'Times New Roman';">Issuance of shares in consulting agreement&#160; <br />
                        </span> </div>
                    </div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" id="Fact_7467602b1def44c7aeb4a1ad6cb3a675" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">267,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" id="Fact_0abef650f456488cb87a9ec119c48d55" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt; font-family: 'Times New Roman';">Amortization of debt discount</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_717479e0165f408a87718859a9a77e29" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">233,523</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_89711dc8adb6425ea2d896c833e45a70" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Depreciation expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div>
                    <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_30ea2e1bfb6c4f538eb1138e594faf49" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,891</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_1effacaa472b43fa8d349155b5fd1ae7" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">86</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Operating lease expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_3ff6b85afbff44cfaf2abb10e7fb5649" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">120,514</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_78b26f555f224e5ea15fc0440b10bb7a" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">120,514</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;">
                  <div style="text-align: left; font-size: 10pt; margin-left: 18pt; font-family: 'Times New Roman';">Finance lease depreciation expense</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" id="Fact_6eb39af57a3e46adb7508ef11621af06" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,627</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" id="Fact_44f7150ed1914139b11ee4bf292a22f5" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-family: 'Times New Roman';">Changes in assets and liabilities:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Prepaid expenses and other assets</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_0a2a93bb0b9d40cb9eca4424e3016d06" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">277,272</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_7e086e35841945259299d561ac90d96a" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,160,341</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;">
                  <div style="text-align: left; font-size: 10pt; margin-left: 27pt;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;"><span style="font-family: 'Times New Roman';">Accounts payable <br />
                      </span> </div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>
                    <div><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_951663059c2e42ad98b5a398d3abc295" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,195,618</ix:nonFraction><br />
                      </span> </div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_857a09c7db0742afa591ce2ef104490a" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">568,588</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Accrued expenses</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_d8d80fd486df4ec58334a6ee546780ce" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">4,937,383</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_41a88b3dbad54194aee151d6640f36fb" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">115,217</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 34.2pt; font-family: 'Times New Roman';">Operating lease liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" id="Fact_8c8853832d0e4eceb56f836bd6187d2c" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">179,136</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" id="Fact_74fe5700c4a9478790a22e03f7b08d46" contextRef="c20220101to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">116,783</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 43.2pt; font-family: 'Times New Roman';">Net cash used in operating activities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_c5ac124a352a4a83a36cfc1d7c4bc467" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">18,003,030</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_d0a00e8ec5c54f25b89163ae7be0de7a" contextRef="c20220101to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">12,287,867</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Proceeds from exercise of stock options</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_c59164d4f519492e854a817aa1d03a67" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,849</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_47c472dc02ef4c519412a1d9ebb06985" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">29,917</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt;"><span style="font-family: 'Times New Roman';">Payments of finance lease obligations<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_879b6ec4621043b08f8972eb9f4a1baa" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33,253</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_b3468c1344b146828d1e890bbffb8254" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="margin-left: 9pt; font-family: 'Times New Roman';">Proceeds from issuance of common stock, net of issuance costs</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_7c94403d1f1d49ac94d9819ebc68919a" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,832,265</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_776f7d59c34d4a8b94c9e9e591b2f801" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 43.2pt; font-family: 'Times New Roman';">Net cash provided by financing activities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_b11b937e8275454d937fd48b58de6415" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,807,861</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_7c1f96dcfe7346fb8109b9033bd46a71" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">29,917</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman';">Net increase in cash and cash equivalents</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div>
                    <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_91e95a87490642d5b6c30068e4fd5c82" contextRef="c20230101to20230630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">13,195,169</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div>
                    <div style="font-family: 'Times New Roman';">)</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman';">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_7ec88691f4db4bf38136fd10e2f3e0a2" contextRef="c20220101to20220630" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">12,257,950</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Cash and cash equivalents at beginning of period</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_86e648fde6a24b3ea45b69f6933221fc" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">73,820,160</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_d939ad32a82440209ddc0e0a6bf52e7e" contextRef="c20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">65,242,622</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-weight: bold; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">Cash and cash equivalents at the end of period</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_4853376a58594fbd992a5c84852efa40" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,624,991</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_fcb26aaa34d54959934454a085a3b3fa" contextRef="c20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">52,984,672</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Supplemental information of cash and non-cash transactions:</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: normal;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for interest</div>
                    </div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_e645b65d62344937a47ca1d8ff1f0e89" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,962,241</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_ab2b72c2940341808e49aa4540b0ae6a" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>


</table>
          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div style="font-family: 'Times New Roman';">See accompanying notes to the condensed consolidated financial statements.</div>

          <div> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">6</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div>
                <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                  </a></div>

              </div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div style="text-align: justify;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-weight: bold;">
            <div style="text-align: center;"><!--Anchor--><span style="font-family: 'Times New Roman';">PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY</span></div>

            <div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"><!--Anchor--><!--Anchor--><!--Anchor--><a id="NotestoCondensed"><!--Anchor--></a><span style="font-family: 'Times New Roman';">Notes







                  to Condensed Consolidated Financial Statements (Unaudited)</span></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"> <span style="font-family: 'Times New Roman';"><br />
                </span> </div>

            </div>

          </div>
<ix:nonNumeric name="us-gaap:NatureOfOperations" id="Text_f99c036f06914cada08548bd403cf17e" contextRef="c20230101to20230630" escape="true" continuedAt="Text_a85e7c91b29248338004aac4f2b2e4bd1">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_a85e7c91b29248338004aac4f2b2e4bd1" continuedAt="Text_a85e7c91b29248338004aac4f2b2e4bd2">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Note 1 <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211; </span>Nature of Operations</span><span style="font-family: 'Times New Roman';"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_a85e7c91b29248338004aac4f2b2e4bd2" continuedAt="Text_a85e7c91b29248338004aac4f2b2e4bd3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a85e7c91b29248338004aac4f2b2e4bd3" continuedAt="Text_a85e7c91b29248338004aac4f2b2e4bd4">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-size: 10pt; font-style: normal; font-weight: bold;"> <br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_a85e7c91b29248338004aac4f2b2e4bd4" continuedAt="Text_a85e7c91b29248338004aac4f2b2e4bd5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt;">
            <div>
              <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">
                <ix:continuation id="Text_a85e7c91b29248338004aac4f2b2e4bd5" continuedAt="Text_a85e7c91b29248338004aac4f2b2e4bd6">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">PDS Biotechnology Corporation, a Delaware
                    corporation (the &#8220;Company&#8221; or &#8220;PDS Biotech&#8221;), is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on its Versamune</span><span style="font-family: 'Times New Roman';"><sup>&#174;</sup><span style="font-size: 10pt;">, Versamune</span><sup>&#174;</sup><span style="font-size: 10pt;"> plus PDS0301 and Infectimune</span><sup>&#174;</sup><span style="font-size: 10pt;"> T cell-activating platforms and
                      PDS0301 tumor targeting immunocytokine. The Company believes its targeted immunotherapies have potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of
                      T cells.&#160; Versamune, and Versamune plus PDS0301 for treatments in oncology and Infectimune, for treatments in infectious disease.&#160; When paired with an antigen, which is a disease-related protein that is recognizable by the immune
                      system, Versamune and Infectimune have both been shown to induce, </span><span style="font-size: 10pt; font-style: italic;">in vivo,</span><span style="font-size: 10pt;"> large quantities of high-quality, highly potent polyfunctional
                      CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies.&#160; Versamune
                      plus PDS0301 enhances the proliferation, potency and longevity of T cells in the tumor microenvironment and works synergistically to overcome tumor immune suppression.</span></span></div>
</ix:continuation>
                <ix:continuation id="Text_a85e7c91b29248338004aac4f2b2e4bd6" continuedAt="Text_a85e7c91b29248338004aac4f2b2e4bd7">
<div><span style="font-family: 'Times New Roman';"><br />
                  </span> </div>
</ix:continuation>
                <ix:continuation id="Text_a85e7c91b29248338004aac4f2b2e4bd7">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s immuno-oncology clinical candidates are of potential interest for use as a component of combination
                  clinical candidates (for example, in combination with other leading technologies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or refractory cancers. The Company is also
                  evaluating our immunotherapies as monotherapies in early-stage disease.&#160; PDS Biotech is developing targeted clinical candidates to treat several cancers including Human Papillomavirus (HPV)-positive cancers, melanoma, colorectal, lung,
                  breast and prostate cancers. The Company infectious disease candidates are of potential interest for use in universal influenza vaccines.</div>
</ix:continuation>
              </div>

            </div>

          </div>
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

          <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Text_468c865464894a079c214101bfc6ddb1" contextRef="c20230101to20230630" escape="true" continuedAt="Text_5add73856b4046279d435ab586309c751">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c751" continuedAt="Text_5add73856b4046279d435ab586309c752">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 2 &#8211; Summary of Significant Accounting
            Policies</div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c752" continuedAt="Text_5add73856b4046279d435ab586309c753">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c753" continuedAt="Text_5add73856b4046279d435ab586309c754">
<div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c754" continuedAt="Text_5add73856b4046279d435ab586309c755"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_ae15636a958f48f590ed8b2b8efa9524" contextRef="c20230101to20230630" escape="true" continuedAt="Text_0035c038b03b44f3b7d4d8b00672845d1">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c755" continuedAt="Text_5add73856b4046279d435ab586309c756"><ix:continuation id="Text_0035c038b03b44f3b7d4d8b00672845d1" continuedAt="Text_0035c038b03b44f3b7d4d8b00672845d2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">Unaudited interim financial statements:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c756" continuedAt="Text_5add73856b4046279d435ab586309c757"><ix:continuation id="Text_0035c038b03b44f3b7d4d8b00672845d2" continuedAt="Text_0035c038b03b44f3b7d4d8b00672845d3">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>
</ix:continuation></ix:continuation></div>

        <ix:continuation id="Text_5add73856b4046279d435ab586309c757" continuedAt="Text_5add73856b4046279d435ab586309c758"><ix:continuation id="Text_0035c038b03b44f3b7d4d8b00672845d3" continuedAt="Text_0035c038b03b44f3b7d4d8b00672845d4">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_5add73856b4046279d435ab586309c758" continuedAt="Text_5add73856b4046279d435ab586309c759"><ix:continuation id="Text_0035c038b03b44f3b7d4d8b00672845d4" continuedAt="Text_0035c038b03b44f3b7d4d8b00672845d5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
          </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_5add73856b4046279d435ab586309c759" continuedAt="Text_5add73856b4046279d435ab586309c7510"><ix:continuation id="Text_0035c038b03b44f3b7d4d8b00672845d5" continuedAt="Text_0035c038b03b44f3b7d4d8b00672845d6">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_5add73856b4046279d435ab586309c7510" continuedAt="Text_5add73856b4046279d435ab586309c7511"><ix:continuation id="Text_0035c038b03b44f3b7d4d8b00672845d6">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The interim balance sheet at June 30, 2023, the statements of operations and comprehensive loss and changes in stockholders&#8217; equity and cash flows for the three and six months ended June 30, 2023 and 2022 are
              unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As
              permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the
              Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations
              for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The balance sheet as of December 31, 2022
              included herein was derived from the audited consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and
              notes thereto as of and for the year ended December 31, 2022, filed by the Company with the SEC in its Annual Report on Form 10-K on March 28, 2023.</span></span><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_5add73856b4046279d435ab586309c7511" continuedAt="Text_5add73856b4046279d435ab586309c7512">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div><ix:continuation id="Text_5add73856b4046279d435ab586309c7512" continuedAt="Text_5add73856b4046279d435ab586309c7513">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7513" continuedAt="Text_5add73856b4046279d435ab586309c7514">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7514" continuedAt="Text_5add73856b4046279d435ab586309c7515"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_8e8f7dfa7f71490682a0f73c10591bb1" contextRef="c20230101to20230630" escape="true" continuedAt="Text_a2b9d12bdadc406e92ea59eef12899701">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7515" continuedAt="Text_5add73856b4046279d435ab586309c7516"><ix:continuation id="Text_a2b9d12bdadc406e92ea59eef12899701" continuedAt="Text_a2b9d12bdadc406e92ea59eef12899702">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7516" continuedAt="Text_5add73856b4046279d435ab586309c7517"><ix:continuation id="Text_a2b9d12bdadc406e92ea59eef12899702" continuedAt="Text_a2b9d12bdadc406e92ea59eef12899703">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7517" continuedAt="Text_5add73856b4046279d435ab586309c7518"><ix:continuation id="Text_a2b9d12bdadc406e92ea59eef12899703" continuedAt="Text_a2b9d12bdadc406e92ea59eef12899704">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7518" continuedAt="Text_5add73856b4046279d435ab586309c7519"><ix:continuation id="Text_a2b9d12bdadc406e92ea59eef12899704" continuedAt="Text_a2b9d12bdadc406e92ea59eef12899705">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7519" continuedAt="Text_5add73856b4046279d435ab586309c7520"><ix:continuation id="Text_a2b9d12bdadc406e92ea59eef12899705">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of condensed consolidated financial
            statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements
            and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates. The most significant estimate relates to the fair value
            of securities underlying stock-based compensation.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7520" continuedAt="Text_5add73856b4046279d435ab586309c7521">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7521" continuedAt="Text_5add73856b4046279d435ab586309c7522">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7522" continuedAt="Text_5add73856b4046279d435ab586309c7523"><ix:nonNumeric name="pdsb:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" id="Text_c545e5abd9404e599145b2e2902aa2a4" contextRef="c20230101to20230630" escape="true" continuedAt="Text_1f4edf904b874acba3fad362c3e5258e1">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7523" continuedAt="Text_5add73856b4046279d435ab586309c7524"><ix:continuation id="Text_1f4edf904b874acba3fad362c3e5258e1" continuedAt="Text_1f4edf904b874acba3fad362c3e5258e2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7524" continuedAt="Text_5add73856b4046279d435ab586309c7525"><ix:continuation id="Text_1f4edf904b874acba3fad362c3e5258e2" continuedAt="Text_1f4edf904b874acba3fad362c3e5258e3">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <div>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 10pt;"><ix:continuation id="Text_5add73856b4046279d435ab586309c7525" continuedAt="Text_5add73856b4046279d435ab586309c7526"><ix:continuation id="Text_1f4edf904b874acba3fad362c3e5258e3" continuedAt="Text_1f4edf904b874acba3fad362c3e5258e4">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </span></div>
</ix:continuation></ix:continuation>
                <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div>
                    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 10pt;">
                      <div>
                        <ix:continuation id="Text_5add73856b4046279d435ab586309c7526" continuedAt="Text_5add73856b4046279d435ab586309c7527"><ix:continuation id="Text_1f4edf904b874acba3fad362c3e5258e4" continuedAt="Text_1f4edf904b874acba3fad362c3e5258e5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its clinical candidates, the ability to preserve its cash resources, the Company&#8217;s review of strategic alternatives, the
                          ability to add clinical candidates to its pipeline, the Company&#8217;s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by
                          other companies, the price of, and demand for, Company products if approved for sale, the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the ability to raise capital, and
                          the effects of health epidemics, pandemics, or outbreaks of infectious diseases.</div>
</ix:continuation></ix:continuation>
                      </div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>

          <ix:continuation id="Text_5add73856b4046279d435ab586309c7527" continuedAt="Text_5add73856b4046279d435ab586309c7528"><ix:continuation id="Text_1f4edf904b874acba3fad362c3e5258e5" continuedAt="Text_1f4edf904b874acba3fad362c3e5258e6">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7528" continuedAt="Text_5add73856b4046279d435ab586309c7529"><ix:continuation id="Text_1f4edf904b874acba3fad362c3e5258e6" continuedAt="Text_1f4edf904b874acba3fad362c3e5258e7">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">7</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div>
                <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                  </a></div>

              </div>

            </div>

          </div>

          <ix:continuation id="Text_5add73856b4046279d435ab586309c7529" continuedAt="Text_5add73856b4046279d435ab586309c7530"><ix:continuation id="Text_1f4edf904b874acba3fad362c3e5258e7">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#8217;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7530" continuedAt="Text_5add73856b4046279d435ab586309c7531">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7531" continuedAt="Text_5add73856b4046279d435ab586309c7532">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7532" continuedAt="Text_5add73856b4046279d435ab586309c7533"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Text_01bbd76af7a6433f8426790f730739da" contextRef="c20230101to20230630" escape="true" continuedAt="Text_06db331e76384724b464fb8514a052c51">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7533" continuedAt="Text_5add73856b4046279d435ab586309c7534"><ix:continuation id="Text_06db331e76384724b464fb8514a052c51" continuedAt="Text_06db331e76384724b464fb8514a052c52">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7534" continuedAt="Text_5add73856b4046279d435ab586309c7535"><ix:continuation id="Text_06db331e76384724b464fb8514a052c52" continuedAt="Text_06db331e76384724b464fb8514a052c53">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7535" continuedAt="Text_5add73856b4046279d435ab586309c7536"><ix:continuation id="Text_06db331e76384724b464fb8514a052c53" continuedAt="Text_06db331e76384724b464fb8514a052c54">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7536" continuedAt="Text_5add73856b4046279d435ab586309c7537"><ix:continuation id="Text_06db331e76384724b464fb8514a052c54" continuedAt="Text_06db331e76384724b464fb8514a052c55">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7537" continuedAt="Text_5add73856b4046279d435ab586309c7538"><ix:continuation id="Text_06db331e76384724b464fb8514a052c55">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a
            maturity weighted average of less than three months to be cash equivalents. The Company&#8217;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7538" continuedAt="Text_5add73856b4046279d435ab586309c7539">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

        <ix:continuation id="Text_5add73856b4046279d435ab586309c7539" continuedAt="Text_5add73856b4046279d435ab586309c7540">
<div><span style="font-family: 'Times New Roman';"> <br />
        </span></div>
</ix:continuation>
        <div><ix:continuation id="Text_5add73856b4046279d435ab586309c7540" continuedAt="Text_5add73856b4046279d435ab586309c7541"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_17d0a550b2da44a2a4ae7181cf80533c" contextRef="c20230101to20230630" escape="true" continuedAt="Text_f52658b550d44fed91f213feb4e317011">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7541" continuedAt="Text_5add73856b4046279d435ab586309c7542"><ix:continuation id="Text_f52658b550d44fed91f213feb4e317011" continuedAt="Text_f52658b550d44fed91f213feb4e317012">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7542" continuedAt="Text_5add73856b4046279d435ab586309c7543"><ix:continuation id="Text_f52658b550d44fed91f213feb4e317012" continuedAt="Text_f52658b550d44fed91f213feb4e317013">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7543" continuedAt="Text_5add73856b4046279d435ab586309c7544"><ix:continuation id="Text_f52658b550d44fed91f213feb4e317013" continuedAt="Text_f52658b550d44fed91f213feb4e317014">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7544" continuedAt="Text_5add73856b4046279d435ab586309c7545"><ix:continuation id="Text_f52658b550d44fed91f213feb4e317014" continuedAt="Text_f52658b550d44fed91f213feb4e317015">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7545" continuedAt="Text_5add73856b4046279d435ab586309c7546"><ix:continuation id="Text_f52658b550d44fed91f213feb4e317015" continuedAt="Text_f52658b550d44fed91f213feb4e317016">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#8217;s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on
            behalf of the Company.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7546" continuedAt="Text_5add73856b4046279d435ab586309c7547"><ix:continuation id="Text_f52658b550d44fed91f213feb4e317016" continuedAt="Text_f52658b550d44fed91f213feb4e317017">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7547" continuedAt="Text_5add73856b4046279d435ab586309c7548"><ix:continuation id="Text_f52658b550d44fed91f213feb4e317017" continuedAt="Text_f52658b550d44fed91f213feb4e317018">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7548" continuedAt="Text_5add73856b4046279d435ab586309c7549"><ix:continuation id="Text_f52658b550d44fed91f213feb4e317018" continuedAt="Text_f52658b550d44fed91f213feb4e317019">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7549" continuedAt="Text_5add73856b4046279d435ab586309c7550"><ix:continuation id="Text_f52658b550d44fed91f213feb4e317019">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical trial site activations or information provided by vendors on their actual costs incurred. Payments
            for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7550" continuedAt="Text_5add73856b4046279d435ab586309c7551">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7551" continuedAt="Text_5add73856b4046279d435ab586309c7552">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7552" continuedAt="Text_5add73856b4046279d435ab586309c7553"><ix:nonNumeric name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="Text_d55a0bcd06fb41e088a5e0ddd7a36446" contextRef="c20230101to20230630" escape="true" continuedAt="Text_2c5411b6c66a4b6097078510f4b7671d1">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7553" continuedAt="Text_5add73856b4046279d435ab586309c7554"><ix:continuation id="Text_2c5411b6c66a4b6097078510f4b7671d1" continuedAt="Text_2c5411b6c66a4b6097078510f4b7671d2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7554" continuedAt="Text_5add73856b4046279d435ab586309c7555"><ix:continuation id="Text_2c5411b6c66a4b6097078510f4b7671d2" continuedAt="Text_2c5411b6c66a4b6097078510f4b7671d3">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7555" continuedAt="Text_5add73856b4046279d435ab586309c7556"><ix:continuation id="Text_2c5411b6c66a4b6097078510f4b7671d3" continuedAt="Text_2c5411b6c66a4b6097078510f4b7671d4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7556" continuedAt="Text_5add73856b4046279d435ab586309c7557"><ix:continuation id="Text_2c5411b6c66a4b6097078510f4b7671d4" continuedAt="Text_2c5411b6c66a4b6097078510f4b7671d5">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7557" continuedAt="Text_5add73856b4046279d435ab586309c7558"><ix:continuation id="Text_2c5411b6c66a4b6097078510f4b7671d5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7558" continuedAt="Text_5add73856b4046279d435ab586309c7559">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7559" continuedAt="Text_5add73856b4046279d435ab586309c7560">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7560" continuedAt="Text_5add73856b4046279d435ab586309c7561"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_b1e49b3b2a11499ea3e20799bd91936b" contextRef="c20230101to20230630" escape="true" continuedAt="Text_7c1ab08794d94cb7906bc0158f7ab5de1">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7561" continuedAt="Text_5add73856b4046279d435ab586309c7562"><ix:continuation id="Text_7c1ab08794d94cb7906bc0158f7ab5de1" continuedAt="Text_7c1ab08794d94cb7906bc0158f7ab5de2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7562" continuedAt="Text_5add73856b4046279d435ab586309c7563"><ix:continuation id="Text_7c1ab08794d94cb7906bc0158f7ab5de2" continuedAt="Text_7c1ab08794d94cb7906bc0158f7ab5de3">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7563" continuedAt="Text_5add73856b4046279d435ab586309c7564"><ix:continuation id="Text_7c1ab08794d94cb7906bc0158f7ab5de3" continuedAt="Text_7c1ab08794d94cb7906bc0158f7ab5de4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7564" continuedAt="Text_5add73856b4046279d435ab586309c7565"><ix:continuation id="Text_7c1ab08794d94cb7906bc0158f7ab5de4" continuedAt="Text_7c1ab08794d94cb7906bc0158f7ab5de5">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_5add73856b4046279d435ab586309c7565" continuedAt="Text_5add73856b4046279d435ab586309c7566"><ix:continuation id="Text_7c1ab08794d94cb7906bc0158f7ab5de5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation
              (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order
              to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest
              rate and dividend yield. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company
              recognizes forfeitures as they occur.</div>
</ix:continuation></ix:continuation>
          </div>
<ix:continuation id="Text_5add73856b4046279d435ab586309c7566" continuedAt="Text_5add73856b4046279d435ab586309c7567">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7567" continuedAt="Text_5add73856b4046279d435ab586309c7568">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7568" continuedAt="Text_5add73856b4046279d435ab586309c7569"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_267cafa3f35f467f880e864ab04514b9" contextRef="c20230101to20230630" escape="true" continuedAt="Text_95546061e0994f0c8701b74cd905b7271">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7569" continuedAt="Text_5add73856b4046279d435ab586309c7570"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b7271" continuedAt="Text_95546061e0994f0c8701b74cd905b7272">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7570" continuedAt="Text_5add73856b4046279d435ab586309c7571"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b7272" continuedAt="Text_95546061e0994f0c8701b74cd905b7273">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7571" continuedAt="Text_5add73856b4046279d435ab586309c7572"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b7273" continuedAt="Text_95546061e0994f0c8701b74cd905b7274">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7572" continuedAt="Text_5add73856b4046279d435ab586309c7573"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b7274" continuedAt="Text_95546061e0994f0c8701b74cd905b7275">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7573" continuedAt="Text_5add73856b4046279d435ab586309c7574"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b7275" continuedAt="Text_95546061e0994f0c8701b74cd905b7276">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7574" continuedAt="Text_5add73856b4046279d435ab586309c7575"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b7276" continuedAt="Text_95546061e0994f0c8701b74cd905b7277">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7575" continuedAt="Text_5add73856b4046279d435ab586309c7576"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b7277" continuedAt="Text_95546061e0994f0c8701b74cd905b7278">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7576" continuedAt="Text_5add73856b4046279d435ab586309c7577"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b7278" continuedAt="Text_95546061e0994f0c8701b74cd905b7279"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_bd6c17c1239342398b7bffdd5d70af4d" contextRef="c20230101to20230630" escape="true" continuedAt="Text_3dcbc2fd704c4951abdbb13358f6cdd11">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7577" continuedAt="Text_5add73856b4046279d435ab586309c7578"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b7279" continuedAt="Text_95546061e0994f0c8701b74cd905b72710"><ix:continuation id="Text_3dcbc2fd704c4951abdbb13358f6cdd11" continuedAt="Text_3dcbc2fd704c4951abdbb13358f6cdd12">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7578" continuedAt="Text_5add73856b4046279d435ab586309c7579"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b72710" continuedAt="Text_95546061e0994f0c8701b74cd905b72711"><ix:continuation id="Text_3dcbc2fd704c4951abdbb13358f6cdd12" continuedAt="Text_3dcbc2fd704c4951abdbb13358f6cdd13">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7579" continuedAt="Text_5add73856b4046279d435ab586309c7580"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b72711" continuedAt="Text_95546061e0994f0c8701b74cd905b72712"><ix:continuation id="Text_3dcbc2fd704c4951abdbb13358f6cdd13" continuedAt="Text_3dcbc2fd704c4951abdbb13358f6cdd14">
<div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7580" continuedAt="Text_5add73856b4046279d435ab586309c7581"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b72712" continuedAt="Text_95546061e0994f0c8701b74cd905b72713"><ix:continuation id="Text_3dcbc2fd704c4951abdbb13358f6cdd14" continuedAt="Text_3dcbc2fd704c4951abdbb13358f6cdd15">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7581" continuedAt="Text_5add73856b4046279d435ab586309c7582"><ix:continuation id="Text_95546061e0994f0c8701b74cd905b72713"><ix:continuation id="Text_3dcbc2fd704c4951abdbb13358f6cdd15">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><span style="font-family: 'Times New Roman';"><br />
                  </span> </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="1" colspan="6">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: normal;"> <span style="font-weight: bold; font-family: 'Times New Roman';">2023</span><span style="font-family: 'Times New Roman';"><br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2022</span><span style="font-family: 'Times New Roman';"><br />
                    </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp; width: 76%; background-color: #CCEEFF;" colspan="1">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &#38; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_58d5e7e358b4478caabeac00efbae576" contextRef="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,324,402</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &#38; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_c847eb30c65349ceb576505381a14364" contextRef="c20220101to20220630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,289,943</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp; width: 76%; padding-bottom: 2px;" colspan="1">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &#38; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_f3286673525f4c7f9fbcdcbfed2a80b1" contextRef="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">506,229</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &#38; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_85c1740bb69645b58c8ac07c6048ec93" contextRef="c20220101to20220630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">124,604</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Total</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &#38; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_018365f9d7f846cc9ec07e2798542358" contextRef="c20230101to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,830,631</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: &#38; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_29b4b67038e34d1a85bcebfb7695c8f1" contextRef="c20220101to20220630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,414,547</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7582" continuedAt="Text_5add73856b4046279d435ab586309c7583">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7583" continuedAt="Text_5add73856b4046279d435ab586309c7584">
<div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_5add73856b4046279d435ab586309c7584" continuedAt="Text_5add73856b4046279d435ab586309c7585">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">8</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div>
                <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                  </a></div>

              </div>

            </div>

          </div>

          <div><ix:continuation id="Text_5add73856b4046279d435ab586309c7585" continuedAt="Text_5add73856b4046279d435ab586309c7586">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div><ix:continuation id="Text_5add73856b4046279d435ab586309c7586" continuedAt="Text_5add73856b4046279d435ab586309c7587"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_947124b4214a4a51a357f82d9362a009" contextRef="c20230101to20230630" escape="true" continuedAt="Text_4c0b1921e9e74c7787158beac98ea9961">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c7587" continuedAt="Text_5add73856b4046279d435ab586309c7588"><ix:continuation id="Text_4c0b1921e9e74c7787158beac98ea9961" continuedAt="Text_4c0b1921e9e74c7787158beac98ea9962">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(I)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Income taxes:</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c7588" continuedAt="Text_5add73856b4046279d435ab586309c7589"><ix:continuation id="Text_4c0b1921e9e74c7787158beac98ea9962" continuedAt="Text_4c0b1921e9e74c7787158beac98ea9963">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

            <ix:continuation id="Text_5add73856b4046279d435ab586309c7589" continuedAt="Text_5add73856b4046279d435ab586309c7590"><ix:continuation id="Text_4c0b1921e9e74c7787158beac98ea9963" continuedAt="Text_4c0b1921e9e74c7787158beac98ea9964">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <div>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c7590" continuedAt="Text_5add73856b4046279d435ab586309c7591"><ix:continuation id="Text_4c0b1921e9e74c7787158beac98ea9964" continuedAt="Text_4c0b1921e9e74c7787158beac98ea9965">
<div><span style="font-family: 'Times New Roman';"><br />
                </span> </div>
</ix:continuation></ix:continuation>
            </div>

            <ix:continuation id="Text_5add73856b4046279d435ab586309c7591" continuedAt="Text_5add73856b4046279d435ab586309c7592"><ix:continuation id="Text_4c0b1921e9e74c7787158beac98ea9965" continuedAt="Text_4c0b1921e9e74c7787158beac98ea9966">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <div><ix:continuation id="Text_5add73856b4046279d435ab586309c7592" continuedAt="Text_5add73856b4046279d435ab586309c7593"><ix:continuation id="Text_4c0b1921e9e74c7787158beac98ea9966" continuedAt="Text_4c0b1921e9e74c7787158beac98ea9967">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c7593" continuedAt="Text_5add73856b4046279d435ab586309c7594"><ix:continuation id="Text_4c0b1921e9e74c7787158beac98ea9967">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c7594" continuedAt="Text_5add73856b4046279d435ab586309c7595">
<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

            <ix:continuation id="Text_5add73856b4046279d435ab586309c7595" continuedAt="Text_5add73856b4046279d435ab586309c7596">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c7596" continuedAt="Text_5add73856b4046279d435ab586309c7597">
<div><span style="font-family: 'Times New Roman';"><br />
                </span> </div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_5add73856b4046279d435ab586309c7597" continuedAt="Text_5add73856b4046279d435ab586309c7598">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div><ix:continuation id="Text_5add73856b4046279d435ab586309c7598" continuedAt="Text_5add73856b4046279d435ab586309c7599">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
              <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><ix:continuation id="Text_5add73856b4046279d435ab586309c7599" continuedAt="Text_5add73856b4046279d435ab586309c75100">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                <div><ix:continuation id="Text_5add73856b4046279d435ab586309c75100" continuedAt="Text_5add73856b4046279d435ab586309c75101">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                  <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><ix:continuation id="Text_5add73856b4046279d435ab586309c75101" continuedAt="Text_5add73856b4046279d435ab586309c75102">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                    <div><ix:continuation id="Text_5add73856b4046279d435ab586309c75102" continuedAt="Text_5add73856b4046279d435ab586309c75103"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_9d8ae5da59e54622be3ed11c8b60726e" contextRef="c20230101to20230630" escape="true" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c71">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
                      <div>
                        <ix:continuation id="Text_5add73856b4046279d435ab586309c75103" continuedAt="Text_5add73856b4046279d435ab586309c75104"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c71" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c72">
<div>
                          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">(J)</div>
                                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">Fair value of financial instruments:</div>
                                </td>

  </tr>


</table>
                        </div>
</ix:continuation></ix:continuation>
                      </div>

                      <ix:continuation id="Text_5add73856b4046279d435ab586309c75104" continuedAt="Text_5add73856b4046279d435ab586309c75105"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c72" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c73">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                    <ix:continuation id="Text_5add73856b4046279d435ab586309c75105" continuedAt="Text_5add73856b4046279d435ab586309c75106"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c73" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c74">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
                    <div>
                      <ix:continuation id="Text_5add73856b4046279d435ab586309c75106" continuedAt="Text_5add73856b4046279d435ab586309c75107"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c74" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c75">
<div style="display:none;"><br /></div>
<div style="text-indent: 0px;"><span style="font-family: 'Times New Roman';"><br />
                        </span> </div>
</ix:continuation></ix:continuation>
                    </div>

                    <ix:continuation id="Text_5add73856b4046279d435ab586309c75107" continuedAt="Text_5add73856b4046279d435ab586309c75108"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c75" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c76">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
                    <div>
                      <ix:continuation id="Text_5add73856b4046279d435ab586309c75108" continuedAt="Text_5add73856b4046279d435ab586309c75109"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c76" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c77">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</div>
</ix:continuation></ix:continuation>
                    </div>

                    <ix:continuation id="Text_5add73856b4046279d435ab586309c75109" continuedAt="Text_5add73856b4046279d435ab586309c75110"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c77" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c78">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                  <ix:continuation id="Text_5add73856b4046279d435ab586309c75110" continuedAt="Text_5add73856b4046279d435ab586309c75111"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c78" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c79">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                <ix:continuation id="Text_5add73856b4046279d435ab586309c75111" continuedAt="Text_5add73856b4046279d435ab586309c75112"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c79" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c710">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

              <ix:continuation id="Text_5add73856b4046279d435ab586309c75112" continuedAt="Text_5add73856b4046279d435ab586309c75113"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c710" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c711">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <div>
                <ix:continuation id="Text_5add73856b4046279d435ab586309c75113" continuedAt="Text_5add73856b4046279d435ab586309c75114"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c711" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c712">
<div><span style="font-family: 'Times New Roman';"><br />
                  </span> </div>
</ix:continuation></ix:continuation>
                <ix:continuation id="Text_5add73856b4046279d435ab586309c75114" continuedAt="Text_5add73856b4046279d435ab586309c75115"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c712" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c713">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three levels of the fair value hierarchy are as follows:</div>
</ix:continuation></ix:continuation>
                <ix:continuation id="Text_5add73856b4046279d435ab586309c75115" continuedAt="Text_5add73856b4046279d435ab586309c75116"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c713" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c714">
<div><span style="font-family: 'Times New Roman';"><br />
                  </span> </div>
</ix:continuation></ix:continuation>
              </div>

              <ix:continuation id="Text_5add73856b4046279d435ab586309c75116" continuedAt="Text_5add73856b4046279d435ab586309c75117"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c714" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c715">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75117" continuedAt="Text_5add73856b4046279d435ab586309c75118"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c715" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c716">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br />
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1 &#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75118" continuedAt="Text_5add73856b4046279d435ab586309c75119"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c716" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c717">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75119" continuedAt="Text_5add73856b4046279d435ab586309c75120"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c717" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c718">
<div><span style="font-family: 'Times New Roman';"><br />
                </span> </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75120" continuedAt="Text_5add73856b4046279d435ab586309c75121"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c718" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c719">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75121" continuedAt="Text_5add73856b4046279d435ab586309c75122"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c719" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c720">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br />
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 2 &#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75122" continuedAt="Text_5add73856b4046279d435ab586309c75123"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c720" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c721">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75123" continuedAt="Text_5add73856b4046279d435ab586309c75124"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c721" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c722">
<div><span style="font-family: 'Times New Roman';"><br />
                </span> </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75124" continuedAt="Text_5add73856b4046279d435ab586309c75125"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c722" continuedAt="Text_d2dde512ad824cffa2a144cf18d8b0c723">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75125" continuedAt="Text_5add73856b4046279d435ab586309c75126"><ix:continuation id="Text_d2dde512ad824cffa2a144cf18d8b0c723">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br />
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 3 &#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</div>
                    </td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_5add73856b4046279d435ab586309c75126" continuedAt="Text_5add73856b4046279d435ab586309c75127">
<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75127" continuedAt="Text_5add73856b4046279d435ab586309c75128">
<div><span style="font-family: 'Times New Roman';"><br />
                </span> </div>
</ix:continuation>
              <ix:continuation id="Text_5add73856b4046279d435ab586309c75128" continuedAt="Text_5add73856b4046279d435ab586309c75129">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
              <div><ix:continuation id="Text_5add73856b4046279d435ab586309c75129" continuedAt="Text_5add73856b4046279d435ab586309c75130">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
                <div><ix:continuation id="Text_5add73856b4046279d435ab586309c75130" continuedAt="Text_5add73856b4046279d435ab586309c75131"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="Text_06d525e453a04cfd9dbad2bf11afc5b7" contextRef="c20230101to20230630" escape="true" continuedAt="Text_56e9b951db0642c3b618f4e598c4a69b1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
                  <ix:continuation id="Text_5add73856b4046279d435ab586309c75131" continuedAt="Text_5add73856b4046279d435ab586309c75132"><ix:continuation id="Text_56e9b951db0642c3b618f4e598c4a69b1" continuedAt="Text_56e9b951db0642c3b618f4e598c4a69b2">
<table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(K)</span></div>
                        </td>

    <td style="align: left; vertical-align: top; width: auto;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Leases:</span></div>
                        </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
                  <ix:continuation id="Text_5add73856b4046279d435ab586309c75132" continuedAt="Text_5add73856b4046279d435ab586309c75133"><ix:continuation id="Text_56e9b951db0642c3b618f4e598c4a69b2" continuedAt="Text_56e9b951db0642c3b618f4e598c4a69b3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

                <ix:continuation id="Text_5add73856b4046279d435ab586309c75133" continuedAt="Text_5add73856b4046279d435ab586309c75134"><ix:continuation id="Text_56e9b951db0642c3b618f4e598c4a69b3" continuedAt="Text_56e9b951db0642c3b618f4e598c4a69b4">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation></div>

              <ix:continuation id="Text_5add73856b4046279d435ab586309c75134" continuedAt="Text_5add73856b4046279d435ab586309c75135"><ix:continuation id="Text_56e9b951db0642c3b618f4e598c4a69b4" continuedAt="Text_56e9b951db0642c3b618f4e598c4a69b5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
              <div style="font-family: 'Times New Roman', serif; font-size: 10pt; text-align: justify; text-indent: 36pt;">
                <ix:continuation id="Text_5add73856b4046279d435ab586309c75135" continuedAt="Text_5add73856b4046279d435ab586309c75136"><ix:continuation id="Text_56e9b951db0642c3b618f4e598c4a69b5" continuedAt="Text_56e9b951db0642c3b618f4e598c4a69b6">
<div style="display:none;"><br /></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br />
                  </span> </div>
</ix:continuation></ix:continuation>
                <ix:continuation id="Text_5add73856b4046279d435ab586309c75136"><ix:continuation id="Text_56e9b951db0642c3b618f4e598c4a69b6">
<div style="display:none;"><br /></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#8220;ASC 842&#8221;). Both financing and operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#8217;s consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to
                  make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the
                  lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</div>
</ix:continuation></ix:continuation>
              </div>
<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>
</div>

            <div><span style="font-family: 'Times New Roman';"> </span></div>

            <div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>

            <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
   <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="Text_3c4156a7dd5c4ae7a6d201702ce741d3" contextRef="c20230101to20230630" escape="true" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c1761">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c1761" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c1762">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 3 &#8211; Liquidity</div>
</ix:continuation>
          <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c1762" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c1763">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c1763" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c1764">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c1764" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c1765">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-transform: none;">
            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c1765" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c1766">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">As of June 30, 2023, the
              Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_2e30faa3fe564db48d9db199832dee3a" contextRef="c20230630" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.6</ix:nonFraction> million of cash and cash equivalents. The Company&#8217;s primary uses of cash are to fund operating expenses,
              primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change to the Company&#8217;s outstanding accounts payable and accrued
              expenses.</div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c1766" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c1767">
<div><span style="font-family: 'Times New Roman';"><br />
                </span> </div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c1767" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c1768">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2022, the Company received approximately $<ix:nonFraction name="pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" id="Fact_3413a4cbc8814a76a2e44d6deed28f43" contextRef="c20220401to20220430" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant the Company&#8217;s participation in the New Jersey Technology
              Business Tax Certificate Transfer NOL program for tax year 2020.</div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c1768" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c1769">
<div><span style="font-family: 'Times New Roman';"><br />
                </span> </div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c1769" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17610">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC
              for the issuance of common stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $<ix:nonFraction name="pdsb:ShelfRegistrationStatementAvailableForFutureSale" id="Fact_105cc8ccc71344debcd6d892a74a43e5" contextRef="c20220831" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">150</ix:nonFraction>
              million, $<ix:nonFraction name="pdsb:PlacementSharesAvailableForFutureSale" id="Fact_75a6262766cb4ef48c8902cd6f607eac" contextRef="c20220831" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction> million of which covers the offer, issuance and sale by the Company of its common stock under the Sales Agreement (as
              discussed below).&#160; The 2022 Shelf Registration Statement was declared effective on September 2, 2022.</div>
</ix:continuation>
            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17610" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17611">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">9</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div>
                  <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                    </a></div>

                </div>

              </div>

            </div>

            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17611" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17612">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley
              Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock,
              having an aggregate offering price of up to $<ix:nonFraction name="pdsb:PlacementSharesAvailableForFutureSale" id="Fact_6016895080224eec9eca9aa07b163262" contextRef="c20220831" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">50</ix:nonFraction> million, or the Placement Shares, through or to the Agents, as sales agents or
              principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in
              Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company&#8217;s common stock. The Agents will use commercially
              reasonable efforts to sell the Placement Shares from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the
              Agents a commission equal to three percent (<ix:nonFraction name="pdsb:CommissionPercentage" id="Fact_135376385d954ef28f1d2222f3083b61" contextRef="c20220801to20220831" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%) of the gross sales proceeds of any Placement Shares sold through the Agents under
              the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company is not obligated to make any sales of its common stock under the Sales Agreement.&#160; The offering of Placement
              Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. For the year ended December
              31, 2022, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_a0a33ae57ea448f79c2df3deec9dbbb3" contextRef="c20220101to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,238,491</ix:nonFraction> shares of common stock with a net value of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_7681cbd4e3014a64892e518a4795921e" contextRef="c20220101to20221231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.9</ix:nonFraction> million pursuant to the Sales Agreement. During the three and six months ended June 30, 2023, we sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_d1bb121572224748aa92a8d3d5906361" contextRef="c20230401to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">43,169</ix:nonFraction> shares of our common stock with a net value of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_4ee13ea9b1d642b3943438d82756ba2f" contextRef="c20230401to20230630" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>
              million and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_7fb2e6085cd54af88ec3aed56c659c31" contextRef="c20230101to20230630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">596,462</ix:nonFraction> share of our common with a net value of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_be54667a9d9a4d5d8869061dd791c113" contextRef="c20230101to20230630" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction> million, respectively, pursuant to the Sales Agreement.</div>
</ix:continuation>
            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17612" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17613">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17613" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17614">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with
                Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders.&#160; The Loan and Security Agreement provides for the following <ix:nonFraction name="pdsb:DebtInstrumentNumberOfIndependentTermLoans" id="Fact_9da00dc5d61a4cb5a63dcb6bdb7340d2" contextRef="c20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">6</ix:nonFraction> separate and independent term loans: (a) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_bdfca3eec53c4b44bde8bf7634d98706" contextRef="c20220831_DebtInstrumentAxis_LoanAMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,500,000</ix:nonFraction>,
                or Loan A, (b) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_416b5967a00f43b6b8ca575e2e1f6def" contextRef="c20220831_DebtInstrumentAxis_LoanBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction>, or Loan B, (c) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_3191e5336d844fc2b66174f6fe35c0e8" contextRef="c20220831_DebtInstrumentAxis_LoanCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,750,000</ix:nonFraction>, or Loan C, (d) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_15bfa2c3a7b743b98524f2323906efb1" contextRef="c20220831_DebtInstrumentAxis_LoanDMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,750,000</ix:nonFraction>, or Loan D, (e) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" id="Fact_63c8257cceb34928ab283d57c602e537" contextRef="c20230630_DebtInstrumentAxis_LoanEMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction>, or
                Loan E, and (f) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" id="Fact_00832118ec6e470f931472aab11b2063" contextRef="c20230630_DebtInstrumentAxis_LoanFMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction>, or Loan F, (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and
                Loan F, individually a Loan and, collectively, the Loans).&#160; Loan A, Loan B, Loan C<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">, and Loan D were delivered to the Company on August 24, 2022.&#160; Loan E and Loan F are uncommitted Loans that could have been advanced by the lenders upon the Parties agreement prior to July 31, 2023 upon the
                  satisfaction of certain conditions. The Parties are in discussion to extend this option, however, there is no guarantee that such an option will be extended on terms favorable to the Company or its existing stockholders, or at all. The
                  Company may only use the proceeds of the Loans for working capital or general corporate purposes.&#160; Each Loan matures on the <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_7e4ba71e239c46db88f6877256b8aaee" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">48</ix:nonNumeric>-month
                  anniversary following the applicable funding date unless accelerated pursuant to certain events of default.</span> Payments on the principal balance begin on October 1, 2024 and are paid monthly in the succeeding <ix:nonNumeric name="pdsb:DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" id="Fact_c4ee888719a74e9e8e5dbc1a9aeb4479" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">24</ix:nonNumeric> months. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) </span>the per annum rate of
                interest from time to time published in The Wall Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#8220;prime rate&#8221; then in effect, plus (b) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" id="Fact_82fb301b3b564f2093d84469268e868f" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_VariableRateAxis_PrimeRateMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.75</ix:nonFraction>%; provided that, in the event such rate of interest is less than <ix:nonFraction name="pdsb:DebtInstrumentVariableRate" id="Fact_8df8dfa5b9f54f04949187b19d5bbee0" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.00</ix:nonFraction>%,
                such rate shall be deemed to be <ix:nonFraction name="pdsb:DebtInstrumentVariableRate" id="Fact_17e304f0160443a49d740ab7dbc8bf2d" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.00</ix:nonFraction>% for purposes of calculating the interest rate. Interest is payable on a monthly basis
                based on each Loan principal amount outstanding the preceding month.&#160; The Company, at its option upon at least ten (<ix:nonNumeric name="pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment" id="Fact_141edf28094c4f6d964978791c6736b5" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember" format="ixt-sec:durday">10</ix:nonNumeric>) business
                days&#8217; written notice to the lenders, may prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the
                Loans; plus (ii) an amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date (as defined in the Loan and Security Agreement) applicable to such Loan, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod1" id="Fact_42a1b3d9dea24d2ba149bb8d1e6dea46" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan, but on or before the date that is <ix:nonNumeric name="pdsb:DebtInstrumentThresholdPeriod" id="Fact_5c64435ab8ef4933bd367f2547fe71c0" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months after such Loan Amortization Date, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod2" id="Fact_3f3ad5e13bf94592a5e3f7e159b39f0d" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%
                of the then outstanding principal balance of such Loan, or (C) if such Loan is prepaid more than <ix:nonNumeric name="pdsb:DebtInstrumentThresholdPeriod" id="Fact_58aca750d22448a5870553921968fb0a" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months after the Loan
                Amortization Date but prior to the stated maturity date applicable to such Loan, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod3" id="Fact_6e70ffe1a62048feb3e85c934909f4c5" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>% of the then outstanding principal balance of
                such Loan;&#160;plus&#160;(iii) the outstanding principal balance of such Loan;&#160;plus&#160;(iv) all other sums, if any, that shall have become due and payable thereunder.&#160; <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod4" id="Fact_ffa1443d135e4a668fee34644e47c560" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> prepayment premium will be applied to any outstanding balance of any Loan paid on the stated maturity date.</div>
</ix:continuation>
            </div>

            <div>
              <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17614" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17615">
<div><span style="font-family: 'Times New Roman';"><br />
                </span> </div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17615" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17616">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Loan and Security Agreement contains customary representations, warranties and covenants, including covenants by the
              Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates, and
              fundamental changes.</div>
</ix:continuation>
            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17616" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17617">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
            <div>
              <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17617" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17618">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2023, the Company received approximately $<ix:nonFraction name="pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" id="Fact_425cd80196634510b32e4f5e4d321603" contextRef="c20230401to20230430" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction> million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company&#8217;s participation in the New Jersey Technology
                Business Tax Certificate Transfer NOL program for tax year 2021.</div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17618" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17619">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17619" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17620">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash
              used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change in its outstanding accounts payable and accrued expenses.</div>
</ix:continuation>
            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17620" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17621">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">10</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div>
                  <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                    </a></div>

                </div>

              </div>

            </div>

            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17621" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17622">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial
              doubt about its ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q.&#160; The Company&#8217;s budgeted cash requirements in 2023 and beyond include expenses related to continuing development and
              clinical trials.&#160; Based on its available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, management believes there are sufficient funds to continue operations and
              research and development programs <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for 12 months following the filing of this Quarterly Report on Form 10-Q</span>.</div>
</ix:continuation>
            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17622" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17623">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17623" continuedAt="Text_5d529548ee4c4d3cb95454e5ab24c17624">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company plans to continue to fund its operations and capital funding needs through equity and/or debt financings.
              However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders.&#160; The Company may also enter into
              government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to the Company&#8217;s stockholders. Incurring debt financing would
              result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict its operations. If the Company is unable to raise additional capital in sufficient amounts or
              on acceptable terms, we may be required to delay, limit, reduce, or terminate its clinical development or future commercialization efforts or grant rights to third parties to develop and market immunotherapies that the Company would otherwise
              prefer to develop and market itself. Any of these actions could harm its business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect the Company&#8217;s ability to operate as a going concern.</div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_5d529548ee4c4d3cb95454e5ab24c17624">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

            <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
              </span> </div>

            <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_73560b82835844c09425c66d391eb93d" contextRef="c20230101to20230630" escape="true" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a1" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a2">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 4 &#8211; Fair Value of Financial Instruments</div>
</ix:continuation>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a2" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a3" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a4" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a5" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a6">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">There were <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Fact_f2ec1a7358a049e2bf5a09df6ab02f8f" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Fact_adfd5be06c3446dba935032647928571" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Fact_84eb7a2944ed492b95c31981cad066ec" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Fact_18ed41f3de8544fc9f1581f5bbf13461" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Fact_0696aef957f34e2c85e2c02531ab255b" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Fact_eb72031be6174b52a99e3c1fa1b02b7b" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Fact_150b98f937de42c680b9ea2bd3c938ba" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Fact_fa16382c96d8465aa7048fb6d86044ed" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers among Levels 1, 2, or 3 during the three and six months ended June 30, 2023 or 2022.</div>
</ix:continuation>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a6" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a7">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a7" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a8">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a8" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a9"><ix:nonNumeric name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="Text_b10d17043f62400a903fe724ce9a939b" contextRef="c20230101to20230630" escape="true" continuedAt="Text_862d9c1576754a658f8552e3e9595e921">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a9" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a10"><ix:continuation id="Text_862d9c1576754a658f8552e3e9595e921">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of <span style="text-indent: 0pt;">June 30</span>, <span style="text-indent: 0pt;">2023</span>: (unaudited)</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_3496c4a8cf96434aa781747e6ad072f4" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,624,991</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_2e5743260f674b869750998a91e757c6" contextRef="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,624,991</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_a0e30c10954649a78b95ac3146efdeb9" contextRef="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_9a79764b4efd45289e43ac3538ae2202" contextRef="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December
                      31, <span style="text-indent: 0pt;">2022</span></span></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_d8799d0f3c3f42829df75ce79e5c86d0" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">73,820,160</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_94bcf8fe414247699e5246ad40923f27" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">73,820,160</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_a5ce73417c7d4125ab11d4524b6836b4" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_068fc8d640854107acd48fdcdccba068" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a10" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a11">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a11" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a12">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a12" continuedAt="Text_a7816bcf595e4c698b5968dc4922bf3a13">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">
            <ix:continuation id="Text_a7816bcf595e4c698b5968dc4922bf3a13">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;">The carrying value of the Note Payable approximated its fair value at June 30,
              2023 due to its variable rate.</div>
</ix:continuation>
          </div>
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_c84c9041eb47400f877f5e85c2adee8d" contextRef="c20230101to20230630" escape="true" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b81">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b81" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b82">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 5 &#8211; Leases</div>
</ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b82" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b83">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b83" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b84">
<div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b84" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b85">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b85" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b86">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Operating Lease:</span></div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b86" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b87">
<div><span style="font-family: 'Times New Roman';"> <br />
          </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b87" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b88">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effective March 5, 2020, the Company entered into a sublease for approximately <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" id="Fact_f93aab5277d34383a293644e4fe4f805" contextRef="c20230630" unitRef="U006" decimals="0" scale="0" format="ixt:num-dot-decimal">11,200</ix:nonFraction> square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 and will continue for a term of forty
              (<ix:nonNumeric name="us-gaap:LessorOperatingLeaseTermOfContract" id="Fact_35c8b80803024f4091676956b12348bd" contextRef="c20230630" format="ixt-sec:durmonth">40</ix:nonNumeric>) months with an option to renew through October 31, 2027. As of June 30, 2023 there are two (<ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Fact_01e250fb0808468fa5d0e7d492ff8944" contextRef="c20230630" format="ixt-sec:durmonth">2</ix:nonNumeric>) months remaining in the sublease term. Upon inception of the sublease, the Company recognized approximately $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_8a9f9bee0e7045f7af37a9b301fb82f6" contextRef="c20200501" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_51b8c027716642b99666dece125c1d9c" contextRef="c20200501" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction></ix:nonFraction> million of a ROU asset and operating lease liabilities. The discount rate used to measure the operating lease liability as of May 1, 2020
              was <ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" id="Fact_09080085ee1e4a57b6ad4ac0a645ee2d" contextRef="c20200501" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.15</ix:nonFraction>%. Throughout the period described above the Company has maintained, and continues to maintain, a month-to-month lease for
              its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.</div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b88" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b89">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b89" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b810">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b810" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b811"><ix:nonNumeric name="pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" id="Text_e53fc6fae7d04841af06125cd44cb1e0" contextRef="c20230101to20230630" escape="true" continuedAt="Text_5921453830864e74b9079273e30c8ce61">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b811" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b812"><ix:continuation id="Text_5921453830864e74b9079273e30c8ce61" continuedAt="Text_5921453830864e74b9079273e30c8ce62">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Supplemental cash flow information related to operating
            leases is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b812" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b813"><ix:continuation id="Text_5921453830864e74b9079273e30c8ce62" continuedAt="Text_5921453830864e74b9079273e30c8ce63">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b813" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b814"><ix:continuation id="Text_5921453830864e74b9079273e30c8ce63" continuedAt="Text_5921453830864e74b9079273e30c8ce64">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b814" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b815"><ix:continuation id="Text_5921453830864e74b9079273e30c8ce64" continuedAt="Text_5921453830864e74b9079273e30c8ce65">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b815" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b816"><ix:continuation id="Text_5921453830864e74b9079273e30c8ce65">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2023<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2022<br />
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                  <div style="font-family: 'Times New Roman';">Cash paid for operating lease liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div>
                    <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_cf88223345a1491984df38ae918a6065" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">179,136</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_996ef5fac0214723bc0cf6bb7b08cf0d" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">116,783</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b816" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b817">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

        <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b817" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b818">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b818" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b819">
<div> <span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b819" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b820">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">11</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                </a></div>

            </div>

          </div>

        </div>

        <div><ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b820" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b821"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_ff0e5466c1cc434c827689fab180362e" contextRef="c20230101to20230630" escape="true" continuedAt="Text_665baf740eeb4485bd5633992cb7ca5c1">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b821" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b822"><ix:continuation id="Text_665baf740eeb4485bd5633992cb7ca5c1" continuedAt="Text_665baf740eeb4485bd5633992cb7ca5c2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Maturity of the Company&#8217;s operating lease liability is as
            follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b822" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b823"><ix:continuation id="Text_665baf740eeb4485bd5633992cb7ca5c2" continuedAt="Text_665baf740eeb4485bd5633992cb7ca5c3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b823" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b824"><ix:continuation id="Text_665baf740eeb4485bd5633992cb7ca5c3" continuedAt="Text_665baf740eeb4485bd5633992cb7ca5c4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b824" continuedAt="Text_ed587b55abf64cb9b9493bd1d54126b825"><ix:continuation id="Text_665baf740eeb4485bd5633992cb7ca5c4" continuedAt="Text_665baf740eeb4485bd5633992cb7ca5c5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ed587b55abf64cb9b9493bd1d54126b825"><ix:continuation id="Text_665baf740eeb4485bd5633992cb7ca5c5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: &#38;amp;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Year ended December 31,</div>
                </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2023</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_bbf32e3e5e5549c988ea60f82ddc78a8" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,333</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2024</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_4896e154fb3746a3bf885db78dee7928" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2025</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_571d86250b684e14a56bfd24bd5ffc88" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2026</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_46d43b3014764d29a4504488382fc5bd" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2027 and after</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="pdsb:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" id="Fact_3b94591683c74ce0b63ca6d133379290" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total future minimum lease payments</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_968ab27a93c84955b001ad137e275fd9" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,333</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Less imputed interest</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_202c5acc5ee1460abf1fca47d939bcc5" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">683</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_34e3d982cc9946f28ef28c15fa8e0e85" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">59,650</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><ix:nonNumeric name="us-gaap:LesseeFinanceLeasesTextBlock" id="Text_41fd09658afd4ab184eb1cf9960421fd" contextRef="c20230101to20230630" escape="true" continuedAt="Text_b35d56e55f5947eabf22a94a136cd3121">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd3121" continuedAt="Text_b35d56e55f5947eabf22a94a136cd3122">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Financing Lease:</span></div>
</ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd3122" continuedAt="Text_b35d56e55f5947eabf22a94a136cd3123">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd3123" continuedAt="Text_b35d56e55f5947eabf22a94a136cd3124">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation><ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd3124" continuedAt="Text_b35d56e55f5947eabf22a94a136cd3125"><ix:nonNumeric name="pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" id="Text_b073d91e77ab4362937f69077b4cbdb8" contextRef="c20230101to20230630" escape="true" continuedAt="Text_7373955ed3cb491f9c22d827d94f8a151">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd3125" continuedAt="Text_b35d56e55f5947eabf22a94a136cd3126"><ix:continuation id="Text_7373955ed3cb491f9c22d827d94f8a151" continuedAt="Text_7373955ed3cb491f9c22d827d94f8a152">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company has financed certain
              laboratory equipment as follows: </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd3126" continuedAt="Text_b35d56e55f5947eabf22a94a136cd3127"><ix:continuation id="Text_7373955ed3cb491f9c22d827d94f8a152" continuedAt="Text_7373955ed3cb491f9c22d827d94f8a153">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd3127" continuedAt="Text_b35d56e55f5947eabf22a94a136cd3128"><ix:continuation id="Text_7373955ed3cb491f9c22d827d94f8a153" continuedAt="Text_7373955ed3cb491f9c22d827d94f8a154">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd3128" continuedAt="Text_b35d56e55f5947eabf22a94a136cd3129"><ix:continuation id="Text_7373955ed3cb491f9c22d827d94f8a154" continuedAt="Text_7373955ed3cb491f9c22d827d94f8a155">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd3129" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31210"><ix:continuation id="Text_7373955ed3cb491f9c22d827d94f8a155">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of June 30,</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';">2023<br />
                      </span> </div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2022<br />
                      </span> </div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for finance lease liabilities</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:FinanceLeasePrincipalAndInterestPayments" id="Fact_7d01b18a9f824e2084f83a2e916db4f6" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">43,221</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:FinanceLeasePrincipalAndInterestPayments" id="Fact_f95c39f295a642baac30906778ff3b32" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31210" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31211">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31211" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31212">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation><ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31212" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31213"><ix:nonNumeric name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Text_b058af5d7b1f4beda78c3242f6dbdf5d" contextRef="c20230101to20230630" escape="true" continuedAt="Text_cb871baa3593492eb5f217e37c656b7b1">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31213" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31214"><ix:continuation id="Text_cb871baa3593492eb5f217e37c656b7b1" continuedAt="Text_cb871baa3593492eb5f217e37c656b7b2">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"> Maturity of the Company&#8217;s financing lease liability is as follows:</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31214" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31215"><ix:continuation id="Text_cb871baa3593492eb5f217e37c656b7b2" continuedAt="Text_cb871baa3593492eb5f217e37c656b7b3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31215" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31216"><ix:continuation id="Text_cb871baa3593492eb5f217e37c656b7b3" continuedAt="Text_cb871baa3593492eb5f217e37c656b7b4">
<div> <span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31216" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31217"><ix:continuation id="Text_cb871baa3593492eb5f217e37c656b7b4" continuedAt="Text_cb871baa3593492eb5f217e37c656b7b5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31217" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31218"><ix:continuation id="Text_cb871baa3593492eb5f217e37c656b7b5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Year ended June 30,</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2023<br />
                      </span> </div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_70c662006c664101a086ed6973968bdf" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">34,924</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2024</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman';">$ <br />
                    </span> </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_545fbe3337a447ee8e6ebfe8a3f2ce7d" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">69,850</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2025</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman';">$ <br />
                    </span> </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" id="Fact_ccff53db136a4d308572775cb96882a9" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">69,850</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2026</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman';">$ <br />
                    </span> </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" id="Fact_5c10b8e99d484139a920eae17cbb4e85" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,108</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2027 and after</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1"><span style="font-family: 'Times New Roman';">$ <br />
                    </span> </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="pdsb:FinanceLeaseLiabilityToBePaidYearFourAndThereafter" id="Fact_e98b765ad5d2444ab759af34c1b54283" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,724</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total future minimum lease payments</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" id="Fact_1056b28874cd43eaaf1343f89aff2004" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">241,456</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less imputed interest</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" id="Fact_4edfc7375bee4715b4070dfe99de80fd" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">36,642</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Remaining lease liability</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" id="Fact_d2c52c7fba30430b938ba5aa72eac6fb" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">204,814</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31218" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31219">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31219" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31220">
<div><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31220" continuedAt="Text_b35d56e55f5947eabf22a94a136cd31221">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_b35d56e55f5947eabf22a94a136cd31221">
<div style="display:none;"><br /></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company entered into <ix:nonFraction name="pdsb:LesseeFinanceLeaseNumberOfLeases" id="Fact_18ba008e5ecf4f2c86d5fb6df3621fde" contextRef="c20230101to20230630" unitRef="U007" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction>
              financing leases for laboratory equipment with a total cost of $<ix:nonFraction name="pdsb:FinanceLeaseCost" id="Fact_9dddca1ca72641fcac27e3217386541a" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">251,959</ix:nonFraction> with <span style="-sec-ix-hidden:Fact_f0c3462c2ee44efcb853f792cd6a38ad">four</span> to <ix:nonNumeric name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="Fact_5d78b7a795de46e69db72ade6f393217" contextRef="c20230630_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> terms and a capitalized interest rate of
              <ix:nonFraction name="us-gaap:LesseeFinanceLeaseDiscountRate" id="Fact_3629cd398f574c9894a6b0d03d957a80" contextRef="c20230630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.15</ix:nonFraction>%. Each of the lease agreements include a bargain purchase option to acquire the equipment at the end of the lease term. The
              aggregate monthly payments are approximately $<ix:nonFraction name="pdsb:LesseeFinanceLeaseMonthlyRentalExpense" id="Fact_133327ee86704d0eac55541f2e7e7e1d" contextRef="c20230101to20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction>,000. In the six months ended June 30, 2023, the Company exercised a bargain
              purchase option, which resulted in recognition of property and equipment of $<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentAdditions" id="Fact_c15d648d4c67400288f66079cd3f0614" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">151,490</ix:nonFraction>.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
   <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_32a268bf225b4809b33cf77488db16a5" contextRef="c20230101to20230630" escape="true" continuedAt="Text_1caa0e455b4a42d7a02c6176e783108b1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
        <ix:continuation id="Text_1caa0e455b4a42d7a02c6176e783108b1" continuedAt="Text_1caa0e455b4a42d7a02c6176e783108b2">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 6 &#8211; Accrued Expenses</div>
</ix:continuation>
        <ix:continuation id="Text_1caa0e455b4a42d7a02c6176e783108b2" continuedAt="Text_1caa0e455b4a42d7a02c6176e783108b3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_1caa0e455b4a42d7a02c6176e783108b3" continuedAt="Text_1caa0e455b4a42d7a02c6176e783108b4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation><ix:continuation id="Text_1caa0e455b4a42d7a02c6176e783108b4" continuedAt="Text_1caa0e455b4a42d7a02c6176e783108b5"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_c8d65d70ec0f4b9390897c4a8e85dfdd" contextRef="c20230101to20230630" escape="true" continuedAt="Text_a1eea515a9f9459e8299ef8d28c7c7cc1">
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_1caa0e455b4a42d7a02c6176e783108b5" continuedAt="Text_1caa0e455b4a42d7a02c6176e783108b6"><ix:continuation id="Text_a1eea515a9f9459e8299ef8d28c7c7cc1" continuedAt="Text_a1eea515a9f9459e8299ef8d28c7c7cc2">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Accrued expenses and other liabilities consist of the
          following:</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1caa0e455b4a42d7a02c6176e783108b6" continuedAt="Text_1caa0e455b4a42d7a02c6176e783108b7"><ix:continuation id="Text_a1eea515a9f9459e8299ef8d28c7c7cc2" continuedAt="Text_a1eea515a9f9459e8299ef8d28c7c7cc3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1caa0e455b4a42d7a02c6176e783108b7" continuedAt="Text_1caa0e455b4a42d7a02c6176e783108b8"><ix:continuation id="Text_a1eea515a9f9459e8299ef8d28c7c7cc3" continuedAt="Text_a1eea515a9f9459e8299ef8d28c7c7cc4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1caa0e455b4a42d7a02c6176e783108b8" continuedAt="Text_1caa0e455b4a42d7a02c6176e783108b9"><ix:continuation id="Text_a1eea515a9f9459e8299ef8d28c7c7cc4" continuedAt="Text_a1eea515a9f9459e8299ef8d28c7c7cc5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1caa0e455b4a42d7a02c6176e783108b9"><ix:continuation id="Text_a1eea515a9f9459e8299ef8d28c7c7cc5">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">June 30, 2023</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; text-align: center;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="background-color: rgb(204, 238, 255); vertical-align: middle; white-space: nowrap; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div>
                  <div style="font-family: 'Times New Roman';">Accrued research and development</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="pdsb:AccruedResearchAndDevelopmentCostsCurrent" id="Fact_1d64e1edc81449008d17caa213c53fdf" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">874,200</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="pdsb:AccruedResearchAndDevelopmentCostsCurrent" id="Fact_9e9e93f4bcc1427bb19bc0d1500c450b" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,645,737</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;">
                <div style="font-family: 'Times New Roman';">Accrued professional fees</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">
                <div>
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_44cb1df96fa846d3a0abdba3950b228f" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">941,515</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_3139c002b71c432d93ba1503f1e55550" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">550,259</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';">Accrued compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" id="Fact_d702c3c66b4b4ca4ab7f24ea79f40ad7" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,268,575</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" id="Fact_01a019aae3ad4a21a760b7a095135810" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,837,330</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" rowspan="1">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accrued interest on debt</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_88af646dc144434caec13f271929c325" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">291,667</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_b1d3b697c4874950af0ea3a5311827ef" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">280,382</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" rowspan="1">Accrued rent</td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" rowspan="1"><ix:nonFraction name="us-gaap:AccruedRentCurrent" id="Fact_1695a70b3b304d8b87e1773a95c5f88a" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">368</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" rowspan="1"><ix:nonFraction name="us-gaap:AccruedRentCurrent" id="Fact_d2780ba71a184a128fc4936c661a855d" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;">
                <div style="margin-left: 9pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_c50e555a01e242af907c18e70b9c851e" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,376,325</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>
                  <div style="font-family: 'Times New Roman';">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>
                  <div style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_b41e80bbb1fd4177b11ede6b415edeb7" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,313,708</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

        <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span> </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">12</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                </a></div>

            </div>

          </div>

        </div>

      </div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
  <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> </span> </span></div>

  <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

    <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_c437c32b26e1418682eb12f87af9e911" contextRef="c20230101to20230630" escape="true" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd33821">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd33821" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd33822">
<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Note 7 &#8211; Stock-Based Compensation</div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd33822" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd33823">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd33823" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd33824">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br />
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd33824" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd33825">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd33825" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd33826">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">In 2014, the Company&#8217;s stockholders approved the 2014
            Equity Incentive Plan pursuant to which the Company may grant up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_86067fbc1db34767989387a4d9917487" contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">91,367</ix:nonFraction> shares as ISOs, NQs and restricted stock units (&#8220;RSUs&#8221;),
            subject to increases as hereafter described (the &#8220;Plan Limit&#8221;). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive
            Plan, the Plan Limit was and shall be increased by the lesser of (x) <ix:nonFraction name="pdsb:PercentageOfCommonStockOutstanding" id="Fact_0fe28907156f4ceca34b436a0913541d" contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the number of shares of Common Stock outstanding as of
            the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_39155fcd843941f49dbd475668d4ac08" contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">826,292</ix:nonFraction> shares.</div>
</ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd33826" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd33827">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br />
            </span> </div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt;">
            <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd33827" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd33828">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;">As previously disclosed, on December 8, 2020, the Board of
              Directors of the Company adopted, subject to stockholder approval, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Inventive Plan (the &#8220;Restated Plan&#8221;), which amended and restated the Amended and Restated PDS
              Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Current Plan&#8221;). At the annual meeting of stockholders on June 17, 2021 the stockholders voted to approve the Restated Plan at the Annual Meeting. The Restated Plan is identical to the
              Current Plan in all material respects, except as follows: (a) the number of shares of Common Stock authorized for issuance under the Restated Plan will increase from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_9b390e0219254175a84a27bfa763b908" contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">826,292</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_59026e91d399413699dc4d1c6ac28b9a" contextRef="c20210617_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,339,243</ix:nonFraction> shares, plus the total number of shares that
              remained available for issuance, that are not covered by outstanding awards issued under the Current Plan, immediately prior to December 8, 2020; and (b) the Restated Plan will terminate on December 7, 2030, unless earlier terminated. On July
              14, 2023, the Company&#8217;s stockholders approved an amendment to the Current Plan increasing the number of shares of common stock for issuance from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_306d69d7abfd40ee86d5b4525a5b6037" contextRef="c20230630_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,165,535</ix:nonFraction>
              to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_6ec023c9f38e450bb2856459de74bb87" contextRef="c20230714_PlanNameAxis_EquityIncentivePlan2014Member_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,565,535</ix:nonFraction> shares. As of June 30, 2023, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_c6ab48f2106b4674be0fc38dbb6e0c40" contextRef="c20230630_PlanNameAxis_EquityIncentivePlan2014Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">178,513</ix:nonFraction> shares available for grant under the Restated Plan. </div>
</ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd33828" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd33829">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd33829" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338210">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338210" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338211">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338211" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338212">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">In 2018, the
              Company&#8217;s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_70af3ccbb8634c8295875d04eef15de0" contextRef="c20181231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">558,071</ix:nonFraction> shares as (i)
              Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards. As of June 30, 2023, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_8a569881c63d47aa89b0f7d8e27b99cd" contextRef="c20230630_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">190,799</ix:nonFraction> shares available for grant under the Restated Plan.<br />
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338212" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338213">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338213" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338214">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338214" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338215">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> </span></div>
</ix:continuation> </div>

        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338215" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338216">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338216" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338217">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block; font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">Pursuant to the terms of the Plans, ISOs have a term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact_86ac4e46573f470fb6ec75fee6d76dc4" contextRef="c20230101to20230630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a
            <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_b6b57db0dd834813a1d4d372d6c7ebd0" contextRef="c20230101to20230630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period. Unless terminated by the Board, the Plans shall continue to remain effective for a term of <ix:nonNumeric name="pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" id="Fact_316352e38eb5458194e8ef9b0c424377" contextRef="c20230101to20230630_PlanNameAxis_EquityCompensationPlansMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding.</span></div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338217" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338218">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338218" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338219">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338219" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338220">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338220" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338221">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="width: 9pt; font-size: 1px; display: inline-block; font-family: 'Times New Roman';" class="HorizontalTab">&#160;</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On June 17, 2019, the Board adopted the 2019 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan was recommended
              for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.<span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> On December 8, 2020, the Company amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under
                the Inducement Plan from <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_8615897054bc460e8e028434429c2522" contextRef="c20201207_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_997004b9313d4dabb7447b6b1030d987" contextRef="c20201208_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> shares.</span> On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_747909e818024aa992b02b2fdb244a66" contextRef="c20220516_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> shares to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_ef1ab83822284fa0999f05ac91f76949" contextRef="c20220517_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,100,000</ix:nonFraction>
              shares.&#160;The 2019 Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the 2019 Inducement Plan may only be made to an
              employee who has not previously been an employee or member of the Board (or any parent or subsidiary of the Company), or following a bona fide period of non-employment by the Company (or a parent or subsidiary of the Company), if he or she is
              granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such
              subsidiary. As of June 30, 2023, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_9e52194f0bcc4c6a9e3d3c934a0bdc1c" contextRef="c20230630_PlanNameAxis_InducementPlan2019Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">185,315</ix:nonFraction> shares available for grant under the 2019 Inducement Plan. </span></div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338221" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338222">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338222" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338223">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br />
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338223" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338224">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div><ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338224" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338225"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_0d4ff581aa6d4e7f9a24f2a492e60771" contextRef="c20230101to20230630" escape="true" continuedAt="Text_e56c9615dec147498eb82d66fa9177531">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338225" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338226"><ix:continuation id="Text_e56c9615dec147498eb82d66fa9177531" continuedAt="Text_e56c9615dec147498eb82d66fa9177532">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The Company&#8217;s stock-based compensation expense related to stock options was recognized in operating expense as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338226" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338227"><ix:continuation id="Text_e56c9615dec147498eb82d66fa9177532" continuedAt="Text_e56c9615dec147498eb82d66fa9177533">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338227" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338228"><ix:continuation id="Text_e56c9615dec147498eb82d66fa9177533" continuedAt="Text_e56c9615dec147498eb82d66fa9177534">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338228" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338229"><ix:continuation id="Text_e56c9615dec147498eb82d66fa9177534" continuedAt="Text_e56c9615dec147498eb82d66fa9177535">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338229" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338230"><ix:continuation id="Text_e56c9615dec147498eb82d66fa9177535">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Three Months Ended June 30,<br />
                    </span> </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six months ended June 30,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023<br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022<br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023<br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022<br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Stock-Based Compensation</div>
                </td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" colspan="2">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" colspan="2">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" colspan="2">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" colspan="2">&#160;</td>

    <td valign="bottom" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Research and development</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_399848f6ab6940d892a4d40dd7df4805" contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">806,548</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f2b58b9aa88340578243b46a5e6f15db" contextRef="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">487,532</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_7838a2cc9c9348478440725247da39cf" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,607,312</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_89ccc06ded4e4476add3327b7bc61298" contextRef="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">856,582</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">General and administrative</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_4b80dfb116db4bc88124a3afd2909426" contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,298,990</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_041c7f7d8adf41bbb0c1a696b34b1ba4" contextRef="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">861,069</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"></div>
                  </div>
                  <br />
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_70ba6896ffa04a1fb42263396d4fad55" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,578,545</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_cab63f4df0bc4e18ba7a23c476c0da66" contextRef="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,620,992</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Total</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_9e91225df29f4ad8a3f11995f6ab8440" contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,105,538</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_142cee1c809f41ec9f217180360138d7" contextRef="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,348,601</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_9daee8b5b3fd4e29b5ea90348b15559b" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,185,857</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_6fa65a61a1d74e73840cd96696a09c1e" contextRef="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,477,574</ix:nonFraction><br />
                      </span> </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338230" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338231">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br class="Apple-interchange-newline" />
            </span></span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338231" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338232">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338232" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338233">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter"></div>

        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">13</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div><ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338233" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338234">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <div style="text-align: justify;"><ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338234" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338235"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_a95acb4203944c9283fabe06595262cd" contextRef="c20230101to20230630" escape="true" continuedAt="Text_b8acc210e64d47499fc4fe4a89636acf1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338235" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338236"><ix:continuation id="Text_b8acc210e64d47499fc4fe4a89636acf1" continuedAt="Text_b8acc210e64d47499fc4fe4a89636acf2">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The fair value of options granted during the three and six months ended June 30, 2023 and 2022 was estimated using the Black-Scholes option
            valuation model utilizing the following assumptions. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_060c83653b194da79d1fcc16c05614ed" contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">29,900</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_6a40040539b845478f28350b0cee9d85" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,154,500</ix:nonFraction> of options granted during the three and six month periods ended June 30, 2023, respectively and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_2c4d291f29cf4bdebeec31f151f2dfea" contextRef="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">494,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_3ef5ffb9505b487fadf3513acb4482b0" contextRef="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,439,005</ix:nonFraction> of options granted during the three and six month
            period ended June 30, 2022, respectively.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338236" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338237"><ix:continuation id="Text_b8acc210e64d47499fc4fe4a89636acf2" continuedAt="Text_b8acc210e64d47499fc4fe4a89636acf3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338237" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338238"><ix:continuation id="Text_b8acc210e64d47499fc4fe4a89636acf3" continuedAt="Text_b8acc210e64d47499fc4fe4a89636acf4">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338238" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338239"><ix:continuation id="Text_b8acc210e64d47499fc4fe4a89636acf4" continuedAt="Text_b8acc210e64d47499fc4fe4a89636acf5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338239" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338240"><ix:continuation id="Text_b8acc210e64d47499fc4fe4a89636acf5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Three Months Ended June 30</span> </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six Months Ended June 30,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022<br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Volatility</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_c542f8af5ffe4e74ad1bc2f46ce48535" contextRef="c20230401to20230630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">143.87</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_44d27e0975be4d349e207d0ca197ee35" contextRef="c20220401to20220630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">100.05</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_d5f0ae6c7d094d89abdc1dd86599a510" contextRef="c20230101to20230630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">142.07</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_6ab92fa967b14da48fcc7c627ea135c8" contextRef="c20220101to20220630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">99.45</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Risk-Free Interest Rate</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_59d9124c61bc42609d6c4611c95a3e26" contextRef="c20230401to20230630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.59</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_557f9bc308874c248569cc6b28b54bfe" contextRef="c20220401to20220630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.60</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_43e2d72d964944c18bd45ebd207c0768" contextRef="c20230101to20230630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.05</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_919ecd621aee4bf3906f4083ce6aebe9" contextRef="c20220101to20220630" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">11.62</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Expected Term in Years</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_ae0d769dfb7c46c0a2c6fd32d3868da8" contextRef="c20230401to20230630" format="ixt-sec:duryear">6.08</ix:nonNumeric></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_c7ce388f7aa04187a1b5c31b1d942e7f" contextRef="c20220401to20220630" format="ixt-sec:duryear">6.02</ix:nonNumeric></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_9795525418994a909b9ff2640a9b1cc1" contextRef="c20230101to20230630" format="ixt-sec:duryear">6.08</ix:nonNumeric></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_05e5e13f0028412c97448795dc42830a" contextRef="c20220101to20220630" format="ixt-sec:duryear">6.43</ix:nonNumeric></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Dividend Rate</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_0b916db09fdb4bfcb9dfa50aef863d9b" contextRef="c20230401to20230630" unitRef="U004" decimals="0" scale="-2" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_9de147e8bc434cbfb98ed0ab852441bf" contextRef="c20220401to20220630" unitRef="U004" decimals="0" scale="-2" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_1130eb8f73844ad68fb38fb19e2774ad" contextRef="c20230101to20230630" unitRef="U004" decimals="INF" scale="-2" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_e1f396286da3426f9adcce13d005318b" contextRef="c20220101to20220630" unitRef="U004" decimals="INF" scale="-2" format="ixt:fixed-zero">&#8211;</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 52%; background-color: #CCEEFF;">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Fair Value of Option on Grant Date</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_0429d8254a4c43f4bcee8ed117a5f15a" contextRef="c20230401to20230630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.09</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_82974d763d714838b1758a1079ff13b4" contextRef="c20220401to20220630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.01</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_1d6a0dfca4d2439681ae8fa9575bd0db" contextRef="c20230101to20230630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.64</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_049480c93340494cb09b96c3a110dae2" contextRef="c20220101to20220630" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.59</ix:nonFraction></div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338240" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338241">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br />
            </span></span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>
<ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338241" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338242"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_eb6c618c5c0b416c89868fac25211833" contextRef="c20230101to20230630" escape="true" continuedAt="Text_e7bd20d0450d46c894843ee5e97843d71">
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338242" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338243"><ix:continuation id="Text_e7bd20d0450d46c894843ee5e97843d71" continuedAt="Text_e7bd20d0450d46c894843ee5e97843d72">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338243" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338244"><ix:continuation id="Text_e7bd20d0450d46c894843ee5e97843d72" continuedAt="Text_e7bd20d0450d46c894843ee5e97843d73">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338244" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338245"><ix:continuation id="Text_e7bd20d0450d46c894843ee5e97843d73" continuedAt="Text_e7bd20d0450d46c894843ee5e97843d74">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br />
          </span> </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338245" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338246"><ix:continuation id="Text_e7bd20d0450d46c894843ee5e97843d74" continuedAt="Text_e7bd20d0450d46c894843ee5e97843d75">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338246" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338247"><ix:continuation id="Text_e7bd20d0450d46c894843ee5e97843d75">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Number</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">of Shares</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercise Price</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Remaining</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Contractual</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Life in Years</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Aggregate</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Intrinsic Value</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_3f702781e54d4a21bb4b9874367ddf29" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,171,311</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_d488481bd4a843319f1915a4bfc5ebfa" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.56</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_916b9188cb9b4f5684af7c22d52b9688" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">7.89</ix:nonNumeric></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_12b0af9dfba1472cb7475cf3044db61a" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,839,589</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Granted</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_034fb239226c4d6daf54ab757cfcebf8" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,154,500</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_e128bc68be844aaabdcae176b4735a7d" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">11.45</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><span style="font-family: 'Times New Roman';"><br />
                  </span> </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br />
                    </span> </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><span style="font-family: 'Times New Roman';"><br />
                  </span> </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercised</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_df8be442f7cf4639a635d946128af093" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,409</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_00f23f567714412c9913fd10cc942d94" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><span style="font-family: 'Times New Roman';"><br />
                </span> </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br />
                    </span> </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><span style="font-family: 'Times New Roman';"><br />
                  </span> </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Forfeited











                      and expired<br />
                    </span> </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" id="Fact_33b492cd5fa245518ead294134745fd4" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"></div>
                </div>
                <br />
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" id="Fact_f71db9c488e6410ba97641f6b7c22c7a" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><span style="font-family: 'Times New Roman';"><br />
                  </span> </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br />
                    </span> </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><span style="font-family: 'Times New Roman';"><br />
                </span> </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">June 30, 2023</span></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_e57e70350e6341a89552fdb264da75bf" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,324,402</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_01997bc014a84730a449b915b6ba3e20" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.85</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_7394599f88db4274ac026041c3eb8df3" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">7.86</ix:nonNumeric></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_412c709137544361b21b13986331f70f" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,645,635</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Vested and expected to vest at <span style="text-indent: 0pt;">June 30, 2023</span></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_1a7e92d2784d467f8e6eb0a96de37e73" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,324,402</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_73c12437374a427d9f419e694aa9c8db" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.85</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Fact_b0421126f39f4a61bba4829bf44a02dd" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">7.86</ix:nonNumeric></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" id="Fact_b982ed66ba114f7b8b119b7746fc6466" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,645,635</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">June 30, 2023</span></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_3745190b2eaa466fb1a91b1568ec532d" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,513,595</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_1f875c86f8e94af48bf98d7c9c2ec890" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.80</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_9f9c453b12cc4c7ba884fa4c783fe1a0" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.83</ix:nonNumeric></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_b0d3f73e56fa488a8400a5b2081a4a6c" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,901,233</ix:nonFraction></div>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338247" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338248">
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br class="Apple-interchange-newline" />
          </span></span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338248" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338249">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">At June 30, 2023 there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_d23196f2bf314ef8a3bed445f4c226ea" contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,357,890</ix:nonFraction> of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_715625624e0a4104883daabd8a8e32f8" contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">2.75</ix:nonNumeric> years.</div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338249" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338250">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338250" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338251">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338251" continuedAt="Text_1ca7df83f1dc47bb92945e06dbbd338252">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_1ca7df83f1dc47bb92945e06dbbd338252">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company entered into an agreement with DC Consulting for certain consulting services
            and issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_a08151dd523646558b36ea60af03aa78" contextRef="c20230101to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> shares in connection with the agreement.</span><span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

        <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br />
          </span> </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

  <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> </span> <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> </span> </span></div>

</div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_cf221a3e72a14d25a9d9ea1dbd54aba0" contextRef="c20230101to20230630" escape="true" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d1" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d2">
<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 8 &#8211; Income Taxes</div>
</ix:continuation>
          <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d2" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d3" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d4">
<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d4" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d5" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d6">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative
            evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation
            of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for <span style="font-size: 10pt;">2023</span> and there will be <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_d8f0b467adf44d90b60abd0faec586a6" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span>
            current income tax expense.&#160; Additionally, there was a full valuation allowance against the net deferred tax assets as of <span style="font-size: 10pt;">June 30, 2023</span> and December 31, <span style="font-size: 10pt;">2022</span>. As
            such, the Company recorded <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_e24c1454b0114aa597343a4365f7c27f" contextRef="c20230101to20230630" unitRef="U002" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span> income tax benefit due to realization uncertainties.</div>
</ix:continuation>
          <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d6" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d7">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d7" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d8">
<div><span style="font-family: 'Times New Roman';"><br />
            </span></div>
</ix:continuation>
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
              <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d8" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d9">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s U.S. statutory rate is <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_cd88beb9f3384d58ad79709cf420b32d" contextRef="c20230401to20230630" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_7b581a49b7e4451d82f0da2b95aa113e" contextRef="c20230101to20230630" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction></ix:nonFraction>%.
                The primary factor impacting the effective tax rate for the three and six months ended <span style="font-size: 10pt;">June 30, 2023</span> is the anticipated full year operating loss which will require full valuation allowances against any
                associated net deferred tax assets.</div>
</ix:continuation>
            </div>

            <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d9" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d10">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d10" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d11">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d11" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d12">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
              <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d12" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d13">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on
                their income tax returns. The Company has analyzed its tax positions and has concluded that as of <span style="font-size: 10pt;">June 30, 2023</span>, there were <ix:nonFraction name="pdsb:LiabilityForUncertainTaxPositions" id="Fact_43dba59874964f59a5f7a1e294a278f0" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> uncertain positions. The Company&#8217;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax
                examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.&#160; The Company did <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_4940c6399bb94cc5b57470a48b9b6541" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_1edd5f463b1c4c98823494b409bacc15" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any unrecognized tax benefits and has <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" id="Fact_e376224a377649c3ade1bde193af77ec" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" id="Fact_04ded47c584a4884a69584f606a92e03" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t
                accrued any interest or penalties for the three and six months ended <span style="font-size: 10pt;">June 30, 2023</span> and for the year ended December 31, <span style="font-size: 10pt;">2022.<br />
                </span></div>
</ix:continuation>
              <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d13" continuedAt="Text_cef3e4bd1f87418eb51c37f0c9b6b73d14">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
                </span></div>
</ix:continuation>
              <ix:continuation id="Text_cef3e4bd1f87418eb51c37f0c9b6b73d14">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">In accordance with the State of New Jersey&#8217;s Technology Business Tax Certificate Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate
                taxpayers, the Company sold New Jersey NOL carryforwards, resulting in the recognition of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_f082557fbb42418cbbec70af185140c0" contextRef="c20230101to20230630" unitRef="U002" decimals="-5" sign="-" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_40e0398831a442bf8c6acf6cc4bd9fb4" contextRef="c20220101to20220630" unitRef="U002" decimals="-5" sign="-" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million of income tax benefit, net of transaction costs in the six months ended June 30, 2023 and 2022, respectively.</div>
</ix:continuation>
            </div>
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-family: 'Times New Roman';"> </span></div>
</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">14</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div>
                <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                  </a></div>

              </div>

            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_52ee43536ad149dfb48cd95e38b71a8a" contextRef="c20230101to20230630" escape="true" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae1">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
      <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae1" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae2">
<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 9 &#8211; Commitments and Contingencies</div>
</ix:continuation>
      <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae2" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

    <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae3" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae4">
<div><span style="font-family: 'Times New Roman';"> <br />
    </span></div>
</ix:continuation>
    <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae4" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae5">
<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Rent</span></div>
</ix:continuation>
    <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae5" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae6">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
    <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae6" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae7">
<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> <br />
      </span></div>
</ix:continuation>
    <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae7" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae8">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
    <div style="font-family: 'Times New Roman';">
      <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae8" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae9">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and six months ended June 30, 2023 was $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_58c91f5117114a64a70a283d9b3d280f" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">126,532</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_714b0d4523de43cebaa19885e977dde9" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">253,202</ix:nonFraction> respectively, compared to the three and six months ended
          June 30, 2022 of $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_316e144192d5426f9315d1f4c78817ab" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">55,500</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_fc64744c8f6d4e28b434a63542737b03" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">111,000</ix:nonFraction>.</span>
      </div>
</ix:continuation>
      <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae9" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae10">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br />
        </span> </div>
</ix:continuation>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae10" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae11">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Exclusive License Agreement</span></div>
</ix:continuation>
        <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae11" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae12">
<div><span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae12" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae13">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">In January 2023, we entered into an exclusive global license agreement
              with Merck KGaA, Darmstadt, Germany for the tumor targeting antibody conjugated IL-12, M9241 (the &#8220;Merck KGaA License Agreement&#8221;). Pursuant</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> to the </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">Merck KGaA License Agreement, the Company agreed to make (i) development</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> and </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">first commercial sale milestone payments totaling up to $<ix:nonFraction name="pdsb:MilestonePaymentsDevelopmentAndFirstCommercialSales" id="Fact_6c8a153768b04d3aa862d5eb13921d61" contextRef="c20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction> million upon
              the achievement</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> of </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">certain milestones, including the dosing of the fifth patient
              in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up to $<ix:nonFraction name="pdsb:MilestonePaymentsAchievementOfCertainAggregateSalesLevels" id="Fact_6647c44b57144fdf8c48b6bd82309b45" contextRef="c20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">105</ix:nonFraction> million upon achieving certain aggregate sales levels of the product.</span></div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae13" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae14">
<div><span style="font-family: 'Times New Roman';"><br />
            </span> </div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae14" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae15">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company also agreed to pay Merck KGaA, Darmstadt, Germany a royalty of <ix:nonFraction name="pdsb:RoyaltyPercentagePaidOnNetSalesOfProduct" id="Fact_4e625d5bf46f4a52bf9ba598673aac3d" contextRef="c20230101to20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) <ix:nonNumeric name="pdsb:TermOfRoyaltyPayment" id="Fact_eda6f8dbfe1a4d75a883a54c96f7e92c" contextRef="c20230101to20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering
            the compound or product in such country. The royalty rate is subject to reduction in that event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or
            if the Company obtains a license to any intellectual property owned or controlled by a third-party which but for such license would be infringed by making, using or selling the compound.</div>
</ix:continuation>
        </div>

      </div>

      <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae15" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae16">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br />
        </span> </div>
</ix:continuation>
    </div>

    <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae16" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae17">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt;"> </span> <span style="font-size: 10pt;"> </span> </span></div>
</ix:continuation>
    <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae17" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae18">
<div style="display:none;"><br /></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Legal Proceedings</span><br />
      </span> </div>
</ix:continuation>
    <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae18" continuedAt="Text_62af41f0c7bf44b8ad92c0b543143bae19">
<div><span style="font-family: 'Times New Roman';"> <br />
    </span></div>
</ix:continuation>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">
      <ix:continuation id="Text_62af41f0c7bf44b8ad92c0b543143bae19">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company is currently not a party to,</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> and the Company&#8217;s</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> property is not currently the subject of,</span><span style="font-family: 'Times New Roman';"> any <span style="font-size: 10pt;">material </span>pending <span style="font-size: 10pt;">legal proceedings.</span> The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary
          course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance.</span></div>
</ix:continuation>
    </div>
<div><span style="font-family: 'Times New Roman';"> </span>
    <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;"> </span> </span></div>

    <div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
      </span> </div>

    <div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
   <div><span style="font-family: 'Times New Roman';"> </span></div>

    <div><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="Text_1e66b360307945beae775da6db05f15a" contextRef="c20230101to20230630" escape="true" continuedAt="Text_2f02d1deac004622bac423fc134b391c1">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c1" continuedAt="Text_2f02d1deac004622bac423fc134b391c2">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">Note 10 &#8211; Venture Loan and Security Agreement</div>
</ix:continuation>
      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c2" continuedAt="Text_2f02d1deac004622bac423fc134b391c3">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c3" continuedAt="Text_2f02d1deac004622bac423fc134b391c4">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c4" continuedAt="Text_2f02d1deac004622bac423fc134b391c5">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_2f02d1deac004622bac423fc134b391c5" continuedAt="Text_2f02d1deac004622bac423fc134b391c6">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c6" continuedAt="Text_2f02d1deac004622bac423fc134b391c7">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In August&#160; 2022, the Company entered into a Venture Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Horizon
            Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the &#8220;Collateral Agent&#8221;), and the other persons party thereto from time to time as lenders (&#8220;Lenders&#8221;).</div>
</ix:continuation>
        </div>

      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c7" continuedAt="Text_2f02d1deac004622bac423fc134b391c8">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c8" continuedAt="Text_2f02d1deac004622bac423fc134b391c9">
<div><span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c9" continuedAt="Text_2f02d1deac004622bac423fc134b391c10">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c10" continuedAt="Text_2f02d1deac004622bac423fc134b391c11">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Term Loan Amounts</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement provides for the following <ix:nonFraction name="pdsb:DebtInstrumentNumberOfIndependentTermLoans" id="Fact_b4288d79394e4b8bbc04e218fed29b4d" contextRef="c20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction> (<ix:nonFraction name="pdsb:DebtInstrumentNumberOfIndependentTermLoans" id="Fact_eb479d054ea348f895be6727c535fafe" contextRef="c20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">6</ix:nonFraction>) separate and independent term loans: (a) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_daa9499244cb4090ae838ff6babe3541" contextRef="c20220831_DebtInstrumentAxis_LoanAMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,500,000</ix:nonFraction>
            (&#8220;Loan A&#8221;), (b) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_2b548ee4eede4a879c7c04f7cd5b63a6" contextRef="c20220831_DebtInstrumentAxis_LoanBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> (&#8220;Loan B&#8221;), (c) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_28a833a97a67442b9e4982bfce4e6742" contextRef="c20220831_DebtInstrumentAxis_LoanCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,750,000</ix:nonFraction> (&#8220;Loan C&#8221;), (d) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_cc0e1014ea4d48898293808a00fc26ce" contextRef="c20220831_DebtInstrumentAxis_LoanDMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,750,000</ix:nonFraction>
            (&#8220;Loan D&#8221;), (e) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" id="Fact_ae27211e10e7485aa206f938854851f6" contextRef="c20230630_DebtInstrumentAxis_LoanEMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction> (&#8220;Loan E&#8221;), and (f) a term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" id="Fact_5f4cb663441948e4933f91c387f06a68" contextRef="c20230630_DebtInstrumentAxis_LoanFMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction> (&#8220;Loan F&#8221;) (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and Loan F, individually a &#8220;Loan&#8221; and, collectively, the &#8220;Loans&#8221;). </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Loan A, Loan B, Loan C, and Loan D were
            delivered to the Company on August 24, 2022. Loan E and Loan F are uncommitted Loans that could have been advanced by the Lenders upon the Parties agreement prior to July 31, 2023 upon the satisfaction by the Company of certain agreed upon
            conditions<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">. The Parties are in
              discussion to extend this option</span>, however, there is no guarantee that such an option will be extended on terms favorable to the Company or its existing stockholders, or at all. The Company may only use the proceeds of the Loans for
            working capital or general corporate purposes.</span></div>
</ix:continuation>
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c11" continuedAt="Text_2f02d1deac004622bac423fc134b391c12">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c12" continuedAt="Text_2f02d1deac004622bac423fc134b391c13">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c13" continuedAt="Text_2f02d1deac004622bac423fc134b391c14">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c14" continuedAt="Text_2f02d1deac004622bac423fc134b391c15">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_2f02d1deac004622bac423fc134b391c15" continuedAt="Text_2f02d1deac004622bac423fc134b391c16">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">
          <div>
            <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c16" continuedAt="Text_2f02d1deac004622bac423fc134b391c17">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-style: italic;">Maturity</span>. Each Loan matures on the <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_cb356b7f9f1e43c9a668191eb3667d49" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">48</ix:nonNumeric>
                month anniversary following the applicable date on which a Loan is made to or on account of the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>under the Loan and Security Agreement (the &#8220;Maturity Date&#8221;) unless accelerated pursuant to agreed upon events of default. All amounts outstanding under each Loan will be due and payable upon
                the earlier of the Maturity Date or the acceleration of the loans and commitments upon an event of default.</span></div>
</ix:continuation>
            <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c17" continuedAt="Text_2f02d1deac004622bac423fc134b391c18">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
          </div>

        </div>

      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c18" continuedAt="Text_2f02d1deac004622bac423fc134b391c19">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c19" continuedAt="Text_2f02d1deac004622bac423fc134b391c20">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Interest Rate</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) the per annum rate of interest from time to time published in The Wall
            Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#8220;prime rate&#8221; then in effect, plus (b) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" id="Fact_7bf38196e5c64ccfb3a32e29cbf31a4b" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_VariableRateAxis_PrimeRateMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">5.75</ix:nonFraction>%;
            provided that, in the event such rate of interest is less than <ix:nonFraction name="pdsb:DebtInstrumentVariableRate" id="Fact_28c9de20f6074d78b26a5311a5f14606" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.00</ix:nonFraction>%, such rate shall be deemed to be <ix:nonFraction name="pdsb:DebtInstrumentVariableRate" id="Fact_5d89cd7c2f9c4c27918c4dcafc3cf6f1" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.00</ix:nonFraction>% for purposes of calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding the
            preceding month.</span></div>
</ix:continuation>
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c20" continuedAt="Text_2f02d1deac004622bac423fc134b391c21">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c21" continuedAt="Text_2f02d1deac004622bac423fc134b391c22">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c22" continuedAt="Text_2f02d1deac004622bac423fc134b391c23">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c23" continuedAt="Text_2f02d1deac004622bac423fc134b391c24">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">15</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
                </a></div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c24" continuedAt="Text_2f02d1deac004622bac423fc134b391c25">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Amortization.</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">&#160;Each Loan shall commence amortization upon the date set forth on the promissory note executed in connection with the respective Loan, upon which the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>is required to commence making equal payments of principal plus accrued interest on the outstanding principal amount of the respect Loan
            (the &#8220;Loan Amortization Date&#8221;), and continuing thereafter on the first business day of each calendar month through the Maturity Date.</span></div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c25" continuedAt="Text_2f02d1deac004622bac423fc134b391c26">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c26" continuedAt="Text_2f02d1deac004622bac423fc134b391c27">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c27" continuedAt="Text_2f02d1deac004622bac423fc134b391c28">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c28" continuedAt="Text_2f02d1deac004622bac423fc134b391c29">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Prepayment Premium.</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">&#160;The <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>may, at its option upon at least ten (<ix:nonNumeric name="pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment" id="Fact_19ca51bd48314e528009035770771c23" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember" format="ixt-sec:durday">10</ix:nonNumeric>) business days&#8217; written
            notice to the Lenders, prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each Lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an
            amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date applicable to such Loan, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod1" id="Fact_59d21217a3f848f5b1d4ece3294185b4" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="-2" format="ixt-sec:numwordsen">three </ix:nonFraction>percent (<ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod1" id="Fact_0e712b060e2548d2a2df5ec30e5df02f" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>%) of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan,
            but on or before the date that is twelve (<ix:nonNumeric name="pdsb:DebtInstrumentThresholdPeriod" id="Fact_175403ef47354e86a6239bb14b4cf8bd" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">12</ix:nonNumeric>) months after such Loan Amortization Date, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod2" id="Fact_7938634d7b654b748686a03d2ec197f4" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="-2" format="ixt-sec:numwordsen">two </ix:nonFraction>percent (<ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod2" id="Fact_5d26db88ee874918958288b7f8e3ea6a" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%) of the then outstanding principal balance of
            such Loan, or (C) if such Loan is prepaid more than twelve (<ix:nonNumeric name="pdsb:DebtInstrumentThresholdPeriod" id="Fact_431ce041343f4208b4002dd64b68ae48" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" format="ixt-sec:durmonth">12</ix:nonNumeric>) months after the Loan Amortization Date but prior to the stated
            Maturity Date applicable to such Loan, <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod3" id="Fact_2d53c11949b14cbab4cc99b077859e98" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="-2" format="ixt-sec:numwordsen">one </ix:nonFraction>percent (<ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod3" id="Fact_d3c7f13d9dea4be5b67967164b502bfd" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction>%) of the then outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iii) the outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iv) all other sums, if any, that shall have become due and payable hereunder.&#160; <ix:nonFraction name="pdsb:DebtInstrumentPrepaymentPremiumPeriod4" id="Fact_90b3a702eef249b19e1fc789332ecc3b" contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> prepayment premium will be
            applied to any outstanding balance of any Loan paid on the stated Maturity Date.</span></div>
</ix:continuation>
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c29" continuedAt="Text_2f02d1deac004622bac423fc134b391c30">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> <br />
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c30" continuedAt="Text_2f02d1deac004622bac423fc134b391c31">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Security</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">.</span><span style="font-family: 'Times New Roman';"> The Company&#8217;s obligations are secured by a security interest in all of the assets of the Company, subject
            to limited exceptions and excluding the Company&#8217;s intellectual property. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span></span>
        </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c31" continuedAt="Text_2f02d1deac004622bac423fc134b391c32">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c32" continuedAt="Text_2f02d1deac004622bac423fc134b391c33">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c33" continuedAt="Text_2f02d1deac004622bac423fc134b391c34">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c34" continuedAt="Text_2f02d1deac004622bac423fc134b391c35">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Covenants; Representations and Warranties; Other Provisions</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement contains customary representations, warranties and covenants, including
            covenants by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with
            affiliates, and fundamental changes.</span></div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c35" continuedAt="Text_2f02d1deac004622bac423fc134b391c36">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c36" continuedAt="Text_2f02d1deac004622bac423fc134b391c37">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c37" continuedAt="Text_2f02d1deac004622bac423fc134b391c38">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 9pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_2f02d1deac004622bac423fc134b391c38" continuedAt="Text_2f02d1deac004622bac423fc134b391c39">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c39" continuedAt="Text_2f02d1deac004622bac423fc134b391c40">
<div style="display:none;"><br /></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Default Provisions</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement provides for events of default customary for term loans of this type, including but not limited to non-payment,
            breaches or defaults in the performance of covenants, insolvency, and bankruptcy by and/or of the Company.</span></div>
</ix:continuation>
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><ix:continuation id="Text_2f02d1deac004622bac423fc134b391c40" continuedAt="Text_2f02d1deac004622bac423fc134b391c41">
<div><span style="font-family: 'Times New Roman';"><br />
          </span></div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c41" continuedAt="Text_2f02d1deac004622bac423fc134b391c42">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Warrant and Debt Discount.</span><span style="font-family: 'Times New Roman';"> In connection with the Loan and Security Agreement, the Company issued Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP warrants to purchase an aggregate total of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_cd92ebbd9e654428bf02a837e4073f77" contextRef="c20220831" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">381,625</ix:nonFraction> shares of the Company&#8217;s common stock at an initial exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_1bc5fa7e5e6742378239c390a34d79dc" contextRef="c20220831" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">3.6685</ix:nonFraction> per share. Each warrant is classified as equity and is exercisable at any time for a period beginning on the date of grant and ending on the earlier of (A) <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_cd5b4714dbc14475a04329fef277d105" contextRef="c20230630" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or
                substantially all of the Company&#8217;s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other
                reorganization) or series of related transactions, in which more than <ix:nonFraction name="pdsb:PercentageOfVotingPowerDisposedOff" id="Fact_ad735a00a7d64950b9e3dffe81ff2901" contextRef="c20230101to20230630_RangeAxis_MinimumMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the voting power of the Company is disposed of, in
                each case, for cash or for marketable securities meeting certain requirements as described in the applicable warrants.&#160; The key assumptions used in the Black-Scholes option pricing model were (i) expected term of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_327536ddf17e4a22907d3062ad12cc95" contextRef="c20230630_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">10</ix:nonNumeric></span>
                years, (ii) a risk-free rate of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Fact_f7e4fb5f4d81402eac7783521bb74843" contextRef="c20230630_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.11</ix:nonFraction>%</span>, (iii) expected volatility of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Fact_3ccd525f02074ad2b298115a72513f7d" contextRef="c20230630_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">93.8</ix:nonFraction>%</span>, (iv) and <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" id="Fact_377cccf854e74319970a5a20f38f30dc" contextRef="c20230630_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U004" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span> estimated dividend
                yield. In addition, the Company incurred third party and lender fees of $<span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" id="Fact_9f2ce7ab0b094ac0a804fd0423bf4296" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">449,329</ix:nonFraction></span>. These proceeds were allocated on a basis that approximates the relative fair value method. The fair value of the warrant and
                fees incurred were recorded as a debt discount and are being recognized as interest expense over the life of the loan and Security Agreement using the effective interest method. The unamortized debt discount was $<span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_22e5aeecae90431d8ecdb886b081e229" contextRef="c20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,683,133</ix:nonFraction></span>
                as of June 30, 2023. The Company recognized interest expense of $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_aad3cce66c294bc7938d7848aa02c0db" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">961,753</ix:nonFraction> and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" id="Fact_a4010d81c23f4ba28c2921192ccd56ab" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,952,272</ix:nonFraction> for the three and six months ended June 30, 2023 and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_774f658b20d341819303fd70f11a592d" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">121,997</ix:nonFraction>
                and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_9bf2477ebefe4dc7baddf7127a21ce81" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">233,523</ix:nonFraction> was related to the amortization of the debt discount for the three and six months ended June 30, 2023.</span></div>
</ix:continuation>
          </div>

        </div>

      </div>

      <ix:continuation id="Text_2f02d1deac004622bac423fc134b391c42">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div style="color: rgb(0, 0, 0); text-align: justify; text-indent: 0px; font-family: 'Times New Roman';"><span style="font-size: 10pt;"> <br />
          </span></div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
   <div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman';"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman';"> </span></div>

        <div><ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Text_a6cabaaa720442fdb8bc1481eada5813" contextRef="c20230101to20230630" escape="true" continuedAt="Text_5c2bc07a2f6144b7abb7f52a36c7d8871">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_5c2bc07a2f6144b7abb7f52a36c7d8871" continuedAt="Text_5c2bc07a2f6144b7abb7f52a36c7d8872">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Note 11 &#8211; Retirement Plan</div>
</ix:continuation>
          <ix:continuation id="Text_5c2bc07a2f6144b7abb7f52a36c7d8872" continuedAt="Text_5c2bc07a2f6144b7abb7f52a36c7d8873">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5c2bc07a2f6144b7abb7f52a36c7d8873" continuedAt="Text_5c2bc07a2f6144b7abb7f52a36c7d8874">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_5c2bc07a2f6144b7abb7f52a36c7d8874" continuedAt="Text_5c2bc07a2f6144b7abb7f52a36c7d8875">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <div style="text-align: justify; text-indent: 36pt;"><ix:continuation id="Text_5c2bc07a2f6144b7abb7f52a36c7d8875" continuedAt="Text_5c2bc07a2f6144b7abb7f52a36c7d8876">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_5c2bc07a2f6144b7abb7f52a36c7d8876">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; text-align: justify; font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">The
                Company has a 401(k) defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_76fa5ff00efb402bbe9337bbed435d52" contextRef="c20230401to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">36,863</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_c9e49b0572964df19e0d469b984eb8e6" contextRef="c20230101to20230630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">131,769</ix:nonFraction> for the three
                and six months ended June 30, 2023, respectively, compared to the three and six months ended June 30, 2022 of $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_4bc6ef137f38467f9704d319a210202b" contextRef="c20220401to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">37,776</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_22cc143fb9cb45bf82f9e69bf858d188" contextRef="c20220101to20220630" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">157,009</ix:nonFraction> respectively<span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span></span></div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>
</div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman';"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">16</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <a id="ITEM2."><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 2.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><span style="font-style: italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim
          condensed consolidated</span>&#160;<span style="font-style: italic;">financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) and with the audited financial statements and notes
          thereto of the Company as of and for the year ended December 31, 2022 on Form 10-K, filed with the Securities and Exchange Commission, or SEC, on March 28, 2023.</span></div>

      <div><br />
      </div>

      <div style="color: #000000; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">This Quarterly Report contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section
        27A of the United States Securities Act of 1933, as amended) concerning the Company and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition,
        or otherwise, based on current beliefs of the Company&#8217;s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend
        upon or refer to future events or conditions, and include words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;forecast,&#8221; &#8220;guidance&#8221;, &#8220;outlook&#8221; and other similar
        expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained
        in any forward-looking statement as a result of various factors, including, without limitation:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Company&#8217;s ability to protect its intellectual property rights;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Company&#8217;s anticipated capital requirements, including the Company&#8217;s anticipated cash runway and the Company&#8217;s current expectations regarding its plans for future equity financings;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Company&#8217;s dependence on additional financing to fund its operations and complete the development and commercialization of its clinical candidates, and the risks that raising such additional capital may
                restrict the Company&#8217;s operations or require the Company to relinquish rights to the Company&#8217;s technologies or clinical candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the Company&#8217;s limited operating history in the Company&#8217;s current line of business, which makes it difficult to evaluate the Company&#8217;s prospects, the Company&#8217;s business plan or the likelihood of the Company&#8217;s
                successful implementation of such business plan;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0103, PDS0203 and other Versamune<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>and










                Infectimune based clinical candidates and the future success of such trials;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the successful implementation of the Company&#8217;s research and development programs and collaborations, including any collaboration trials concerning the Company&#8217;s Versamune and Infectimune based clinical candidates
                and the Company&#8217;s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company&#8217;s clinical candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the success, timing and cost of the Company&#8217;s ongoing clinical trials and anticipated clinical trials for the Company&#8217;s current clinical candidates, including statements regarding the timing of initiation, pace of
                enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data
                reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company&#8217;s ongoing clinical trials;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">expectations for the clinical and preclinical development, manufacturing, regulatory approval, and commercialization of our clinical candidates;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">any Company statements about its understanding of clinical candidates&#8217; mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration
                trials; the acceptance by the market of the Company&#8217;s clinical candidates, if approved;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the timing of and the Company&#8217;s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company&#8217;s clinical candidates; and</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">other factors, including legislative, regulatory, political and economic developments not within the Company&#8217;s control, including unforeseen circumstances or other disruptions to normal business operations arising
                from or related to those listed under Part II, Item 1A. Risk Factors.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">17</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown
        risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.&#160; Given
        these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, whether as a result of new
        information, future events or otherwise.</div>

      <div style="text-align: justify;"><span style="color: #000000;"> </span><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In this Quarterly Report, unless otherwise stated or the context otherwise indicates, references to &#8220;PDS Biotech,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to
        PDS Biotechnology Corporation, a Delaware corporation.</div>

      <div><br />
      </div>

      <div style="color: #000000; font-weight: bold;">Company Overview</div>

      <div><br />
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, Versamune<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> plus PDS0301 and Infectimune<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> T cell-activating platforms and PDS0301 tumor targeting immunocytokine. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches
          through the activation of the right type, quantity and potency of T cells.&#160; Versamune, and Versamune plus PDS0301 are utilized for treatments in oncology and Infectimune, for treatments in infectious disease.&#160; When paired with an antigen, which
          is a disease-related protein that is recognizable by the immune system, Versamune and Infectimune have both been shown to induce, <span style="font-style: italic;">in vivo,</span> large quantities of high-quality, highly potent polyfunctional
          CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies.&#160; Versamune plus
          PDS0301 enhances the proliferation, potency and longevity of T cells in the tumor microenvironment and works synergistically to overcome tumor immune suppression.</div>

      </div>

      <div><br />
      </div>

      <div>
        <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Recent Developments</div>

      </div>

      <div>
        <div><br />
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">
        <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In June 2022, two abstracts were presented at the 2022 American Society of Clinical Oncology Annual Meeting: Abstract number 6041, PDS0101 a novel type 1
          interferon and CD8 T cell activating immunotherapy in combination with pembrolizumab in subjects with recurrent/metastatic HPV16-positive squamous cell carcinoma (HNSCC) and Abstract number 2518, Phase 2 evaluation of the combination of PDS0101,
          M9241 (now PDS0301), and bintrafusp alfa with HPV16-positive malignancies. Also in May 2022, we expanded our VERSATILE-002 clinical trial into Europe and in June 2022, the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) had granted Fast Track
          designation to our lead candidate, PDS0101 in combination with Merck&#8217;s anti-PD-1 therapy, KEYTRUDA&#174; (pembrolizumab). The FDA&#8217;s Fast Track designation is designed to aid in the development and to expedite the review of drug candidate applications
          that could potentially treat serious or life-threatening conditions. In order to receive Fast Track designation, a clinical candidate must also demonstrate the potential to address an unmet medical need. <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Companies with treatments</span> granted this designation are given the opportunity to have more frequent meetings with the FDA throughout the entire dug development and review process, with the goal
          of moving promising new drugs more rapidly through the process. It also provides the opportunity to submit sections of a Biologics License Application (the &#8220;BLA&#8221;) on a rolling basis, where the FDA may review portions of the <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">BLA</span> as they are received instead of waiting for the entire <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">BLA</span> submission. In
          addition, Fast Track designated products are eligible for priority review at the time BLA submission. In October 2022, we announced the successful end-of-phase 2 meeting with the FDA including guidance on key elements of the clinical program that
          will support the submission of a BLA.</div>

      </div>

      <div>
        <div><br />
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">
        <div style="text-align: justify; text-indent: 36pt;">In July 2022, we announced the presentation of universal flu vaccine preclinical data for PDS0202 at the 41<sup>st</sup> American Society of Virology meeting: Abstract number 3733830, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">Infectimune</span><sup style="color: #000000;">&#174;</sup> enhances antibodies elicited by COBRA hemagglutinin influenza vaccine.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In November 2022, we presented data from two Phase 2 clinical trials at the 37<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Annual Meeting for the Society of
        Immunotherapy of Cancer (SITC): Abstract number 674, IMMUNOCERV, an ongoing Phase 2 trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers and Abstract
        number 695, Immune correlates associated with clinical benefit in patients with checkpoint refractory HPV-positive malignancies treated with triple combination immunotherapy.</div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">18</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In December 2022, we executed an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor targeting antibody conjugated IL-12, M9241, which joined our pipeline as
        PDS0301. PDS0301 is a novel investigational tumor-targeting fusion protein of Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is therefore designed to overcome the
        limitations of cytokine therapy which today have resulted in high toxicity and limited therapeutic potential.&#160; The proprietary combination of Versamune plus PDS0301 is designed to overcome tumor immune suppression utilizing a different mechanism
        from immune checkpoint inhibitors (ICI). The ownership of both assets we believe will streamline the registrational process and its use.&#160; The <span style="color: #000000;">combination of Versamune&#174; and IL-12 to overcome immune suppression is
          patented by PDS Biotech</span><span style="color: #D13438;">.</span><span style="color: #000000;">&#160; In a Phase 2 National Cancer Institute (NCI)-led clinical trial in ICI refractory patients, the combination of PDS0101 and PDS0301 administered
          with an investigational bi-functional ICI resulted in a median overall survival of 21 months, which compares favorably to the historical median survival of 3-4 months reported in ICI refractory HPV-positive cancers when treated with ICIs and best
          reported median survival to date with systemic therapy of 8.2 months in ICI refractory head and neck cancer.</span></div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In February 2023, we announced a successful completion of a Type B meeting with the FDA for the triple combination of PDS0101 and PDS0301 with an FDA-approved immune checkpoint
        inhibitor for the treatment of recurrent/metastatic, ICI refractory head and neck cancer that is positive for the human papilloma virus (HPV) type 16. In recent interactions with the FDA, we confirmed the required contents of a clinical protocol
        for the potential registrational trial.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In June 2023, an abstract was presented at the 2023 American Society of Clinical Oncology: Abstract number 6012, Safety and Efficacy of Immune Checkpoint Inhibitor (ICI) Na&#239;ve Cohort from Study of
        PDS0101 and Pembrolizumab in HPV16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC). The abstract was also selected as one of the featured posters to be reviewed by an expert panel in the Head and Neck Cancer discussion session.</div>

      <div><br />
      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;"><span style="text-decoration: underline;">Clinical Candidate Pipeline</span></div>

      <div><br />
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic;">VERSATILE-002: PDS0101 + KEYTRUDA&#174;</div>

      <div><br />
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt;">In November 2020, our VERSATILE-002 Phase 2 clinical trial evaluating the combination of PDS0101 in combination with Merck&#8217;s anti-PD-1 therapy, KEYTRUDA&#174; (pembrolizumab) which is the FDA-approved
          standard of care for first-line treatment of recurrent/ metastatic head and neck cancer commenced.&#160; Enrollment in stage 2 of 2 for the ICI na&#239;ve arm and the ICI refractory arms are&#160;&#160; complete. The clinical trial will evaluate the efficacy and
          safety of this therapeutic combination as a first- and second line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In this PDS Biotech-sponsored trial patients whose cancer has returned following initial treatment or spread will be treated with the combination of PDS0101 and KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> to evaluate if the addition of PDS0101 might improve the efficacy reported in published studies of KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
        alone. Patients in the trial will receive a total of 5 cycles of combination therapy in the context of standard of care KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> therapy administered every three
        weeks until disease progression. The primary endpoint of VERSATILE-002 is the objective response rate&#8211; or ORR &#8211; at six months following initiation of treatment.<span style="color: #000000;"> There are two </span>cohorts in the trial. Cohort 1 is
        for patients who have yet to be treated with an immune checkpoint inhibitor (ICI na&#239;ve) and cohort 2 which consists of patients who have failed immune checkpoint inhibitor therapy (ICI refractory).</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In February 2022, we achieved the preliminary efficacy milestone of at least four or more objective responses of the first 17 patients in the ICI na&#239;ve arm that allowed that arm to proceed to full
        enrollment. We also announced detailed preliminary safety data which showed that the combination is well tolerated without evidence of enhanced or significant toxicity in the first 18 patients in the ICI na&#239;ve arm. <span style="color: #000000;">We
          have completed enrollment in Stage 1 of the ICI refractory arm and we are waiting for sufficient follow up to conduct the futility analysis</span>.</div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">19</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In June 2022, we presented additional preliminary efficacy and safety data from this trial at the ASCO Annual Meeting <span style="color: #000000;">(Weiss J et al. J Clin Oncol 40, 2022 (suppl 16;
          abstr 6041)</span>. The abstract provided preliminary data on 19 patients (safety) with available imaging data for 17 of the 19 patients (efficacy). Highlights from the abstract were as follows:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Confirmed and unconfirmed response rates thus far (tumor shrinkage greater than 30%) seen in 7/17 (41.2%) patients in comparison to the published results of approximately 19% for approved ICIs, used as monotherapy for recurrent or
                metastatic head and neck cancer, with 2 of the 7 having complete responses (CR)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Stable disease (SD) was reported in 6/17 (35.3%) patients, with 4 of the 6 (67%) experiencing tumor shrinkage of less than 30%</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Clinical efficacy (ORR + SD) was seen in 13/17 (76.5%) patients</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Progressive/ongoing disease was reported in 4/17 (23.5%) patients</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Patients had received a median of 4/5 doses of PDS0101 (range 1-5) and 9/35 doses of KEYTRUDA&#174; (range 1-18)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>There were no treatment-related adverse events greater than or equal to Grade 3 (N=19)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>No patients required dose interruption or reduction on the combination treatment</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>No patients discontinued the combination treatment</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>At 9 months of follow up (median not yet achieved):</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 53.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Progression free survival (PFS) rate was 55.2%</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 53.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Overall survival (OS) rate was 87.2%</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.3pt;"><br />
            </td>

    <td style="width: 18.7pt; vertical-align: top;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>no control or comparative studies have been conducted between ICIs and PDS0101</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In May 2022, we expanded this trial into Europe and in June 2022, as described above, we received Fast Track designation from the US FDA for PDS0101 in combination with pembrolizumab.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In August 2022, our independent Data Monitoring Committee (DMC) met and evaluated data from 43 patients and noted there were no Grade 3 or greater treatment-related adverse events attributed to the
        combination. The DMC recommended continuing the trial with no modifications.</div>

      <div><br />
      </div>

      <div>
        <div>
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2022, we announced the results of an end-of-phase 2 meeting with the FDA for PDS0101 in combination with KEYTRUDA<sup>&#174;</sup>.
            We have completed <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">the plan for </span> the Phase 3 clinical program that will support the submission of a <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">BLA</span> for PDS0101<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and have submitted</span> to the FDA<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>

          <div><br />
          </div>

          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2022, we completed the first stage of enrollment in the ICI refractory arm. Cohort follow-up is in
            progress that will permit a futility analysis to determine progression to stage 2 enrollment<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> is in progress</span>.</div>

          <div><br />
          </div>

          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In May 2023, we completed enrollment in the ICI na&#239;ve arm. We <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">filed our</span> amended IND with the FDA<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in the third quarter of 2023</span> and plan to initiate a phase 3 trial for ICI&#160;
            (VERSATILE-003) in the fourth quarter of 2023.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div>
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">In </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">June</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"> 2023, </span>an abstract was presented at the 2023 American Society of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Clinical</span> Oncology: Abstract number 6012, Safety and Efficacy of Immune Checkpoint Inhibitor (ICI) Na&#239;ve Cohort from Study of PDS0101 and Pembrolizumab in
              HPV16-Positive Head and Neck Squamous Cell Carcinoma (HNSCC). The abstract was also selected as one of the featured posters to be reviewed by an <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">expert</span> panel
              in the Head and Neck Cancer discussion session. The data from the abstract is as follows:</div>

          </div>

        </div>

        <div><br />
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Estimated 12-month overall survival rate was 87.1%. Published results are 36-50% with approved ICIs used alone*.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Median progression-free survival was 10.4 months (95% CI 4.2, 15.3). Published results are median PFS of 2-3 months for approved ICIs when used as monotherapy in patients with similar PD-L1 levels*.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>A disease control rate (disease stabilization or tumor shrinkage) of 70.6% (24/34)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Confirmed and unconfirmed objective response rate is 41.2% (14/34 patients), which is identical to the preliminary response rate data PDS Biotech previously reported at ASCO 2022 (7/17 patients). To date these responses have been
                confirmed in nine of the 34 patients (26.5%), including one complete response.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>15/34 patients (44.1%) had stable disease.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>9/34 patients (26.5%) had progressive disease.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>4/48 (8.3%) of patients had a Grade 3 treatment-related adverse event (TRAE). No Grade 4 or higher TRAEs were observed.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">20</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; font-style: italic;">National Cancer Institute: PDS0101+ M9241 (now PDS0301) +Bintrafusp Alfa</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In June 2020, the first patient was dosed under a PDS0101 Cooperative Research and Development Agreement (CRADA), in the NCI led Phase 2 investigator-initiated trial evaluating PDS0101 with an IgG1
        IL-12 (M9241), now PDS0301, and M7824 (Bintrafusp alfa), which is owned by EMD Serono (Merck KGaA) in patients with advanced/refractory HPV-positive cancers who have failed prior treatment. In February 2021, the NCI&#8217;s Phase 2 clinical trial of
        PDS0101 for the treatment of advanced/refractory HPV-positive cancers had achieved its preliminary objective response target in patients na&#239;ve to check point inhibitors which allowed for full enrollment of approximately 20 patients in this group.
        In addition, based on promising results in the ICI na&#239;ve arm, the trial was amended to allow enrollment of a separate cohort of ICI-refractory patients for assessment of safety and activity of the triple combination. Preliminary efficacy assessment
        of the triple combination in this added group of 20 ICI refractory patients has been completed and evaluation of long-term patient survival ongoing.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Preclinical study results arising from this CRADA were published in the Journal for ImmunoTherapy of Cancer,<span style="font-style: italic;"> Immunomodulation to enhance the efficacy of an HPV
          therapeutic vaccine (Journal for ImmunoTherapy of Cancer2020;8:e000612. doi:10.1136/ jitc-2020-000612)</span>, and indicate that PDS0101 generated both HPV-specific T cells and an associated antitumor response when used as a monotherapy. When
        PDS0101 was combined with the two other novel clinical-stage anti-cancer agents, Bintrafusp Alfa and M9241 (which is now owned by us and referred to as PDS0301), the preclinical data suggested that all three therapeutic agents worked
        synergistically to provide superior tumor T cell responses and subsequent tumor regression when compared to any of the agents alone or the 2-component combinations. The published preclinical data demonstrating powerful activity of the triple
        combination appears to be corroborated in the Phase 2 trial, and this triple combination could form the basis of a unique platform providing improved cancer treatments across multiple cancers.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In June 2022, at the 2022 ASCO Annual Meeting, the NCI provided an update to the preliminary data presented at the 2021 meeting (Strauss J et al. <span style="font-style: italic;">J
          Clin Oncol</span> 40, 2022 [suppl 16; abstr 2518]). This included data from 30 HPV16-positive patients and highlights were as follows:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Objective response (OR = <span style="text-decoration: underline;">&gt;</span>30% tumor reduction) was seen in 88% (7/8) of patients with ICI-naive disease; 4/7 (57%) patients&#8217; responses are ongoing (median 17 months).</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">With ICI refractory patients: PDS0301 dosing appears to affect response rates, with 5/8 (63%) patients receiving PDS0301 at 16.8 mcg/kg achieving an OR compared to 1/14 (7%) patients who received PDS0301 at 8
                mcg/kg achieving an OR; 4/6 (67%) patients&#8217; responses are ongoing (median 12 months).</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Tumor reduction was seen in 45% (10/22) of patients with ICI-refractory disease, including patients receiving high or low dose PDS0301.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">In ICI refractory patients treated with high or low dose PDS0301, survival outcomes were similar (p=0.96 by Kaplan Meier analysis). At a median of 12 months of follow up 17/22 (77%) of patients were alive.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">In ICI na&#239;ve patients 6/8 (75%) were alive at median 17 months of follow up.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Similar OR and survival were seen across all types of HPV16-positive cancers.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Preliminary safety data: 13/30 (43%) of patients experienced Grade 3 treatment-related adverse events (AEs), and 2/30 patients (7%) experienced Grade 4 AEs. There were no grade 5 treatment-related AEs.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">We believe the study results to date strongly suggest, in agreement with the published preclinical studies, that all 3 drugs contribute to the clinical outcomes.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">
        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2022, we determined, in agreement with the NCI, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">to select</span> the ICI refractory patients as the preferred treatment group in the on-going PDS0101-based triple combination therapy in advanced HPV-positive cancers and the trial was closed to further enrollment given
          the ICI refractory arm <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">had</span> been fully recruited.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In October 2022, we presented additional expanded interim data as follows:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Survival data:&#160; 66% (19/29) of HPV16-positive ICI refractory patients in the cohort were alive at a median follow up of 16 months.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Safety profile: 48% (24/50) patients experienced Grade 3 treatment-related adverse events (AEs), and 4% (2/50) patients experienced Grade 4 AEs. There were no Grade 3 treatment-related AEs.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">HPV16-positive ICI na&#239;ve patients: 75% (6/8) were alive at a median follow up of 25 months and 38% (3/8) of responders had a complete response.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">21</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In December 2022, we presented expanded interim data as follows:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">Median OS was 21 months in 29 checkpoint inhibitor refractory patients who received the triple combination. The reported historical median OS in patients with ICI refractory disease is
                3-4 months seen with checkpoint inhibitors and best reported median survival to date with systemic therapy of 8.2 months in ICI refractory head and neck cancer.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">In ICI na&#239;ve subjects, 75% remain alive at a median follow-up of 27 months.&#160; As a result, median OS had not yet been reached. Historically median OS for similar patients with platinum
                experienced ICI na&#239;ve disease is 7-11 months.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">Objective response rate (ORR) in ICI refractory patients who received the optimal dose of the triple combination is 63% (5/8).&#160; In current approaches ORR is reported to be less than 10%.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">ORR in ICI na&#239;ve patients with the triple combination is 88%. In current approaches ORR is reported to be less than 25% with FDA-approved ICIs in HPV-positive cancers.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">Safety data had not changed since October&#8217;s update. 48% (24/50) of patients experienced Grade 3 (moderate) treatment-related adverse events (AEs), and 4% (2/50) patients experienced Grade
                4 (severe) AEs, compared with approximately 70% of patients receiving the combination of ICIs and chemotherapy reporting Grade 3 and higher treatment-related AEs.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>
        <div style="text-align: justify; text-indent: 18pt; color: #000000;">In February 2023, we announced the successful completion of a Type B meeting with the FDA for the combination therapy of PDS0101, PDS0301, and an FDA-approved immune checkpoint
          inhibitor for the treatment of recurrent/metastatic HPV-positive ICI-refractory head and neck cancer. We confirmed the required contents of the trial design for a potential registrational trial of the combination.</div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;"> </span><br />
        </div>

      </div>

      <div>
        <div style="text-align: justify; color: #000000; font-style: italic;">MD Anderson Cancer Center (IMMUNOCERV): PDS0101+ Chemoradiotherapy</div>

      </div>

      <div>
        <div><br />
        </div>

      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0); text-align: justify;">
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In October 2020, another PDS0101 Phase 2 IIT was initiated with The University of Texas MD Anderson Cancer Center
          and is actively recruiting patients. This clinical trial is investigating the safety and anti-tumor efficacy of PDS0101 in combination with standard-of-care chemo-radiotherapy, or CRT, and their correlation with critical immunological biomarkers
          in patients with locally advanced cervical cancer. We believe that Versamune has strong T cell induction with the potential to enhance efficacy of the current standard of care CRT treatment in this indication<span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> with the FDA at this meeting</span>.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In November 2022, data from this trial was included in a poster presentation at the 2022 SITC Annual Meeting which included the following:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">9 of the 17 patients had completed a Day 170 post-treatment Positron Emission Tomography, Computed Tomography (PET CT) scan to assess the status of the cancer. This included 78% (7/9) of
                treated patients with advanced cervical cancer (FIGO stage III or IV).</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000;">100% (9/9) of patients treated with the combination of PDS0101 and CRT had an objective response.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); text-align: justify;">89% (8/9) of patients treated with the combination of PDS0101 and CRT demonstrated a complete response (CR) on Day 170 by PET CT. One patient who received 3 of the 5 scheduled doses of
                PDS0101 showed signs of residual disease. One patient who had a CR died from an event unrelated to either their underlying disease or treatment.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000;">1-year disease-free survival and 1-year overall survival of 89% (8/9) in patients treated with the combination of PDS0101 and CRT.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(32, 31, 30); text-align: justify;">As previously reported, data confirm PDS0101 treatment activates HPV16-specific CD8 T cells. This increase was not seen in patients who did not receive PDS0101. The increase in
                HPV16-specific T cells generated by the treatment is positively correlated with tumor cell death, suggesting cytotoxic CD8 T cells are important mediators of antigen-specific immunity.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(32, 31, 30); text-align: justify;">The data affirm that PDS0101 activates Type 1 interferon pathway in humans, mimicking the mechanism previously demonstrated in preclinical studies in animal models.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #201F1E;">Toxicity of PDS0101 remains limited to low-grade local injection site reactions.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic;">Mayo Clinic: PDS0101 Monotherapy and in combination with KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In February 2022, we initiated an Investigator-Initiated Trial (ITT), MC200710, for PDS0101 alone or in combination with the immune checkpoint inhibitor, KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, in patients with HPV-positive oropharyngeal cancer (HPV(+)OPSCC) at high risk of recurrence. The trial is being led by Drs. David Routman, Katharine Price, Kathryn Van
        Abel, and Ashish Chintakuntlawar at Mayo Clinic, a nationally and internationally recognized center of excellence for the treatment of head and neck cancers. We believe that this trial not only broadens our addressable patient population of those
        affected by the increasing incidence of HPV(+)OPSCC, but also allows us to better understand the activity of PDS0101 alone or in combination with KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in earlier
        stages of disease.&#160; This trial is currently open for enrollment.</div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">22</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In this trial, treatment will be administered before patients proceed to transoral robotic surgery (TORS) with curative intent. Treatment in this setting is referred to as
        neoadjuvant treatment. PDS0101 has been shown to induce killer T cells that target and kill HPV-positive cancers, either alone or in combination with ICIs in preclinical studies, and in combination in clinical studies of patients with advanced
        recurrent/metastatic HPV-positive cancers.&#160; This trial will explore whether PDS0101 with or without checkpoint inhibition may increase HPV-specific anti-tumor responses, potentially resulting in tumor shrinkage, pathologic regression, and decreases
        in circulating tumor DNA (ctDNA).</div>

      <div><br />
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic;">PDS0102</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">PDS0102 is an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) from the NCI. PDS0102
        is designed to treat TARP-associated cancers including, acute myeloid leukemia (AML), prostate and breast cancer. In our preclinical work, in the administration of PDS0102, the Versamuine+TARP antigen combination led to the induction of large
        numbers of tumor targeted killer T cells. In addition, the TARP tumor antigen alone has already been studied at the NCI in men with prostate cancer and been shown to be safe, immunogenic with slowing tumor growth rates (NCT00972309). We are
        evaluating the next steps in the clinical development of PDS0102 and are seeking nondilutive financings to move the program into clinical trials.</div>

      <div>
        <div><br />
        </div>

        <div style="text-align: justify; color: #000000; font-style: italic;">PDS0103</div>

        <div><br />
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">In April 2020, the above mentioned PDS Biotech-NCI CRADA was expanded beyond PDS0101 to include clinical and preclinical development of PDS0103. PDS0103 is an investigational immune therapy owned
        by PDS Biotech and designed to treat cancers associated with the mucin-1, or MUC1, oncogenic protein. These include cancers such as ovarian, breast, colorectal and lung cancers. PDS0103 combines Versamune with novel highly immunogenic agonist
        epitopes of MUC1 developed by the NCI and licensed by PDS. PDS0103 is currently in the tech transfer and clinical scale up and manufacturing stage.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MUC1 is highly expressed in several types of cancer and has been shown to be associated with drug resistance and poor disease
          prognosis in breast, colorectal, lung and ovarian cancers, for which PDS0103 is being developed. Expression of MUC1 is often associated with poor disease prognosis, due in part to drug resistance. In preclinical studies, and similarly to PDS0101,
          PDS0103 demonstrated the ability to generate powerful MUC1-specific CD8 killer T cells. In the first quarter of 2022, we held a pre-IND meeting with the FDA on PDS0103 and prepared to submit our IND package <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">by</span> the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">end</span> of 2023. However, the actual submission date may potentially be impacted by the allocation of
          resources to initiate the pivotal trial for PDS0101. Our primary goal is commercialization of PDS0101, and allocation of resources to implement an earlier than planned start of a registrational trial may delay PDS0103 initiation.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Our current pipeline of Versamune based therapies is as follows:</div>

      <div><br />
      </div>

      <div>
        <div style="text-align: center;"><img width="680" height="280" src="image00001.jpg" alt="graphic" /></div>

      </div>

      <div style="text-align: justify;"><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">23</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div>
        <div style="text-align: justify; font-style: italic;"><span style="text-decoration: underline;">IL-12 Oncology Immunocytokine Pipeline</span></div>

        <div><br />
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">PDS0301 (formerly known as NHS-IL-12 and M9241) is a novel investigational antibody conjugated (IgG1), tumor-targeting interleukin 12 (IL-12) immune-cytokine that enhances the
          proliferation, potency and longevity of T cells in the tumor microenvironment. Together with Versamune based immunotherapies PDS0301 works synergistically to overcome tumor immune suppression and to promote a targeted T cell attack against
          cancers. As with Versamune, PDS0301 is given by a simple subcutaneous injection. Clinical data suggests the addition of PDS0301 to Versamune based immunotherapies may demonstrate significant disease control in advanced cancer patients by
          shrinking tumors and/or prolonging life.</div>

      </div>

      <div>
        <div><br />
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt;">With the exclusive global license agreement with Merck KGaA, Darmstadt, Germany for PDS0301, we believe we have simplified our registrational pathway for the NCI-led triple combination by owning
          both PDS0101 and PDS0301 and combining these agents with an FDA approved ICI.&#160; PDS0301 has been designed to overcome the limitations of cytokine therapy as explained above, and based on extensive preclinical studies performed at the NCI
          evaluating PDS0301 as a monotherapy and also in combinations with established standard of care treatments for cancer, we believe that PDS0301 has significant potential as a cytokine therapy independent of Versamune.&#160; Based on the informative
          preclinical studies, a number of ITT Phase 2 trials are currently in progress at the NCI, some of which are outlined below:</div>

      </div>

      <div>
        <div><br />
        </div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Phase II Study Evaluating ICI Na&#239;ve and Refractory Patients with HPV-postive malignancies treated with PDS0301, PDS0101 and bintrafusp alfa.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine PDS0301in Localized High and Intermediate Risk Prostate Cancer Treated with Androgen Deprivation
                  Therapy</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>A Phase I/II Study of PDS0301 in Combination with Docetaxel in Adults with Metastatic Castration Sensitive and Castration Resistant Prostate Cancer</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Phase I/II of PDS0301 going forward as a Monotherapy in Advanced Kaposi Sarcoma</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Phase I/II of PDS0301 in Combination of with a Histone Deacetylase (HDAC) Inhibitor in ICI refractory MUC1-positive colon and bladder cancers among others</div>
              </td>

  </tr>


</table>
      </div>

      <div>
        <div><br />
        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt;">We are working closely with the NCI to determine the best pathway forward for the prioritized PDS0301 studies, as well as evaluating the use of PDS0301 in combination with other Versamune based
          clinical candidates.</div>

      </div>

      <div>
        <div><br />
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; font-style: italic;">Our current pipeline of antibody conjugated PDS0301 based therapies is as follows:</div>

      <div><br />
      </div>

      <div style="text-align: center;"><img width="680" height="274" src="image00002.jpg" alt="graphic" /></div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">24</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div>
        <div style="text-align: justify; font-style: italic;">Infectimune Development Strategy</div>

        <div><br />
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt;">We believe that the key differentiating attributes of the Infectimune platform technology are strong induction of CD8 and CD4 T cells as well as antibodies which can be leveraged to improve
        treatment and preventive options in several infectious disease indications. In January 2022, we presented preclinical data on our universal flu program sponsored by the National Institute of Allergy and Infectious Disease (NIAID) demonstrating the
        potential of the Infectimune technology with computationally designed influenza proteins developed by the laboratory of Dr. Ted Ross at the University of Georgia to generate broadly protective anti-influenza immune responses across multiple strains
        of influenza. This data has provided a unique opportunity to highlight Infectimune&#8217;s potentially transformative utility in the development of more broadly effective and longer lasting protective vaccines. Current preventive and prophylactic vaccine
        approaches and technologies predominantly focus on creating strong induction of antibody responses. However, the induction of T cell responses, in addition to antibody responses, provides more durable and broad protection against infectious
        diseases.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on the promising data with the universal seasonal flu vaccine and the current focus of the NIAID in developing more effective
          flu vaccines, we have decided to opportunistically focus our near-term infectious disease activities to align with the interests of the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. This will involve development of a
          universal seasonal flu vaccine and the potential development of a universal pandemic influenza vaccine based on similar computationally designed antigens as have shown promise with Infectimune.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">In July 2022, universal flu vaccine preclinical data for PDS0202 at the 41<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> American Society of Virology meeting:
        Abstract number 3733830, Infectimune enhances antibodies elicited by COBRA hemagglutinin influenza vaccine. We are evaluating the next steps in the clinical development and funding for PDS0202.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The results for Infectimune based vaccines were published in two separate articles in the peer reviewed journal <span style="font-style: italic;">Viruses</span> in February 2023:
        1. preclinical studies demonstrating complete protection against sickness after lethal challenge with live SARS-CoV-2 or influenza viruses (Gandhapudi SK et al. <span style="font-style: italic;">Viruses</span> 2023, <span style="font-style: italic;">15</span>, 432) and 2. Dramatically enhanced CD4 T cell responses to recombinant influenza proteins compared to leading commercial vaccine adjuvants (Henson TR et al. <span style="font-style: italic;">Viruses</span> 2023, <span style="font-style: italic;">15</span>, 538).</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">
        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have never been profitable and have incurred net losses in each year since inception. Our net losses were $21.2
          million, and $14.3 million for the six months June 30, 2023 and 2022, respectively. As of June 30, 2023, we had an accumulated deficit of $122.8 million. Substantially all of our net losses have resulted from costs incurred in connection with our
          research and development programs and from general and administrative costs associated with these operations.</div>

      </div>

      <div><br />
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">As of June 30, 2023, we had $60.6 million in cash and cash equivalents.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Our future funding requirements will depend on many factors, including the following:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the timing and costs of our planned clinical trials;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the timing and costs of our planned preclinical studies of our Versamune&#174; platform;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the outcome, timing and costs of seeking regulatory approvals;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may enter into;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the amount and timing of any payments we may be required to make in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or patent applications or other
                intellectual property rights; and</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the extent to which we license or acquire other products and technologies.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">25</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-weight: bold;">SELECTED FINANCIAL OPERATIONS OVERVIEW</div>

      <div><br />
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Revenue</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We have not generated any revenues from commercial product sales and do not expect to generate any such revenue in the near future. We may generate revenue in the future from a
        combination of research and development payments, license fees and other upfront payments or milestone payments.</div>

      <div><br />
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Research and development expenses include employee-related expenses, licensing fees to use certain technology in our research and development projects, costs of acquiring,
        developing and manufacturing clinical trial materials, as well as fees paid to consultants and various entities that perform certain research and testing on our behalf. Costs for certain development activities, such as clinical trials, are
        recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities are
        based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expenses. Costs incurred in connection with research and
        development activities are expensed as incurred.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We expect that our research and development expenses will increase significantly over the next several years as we advance our Versamune based immuno-oncology or Infectimune based
        infectious disease candidates into and through clinical trials, pursue regulatory approval of our investigational candidates and prepare for a possible commercial launch, all of which will also require a significant investment in contract and
        internal manufacturing and inventory related costs.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">
        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We
          may never succeed in achieving marketing approval. The probability of successful commercialization of our drug candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing
          capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any
          of our product candidates.</div>

      </div>

      <div><br />
      </div>

      <div style="color: #000000; font-weight: bold;"><span style="text-decoration: underline;">Results of Operations</span></div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: #000000;">The following table summarizes the results of our operations for the three months ended June 30, 2023 and 2022:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Three Months Ended</div>
              <div style="text-align: center; color: #000000;">June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Increase</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;"> 2023</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">2022</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">$ Amount</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">%</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
              <div style="text-align: center; color: #000000;">(in thousands)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Operating expenses:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Research and development expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">8,005</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">3,762</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">4,243</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">113</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">General and administrative expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">4,691</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">3,331</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">1,360</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">41</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Total operating expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">12,696</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">7,093</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">5,603</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">79</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss from operations</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(12,696</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(7,093</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(5,603</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">79</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest income (expense), net</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(245</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">75</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(320</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(427</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Benefit from income taxes</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">1,406</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">1,199</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">207</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">17</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net loss and comprehensive loss</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(11,535</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(5,819</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(5,716</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">98</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">
        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research and development (R&amp;D) expenses increased to $8.0 million <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">for the three months ended June 30, 2023</span> from $3.8 million <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">for the three months ended June 30, 2022</span>. The increase of $4.2
          million is primarily attributable to an increase of $1.4 million in clinical <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">trials</span>, $0.5 million in personnel costs, including $0.2 million in non-cash
          stock-based compensation and $2.3 million in manufacturing <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">expenses</span>.</div>

      </div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">26</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">General and Administrative Expenses</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">General and administrative expenses increased to $4.7 million for the three months ended June 30, 2023 from $3.3 million for the three months ended June 30, 2022. The increase of
        $1.4 million is primarily attributable to an increase of $0.5 million in personnel costs, including $0.4 million in non-cash stock-based compensation and $0.9 million in professional fees.</div>

      <div><br />
      </div>

      <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Benefit from Income Taxes</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="color: #000000;">Income tax benefit was $1.4 million for the three months ended June 30, 2023 and $1.2 million for the three months ended June 30, 2022. The increase of $0.2 million
          was due to an increase in the amount of </span>New Jersey NOL carryforwards<span style="color: #000000;"> sold when compared to the comparable period.</span></div>

      <div style="color: #000000; font-style: italic; font-weight: bold;"> <br />
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Comparison of the Six months June 30, 2023 and 2022</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The following table summarizes the results of our operations for the six months June 30, 2023 and 2022:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Six Months Ended</div>
              <div style="text-align: center; color: #000000;">June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Increase (Decrease)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;"> 2023</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">2022</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">$ Amount</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">%</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="6">
              <div style="text-align: center; color: #000000;">(in thousands)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Operating expenses:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Research and development expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">13,849</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">8,923</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">4,926</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">55</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">General and administrative expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">8,270</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">6,649</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">1,621</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1">
              <div style="color: #000000;">24</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Total operating expenses</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">22,119</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">15,572</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">6,547</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">42</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss from operations</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(22,119</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(15,572</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">(6,547</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: #000000;">42</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest income (expense), net</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(482</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">80</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(562</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(703</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Benefit from income taxes</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">1,406</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">1,199</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">207</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" colspan="1">
              <div style="color: #000000;">17</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net loss and comprehensive loss</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(21,195</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(14,293</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(6,902</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">48</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">%</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: rgb(0, 0, 0); text-align: justify;">
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Research and development (R&amp;D) expenses increased to $13.8 million for the six months June 30, 2023 from $8.9
          million <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">for the six months ended June 30, 2022</span>. The increase of $4.9 million was primarily attributable to an increase in personnel costs of $1.4 million,
          including $0.7 million in non-cash stock-based compensation, clinical <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">trials</span> of $1.6 million and manufacturing <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">expenses</span> of $1.9 million.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">General and Administrative Expenses</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">General and administrative expenses increased to $8.3 million for the six months June 30, 2023 from $6.6 million for the six months ended June 30, 2022. The increase of $1.6
        million was primarily attributable to an increase in personnel costs of $1.2 million, including $1.0 million in non-cash stock-based compensation and professional and legal costs of $0.4 million.</div>

      <div><br />
      </div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Benefit from Income Taxes</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">Income tax benefit was $1.4 million for the six months ended June 30, 2023 and $1.2 million for the six months ended June 30, 2022. The increase of $0.2 million
          was due to an increase in the amount of </span>New Jersey NOL carryforwards<span style="color: #000000;"> sold when compared to the comparable period.</span></div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">27</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-weight: bold;">Liquidity and Capital Resources</div>

      <div><br />
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In April 2022, we received approximately $1.2 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant our participation in the New
          Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2020.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In August 2022, we filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC for the issuance of common stock, preferred stock, warrants, rights,
        debt securities, and units, up to an aggregate amount of $150 million, $50 million of which covers the offer, issuance and sale by us of our common stock under the Sales Agreement (as discussed below).&#160; The 2022 Shelf Registration Statement was
        declared effective on September 2, 2022.</div>

      <div><br />
      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In August 2022, we entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the
          Agents, with respect to an at-the-market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $50 million, or the Placement Shares,
          through or to the Agents, as sales agents or principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an
          &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for our common stock. The Agents will
          use commercially reasonable efforts to sell the Placement Shares from time to time, based upon our instructions (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay the Agents a
          commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under the Sales Agreement, and also have provided the Agents with customary indemnification and contribution rights. We are not
          obligated to make any sales of our common stock under the Sales Agreement.&#160; The offering of Placement Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or
          (ii) termination of the Sales Agreement in accordance with its terms. For the year ended December 31, 2022, we sold 1,238,491 shares of our common stock with a net value of $9.9 million pursuant to the Sales Agreement. During the three and six
          months ended June 30, 2023, we sold 43,169 shares of our common stock with a net value of $0.2 million and 576,462 share of our common with a net value of $4.8 million, respectively, pursuant to the Sales Agreement.</div>

        <div><br />
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">
        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2022, we entered into a venture loan and security agreement, or the Loan and Security Agreement, with
            Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders.&#160; The Loan and Security Agreement provides for the following 6 separate and independent term loans: (a) a term loan in the amount of
            $7,500,000, or Loan A, (b) a term loan in the amount of $10,000,000, or Loan B, (c) a term loan in the amount of $3,750,000, or Loan C, (d) a term loan in the amount of $3,750,000, or Loan D, (e) a term loan in the amount of $5,000,000, or Loan
            E, and (f) a term loan in the amount of $5,000,000, or Loan F, (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and Loan F, individually a Loan and, collectively, the Loans).&#160; Loan A, Loan B, Loan C, and Loan D were delivered to us on
            August 24, 2022. Loan E and Loan F are uncommitted Loans that <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">could have been</span> advanced by the lenders upon <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">the Parties agreement</span> prior to July 31, 2023 upon the satisfaction of certain agreed upon conditions. The Parties are in discussion to extend this option, however, there is no guarantee that such an option
            will be extended on terms favorable to the Company or its existing stockholders, or at all. We may only use the proceeds of the Loans for working capital or general corporate purposes.&#160; Each Loan matures on the 48-month anniversary following
            the applicable funding date unless accelerated pursuant to agreed upon events of default. Payments on the principal balance begin on October 1, 2024 and are paid monthly in the succeeding 24 months. The principal balance of each Loan bears a
            floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) the per annum rate of interest from time to time published in The Wall Street Journal as contemplated by the Loan and Security
            Agreement, or any successor publication thereto, as the &#8220;prime rate&#8221; then in effect, plus (b) 5.75%; provided that, in the event such rate of interest is less than 4.00%, such rate shall be deemed to be 4.00% for purposes of calculating the
            interest rate.</div>

        </div>

      </div>

      <div>
        <div><br />
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Interest is payable on a monthly basis based on each Loan principal amount outstanding the preceding month.&#160; We, at our option upon at least ten (10) business days&#8217; written notice
        to the lenders, may prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an amount
        equal to (A) if such Loan is prepaid on or before the Loan Amortization Date (as defined in the Loan and Security Agreement) applicable to such Loan, 3% of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the
        Loan Amortization Date applicable to such Loan, but on or before the date that is 12 months after such Loan Amortization Date, 2% of the then outstanding principal balance of such Loan, or (C) if such Loan is prepaid more than 12 months after the
        Loan Amortization Date but prior to the stated maturity date applicable to such Loan, 1% of the then outstanding principal balance of such Loan; <span style="font-style: italic;">plus</span> (iii) the outstanding principal balance of such Loan; <span style="font-style: italic;">plus</span> (iv) all other sums, if any, that shall have become due and payable thereunder.&#160; No prepayment premium will be applied to any outstanding balance of any Loan paid on the stated maturity date.</div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">28</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div>
        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In connection with the Loan and Security Agreement, we issued Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP warrants to purchase an aggregate total of
          381,625 shares of our common stock at an initial exercise price of $3.6685 per share. Each warrant is classified as equity and is exercisable at any time for a period beginning on the date of grant and ending on the earlier of (A) 10 years from
          the date of grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the our property or business, or (ii) its merger into or consolidation with any other corporation (other
          than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of, in each case, for cash or
          for marketable securities meeting certain requirements as described in the applicable warrants.&#160; The key assumptions used in Black-Scholes option pricing model were (i) expected term of 10 years, (ii) a risk-free rate of 3.11%, (iii) expected
          volatility of 93.8%, and (iv) no estimated dividend yield.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;">In April 2023, we received approximately $1.4 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant our participation in the New
          Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2021.</div>

        <div style="text-align: justify; text-indent: 36pt; color: #000000;"> <br />
        </div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">As of June 30, 2023, we had $60.6 million in cash and cash equivalents. Our primary uses of cash are to fund operating expenses, primarily research and development expenditures.
        Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">
        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt
          about our ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q.&#160; Based on such evaluation and our current plans, which are subject to change, management believes that our existing cash and
          cash equivalents as of June 30, 2023 will be sufficient to satisfy our operating cash needs<span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> for 12 months following the filing of this Quarterly Report on Form 10-Q</span>.</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We plan to continue to fund our operations and capital funding needs through equity and/or debt financings. However, we cannot be certain that additional financing will be available
        when needed or that, if available, financing will be obtained on terms favorable to us or our existing stockholders. We may also enter into government funding programs and consider selectively partnering for clinical development and
        commercialization. The sale of additional equity would result in additional dilution to our stockholders. Incurring debt financing would result in debt service obligations, and the instruments governing such debt could provide for operating and
        financing covenants that would restrict our operations. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may be required to delay, limit, reduce, or terminate our clinical development or future
        commercialization efforts or grant rights to develop and market immunotherapies that we would otherwise prefer to develop and market ourselves. Any of these actions could harm our business, results of operations and prospects.</div>

      <div><br />
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Cash Flows</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; color: #000000;">The following table shows a summary of our cash flows for each of the periods indicated (in thousands):</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: #000000;">Six Months Ended June 30,</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;"> 2023</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: #000000;">2022</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
              <div>
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net cash used in operating activities</div>
              </div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(18,003</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(12,288</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net cash provided by financing activities</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">4,808</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: #000000;">30</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net increase in cash and cash equivalents</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(13,195</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: #000000;">(12,258</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: #000000;">)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="font-weight: bold;">Net Cash Used in Operating Activities</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">Net cash used in operating activities was $18.0 million and $12.3 million for the six months ended June 30, 2023 and 2022, respectively. The increase in net cash
          used in operating activities of $5.7 million was primarily </span>due to an increase in net loss of $6.9 million, reduced by the increase in the non-cash stock-based compensation expense of $2.0 million, offset by changes in the timing of
        working capital requirements, including changes in prepaid expenses and other assets, accrued expenses and accounts payable.</div>

      <div><br />
      </div>

      <div style="color: #000000; font-weight: bold;">Net Cash Provided by Financing Activities</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Net cash provided by financing activities for the six months ended June 30, 2023 was due to the receipt of net proceeds of $4.8 million due to the sale of common stock under the&#160;
        Sales Agreement.</div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">29</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Operating Capital Requirements</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To date, we have not generated any product revenue. We do not know when, or if, we will generate any product revenue
        and we do not expect to generate significant product revenue unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. We anticipate that we will continue to generate losses for the
        foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our vaccine candidates, and begin to commercialize any approved vaccine candidates. We are subject to all of the risks
        incident to the development of new products, and may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. We expect to incur additional costs associated with operating as a public
        company and anticipate that we will need substantial additional funding in connection with our continuing operations.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt
        about our ability to continue as a going concern within one year after the filing of this Quarterly Report. Our budgeted cash requirements in 2023 and beyond include expenses related to continuing development and clinical studies. We believe that
        our existing cash and cash equivalents as of June 30, 2023 are sufficient to continue operations and research and development programs <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for 12 months following</span> the
        <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">filing</span> of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">this Quarterly Report on Form 10-Q</span>. Until we can generate significant
        cash from our operations, we expect to continue to fund our operations with available financial resources. These financial resources may not be adequate to sustain our operations.</div>

      <div><span style="color: #000000;"> </span><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we
        expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding
        requirements will depend on many factors, including, but not limited to:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the initiation, progress, timing, costs and results of our planned clinical trials;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the effects of health epidemics, pandemics, or outbreaks of infectious diseases, on our business operations, financial condition, results of operations and cash flows;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the outcome, timing and cost of meeting regulatory requirements established by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory
                authorities;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us now or in the future;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the effect of competing technological and market developments;</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the cost of establishing sales, marketing and distribution capabilities in regions where we choose to commercialize our products on our own; and</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the initiation, progress, timing and results of our commercialization of our clinical candidates, if approved, for commercial sale.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Please see the section titled &#8220;Risk Factors&#8221; elsewhere in the Quarterly Report and Annual Report for additional risks associated with our operations.</div>

      <div><br />
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">Purchase Commitments</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We have no material non-cancelable purchase commitments with service providers as we have generally contracted on a cancelable, purchase order basis.</div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">30</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <div style="color: #000000; font-weight: bold;">Critical Accounting Policies and Estimates</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S.
        GAAP. Our accounting policies are more fully described in Note 2 to the consolidated financial statements included in this Quarterly Report on Form 10-Q.&#160; As described in Note 2, the preparation of these financial statements requires us to make
        estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred
        during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
        value of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ from these estimates under different assumptions or
        conditions. We believe that the discussion in our management&#8217;s discussion and analysis addresses our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations
        and require management&#8217;s most difficult, subjective and complex judgments.</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt;">There have been no material changes to our critical accounting policies and estimates during the six months ended June 30, 2023 from those disclosed in our Annual Report on Form 10-K for the year
        ended December 31, 2022.</div>

      <div><br />
      </div>

      <div style="text-align: justify; color: #000000; font-weight: bold;">Off-Balance Sheet Arrangements</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</div>

      <div><br />
      </div>

      <div style="color: #000000; font-weight: bold;">Smaller Reporting Company</div>

      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">As of January 1, 2021, we were no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. However, we remain a &#8220;smaller
        reporting company,&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We will cease to be a smaller reporting company if we have a non-affiliate public float in excess of $250 million and annual revenues in excess of
        $100 million, or a non-affiliate public float in excess of $700 million, determined on an annual basis. As a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to
        other public companies that are not smaller reporting companies. We will continue to take advantage of some or all of the available exemptions.</div>

      <div><br />
      </div>

      <a id="ITEM3"><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 3:</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>
        <div style="color: #000000; font-style: italic;">Interest Rate Risk</div>

        <div><span style="color: #000000;"> </span><br />
        </div>

      </div>

      <div>
        <div style="text-indent: 36pt; color: rgb(0, 0, 0); text-align: justify;">We are exposed to market risks in the ordinary course of our business and from changes in the interest rate on our debt borrowings. These market risks are principally limited
          to interest rate fluctuations. As of June 30, 2023, our cash equivalents consisted of bank deposits and money market accounts and our debt is a variable interest rate instrument. Our primary exposure to market risk is interest income sensitivity,
          which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal and liquidity while maximizing income without significantly increasing risk. We do not enter
          into investments for trading or speculative purposes. Due to the short-term nature of our investment portfolio and debt agreement, we do not believe an immediate 100 basis point increase in interest rates would have a material effect on the fair
          market value of our portfolio, and, accordingly, we do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates.</div>

      </div>

      <div>
        <div><span style="color: #000000;"> </span><br />
        </div>

        <div style="color: #000000; font-style: italic;">Inflation Risk</div>

        <div><span style="color: #000000;"> </span><br />
        </div>

      </div>

      <div>
        <div style="text-indent: 36pt; color: rgb(0, 0, 0); text-align: justify;">Inflation generally affects us by increasing our cost of labor and pricing of contracts. We do not believe that inflation has had a material effect on our business, financial
          condition, or results of operations during the three months ended June 30, 2023.</div>

      </div>

      <div><br />
      </div>

      <div style="font-weight: bold;">
        <a id="ITEM4"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 4:</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: #000000; font-weight: bold;">CONTROLS AND PROCEDURES<br />
                </div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-weight: bold;">
        <div>
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Evaluation of Disclosure Controls and Procedures</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div style="font-weight: normal;">
          <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">An evaluation was carried out, under the supervision of and with the participation of our management, including
            our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934, or the Exchange Act, as of the
            end of the period covered by this report. Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to
            be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</div>

        </div>

      </div>

      <div style="font-weight: bold;"> <br />
      </div>

      <div style="font-weight: bold;">Changes in Internal Control over Financial Reporting</div>

      <div><br />
      </div>

      <div style="text-indent: 36pt; text-align: justify;">There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation identified
        above that occurred during the quarter ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>

      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">31</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <a id="OTHERINFORMATION"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">PART II.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">OTHER INFORMATION</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <a id="LEGALPROCEEDINGS"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 1.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">LEGAL PROCEEDINGS</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The information in Note 9 to the Condensed Consolidated Financial Statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.
        There are no matters which constitute material pending legal proceedings to which we are a party other than those incorporated into this item by reference from Note 9 to our Condensed Consolidated Financial Statements for the quarter ended June 30,
        2023 contained in this Quarterly Report on Form 10-Q.</div>

      <div><br />
      </div>

      <a id="RISKFACTORS"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 1A.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">RISK FACTORS</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">There have been no material changes from our risk factors as previously reported in our Annual Report on Form 10-K for the year ended December 31, 2022. However, any investment in
        our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our unaudited interim condensed consolidated financial
        statements and accompanying notes, our Annual Report on Form 10-K for the year ended December 31, 2022 filed on March 28, 2023, including our financial statements and related notes contained therein, and the additional information in the other
        reports we file with the Securities and Exchange Commission. These risks may result in material harm to our business and our financial condition and results of operations. In this event, the market price of our common stock may decline and you
        could lose part or all of your investment.<span style="font-style: italic;">&#160;</span>Additional risks that we currently believe are immaterial may also impair our business operations. Our business, financial conditions and future prospects and the
        trading price of our common stock could be harmed as a result of any of these risks.</div>

      <div style="text-align: justify; text-indent: 36pt;"><br />
      </div>

      <a id="UNREGISTEREDSALESOFEQUITY"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 2.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">In April 2023, the Company entered into a consulting agreement with DC Consulting LLC pursuant to which DC Consulting LLC will provide the Company with certain management consulting
        services. The term of the consulting agreement commenced on April 12, 2023 and will terminate on October 10, 2023.&#160; In consideration for the services to be rendered under the consulting agreement, the Company agreed to pay DC Consulting LLC up to
        $100,000 in cash and issued DC Consulting LLC 100,000&#160; unregistered shares of the Company&#8217;s common stock having a fair value of approximately $659,000 on the date of issuance.</div>

      <div><br />
      </div>

      <a id="DEFAULTSUPONSENIORSECURIT"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 3.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">DEFAULTS UPON SENIOR SECURITIES</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-indent: 36pt; color: #000000;">None.</div>

      <div><br />
      </div>

      <a id="MINESAFETYDISCLOSURES"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 4.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">MINE SAFETY DISCLOSURES</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-indent: 36pt; color: #000000;">Not applicable.</div>

      <div><br />
      </div>

      <a id="ITEM5."><!--Anchor--></a>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 5.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">OTHER INFORMATION</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; color: #000000;">During the quarter ended June 30, 2023, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) <ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" id="Fact_3c223fd2197d4bb48e9b4a2fb383457a" contextRef="c20230401to20230630" format="ixt:fixed-false"><ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" id="Fact_0c9e33be4c1b4c6e97a6cd5dcc42424f" contextRef="c20230401to20230630" format="ixt:fixed-false">adopted</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" id="Fact_3e9cf043c3bf451abee910aed088a622" contextRef="c20230401to20230630" format="ixt:fixed-false"><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" id="Fact_27be61a61f9b4920a9793e636adc5f76" contextRef="c20230401to20230630" format="ixt:fixed-false">terminated</ix:nonNumeric></ix:nonNumeric> or modified
        a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).</div>

      <div><br />
      </div>

      <a id="EXHIBITS"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 6.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: #000000; font-weight: bold;">EXHIBITS</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">32</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <a id="EXHIBITINDEX"><!--Anchor--></a>
      <div style="text-align: center; color: #000000; font-weight: bold;">EXHIBIT INDEX</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9.27%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; font-weight: bold;">Number</div>
            </td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Exhibit Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036123034826/brhc20055890_ex10-1.htm">10.1+</a></div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and
                Exchange Commission on July 17, 2023).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="brhc20057346_ex31-1.htm">31.1*</a></div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley
                Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="brhc20057346_ex31-2.htm">31.2*</a></div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley
                Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="brhc20057346_ex32-1.htm">32.1 *</a></div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;"><a href="brhc20057346_ex32-2.htm">32.2 *</a></div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.INS*</div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.SCH*</div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">XBRL Taxonomy Extension Schema Document</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.CAL*</div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">XBRL Taxonomy Extension Calculation Linkbase Document</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.DEF*</div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">XBRL Taxonomy Extension Definition Linkbase Document</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.LAB*</div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">XBRL Taxonomy Extension Label Linkbase Document</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">101.PRE*</div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">XBRL Taxonomy Extension Presentation Linkbase Document</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top;">&#160;</td>

    <td style="width: 1.42%; vertical-align: top;">&#160;</td>

    <td style="width: 90%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.27%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">104</div>
            </td>

    <td style="width: 1.42%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; margin-right: 4.5pt;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Filed herewith (unless otherwise noted as being furnished herewith)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: #000000;">+</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">Indicates management compensatory plan or arrangement.</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageFooter" style="width: 100%;"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">33</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="font-style: italic; font-size: 8pt; text-transform: capitalize; text-align: left;"> <a href="#INDEX">Index</a><a href="#INDEX"><br />
              </a></div>

          </div>

        </div>

      </div>

      <a id="SIGNATURES"><!--Anchor--></a>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>

      <div><br />
      </div>

      <div style="text-align: justify;">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="2">
              <div>PDS Biotechnology Corporation</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">August 14, 2023</div>
            </td>

    <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>

    <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Frank Bedu-Addo</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Frank Bedu-Addo</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>President and Chief Executive Officer</div>
              <div>(Principal Executive Officer)</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">August 14, 2023</div>
            </td>

    <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>

    <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ <span style="color: #000000;">Matthew Hill</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div style="color: #000000;">Matthew Hill</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>Chief Financial Officer</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 47%; vertical-align: top;">
              <div>(Principal Financial and Accounting Officer)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div><br />
      </div>

      <div>
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">34</span></div>

      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>


  </div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>brhc20057346_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 31.1</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div><font style="color: #000000;">I, </font>Frank Bedu-Addo<font style="color: #000000;">, certify that:</font></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended June 30, 2023;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
              statements were made, not misleading with respect to the period covered by this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
              and cash flows of the registrant as of, and for, the periods presented in this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
              over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18.2pt;"><br>
          </td>
          <td style="width: 17.8pt; vertical-align: top; color: #000000;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
              consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18.2pt;"><br>
          </td>
          <td style="width: 17.8pt; vertical-align: top; color: #000000;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
              financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18.2pt;"><br>
          </td>
          <td style="width: 17.8pt; vertical-align: top; color: #000000;">c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
              period covered by this report based on such evaluation; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18.2pt;"><br>
          </td>
          <td style="width: 17.8pt; vertical-align: top; color: #000000;">d)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably
              likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the
              registrant's board of directors (or persons performing the equivalent functions):</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record,
              process, summarize and report financial information; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.21%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Dated: August 14, 2023</div>
          </td>
          <td style="width: 29.86%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000;">/s/ Frank Bedu-Addo</div>
          </td>
          <td style="width: 19.93%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 29.86%; vertical-align: top;">
            <div style="text-align: center;">Frank Bedu-Addo</div>
          </td>
          <td style="width: 19.93%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 29.86%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000;">President and Chief Executive Officer</div>
          </td>
          <td style="width: 19.93%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 29.86%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000;">(Principal Executive Officer)</div>
          </td>
          <td style="width: 19.93%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>brhc20057346_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 31.2</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO SECTION 302</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div style="color: #000000;">I, Matthew Hill, certify that:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: rgb(0, 0, 0);">I have reviewed this Quarterly Report on Form 10-Q of PDS Biotechnology Corporation for the period ended June 30, 2023;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
              statements were made, not misleading with respect to the period covered by this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
              and cash flows of the registrant as of, and for, the periods presented in this report;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
              over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
              consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
              financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
              period covered by this report based on such evaluation; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">d)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably
              likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: #000000;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the
              registrant's board of directors (or persons performing the equivalent functions):</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record,
              process, summarize and report financial information; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.21%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Dated: August 14, 2023</div>
          </td>
          <td style="width: 30%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000;">/s/ Matthew Hill</div>
          </td>
          <td style="width: 19.79%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center; color: #000000;">Matthew Hill</div>
          </td>
          <td style="width: 19.79%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000;">Chief Financial Officer</div>
          </td>
          <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000;">(Principal Financial and Accounting Officer)</div>
          </td>
          <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>brhc20057346_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 32.1</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="color: #000000;">In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended </font><font style="color: rgb(0, 0, 0);">June 30, 2023 (the &#8220;Report&#8221;), I, </font>Frank Bedu-Addo<font style="color: #000000;">, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. &#167; 1350, as
          adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 that:</font></div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 54pt; vertical-align: top; color: #000000;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 54pt; vertical-align: top; color: #000000;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.8%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Dated: August 14, 2023</div>
          </td>
          <td style="width: 30.14%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; color: #000000;">/s/ Frank Bedu-Addo</div>
          </td>
          <td style="width: 20.06%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.8%; vertical-align: top;">&#160;</td>
          <td style="width: 30.14%; vertical-align: top;">
            <div style="text-align: center;">Frank Bedu-Addo</div>
          </td>
          <td style="width: 20.06%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.8%; vertical-align: top;">&#160;</td>
          <td style="width: 30.14%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000;">President and Chief Executive Officer</div>
          </td>
          <td style="width: 20.06%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.8%; vertical-align: top;">&#160;</td>
          <td style="width: 30.14%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000;">(Principal Executive Officer)</div>
          </td>
          <td style="width: 20.06%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>brhc20057346_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 32.2</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">CERTIFICATION</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO 18 U.S.C. SECTION 1350</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
    <div style="text-align: center; color: #000000; font-weight: bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div><br>
    </div>
    <div style="text-align: justify; color: #000000;">In connection with the accompanying Quarterly Report of PDS Biotechnology Corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended June 30, 2023 (the &#8220;Report&#8221;), I, Matthew Hill, Chief
        Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 that:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 54pt; vertical-align: top; color: #000000;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 54pt; vertical-align: top; color: #000000;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.21%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Dated: August 14, 2023</div>
          </td>
          <td style="width: 30%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center;"><font style="color: #000000;">/s/ Matthew Hill</font></div>
          </td>
          <td style="width: 19.79%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center; color: #000000;">Matthew Hill</div>
          </td>
          <td style="width: 19.79%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000;">Chief Financial Officer</div>
          </td>
          <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.21%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: bottom;">
            <div style="text-align: center; color: #000000;">(Principal Financial and Accounting Officer)</div>
          </td>
          <td style="width: 19.79%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pdsb-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.7.1.5162 Broadridge-->
<xs:schema targetNamespace="http://pdsbiotech.com/20230630" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:pdsb="http://pdsbiotech.com/20230630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: Condensed Consolidated Balance Sheets-->
        <link:definition>010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/NatureOfOperations" id="NatureOfOperations">
        <link:definition>060100 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/Liquidity" id="Liquidity">
        <link:definition>060300 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>060400 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/Leases" id="Leases">
        <link:definition>060500 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>060600 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>060700 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>060800 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>060900 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" id="VentureLoanAndSecurityAgreement">
        <link:definition>061000 - Disclosure - Venture Loan and Security Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/RetirementPlan" id="RetirementPlan">
        <link:definition>061100 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/InsiderTradingArrangements" id="InsiderTradingArrangements">
        <link:definition>061200 - Disclosure - Insider Trading Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>080400 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LeasesTables" id="LeasesTables">
        <!--Parent Role: Leases-->
        <link:definition>080500 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>080600 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>080700 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <!--Parent Role: Summary of Significant Accounting Policies-->
        <link:definition>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LiquidityDetails" id="LiquidityDetails">
        <!--Parent Role: Liquidity-->
        <link:definition>090300 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" id="FairValueOfFinancialInstrumentsDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090400 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails" id="LeasesOperatingLeaseDetails">
        <!--Parent Role: Leases-->
        <link:definition>090500 - Disclosure - Leases, Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails" id="LeasesFinancingLeaseDetails">
        <!--Parent Role: Leases-->
        <link:definition>090510 - Disclosure - Leases, Financing Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>090600 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" id="StockbasedCompensationEquityCompensationPlansDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" id="StockbasedCompensationStockbasedCompensationExpenseDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" id="StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" id="StockbasedCompensationStockOptionActivityDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090800 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>090900 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails" id="VentureLoanAndSecurityAgreementDetails">
        <!--Parent Role: Venture Loan and Security Agreement-->
        <link:definition>091000 - Disclosure - Venture Loan and Security Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pdsbiotech.com/role/RetirementPlanDetails" id="RetirementPlanDetails">
        <!--Parent Role: Retirement Plan-->
        <link:definition>091100 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xs:element name="AccruedResearchAndDevelopmentCostsCurrent" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PercentageOfCommonStockOutstanding" id="pdsb_PercentageOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EquityCompensationPlansMember" id="pdsb_EquityCompensationPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2014Member" id="pdsb_EquityIncentivePlan2014Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InducementPlan2019Member" id="pdsb_InducementPlan2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2018Member" id="pdsb_EquityIncentivePlan2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncentiveStockOptionsMember" id="pdsb_IncentiveStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentPrepaymentPremiumPeriod4" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod4" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentNumberOfIndependentTermLoans" id="pdsb_DebtInstrumentNumberOfIndependentTermLoans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="DebtInstrumentPrepaymentPremiumPeriod1" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod1" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentWrittenNoticePeriodForPrepayment" id="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TermLoansMember" id="pdsb_TermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanFMember" id="pdsb_LoanFMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanCMember" id="pdsb_LoanCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanDMember" id="pdsb_LoanDMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanAMember" id="pdsb_LoanAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LoanBMember" id="pdsb_LoanBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentPrepaymentPremiumPeriod3" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod3" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentVariableRate" id="pdsb_DebtInstrumentVariableRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentPrepaymentPremiumPeriod2" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod2" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LoanEMember" id="pdsb_LoanEMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfVotingPowerDisposedOff" id="pdsb_PercentageOfVotingPowerDisposedOff" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentThresholdPeriod" id="pdsb_DebtInstrumentThresholdPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LiabilityForUncertainTaxPositions" id="pdsb_LiabilityForUncertainTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" id="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LesseeFinanceLeaseNumberOfLeases" id="pdsb_LesseeFinanceLeaseNumberOfLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LesseeFinanceLeaseMonthlyRentalExpense" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="FinanceLeaseCost" id="pdsb_FinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="FinanceLeasePrincipalAndInterestPayments" id="pdsb_FinanceLeasePrincipalAndInterestPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" id="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LiquidityAbstract" id="pdsb_LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommissionPercentage" id="pdsb_CommissionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlacementSharesAvailableForFutureSale" id="pdsb_PlacementSharesAvailableForFutureSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ShelfRegistrationStatementAvailableForFutureSale" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" id="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" id="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="RoyaltyPercentagePaidOnNetSalesOfProduct" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TermOfRoyaltyPayment" id="pdsb_TermOfRoyaltyPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="MilestonePaymentsDevelopmentAndFirstCommercialSales" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="MerckKGaALicenseAgreementMember" id="pdsb_MerckKGaALicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pdsb-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.7.1.5162 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LeasesFinancingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LeasesOperatingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="FinanceLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to FinanceLeaseLiabilityCurrent" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="FinanceLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to FinanceLeaseLiabilityNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="SecuredLongTermDebt" xlink:title="calculation: Liabilities to SecuredLongTermDebt" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="FinanceLeaseRightOfUseAsset" xlink:title="FinanceLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="FinanceLeaseRightOfUseAsset" xlink:title="calculation: Assets to FinanceLeaseRightOfUseAsset" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: InterestIncomeExpenseNonoperatingNet to InvestmentIncomeInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="InterestExpense" xlink:title="calculation: InterestIncomeExpenseNonoperatingNet to InterestExpense" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="InterestIncomeExpenseNonoperatingNet" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to InterestIncomeExpenseNonoperatingNet" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="FinanceLeaseRightOfUseAssetAmortization" xlink:title="FinanceLeaseRightOfUseAssetAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="FinanceLeaseRightOfUseAssetAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to FinanceLeaseRightOfUseAssetAmortization" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="Depreciation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to Depreciation" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IssuanceOfStockAndWarrantsForServicesOrClaims" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseRightOfUseAssetAmortizationExpense" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOperatingLeaseLiability" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="17.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FinanceLeasePrincipalPayments" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FinanceLeasePrincipalPayments" order="16.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="15.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" xlink:title="FinanceLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityToBePaidYearFourAndThereafter" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsDueYearTwo" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: FinanceLeaseLiabilityPaymentsDue to FinanceLeaseLiabilityPaymentsDueYearThree" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrent" xlink:label="AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedRentCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedRentCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedResearchAndDevelopmentCostsCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="InterestPayableCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to InterestPayableCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="WorkersCompensationLiabilityCurrent" xlink:title="WorkersCompensationLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="WorkersCompensationLiabilityCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to WorkersCompensationLiabilityCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedProfessionalFeesCurrent" order="1.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pdsb-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.7.1.5162 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#RetirementPlanDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#VentureLoanAndSecurityAgreementDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationEquityCompensationPlansDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LeasesFinancingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LeasesOperatingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#FairValueOfFinancialInstrumentsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LiquidityDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LeasesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pdsb-20230630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlan" xlink:type="simple" xlink:href="pdsb-20230630.xsd#RetirementPlan" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" xlink:type="simple" xlink:href="pdsb-20230630.xsd#VentureLoanAndSecurityAgreement" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pdsb-20230630.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpenses" xlink:type="simple" xlink:href="pdsb-20230630.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/Leases" xlink:type="simple" xlink:href="pdsb-20230630.xsd#Leases" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="pdsb-20230630.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/Liquidity" xlink:type="simple" xlink:href="pdsb-20230630.xsd#Liquidity" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="pdsb-20230630.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/NatureOfOperations" xlink:type="simple" xlink:href="pdsb-20230630.xsd#NatureOfOperations" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="pdsb-20230630.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueIssuedForServices" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssues" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/NatureOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/Liquidity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/Leases" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpenses" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlan" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="BusinessCombinationConsiderationTransferredAbstract" xlink:title="definition: DebtInstrumentLineItems to BusinessCombinationConsiderationTransferredAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: DebtInstrumentLineItems to CashAndCashEquivalentsAtCarryingValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:label="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:label="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="ShelfRegistrationStatementAvailableForFutureSale" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="definition: DebtInstrumentLineItems to ShelfRegistrationStatementAvailableForFutureSale" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_PlacementSharesAvailableForFutureSale" xlink:label="PlacementSharesAvailableForFutureSale" xlink:title="PlacementSharesAvailableForFutureSale" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PlacementSharesAvailableForFutureSale" xlink:title="definition: DebtInstrumentLineItems to PlacementSharesAvailableForFutureSale" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_CommissionPercentage" xlink:label="CommissionPercentage" xlink:title="CommissionPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CommissionPercentage" xlink:title="definition: DebtInstrumentLineItems to CommissionPercentage" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: DebtInstrumentLineItems to StockIssuedDuringPeriodSharesNewIssues" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromIssuanceOfCommonStock" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentNumberOfIndependentTermLoans" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnusedBorrowingCapacityAmount" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTerm" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:label="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentBasisSpreadOnVariableRate1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentVariableRate" xlink:label="DebtInstrumentVariableRate" xlink:title="DebtInstrumentVariableRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentVariableRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentVariableRate" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentWrittenNoticePeriodForPrepayment" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod1" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentThresholdPeriod" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentThresholdPeriod" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod2" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod3" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod4" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="22.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="definition: DebtInstrumentNameDomain to TermLoansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanAMember" xlink:title="definition: TermLoansMember to LoanAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanBMember" xlink:title="definition: TermLoansMember to LoanBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanCMember" xlink:title="definition: TermLoansMember to LoanCMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanDMember" xlink:title="definition: TermLoansMember to LoanDMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanEMember" xlink:title="definition: TermLoansMember to LoanEMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanFMember" xlink:title="definition: TermLoansMember to LoanFMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="definition: DebtInstrumentTable to VariableRateAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain_2" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain_2" xlink:title="definition: VariableRateAxis to VariableRateDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="PrimeRateMember" xlink:title="PrimeRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="PrimeRateMember" xlink:title="definition: VariableRateDomain to PrimeRateMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to CashAndCashEquivalentsFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="LesseeFinanceLeaseDescriptionAbstract" xlink:title="LesseeFinanceLeaseDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseDescriptionAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:label="LesseeFinanceLeaseNumberOfLeases" xlink:title="LesseeFinanceLeaseNumberOfLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseNumberOfLeases" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseNumberOfLeases" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_FinanceLeaseCost" xlink:label="FinanceLeaseCost" xlink:title="FinanceLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="FinanceLeaseCost" xlink:title="definition: LesseeLeaseDescriptionLineItems to FinanceLeaseCost" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="LesseeFinanceLeaseTermOfContract1" xlink:title="LesseeFinanceLeaseTermOfContract1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseTermOfContract1" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseTermOfContract1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="LesseeFinanceLeaseDiscountRate" xlink:title="LesseeFinanceLeaseDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseDiscountRate" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseDiscountRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:label="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseMonthlyRentalExpense" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="PropertyPlantAndEquipmentAdditions" xlink:title="PropertyPlantAndEquipmentAdditions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="PropertyPlantAndEquipmentAdditions" xlink:title="definition: LesseeLeaseDescriptionLineItems to PropertyPlantAndEquipmentAdditions" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="definition: LesseeLeaseDescriptionTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_PercentageOfCommonStockOutstanding" xlink:label="PercentageOfCommonStockOutstanding" xlink:title="PercentageOfCommonStockOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PercentageOfCommonStockOutstanding" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PercentageOfCommonStockOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_EquityCompensationPlansMember" xlink:label="EquityCompensationPlansMember" xlink:title="EquityCompensationPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityCompensationPlansMember" xlink:title="definition: PlanNameDomain to EquityCompensationPlansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_EquityIncentivePlan2014Member" xlink:label="EquityIncentivePlan2014Member" xlink:title="EquityIncentivePlan2014Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityCompensationPlansMember" xlink:to="EquityIncentivePlan2014Member" xlink:title="definition: EquityCompensationPlansMember to EquityIncentivePlan2014Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_EquityIncentivePlan2018Member" xlink:label="EquityIncentivePlan2018Member" xlink:title="EquityIncentivePlan2018Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityCompensationPlansMember" xlink:to="EquityIncentivePlan2018Member" xlink:title="definition: EquityCompensationPlansMember to EquityIncentivePlan2018Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_InducementPlan2019Member" xlink:label="InducementPlan2019Member" xlink:title="InducementPlan2019Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityCompensationPlansMember" xlink:to="InducementPlan2019Member" xlink:title="definition: EquityCompensationPlansMember to InducementPlan2019Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeStockOptionMember" xlink:to="IncentiveStockOptionsMember" xlink:title="definition: EmployeeStockOptionMember to IncentiveStockOptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to SubsequentEventTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="26.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsAbstract" xlink:title="definition: OtherCommitmentsLineItems to OtherCommitmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="OperatingLeaseCost" xlink:title="definition: OtherCommitmentsLineItems to OperatingLeaseCost" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:label="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="definition: OtherCommitmentsLineItems to MilestonePaymentsDevelopmentAndFirstCommercialSales" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:label="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="definition: OtherCommitmentsLineItems to MilestonePaymentsAchievementOfCertainAggregateSalesLevels" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:label="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="definition: OtherCommitmentsLineItems to RoyaltyPercentagePaidOnNetSalesOfProduct" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_TermOfRoyaltyPayment" xlink:label="TermOfRoyaltyPayment" xlink:title="TermOfRoyaltyPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsLineItems" xlink:to="TermOfRoyaltyPayment" xlink:title="definition: OtherCommitmentsLineItems to TermOfRoyaltyPayment" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsTable" xlink:title="definition: OtherCommitmentsLineItems to OtherCommitmentsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsAxis" xlink:title="definition: OtherCommitmentsTable to OtherCommitmentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain" xlink:title="definition: OtherCommitmentsAxis to OtherCommitmentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain_2" xlink:title="OtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain_2" xlink:title="definition: OtherCommitmentsAxis to OtherCommitmentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_MerckKGaALicenseAgreementMember" xlink:label="MerckKGaALicenseAgreementMember" xlink:title="MerckKGaALicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OtherCommitmentsDomain" xlink:to="MerckKGaALicenseAgreementMember" xlink:title="definition: OtherCommitmentsDomain to MerckKGaALicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OtherCommitmentsTable" xlink:to="RangeAxis" xlink:title="definition: OtherCommitmentsTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentNumberOfIndependentTermLoans" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnusedBorrowingCapacityAmount" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTerm" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentBasisSpreadOnVariableRate1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentVariableRate" xlink:label="DebtInstrumentVariableRate" xlink:title="DebtInstrumentVariableRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentVariableRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentVariableRate" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentWrittenNoticePeriodForPrepayment" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentThresholdPeriod" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentThresholdPeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod2" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod3" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPrepaymentPremiumPeriod4" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="definition: DebtInstrumentLineItems to WarrantsAndRightsOutstandingTerm" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_PercentageOfVotingPowerDisposedOff" xlink:label="PercentageOfVotingPowerDisposedOff" xlink:title="PercentageOfVotingPowerDisposedOff" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PercentageOfVotingPowerDisposedOff" xlink:title="definition: DebtInstrumentLineItems to PercentageOfVotingPowerDisposedOff" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="definition: DebtInstrumentLineItems to WarrantsAndRightsOutstandingMeasurementInput" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="definition: DebtInstrumentLineItems to PaymentsOfDebtIssuanceCosts" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscount" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestExpenseDebt" xlink:title="definition: DebtInstrumentLineItems to InterestExpenseDebt" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="definition: DebtInstrumentLineItems to AmortizationOfDebtDiscountPremium" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="23.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="definition: DebtInstrumentNameDomain to TermLoansMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanAMember" xlink:title="definition: TermLoansMember to LoanAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanBMember" xlink:title="definition: TermLoansMember to LoanBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanCMember" xlink:title="definition: TermLoansMember to LoanCMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanDMember" xlink:title="definition: TermLoansMember to LoanDMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanEMember" xlink:title="definition: TermLoansMember to LoanEMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TermLoansMember" xlink:to="LoanFMember" xlink:title="definition: TermLoansMember to LoanFMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="definition: DebtInstrumentTable to VariableRateAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain_2" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain_2" xlink:title="definition: VariableRateAxis to VariableRateDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="PrimeRateMember" xlink:title="PrimeRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="PrimeRateMember" xlink:title="definition: VariableRateDomain to PrimeRateMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="MeasurementInputTypeAxis" xlink:title="definition: DebtInstrumentTable to MeasurementInputTypeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain_2" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain_2" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlanDetails" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pdsb-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.7.1.5162 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:label xlink:type="resource" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US" id="ecd_InsiderTradingArrLineItems_lbl">Insider Trading Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:title="label: InsiderTradingArrLineItems to ecd_InsiderTradingArrLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag_lbl">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag_lbl" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrAdoptedFlag_lbl1" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag_lbl1">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl1" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag_lbl">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag_lbl" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrTrmntdFlag_lbl1" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag_lbl1">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl1" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag_lbl">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag_lbl" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag_lbl1">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag_lbl">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag_lbl" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag_lbl1">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Depreciation_lbl" xml:lang="en-US" id="us-gaap_Depreciation_lbl">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl1" xml:lang="en-US" id="us-gaap_Depreciation_lbl1">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl1" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US" id="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl">Issuance of shares in consulting agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1" xml:lang="en-US" id="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1" xlink:title="label: IssuanceOfStockAndWarrantsForServicesOrClaims to us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">Condensed Consolidated Balance Sheets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl">Net loss per share, basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium_lbl">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl">Cash Equivalents and Concentration of Cash Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock, $0.00033 par value, 75,000,000 shares authorized at June 30, 2023 and December 31, 2022, 30,868,188 shares and 30,170,317 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl">Current income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock_lbl">Venture Loan and Security Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock_lbl1">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl1" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl">Face amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl1">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain_lbl">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl">Unamortized debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl">Uncommitted loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xlink:title="label: DebtInstrumentUnusedBorrowingCapacityAmount to us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1" xlink:title="label: DebtInstrumentUnusedBorrowingCapacityAmount to us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract_lbl">Venture Loan and Security Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract_lbl1">Debt Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl1" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis_lbl">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTable_lbl">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl">Debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1">Payments of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">Net loss per share, diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl">Federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl">Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl1">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl">Accrued interest and penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:title="label: IncomeTaxExaminationPenaltiesAndInterestAccrued to us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="us-gaap_InterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestExpense_lbl1">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" id="us-gaap_InterestExpenseDebt_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseDebt_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseDebt_lbl1">Interest Expense, Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl1" xlink:title="label: InterestExpenseDebt to us-gaap_InterestExpenseDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAbstract_lbl">LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:title="label: LiabilitiesAbstract to us-gaap_LiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAbstract_lbl1">Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl1" xlink:title="label: LiabilitiesAbstract to us-gaap_LiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl">Interest income (expenses), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrentAbstract_lbl">Noncurrent liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:title="label: LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesNoncurrentAbstract_lbl1">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl1" xlink:title="label: LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Proceeds from issuance of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecuredLongTermDebt_lbl" xml:lang="en-US" id="us-gaap_SecuredLongTermDebt_lbl">Note payable, net of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredLongTermDebt" xlink:to="us-gaap_SecuredLongTermDebt_lbl" xlink:title="label: SecuredLongTermDebt to us-gaap_SecuredLongTermDebt_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl">Number of shares authorized for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl">Shares available for grant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl">Fair value of option on grant date (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl">Options outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1">Options outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl">Options outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1">Options outstanding, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl">Exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl">Exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">Condensed Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Number of shares of common stock that can be purchased with warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">Supplemental information of cash and non-cash transactions:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits_lbl">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrants to Purchase Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl1" xml:lang="en-US" id="us-gaap_WarrantMember_lbl1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="PropertyPlantAndEquipmentAdditions" xlink:title="PropertyPlantAndEquipmentAdditions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAdditions_lbl">Recognition of property and equipment from bargain purchase option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xlink:title="label: PropertyPlantAndEquipmentAdditions to us-gaap_PropertyPlantAndEquipmentAdditions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAdditions_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAdditions_lbl1">Property, Plant and Equipment, Additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl1" xlink:title="label: PropertyPlantAndEquipmentAdditions to us-gaap_PropertyPlantAndEquipmentAdditions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl1">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest_lbl">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest_lbl1" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest_lbl1">Investment Income, Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl1" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl">Quoted Prices in Active Markets (Level 1) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl">Quoted Prices in Inactive Markets (Level 2) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl">Significant Unobservable Inputs (Level 3) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="FairValueByBalanceSheetGroupingTextBlock" xlink:title="FairValueByBalanceSheetGroupingTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:title="label: FairValueByBalanceSheetGroupingTextBlock to us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" xlink:title="label: FairValueByBalanceSheetGroupingTextBlock to us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl1" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Antidilutive impact to EPS (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl">Per share information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl">Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl">Net Loss per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl">Common stock reserved for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Equity, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl">Income tax benefit due to realization uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl">Benefit from income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Benefit for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl2">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EmployeeStockOptionMember_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl1">Stock Options to Purchase Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl1" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl2" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl2">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl2" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl">Forfeited and expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl">Forfeited and expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl">Patent Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl">Issuances of common stock from the Sales Agreement, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl">Issuances of common stock, from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl">Issuances of common stock from the Sales Agreement, net (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1">Issuance of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Issuances of common stock, from exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1">Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl">Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl">Vested and expected to vest (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl">Vested and expected to vest, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Assumptions Used in Determining Fair Value of Stock Options and Warrants Granted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl">Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" xlink:title="label: BusinessCombinationConsiderationTransferredAbstract to us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" xlink:title="label: BusinessCombinationConsiderationTransferredAbstract to us-gaap_BusinessCombinationConsiderationTransferredAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" id="us-gaap_LeasesAbstract_lbl">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" id="us-gaap_NatureOfOperations_lbl">Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:title="label: NatureOfOperations to us-gaap_NatureOfOperations_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl1">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl">Accrued professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl1">Accrued Professional Fees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrent" xlink:label="AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedRentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedRentCurrent_lbl">Accrued rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xlink:title="label: AccruedRentCurrent to us-gaap_AccruedRentCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_InterestPayableCurrent_lbl">Accrued interest on debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:title="label: InterestPayableCurrent to us-gaap_InterestPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="WorkersCompensationLiabilityCurrent" xlink:title="WorkersCompensationLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_WorkersCompensationLiabilityCurrent_lbl">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:title="label: WorkersCompensationLiabilityCurrent to us-gaap_WorkersCompensationLiabilityCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl">Stock based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl">Transfers into Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl">Transfers out of Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl">Interest income (expenses), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:title="label: InterestIncomeExpenseNonoperatingNet to us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xml:lang="en-US" id="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" xlink:title="label: InterestIncomeExpenseNonoperatingNet to us-gaap_InterestIncomeExpenseNonoperatingNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract_lbl">Accrued Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">Nature of Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl">Accrued Expenses and Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract_lbl">Fair Value of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract_lbl">Venture Loan and Security Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl">Retirement Plan [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:title="label: CompensationAndRetirementDisclosureAbstract to us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl">Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl">Assumptions Used to Value Stock Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract_lbl">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_lbl">Fair Value Transfers Between Levels [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl">Exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl">Unaudited Interim Financial Statements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl">401(k) employer contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl">Unamortized stock compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl">Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl">Unamortized Stock Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl">Issuance of common stock for consulting agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xlink:title="label: StockIssuedDuringPeriodValueIssuedForServices to us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl">Shares issued for consulting services (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1">Issuance of common stock for consulting agreement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl">Options outstanding, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl">Exercisable, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl">Vested and expected to vest, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl">Period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" id="us-gaap_AreaOfRealEstateProperty_lbl">Area of office space under sublease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xlink:title="label: AreaOfRealEstateProperty to us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AreaOfRealEstateProperty_lbl1" xml:lang="en-US" id="us-gaap_AreaOfRealEstateProperty_lbl1">Area of Real Estate Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl1" xlink:title="label: AreaOfRealEstateProperty to us-gaap_AreaOfRealEstateProperty_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl">Margin on variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:title="label: DebtInstrumentBasisSpreadOnVariableRate1 to us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1" xlink:title="label: DebtInstrumentBasisSpreadOnVariableRate1 to us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract_lbl">Fair Value of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1">Fair Value, Net Asset (Liability) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" id="us-gaap_OtherCommitmentsTable_lbl">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:title="label: OtherCommitmentsTable to us-gaap_OtherCommitmentsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US" id="us-gaap_OtherCommitmentsAxis_lbl">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:title="label: OtherCommitmentsAxis to us-gaap_OtherCommitmentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" id="us-gaap_OtherCommitmentsDomain_lbl">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" xlink:title="label: OtherCommitmentsDomain to us-gaap_OtherCommitmentsDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" id="us-gaap_OtherCommitmentsLineItems_lbl">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:title="label: OtherCommitmentsLineItems to us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherCommitmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherCommitmentsAbstract_lbl">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract_lbl" xlink:title="label: OtherCommitmentsAbstract to us-gaap_OtherCommitmentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCommitmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_OtherCommitmentsAbstract_lbl1">Other Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract_lbl1" xlink:title="label: OtherCommitmentsAbstract to us-gaap_OtherCommitmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl">Term of option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTerm_lbl">Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:title="label: DebtInstrumentTerm to us-gaap_DebtInstrumentTerm_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="us-gaap_VariableRateAxis_lbl">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:title="label: VariableRateAxis to us-gaap_VariableRateAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="us-gaap_VariableRateDomain_lbl">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xlink:title="label: VariableRateDomain to us-gaap_VariableRateDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="PrimeRateMember" xlink:title="PrimeRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrimeRateMember_lbl" xml:lang="en-US" id="us-gaap_PrimeRateMember_lbl">Prime Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:title="label: PrimeRateMember to us-gaap_PrimeRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Exercise price of warrants (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="SubstantialDoubtAboutGoingConcernTextBlock" xlink:title="SubstantialDoubtAboutGoingConcernTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US" id="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl">Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:title="label: SubstantialDoubtAboutGoingConcernTextBlock to us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl1">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl1" xlink:title="label: SubstantialDoubtAboutGoingConcernTextBlock to us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseCost_lbl">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl">Future Payments for Finance Lease Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:title="label: FinanceLeaseLiabilitiesPaymentsDueAbstract to us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="CashFlowOperatingActivitiesLesseeAbstract" xlink:title="CashFlowOperatingActivitiesLesseeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xml:lang="en-US" id="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl">Supplemental Cash Flow Information Related to Operating Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:title="label: CashFlowOperatingActivitiesLesseeAbstract to us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:label="CashFlowFinancingActivitiesLesseeAbstract" xlink:title="CashFlowFinancingActivitiesLesseeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowFinancingActivitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowFinancingActivitiesLesseeAbstract_lbl" xml:lang="en-US" id="us-gaap_CashFlowFinancingActivitiesLesseeAbstract_lbl">Supplemental Cash Flow Information Related to Finance Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowFinancingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowFinancingActivitiesLesseeAbstract_lbl" xlink:title="label: CashFlowFinancingActivitiesLesseeAbstract to us-gaap_CashFlowFinancingActivitiesLesseeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="FinanceLeaseRightOfUseAsset" xlink:title="FinanceLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseRightOfUseAsset_lbl">Financing lease right-to-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:title="label: FinanceLeaseRightOfUseAsset to us-gaap_FinanceLeaseRightOfUseAsset_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl">Operating lease right-to-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl1">Right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl">Future Payments for Operating Lease Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDiscountRate_lbl">Discount rate used to measure operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:title="label: LesseeOperatingLeaseDiscountRate to us-gaap_LesseeOperatingLeaseDiscountRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDiscountRate_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDiscountRate_lbl1">Lessee, Operating Lease, Discount Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl1" xlink:title="label: LesseeOperatingLeaseDiscountRate to us-gaap_LesseeOperatingLeaseDiscountRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="LesseeFinanceLeaseDiscountRate" xlink:title="LesseeFinanceLeaseDiscountRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseDiscountRate_lbl">Finance lease liability capitalized interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xlink:title="label: LesseeFinanceLeaseDiscountRate to us-gaap_LesseeFinanceLeaseDiscountRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionTable_lbl">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:title="label: LesseeLeaseDescriptionTable to us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionLineItems_lbl">Lessee, Lease, Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:title="label: LesseeLeaseDescriptionLineItems to us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl">Operating Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:title="label: LesseeOperatingLeaseDescriptionAbstract to us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1" xlink:title="label: LesseeOperatingLeaseDescriptionAbstract to us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="LesseeFinanceLeaseDescriptionAbstract" xlink:title="LesseeFinanceLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl">Financing Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xlink:title="label: LesseeFinanceLeaseDescriptionAbstract to us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1">Lessee, Finance Lease, Description [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" xlink:title="label: LesseeFinanceLeaseDescriptionAbstract to us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1">Cash and cash equivalents at the end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl">Cash paid for operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl">Payments of finance lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl1">Finance Lease, Principal Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl">Future Payments for Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="FinanceLeaseRightOfUseAssetAmortization" xlink:title="FinanceLeaseRightOfUseAssetAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl">Finance lease depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:title="label: FinanceLeaseRightOfUseAssetAmortization to us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" xlink:title="label: FinanceLeaseRightOfUseAssetAmortization to us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" xlink:title="FinanceLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiability_lbl">Remaining lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:title="label: FinanceLeaseLiability to us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiability_lbl1">Finance Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl1" xlink:title="label: FinanceLeaseLiability to us-gaap_FinanceLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityCurrent_lbl">Financing lease obligation-short term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:title="label: FinanceLeaseLiabilityCurrent to us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:title="label: FinanceLeaseLiabilityUndiscountedExcessAmount to us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: FinanceLeaseLiabilityUndiscountedExcessAmount to us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl">Financing lease obligation-long term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:title="label: FinanceLeaseLiabilityNoncurrent to us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" xlink:title="FinanceLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:title="label: FinanceLeaseLiabilityPaymentsDue to us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1">Finance Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDue to us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:title="label: FinanceLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:title="label: FinanceLeaseLiabilityPaymentsDueYearThree to us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDueYearThree to us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:title="label: FinanceLeaseLiabilityPaymentsDueYearTwo to us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsDueYearTwo to us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:title="label: FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:title="label: FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl">Future Payments for Financing Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:title="label: FinanceLeaseLiabilityMaturityTableTextBlock to us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:title="label: FinanceLeaseLiabilityMaturityTableTextBlock to us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl1">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiability_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl2">Operating Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl2" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl">Operating lease obligation-short term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl1">Operating Lease, Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="LesseeFinanceLeasesTextBlock" xlink:title="LesseeFinanceLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeFinanceLeasesTextBlock_lbl">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xlink:title="label: LesseeFinanceLeasesTextBlock to us-gaap_LesseeFinanceLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeasesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeFinanceLeasesTextBlock_lbl1">Lessee, Finance Leases [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_lbl1" xlink:title="label: LesseeFinanceLeasesTextBlock to us-gaap_LesseeFinanceLeasesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeLeasesPolicyTextBlock_lbl">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:title="label: LesseeLeasesPolicyTextBlock to us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock_lbl">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock_lbl1">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeAxis_lbl">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:title="label: MeasurementInputTypeAxis to us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedDividendRateMember_lbl">Estimated Dividend Yield [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:title="label: MeasurementInputExpectedDividendRateMember to us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedTermMember_lbl">Expected Term [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:title="label: MeasurementInputExpectedTermMember to us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputPriceVolatilityMember_lbl">Expected Volatility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:title="label: MeasurementInputPriceVolatilityMember to us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl">Risk-free Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:title="label: MeasurementInputRiskFreeInterestRateMember to us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeDomain_lbl">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xlink:title="label: MeasurementInputTypeDomain to us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl">Warrants measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:title="label: WarrantsAndRightsOutstandingMeasurementInput to us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="LesseeFinanceLeaseTermOfContract1" xlink:title="LesseeFinanceLeaseTermOfContract1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xml:lang="en-US" id="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl">Term of financing lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:title="label: LesseeFinanceLeaseTermOfContract1 to us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="LessorOperatingLeaseTermOfContract" xlink:title="LessorOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xml:lang="en-US" id="us-gaap_LessorOperatingLeaseTermOfContract_lbl">Term of sublease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl" xlink:title="label: LessorOperatingLeaseTermOfContract to us-gaap_LessorOperatingLeaseTermOfContract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseTermOfContract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LessorOperatingLeaseTermOfContract_lbl1" xml:lang="en-US" id="us-gaap_LessorOperatingLeaseTermOfContract_lbl1">Lessor, Operating Lease, Term of Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LessorOperatingLeaseTermOfContract" xlink:to="us-gaap_LessorOperatingLeaseTermOfContract_lbl1" xlink:title="label: LessorOperatingLeaseTermOfContract to us-gaap_LessorOperatingLeaseTermOfContract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl">Term of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1">Warrants and Rights Outstanding, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl">Remaining sublease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:title="label: LesseeOperatingLeaseRemainingLeaseTerm to us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiability to us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis_lbl" xml:lang="en-US" id="srt_RangeAxis_lbl">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:title="label: RangeAxis to srt_RangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember_lbl" xml:lang="en-US" id="srt_RangeMember_lbl">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl" xlink:title="label: RangeMember to srt_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl" xml:lang="en-US" id="srt_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:title="label: MaximumMember to srt_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember_lbl" xml:lang="en-US" id="srt_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:title="label: MinimumMember to srt_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" id="dei_DocumentQuarterlyReport_lbl">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:title="label: DocumentQuarterlyReport to dei_DocumentQuarterlyReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness_lbl" xml:lang="en-US" id="dei_EntitySmallBusiness_lbl">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:title="label: AccruedResearchAndDevelopmentCostsCurrent to pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" xml:lang="en-US" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1">Accrued Research and Development Costs, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" xlink:title="label: AccruedResearchAndDevelopmentCostsCurrent to pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl2" xml:lang="en-US" id="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl2">Accrued research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentCostsCurrent" xlink:to="pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl2" xlink:title="label: AccruedResearchAndDevelopmentCostsCurrent to pdsb_AccruedResearchAndDevelopmentCostsCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_PercentageOfCommonStockOutstanding" xlink:label="PercentageOfCommonStockOutstanding" xlink:title="PercentageOfCommonStockOutstanding" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" id="pdsb_PercentageOfCommonStockOutstanding_lbl">Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockOutstanding" xlink:to="pdsb_PercentageOfCommonStockOutstanding_lbl" xlink:title="label: PercentageOfCommonStockOutstanding to pdsb_PercentageOfCommonStockOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfCommonStockOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PercentageOfCommonStockOutstanding_lbl1" xml:lang="en-US" id="pdsb_PercentageOfCommonStockOutstanding_lbl1">Percentage of Common Stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockOutstanding" xlink:to="pdsb_PercentageOfCommonStockOutstanding_lbl1" xlink:title="label: PercentageOfCommonStockOutstanding to pdsb_PercentageOfCommonStockOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfCommonStockOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PercentageOfCommonStockOutstanding_lbl2" xml:lang="en-US" id="pdsb_PercentageOfCommonStockOutstanding_lbl2">Percentage of Common Stock outstanding used to determine annual increase in the plan limit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockOutstanding" xlink:to="pdsb_PercentageOfCommonStockOutstanding_lbl2" xlink:title="label: PercentageOfCommonStockOutstanding to pdsb_PercentageOfCommonStockOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_EquityCompensationPlansMember" xlink:label="EquityCompensationPlansMember" xlink:title="EquityCompensationPlansMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityCompensationPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_EquityCompensationPlansMember_lbl" xml:lang="en-US" id="pdsb_EquityCompensationPlansMember_lbl">Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityCompensationPlansMember" xlink:to="pdsb_EquityCompensationPlansMember_lbl" xlink:title="label: EquityCompensationPlansMember to pdsb_EquityCompensationPlansMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityCompensationPlansMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_EquityCompensationPlansMember_lbl1" xml:lang="en-US" id="pdsb_EquityCompensationPlansMember_lbl1">Equity Compensation Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityCompensationPlansMember" xlink:to="pdsb_EquityCompensationPlansMember_lbl1" xlink:title="label: EquityCompensationPlansMember to pdsb_EquityCompensationPlansMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityCompensationPlansMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_EquityCompensationPlansMember_lbl2" xml:lang="en-US" id="pdsb_EquityCompensationPlansMember_lbl2">The Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityCompensationPlansMember" xlink:to="pdsb_EquityCompensationPlansMember_lbl2" xlink:title="label: EquityCompensationPlansMember to pdsb_EquityCompensationPlansMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_EquityIncentivePlan2014Member" xlink:label="EquityIncentivePlan2014Member" xlink:title="EquityIncentivePlan2014Member" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2014Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_EquityIncentivePlan2014Member_lbl" xml:lang="en-US" id="pdsb_EquityIncentivePlan2014Member_lbl">In 2014, the Company's stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units ("RSUs"), subject to increases (the "Plan Limit"). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to 826,292 shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2014Member" xlink:to="pdsb_EquityIncentivePlan2014Member_lbl" xlink:title="label: EquityIncentivePlan2014Member to pdsb_EquityIncentivePlan2014Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2014Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_EquityIncentivePlan2014Member_lbl1" xml:lang="en-US" id="pdsb_EquityIncentivePlan2014Member_lbl1">Equity Incentive Plan 2014 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2014Member" xlink:to="pdsb_EquityIncentivePlan2014Member_lbl1" xlink:title="label: EquityIncentivePlan2014Member to pdsb_EquityIncentivePlan2014Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2014Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_EquityIncentivePlan2014Member_lbl2" xml:lang="en-US" id="pdsb_EquityIncentivePlan2014Member_lbl2">2014 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2014Member" xlink:to="pdsb_EquityIncentivePlan2014Member_lbl2" xlink:title="label: EquityIncentivePlan2014Member to pdsb_EquityIncentivePlan2014Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_InducementPlan2019Member" xlink:label="InducementPlan2019Member" xlink:title="InducementPlan2019Member" />
    <link:label xlink:type="resource" xlink:label="pdsb_InducementPlan2019Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_InducementPlan2019Member_lbl" xml:lang="en-US" id="pdsb_InducementPlan2019Member_lbl">The 2019 Inducement Plan provides for the grant of non-qualified stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2019Member" xlink:to="pdsb_InducementPlan2019Member_lbl" xlink:title="label: InducementPlan2019Member to pdsb_InducementPlan2019Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_InducementPlan2019Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_InducementPlan2019Member_lbl1" xml:lang="en-US" id="pdsb_InducementPlan2019Member_lbl1">Inducement Plan 2019 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2019Member" xlink:to="pdsb_InducementPlan2019Member_lbl1" xlink:title="label: InducementPlan2019Member to pdsb_InducementPlan2019Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_InducementPlan2019Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_InducementPlan2019Member_lbl2" xml:lang="en-US" id="pdsb_InducementPlan2019Member_lbl2">2019 Inducement Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2019Member" xlink:to="pdsb_InducementPlan2019Member_lbl2" xlink:title="label: InducementPlan2019Member to pdsb_InducementPlan2019Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_EquityIncentivePlan2018Member" xlink:label="EquityIncentivePlan2018Member" xlink:title="EquityIncentivePlan2018Member" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_EquityIncentivePlan2018Member_lbl" xml:lang="en-US" id="pdsb_EquityIncentivePlan2018Member_lbl">In 2018, the Company's stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2018Member" xlink:to="pdsb_EquityIncentivePlan2018Member_lbl" xlink:title="label: EquityIncentivePlan2018Member to pdsb_EquityIncentivePlan2018Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2018Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_EquityIncentivePlan2018Member_lbl1" xml:lang="en-US" id="pdsb_EquityIncentivePlan2018Member_lbl1">Equity Incentive Plan 2018 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2018Member" xlink:to="pdsb_EquityIncentivePlan2018Member_lbl1" xlink:title="label: EquityIncentivePlan2018Member to pdsb_EquityIncentivePlan2018Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_EquityIncentivePlan2018Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_EquityIncentivePlan2018Member_lbl2" xml:lang="en-US" id="pdsb_EquityIncentivePlan2018Member_lbl2">2018 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2018Member" xlink:to="pdsb_EquityIncentivePlan2018Member_lbl2" xlink:title="label: EquityIncentivePlan2018Member to pdsb_EquityIncentivePlan2018Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_IncentiveStockOptionsMember_lbl" xml:lang="en-US" id="pdsb_IncentiveStockOptionsMember_lbl">Incentive stock options (ISOs) under the equity compensation plans that may be granted only to employees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="pdsb_IncentiveStockOptionsMember_lbl" xlink:title="label: IncentiveStockOptionsMember to pdsb_IncentiveStockOptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_IncentiveStockOptionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_IncentiveStockOptionsMember_lbl1" xml:lang="en-US" id="pdsb_IncentiveStockOptionsMember_lbl1">Incentive Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="pdsb_IncentiveStockOptionsMember_lbl1" xlink:title="label: IncentiveStockOptionsMember to pdsb_IncentiveStockOptionsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_IncentiveStockOptionsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_IncentiveStockOptionsMember_lbl2" xml:lang="en-US" id="pdsb_IncentiveStockOptionsMember_lbl2">Incentive Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="pdsb_IncentiveStockOptionsMember_lbl2" xlink:title="label: IncentiveStockOptionsMember to pdsb_IncentiveStockOptionsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl" xml:lang="en-US" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl">Term the Plan shall continue to remain effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:to="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan to pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl1" xml:lang="en-US" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Term of Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:to="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan to pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl2" xml:lang="en-US" id="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl2">Term of plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:to="pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan to pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl">The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid on the stated maturity date of the loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod4" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod4 to pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1">Debt Instrument, Prepayment Premium, Period 4</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod4" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod4 to pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl2">Prepayment premium paid if loan is paid on stated maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod4" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl2" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod4 to pdsb_DebtInstrumentPrepaymentPremiumPeriod4_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl">The number of independent term loans provided for under the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfIndependentTermLoans" xlink:to="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl" xlink:title="label: DebtInstrumentNumberOfIndependentTermLoans to pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1">Debt Instrument, Number of Independent Term Loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfIndependentTermLoans" xlink:to="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1" xlink:title="label: DebtInstrumentNumberOfIndependentTermLoans to pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl2">Number of independent term loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfIndependentTermLoans" xlink:to="pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl2" xlink:title="label: DebtInstrumentNumberOfIndependentTermLoans to pdsb_DebtInstrumentNumberOfIndependentTermLoans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl">The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid on or before the Loan Amortization date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod1" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod1 to pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1">Debt Instrument, Prepayment Premium, Period 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod1" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod1 to pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl2">Prepayment premium paid if loan is prepaid on or before Loan Amortization date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod1" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl2" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod1 to pdsb_DebtInstrumentPrepaymentPremiumPeriod1_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl">Period of time prior to prepaying all of the outstanding loan that written notice must be provided by the borrower, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:to="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl" xlink:title="label: DebtInstrumentWrittenNoticePeriodForPrepayment to pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1">Debt Instrument, Written Notice Period for Prepayment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:to="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1" xlink:title="label: DebtInstrumentWrittenNoticePeriodForPrepayment to pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl2">Written notice period for prepayment of outstanding loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:to="pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl2" xlink:title="label: DebtInstrumentWrittenNoticePeriodForPrepayment to pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_TermLoansMember_lbl" xml:lang="en-US" id="pdsb_TermLoansMember_lbl">On August 24, 2022, the Company, as borrower (the "Borrower"), entered into a Venture Loan and Security Agreement (the "Loan and Security Agreement") by and among Borrower, PDS Operating Corporation, as guarantor ("Guarantor", including the Borrower and any subsidiary of the Borrower party thereto from time to time, collectively, the "Loan Parties" and each individually a "Loan Party") , the persons party thereto from time to time as lenders (collectively, the "Lenders"), and Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the "Collateral Agent"). The Loan and Security Agreement provides for six separate and independent term loans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="pdsb_TermLoansMember_lbl" xlink:title="label: TermLoansMember to pdsb_TermLoansMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermLoansMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_TermLoansMember_lbl1" xml:lang="en-US" id="pdsb_TermLoansMember_lbl1">Term Loans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="pdsb_TermLoansMember_lbl1" xlink:title="label: TermLoansMember to pdsb_TermLoansMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermLoansMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_TermLoansMember_lbl2" xml:lang="en-US" id="pdsb_TermLoansMember_lbl2">Term Loans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoansMember" xlink:to="pdsb_TermLoansMember_lbl2" xlink:title="label: TermLoansMember to pdsb_TermLoansMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanFMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanFMember_lbl" xml:lang="en-US" id="pdsb_LoanFMember_lbl">One of six separate and independent term loans in the amount of $5,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanFMember" xlink:to="pdsb_LoanFMember_lbl" xlink:title="label: LoanFMember to pdsb_LoanFMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanFMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanFMember_lbl1" xml:lang="en-US" id="pdsb_LoanFMember_lbl1">Loan F [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanFMember" xlink:to="pdsb_LoanFMember_lbl1" xlink:title="label: LoanFMember to pdsb_LoanFMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanFMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanFMember_lbl2" xml:lang="en-US" id="pdsb_LoanFMember_lbl2">Loan F [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanFMember" xlink:to="pdsb_LoanFMember_lbl2" xlink:title="label: LoanFMember to pdsb_LoanFMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanCMember_lbl" xml:lang="en-US" id="pdsb_LoanCMember_lbl">One of six separate and independent term loans in the amount of $3,750,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanCMember" xlink:to="pdsb_LoanCMember_lbl" xlink:title="label: LoanCMember to pdsb_LoanCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanCMember_lbl1" xml:lang="en-US" id="pdsb_LoanCMember_lbl1">Loan C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanCMember" xlink:to="pdsb_LoanCMember_lbl1" xlink:title="label: LoanCMember to pdsb_LoanCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanCMember_lbl2" xml:lang="en-US" id="pdsb_LoanCMember_lbl2">Loan C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanCMember" xlink:to="pdsb_LoanCMember_lbl2" xlink:title="label: LoanCMember to pdsb_LoanCMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanDMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanDMember_lbl" xml:lang="en-US" id="pdsb_LoanDMember_lbl">One of six separate and independent term loans in the amount of $3,750,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanDMember" xlink:to="pdsb_LoanDMember_lbl" xlink:title="label: LoanDMember to pdsb_LoanDMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanDMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanDMember_lbl1" xml:lang="en-US" id="pdsb_LoanDMember_lbl1">Loan D [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanDMember" xlink:to="pdsb_LoanDMember_lbl1" xlink:title="label: LoanDMember to pdsb_LoanDMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanDMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanDMember_lbl2" xml:lang="en-US" id="pdsb_LoanDMember_lbl2">Loan D [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanDMember" xlink:to="pdsb_LoanDMember_lbl2" xlink:title="label: LoanDMember to pdsb_LoanDMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanAMember_lbl" xml:lang="en-US" id="pdsb_LoanAMember_lbl">One of six separate and independent term loans in the amount of $7,500,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAMember" xlink:to="pdsb_LoanAMember_lbl" xlink:title="label: LoanAMember to pdsb_LoanAMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanAMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanAMember_lbl1" xml:lang="en-US" id="pdsb_LoanAMember_lbl1">Loan A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAMember" xlink:to="pdsb_LoanAMember_lbl1" xlink:title="label: LoanAMember to pdsb_LoanAMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanAMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanAMember_lbl2" xml:lang="en-US" id="pdsb_LoanAMember_lbl2">Loan A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanAMember" xlink:to="pdsb_LoanAMember_lbl2" xlink:title="label: LoanAMember to pdsb_LoanAMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanBMember_lbl" xml:lang="en-US" id="pdsb_LoanBMember_lbl">One of six separate and independent term loans in the amount of $10,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanBMember" xlink:to="pdsb_LoanBMember_lbl" xlink:title="label: LoanBMember to pdsb_LoanBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanBMember_lbl1" xml:lang="en-US" id="pdsb_LoanBMember_lbl1">Loan B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanBMember" xlink:to="pdsb_LoanBMember_lbl1" xlink:title="label: LoanBMember to pdsb_LoanBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanBMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanBMember_lbl2" xml:lang="en-US" id="pdsb_LoanBMember_lbl2">Loan B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanBMember" xlink:to="pdsb_LoanBMember_lbl2" xlink:title="label: LoanBMember to pdsb_LoanBMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl">The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated Maturity Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod3" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod3 to pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1">Debt Instrument, Prepayment Premium, Period 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod3" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod3 to pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl2">Prepayment premium paid if loan is prepaid more than 12 months after Loan Amortization Date but prior to stated Maturity Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod3" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl2" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod3 to pdsb_DebtInstrumentPrepaymentPremiumPeriod3_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentVariableRate" xlink:label="DebtInstrumentVariableRate" xlink:title="DebtInstrumentVariableRate" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentVariableRate_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentVariableRate_lbl">Minimum base rate to be used in computing the variable rate on the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentVariableRate" xlink:to="pdsb_DebtInstrumentVariableRate_lbl" xlink:title="label: DebtInstrumentVariableRate to pdsb_DebtInstrumentVariableRate_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentVariableRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentVariableRate_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentVariableRate_lbl1">Debt Instrument, Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentVariableRate" xlink:to="pdsb_DebtInstrumentVariableRate_lbl1" xlink:title="label: DebtInstrumentVariableRate to pdsb_DebtInstrumentVariableRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentVariableRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentVariableRate_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentVariableRate_lbl2">Minimum base rate used to compute floating interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentVariableRate" xlink:to="pdsb_DebtInstrumentVariableRate_lbl2" xlink:title="label: DebtInstrumentVariableRate to pdsb_DebtInstrumentVariableRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl">The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid after the Loan Amortization date, but on or before the date that is twelve (12) months after such Loan Amortization Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod2" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod2 to pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1">Debt Instrument, Prepayment Premium, Period 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod2" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod2 to pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl2">Prepayment premium paid if load is prepaid after Loan Amortization date, but on or before date that is 12 months after such Loan Amortization Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPrepaymentPremiumPeriod2" xlink:to="pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl2" xlink:title="label: DebtInstrumentPrepaymentPremiumPeriod2 to pdsb_DebtInstrumentPrepaymentPremiumPeriod2_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LoanEMember_lbl" xml:lang="en-US" id="pdsb_LoanEMember_lbl">One of six separate and independent term loans in the amount of $5,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanEMember" xlink:to="pdsb_LoanEMember_lbl" xlink:title="label: LoanEMember to pdsb_LoanEMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanEMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LoanEMember_lbl1" xml:lang="en-US" id="pdsb_LoanEMember_lbl1">Loan E [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanEMember" xlink:to="pdsb_LoanEMember_lbl1" xlink:title="label: LoanEMember to pdsb_LoanEMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LoanEMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LoanEMember_lbl2" xml:lang="en-US" id="pdsb_LoanEMember_lbl2">Loan E [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoanEMember" xlink:to="pdsb_LoanEMember_lbl2" xlink:title="label: LoanEMember to pdsb_LoanEMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_PercentageOfVotingPowerDisposedOff" xlink:label="PercentageOfVotingPowerDisposedOff" xlink:title="PercentageOfVotingPowerDisposedOff" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfVotingPowerDisposedOff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PercentageOfVotingPowerDisposedOff_lbl" xml:lang="en-US" id="pdsb_PercentageOfVotingPowerDisposedOff_lbl">Percentage of voting power disposed of in a transaction (including a merger or other reorganization) or series of related transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfVotingPowerDisposedOff" xlink:to="pdsb_PercentageOfVotingPowerDisposedOff_lbl" xlink:title="label: PercentageOfVotingPowerDisposedOff to pdsb_PercentageOfVotingPowerDisposedOff_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfVotingPowerDisposedOff_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PercentageOfVotingPowerDisposedOff_lbl1" xml:lang="en-US" id="pdsb_PercentageOfVotingPowerDisposedOff_lbl1">Percentage of Voting Power Disposed off</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfVotingPowerDisposedOff" xlink:to="pdsb_PercentageOfVotingPowerDisposedOff_lbl1" xlink:title="label: PercentageOfVotingPowerDisposedOff to pdsb_PercentageOfVotingPowerDisposedOff_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PercentageOfVotingPowerDisposedOff_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PercentageOfVotingPowerDisposedOff_lbl2" xml:lang="en-US" id="pdsb_PercentageOfVotingPowerDisposedOff_lbl2">Percentage of voting power disposed off</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfVotingPowerDisposedOff" xlink:to="pdsb_PercentageOfVotingPowerDisposedOff_lbl2" xlink:title="label: PercentageOfVotingPowerDisposedOff to pdsb_PercentageOfVotingPowerDisposedOff_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentThresholdPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentThresholdPeriod_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentThresholdPeriod_lbl">Threshold period after the Loan Amortization Date used to determine prepayment premiums on the outstanding principal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentThresholdPeriod" xlink:to="pdsb_DebtInstrumentThresholdPeriod_lbl" xlink:title="label: DebtInstrumentThresholdPeriod to pdsb_DebtInstrumentThresholdPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentThresholdPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentThresholdPeriod_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentThresholdPeriod_lbl1">Debt Instrument, Threshold Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentThresholdPeriod" xlink:to="pdsb_DebtInstrumentThresholdPeriod_lbl1" xlink:title="label: DebtInstrumentThresholdPeriod to pdsb_DebtInstrumentThresholdPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentThresholdPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentThresholdPeriod_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentThresholdPeriod_lbl2">Threshold period after Loan Amortization Date used to determine prepayment premiums</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentThresholdPeriod" xlink:to="pdsb_DebtInstrumentThresholdPeriod_lbl2" xlink:title="label: DebtInstrumentThresholdPeriod to pdsb_DebtInstrumentThresholdPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LiabilityForUncertainTaxPositions" xlink:label="LiabilityForUncertainTaxPositions" xlink:title="LiabilityForUncertainTaxPositions" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiabilityForUncertainTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LiabilityForUncertainTaxPositions_lbl" xml:lang="en-US" id="pdsb_LiabilityForUncertainTaxPositions_lbl">The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityForUncertainTaxPositions" xlink:to="pdsb_LiabilityForUncertainTaxPositions_lbl" xlink:title="label: LiabilityForUncertainTaxPositions to pdsb_LiabilityForUncertainTaxPositions_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiabilityForUncertainTaxPositions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LiabilityForUncertainTaxPositions_lbl1" xml:lang="en-US" id="pdsb_LiabilityForUncertainTaxPositions_lbl1">Liability for Uncertain Tax Positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityForUncertainTaxPositions" xlink:to="pdsb_LiabilityForUncertainTaxPositions_lbl1" xlink:title="label: LiabilityForUncertainTaxPositions to pdsb_LiabilityForUncertainTaxPositions_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiabilityForUncertainTaxPositions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LiabilityForUncertainTaxPositions_lbl2" xml:lang="en-US" id="pdsb_LiabilityForUncertainTaxPositions_lbl2">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilityForUncertainTaxPositions" xlink:to="pdsb_LiabilityForUncertainTaxPositions_lbl2" xlink:title="label: LiabilityForUncertainTaxPositions to pdsb_LiabilityForUncertainTaxPositions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:label="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl">Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" xlink:title="label: LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock to pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1">Lessee, Finance Lease, Supplemental Cash Flow Information Related to Finance Lease [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" xlink:title="label: LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock to pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl2" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl2">Supplemental Cash Flow Information Related to Financing Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:to="pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl2" xlink:title="label: LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock to pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:title="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" id="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl">Tabular disclosure of supplemental cash flow information related to lessee's operating leases and right-of-use assets and lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock to pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1" xml:lang="en-US" id="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1">Lessee, Operating Lease, Supplemental Cash Flow Information Related to Operating Lease [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1" xlink:title="label: LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock to pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl2" xml:lang="en-US" id="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl2">Supplemental Cash Flow Information Related to Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl2" xlink:title="label: LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock to pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:label="LesseeFinanceLeaseNumberOfLeases" xlink:title="LesseeFinanceLeaseNumberOfLeases" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl">The number of finance leases entered into by the lessee during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNumberOfLeases" xlink:to="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" xlink:title="label: LesseeFinanceLeaseNumberOfLeases to pdsb_LesseeFinanceLeaseNumberOfLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1">Lessee, Finance Lease, Number of Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNumberOfLeases" xlink:to="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" xlink:title="label: LesseeFinanceLeaseNumberOfLeases to pdsb_LesseeFinanceLeaseNumberOfLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl2" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl2">Number of financing leases entered into</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseNumberOfLeases" xlink:to="pdsb_LesseeFinanceLeaseNumberOfLeases_lbl2" xlink:title="label: LesseeFinanceLeaseNumberOfLeases to pdsb_LesseeFinanceLeaseNumberOfLeases_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:label="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl">The amount of estimated aggregate monthly rental expense under finance lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseMonthlyRentalExpense" xlink:to="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" xlink:title="label: LesseeFinanceLeaseMonthlyRentalExpense to pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1">Lessee, Finance Lease, Monthly Rental Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseMonthlyRentalExpense" xlink:to="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" xlink:title="label: LesseeFinanceLeaseMonthlyRentalExpense to pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl2" xml:lang="en-US" id="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl2">Aggregate monthly rental payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeFinanceLeaseMonthlyRentalExpense" xlink:to="pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl2" xlink:title="label: LesseeFinanceLeaseMonthlyRentalExpense to pdsb_LesseeFinanceLeaseMonthlyRentalExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_FinanceLeaseCost" xlink:label="FinanceLeaseCost" xlink:title="FinanceLeaseCost" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_FinanceLeaseCost_lbl" xml:lang="en-US" id="pdsb_FinanceLeaseCost_lbl">Amount of lease cost recognized by lessee for finance lease contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseCost" xlink:to="pdsb_FinanceLeaseCost_lbl" xlink:title="label: FinanceLeaseCost to pdsb_FinanceLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_FinanceLeaseCost_lbl1" xml:lang="en-US" id="pdsb_FinanceLeaseCost_lbl1">Finance Lease, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseCost" xlink:to="pdsb_FinanceLeaseCost_lbl1" xlink:title="label: FinanceLeaseCost to pdsb_FinanceLeaseCost_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseCost_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_FinanceLeaseCost_lbl2" xml:lang="en-US" id="pdsb_FinanceLeaseCost_lbl2">Total cost of financing leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseCost" xlink:to="pdsb_FinanceLeaseCost_lbl2" xlink:title="label: FinanceLeaseCost to pdsb_FinanceLeaseCost_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:label="FinanceLeasePrincipalAndInterestPayments" xlink:title="FinanceLeasePrincipalAndInterestPayments" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" xml:lang="en-US" id="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl">Amount of cash outflow for principal and interest payments on finance lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalAndInterestPayments" xlink:to="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" xlink:title="label: FinanceLeasePrincipalAndInterestPayments to pdsb_FinanceLeasePrincipalAndInterestPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" xml:lang="en-US" id="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1">Finance Lease, Principal and Interest Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalAndInterestPayments" xlink:to="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" xlink:title="label: FinanceLeasePrincipalAndInterestPayments to pdsb_FinanceLeasePrincipalAndInterestPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl2" xml:lang="en-US" id="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl2">Cash paid for finance lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalAndInterestPayments" xlink:to="pdsb_FinanceLeasePrincipalAndInterestPayments_lbl2" xlink:title="label: FinanceLeasePrincipalAndInterestPayments to pdsb_FinanceLeasePrincipalAndInterestPayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xml:lang="en-US" id="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl">Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xlink:title="label: FinanceLeaseLiabilityToBePaidYearFourAndThereafter to pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" xml:lang="en-US" id="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1">Finance Lease, Liability, to be Paid, Year Four and Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" xlink:title="label: FinanceLeaseLiabilityToBePaidYearFourAndThereafter to pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl2" xml:lang="en-US" id="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl2">2027 and after</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl2" xlink:title="label: FinanceLeaseLiabilityToBePaidYearFourAndThereafter to pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LiquidityAbstract" xlink:label="LiquidityAbstract" xlink:title="LiquidityAbstract" />
    <link:label xlink:type="resource" xlink:label="pdsb_LiquidityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LiquidityAbstract_lbl1" xml:lang="en-US" id="pdsb_LiquidityAbstract_lbl1">Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAbstract" xlink:to="pdsb_LiquidityAbstract_lbl1" xlink:title="label: LiquidityAbstract to pdsb_LiquidityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_CommissionPercentage" xlink:label="CommissionPercentage" xlink:title="CommissionPercentage" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommissionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_CommissionPercentage_lbl" xml:lang="en-US" id="pdsb_CommissionPercentage_lbl">Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionPercentage" xlink:to="pdsb_CommissionPercentage_lbl" xlink:title="label: CommissionPercentage to pdsb_CommissionPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommissionPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_CommissionPercentage_lbl1" xml:lang="en-US" id="pdsb_CommissionPercentage_lbl1">Commission Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionPercentage" xlink:to="pdsb_CommissionPercentage_lbl1" xlink:title="label: CommissionPercentage to pdsb_CommissionPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_CommissionPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_CommissionPercentage_lbl2" xml:lang="en-US" id="pdsb_CommissionPercentage_lbl2">Commission paid on Placement Shares sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommissionPercentage" xlink:to="pdsb_CommissionPercentage_lbl2" xlink:title="label: CommissionPercentage to pdsb_CommissionPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_PlacementSharesAvailableForFutureSale" xlink:label="PlacementSharesAvailableForFutureSale" xlink:title="PlacementSharesAvailableForFutureSale" />
    <link:label xlink:type="resource" xlink:label="pdsb_PlacementSharesAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_PlacementSharesAvailableForFutureSale_lbl" xml:lang="en-US" id="pdsb_PlacementSharesAvailableForFutureSale_lbl">The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementSharesAvailableForFutureSale" xlink:to="pdsb_PlacementSharesAvailableForFutureSale_lbl" xlink:title="label: PlacementSharesAvailableForFutureSale to pdsb_PlacementSharesAvailableForFutureSale_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_PlacementSharesAvailableForFutureSale_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_PlacementSharesAvailableForFutureSale_lbl1" xml:lang="en-US" id="pdsb_PlacementSharesAvailableForFutureSale_lbl1">Placement Shares, Available for future sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementSharesAvailableForFutureSale" xlink:to="pdsb_PlacementSharesAvailableForFutureSale_lbl1" xlink:title="label: PlacementSharesAvailableForFutureSale to pdsb_PlacementSharesAvailableForFutureSale_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_PlacementSharesAvailableForFutureSale_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_PlacementSharesAvailableForFutureSale_lbl2" xml:lang="en-US" id="pdsb_PlacementSharesAvailableForFutureSale_lbl2">Placement Shares included in at-the-market offering program</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementSharesAvailableForFutureSale" xlink:to="pdsb_PlacementSharesAvailableForFutureSale_lbl2" xlink:title="label: PlacementSharesAvailableForFutureSale to pdsb_PlacementSharesAvailableForFutureSale_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:label="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="ShelfRegistrationStatementAvailableForFutureSale" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" xml:lang="en-US" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl">The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission (the "2020 Shelf Registration Statement") for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the "Shelf Securities") that are available for future sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAvailableForFutureSale" xlink:to="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" xlink:title="label: ShelfRegistrationStatementAvailableForFutureSale to pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" xml:lang="en-US" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1">Shelf Registration Statement, Available for future sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAvailableForFutureSale" xlink:to="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" xlink:title="label: ShelfRegistrationStatementAvailableForFutureSale to pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl2" xml:lang="en-US" id="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl2">Registered securities in Shelf Registration Statement available for future sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationStatementAvailableForFutureSale" xlink:to="pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl2" xlink:title="label: ShelfRegistrationStatementAvailableForFutureSale to pdsb_ShelfRegistrationStatementAvailableForFutureSale_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:label="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" xml:lang="en-US" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl">Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:to="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" xlink:title="label: ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards to pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" xml:lang="en-US" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1">Proceeds from Sale of Unused Net Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:to="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" xlink:title="label: ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards to pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl2" xml:lang="en-US" id="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl2">Proceeds from sale of tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:to="pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl2" xlink:title="label: ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards to pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:label="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl" xml:lang="en-US" id="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl">Period after October 1, 2024 for making monthly payments on the principal balance of the debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:to="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl" xlink:title="label: DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance to pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1" xml:lang="en-US" id="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1">Debt Instrument, Period for making monthly payments on principal balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:to="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1" xlink:title="label: DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance to pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2" xml:lang="en-US" id="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2">Period after October 1, 2024 for making monthly payments on principal balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:to="pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2" xlink:title="label: DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance to pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl">Disclosure of accounting policy for significant risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" xlink:title="label: SignificantRisksAndUncertaintiesPolicyPolicyTextBlock to pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1">Significant Risks and Uncertainties, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" xlink:title="label: SignificantRisksAndUncertaintiesPolicyPolicyTextBlock to pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl2" xml:lang="en-US" id="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl2">Significant Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:to="pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl2" xlink:title="label: SignificantRisksAndUncertaintiesPolicyPolicyTextBlock to pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xml:lang="en-US" id="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl">Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter to pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" xml:lang="en-US" id="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Four and Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter to pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl2" xml:lang="en-US" id="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl2">2027 and after</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:to="pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl2" xlink:title="label: LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter to pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:label="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:label xlink:type="resource" xlink:label="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" xml:lang="en-US" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl">Royalty percentage paid on net sales of the product detailed in the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:to="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" xlink:title="label: RoyaltyPercentagePaidOnNetSalesOfProduct to pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" xml:lang="en-US" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1">Royalty Percentage Paid on Net Sales of Product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:to="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" xlink:title="label: RoyaltyPercentagePaidOnNetSalesOfProduct to pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl2" xml:lang="en-US" id="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl2">Royalty percentage paid on net sales of product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:to="pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl2" xlink:title="label: RoyaltyPercentagePaidOnNetSalesOfProduct to pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_TermOfRoyaltyPayment" xlink:label="TermOfRoyaltyPayment" xlink:title="TermOfRoyaltyPayment" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermOfRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_TermOfRoyaltyPayment_lbl" xml:lang="en-US" id="pdsb_TermOfRoyaltyPayment_lbl">Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfRoyaltyPayment" xlink:to="pdsb_TermOfRoyaltyPayment_lbl" xlink:title="label: TermOfRoyaltyPayment to pdsb_TermOfRoyaltyPayment_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermOfRoyaltyPayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_TermOfRoyaltyPayment_lbl1" xml:lang="en-US" id="pdsb_TermOfRoyaltyPayment_lbl1">Term of Royalty Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfRoyaltyPayment" xlink:to="pdsb_TermOfRoyaltyPayment_lbl1" xlink:title="label: TermOfRoyaltyPayment to pdsb_TermOfRoyaltyPayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_TermOfRoyaltyPayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_TermOfRoyaltyPayment_lbl2" xml:lang="en-US" id="pdsb_TermOfRoyaltyPayment_lbl2">Term of royalty payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfRoyaltyPayment" xlink:to="pdsb_TermOfRoyaltyPayment_lbl2" xlink:title="label: TermOfRoyaltyPayment to pdsb_TermOfRoyaltyPayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:label="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" xml:lang="en-US" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl">Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:to="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" xlink:title="label: MilestonePaymentsAchievementOfCertainAggregateSalesLevels to pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" xml:lang="en-US" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1">Milestone payments, Achievement of Certain Aggregate Sales Levels</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:to="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" xlink:title="label: MilestonePaymentsAchievementOfCertainAggregateSalesLevels to pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl2" xml:lang="en-US" id="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl2">Milestone payments for aggregate sales levels of product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:to="pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl2" xlink:title="label: MilestonePaymentsAchievementOfCertainAggregateSalesLevels to pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:label="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" xml:lang="en-US" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl">Payments to be made for development and first commercial sale milestones detailed in the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:to="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" xlink:title="label: MilestonePaymentsDevelopmentAndFirstCommercialSales to pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" xml:lang="en-US" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1">Milestone payments, Development and first commercial sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:to="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" xlink:title="label: MilestonePaymentsDevelopmentAndFirstCommercialSales to pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl2" xml:lang="en-US" id="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl2">Milestone payments for development and first commercial sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:to="pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl2" xlink:title="label: MilestonePaymentsDevelopmentAndFirstCommercialSales to pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_MerckKGaALicenseAgreementMember" xlink:label="MerckKGaALicenseAgreementMember" xlink:title="MerckKGaALicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="pdsb_MerckKGaALicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pdsb_MerckKGaALicenseAgreementMember_lbl" xml:lang="en-US" id="pdsb_MerckKGaALicenseAgreementMember_lbl">License agreements with each of the Company's executives that generally provide for product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MerckKGaALicenseAgreementMember" xlink:to="pdsb_MerckKGaALicenseAgreementMember_lbl" xlink:title="label: MerckKGaALicenseAgreementMember to pdsb_MerckKGaALicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pdsb_MerckKGaALicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pdsb_MerckKGaALicenseAgreementMember_lbl1" xml:lang="en-US" id="pdsb_MerckKGaALicenseAgreementMember_lbl1">Merck KGaA License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MerckKGaALicenseAgreementMember" xlink:to="pdsb_MerckKGaALicenseAgreementMember_lbl1" xlink:title="label: MerckKGaALicenseAgreementMember to pdsb_MerckKGaALicenseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pdsb_MerckKGaALicenseAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pdsb_MerckKGaALicenseAgreementMember_lbl2" xml:lang="en-US" id="pdsb_MerckKGaALicenseAgreementMember_lbl2">Merck KGaA License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MerckKGaALicenseAgreementMember" xlink:to="pdsb_MerckKGaALicenseAgreementMember_lbl2" xlink:title="label: MerckKGaALicenseAgreementMember to pdsb_MerckKGaALicenseAgreementMember_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pdsb-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.7.1.5162 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#RetirementPlanDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#VentureLoanAndSecurityAgreementDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#IncomeTaxesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationEquityCompensationPlansDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LeasesFinancingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LeasesOperatingLeaseDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#FairValueOfFinancialInstrumentsDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LiquidityDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LiquidityDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="pdsb-20230630.xsd#SummaryOfSignificantAccountingPoliciesDetails" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#LeasesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pdsb-20230630.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pdsb-20230630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="pdsb-20230630.xsd#InsiderTradingArrangements" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/RetirementPlan" xlink:type="simple" xlink:href="pdsb-20230630.xsd#RetirementPlan" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement" xlink:type="simple" xlink:href="pdsb-20230630.xsd#VentureLoanAndSecurityAgreement" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="pdsb-20230630.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="pdsb-20230630.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/AccruedExpenses" xlink:type="simple" xlink:href="pdsb-20230630.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/Leases" xlink:type="simple" xlink:href="pdsb-20230630.xsd#Leases" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="pdsb-20230630.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/Liquidity" xlink:type="simple" xlink:href="pdsb-20230630.xsd#Liquidity" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="pdsb-20230630.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/NatureOfOperations" xlink:type="simple" xlink:href="pdsb-20230630.xsd#NatureOfOperations" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pdsb-20230630.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="pdsb-20230630.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentQuarterlyReport" xlink:title="presentation: CoverAbstract to DocumentQuarterlyReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="FinanceLeaseRightOfUseAsset" xlink:title="FinanceLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="FinanceLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to FinanceLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="FinanceLeaseLiabilityCurrent" xlink:title="FinanceLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="FinanceLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to FinanceLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredLongTermDebt" xlink:label="SecuredLongTermDebt" xlink:title="SecuredLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="SecuredLongTermDebt" xlink:title="presentation: LiabilitiesNoncurrentAbstract to SecuredLongTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="FinanceLeaseLiabilityNoncurrent" xlink:title="FinanceLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="FinanceLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesNoncurrentAbstract to FinanceLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract" xlink:to="LiabilitiesNoncurrentAbstract" xlink:title="presentation: LiabilitiesAbstract to LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAbstract to Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestIncomeExpenseNonoperatingNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestIncomeExpenseNonoperatingNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: IncomeStatementAbstract to ComprehensiveIncomeNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesIssuedForServices" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="FinanceLeaseRightOfUseAssetAmortization" xlink:title="FinanceLeaseRightOfUseAssetAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FinanceLeaseRightOfUseAssetAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to FinanceLeaseRightOfUseAssetAmortization" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FinanceLeasePrincipalPayments" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FinanceLeasePrincipalPayments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/NatureOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureOfOperations" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/Liquidity">
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LiquidityAbstract" xlink:label="LiquidityAbstract" xlink:title="LiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="SubstantialDoubtAboutGoingConcernTextBlock" xlink:title="SubstantialDoubtAboutGoingConcernTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAbstract" xlink:to="SubstantialDoubtAboutGoingConcernTextBlock" xlink:title="presentation: LiquidityAbstract to SubstantialDoubtAboutGoingConcernTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstruments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/Leases">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="LesseeFinanceLeasesTextBlock" xlink:title="LesseeFinanceLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeFinanceLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeFinanceLeasesTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpenses">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DebtDisclosureAbstract to DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlan">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/InsiderTradingArrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrAdoptedFlag" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrAdoptedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrTrmntdFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrTrmntdFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:label="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantRisksAndUncertaintiesPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="LesseeLeasesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to LesseeLeasesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="FairValueByBalanceSheetGroupingTextBlock" xlink:title="FairValueByBalanceSheetGroupingTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueByBalanceSheetGroupingTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueByBalanceSheetGroupingTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:title="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:label="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="FinanceLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to FinanceLeaseLiabilityMaturityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LiquidityAbstract" xlink:label="LiquidityAbstract" xlink:title="LiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanAMember" xlink:title="presentation: TermLoansMember to LoanAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanBMember" xlink:title="presentation: TermLoansMember to LoanBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanCMember" xlink:title="presentation: TermLoansMember to LoanCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanDMember" xlink:title="presentation: TermLoansMember to LoanDMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanEMember" xlink:title="presentation: TermLoansMember to LoanEMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanFMember" xlink:title="presentation: TermLoansMember to LoanFMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="presentation: DebtInstrumentNameDomain to TermLoansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="PrimeRateMember" xlink:title="PrimeRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="PrimeRateMember" xlink:title="presentation: VariableRateDomain to PrimeRateMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="presentation: VariableRateAxis to VariableRateDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="presentation: DebtInstrumentTable to VariableRateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:label="BusinessCombinationConsiderationTransferredAbstract" xlink:title="BusinessCombinationConsiderationTransferredAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:label="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_ShelfRegistrationStatementAvailableForFutureSale" xlink:label="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="ShelfRegistrationStatementAvailableForFutureSale" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ShelfRegistrationStatementAvailableForFutureSale" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ShelfRegistrationStatementAvailableForFutureSale" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_PlacementSharesAvailableForFutureSale" xlink:label="PlacementSharesAvailableForFutureSale" xlink:title="PlacementSharesAvailableForFutureSale" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="PlacementSharesAvailableForFutureSale" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to PlacementSharesAvailableForFutureSale" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_CommissionPercentage" xlink:label="CommissionPercentage" xlink:title="CommissionPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="CommissionPercentage" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to CommissionPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to ProceedsFromIssuanceOfCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentNumberOfIndependentTermLoans" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentFaceAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentUnusedBorrowingCapacityAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentTerm" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:label="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentBasisSpreadOnVariableRate1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentVariableRate" xlink:label="DebtInstrumentVariableRate" xlink:title="DebtInstrumentVariableRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentVariableRate" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentVariableRate" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentWrittenNoticePeriodForPrepayment" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPrepaymentPremiumPeriod1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentThresholdPeriod" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentThresholdPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPrepaymentPremiumPeriod2" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPrepaymentPremiumPeriod3" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationConsiderationTransferredAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="presentation: BusinessCombinationConsiderationTransferredAbstract to DebtInstrumentPrepaymentPremiumPeriod4" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="BusinessCombinationConsiderationTransferredAbstract" xlink:title="presentation: DebtInstrumentLineItems to BusinessCombinationConsiderationTransferredAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: LiquidityAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:title="presentation: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:title="presentation: FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesOperatingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="AreaOfRealEstateProperty" xlink:title="AreaOfRealEstateProperty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="AreaOfRealEstateProperty" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to AreaOfRealEstateProperty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="LessorOperatingLeaseTermOfContract" xlink:title="LessorOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LessorOperatingLeaseTermOfContract" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LessorOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseRemainingLeaseTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="LesseeOperatingLeaseDiscountRate" xlink:title="LesseeOperatingLeaseDiscountRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseDiscountRate" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseDiscountRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="CashFlowOperatingActivitiesLesseeAbstract" xlink:title="CashFlowOperatingActivitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowOperatingActivitiesLesseeAbstract" xlink:to="OperatingLeasePayments" xlink:title="presentation: CashFlowOperatingActivitiesLesseeAbstract to OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="CashFlowOperatingActivitiesLesseeAbstract" xlink:title="presentation: LeasesAbstract to CashFlowOperatingActivitiesLesseeAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/LeasesFinancingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowFinancingActivitiesLesseeAbstract" xlink:label="CashFlowFinancingActivitiesLesseeAbstract" xlink:title="CashFlowFinancingActivitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_FinanceLeasePrincipalAndInterestPayments" xlink:label="FinanceLeasePrincipalAndInterestPayments" xlink:title="FinanceLeasePrincipalAndInterestPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowFinancingActivitiesLesseeAbstract" xlink:to="FinanceLeasePrincipalAndInterestPayments" xlink:title="presentation: CashFlowFinancingActivitiesLesseeAbstract to FinanceLeasePrincipalAndInterestPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="CashFlowFinancingActivitiesLesseeAbstract" xlink:title="presentation: LeasesAbstract to CashFlowFinancingActivitiesLesseeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="FinanceLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:label="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityToBePaidYearFourAndThereafter" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityToBePaidYearFourAndThereafter" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="FinanceLeaseLiabilityPaymentsDue" xlink:title="FinanceLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityPaymentsDue" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityPaymentsDue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiabilityUndiscountedExcessAmount" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="FinanceLeaseLiability" xlink:title="FinanceLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="FinanceLeaseLiability" xlink:title="presentation: FinanceLeaseLiabilitiesPaymentsDueAbstract to FinanceLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to FinanceLeaseLiabilitiesPaymentsDueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:label="LesseeFinanceLeaseDescriptionAbstract" xlink:title="LesseeFinanceLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeFinanceLeaseNumberOfLeases" xlink:label="LesseeFinanceLeaseNumberOfLeases" xlink:title="LesseeFinanceLeaseNumberOfLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseNumberOfLeases" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseNumberOfLeases" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_FinanceLeaseCost" xlink:label="FinanceLeaseCost" xlink:title="FinanceLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="FinanceLeaseCost" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to FinanceLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="LesseeFinanceLeaseTermOfContract1" xlink:title="LesseeFinanceLeaseTermOfContract1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseTermOfContract1" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseTermOfContract1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="LesseeFinanceLeaseDiscountRate" xlink:title="LesseeFinanceLeaseDiscountRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseDiscountRate" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseDiscountRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LesseeFinanceLeaseMonthlyRentalExpense" xlink:label="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="LesseeFinanceLeaseMonthlyRentalExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="LesseeFinanceLeaseMonthlyRentalExpense" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to LesseeFinanceLeaseMonthlyRentalExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="PropertyPlantAndEquipmentAdditions" xlink:title="PropertyPlantAndEquipmentAdditions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeFinanceLeaseDescriptionAbstract" xlink:to="PropertyPlantAndEquipmentAdditions" xlink:title="presentation: LesseeFinanceLeaseDescriptionAbstract to PropertyPlantAndEquipmentAdditions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeFinanceLeaseDescriptionAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeFinanceLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: LeasesAbstract to LesseeLeaseDescriptionTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="AccruedResearchAndDevelopmentCostsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedResearchAndDevelopmentCostsCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedResearchAndDevelopmentCostsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="WorkersCompensationLiabilityCurrent" xlink:title="WorkersCompensationLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="WorkersCompensationLiabilityCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to WorkersCompensationLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="InterestPayableCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to InterestPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRentCurrent" xlink:label="AccruedRentCurrent" xlink:title="AccruedRentCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedRentCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedRentCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_EquityCompensationPlansMember" xlink:label="EquityCompensationPlansMember" xlink:title="EquityCompensationPlansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_EquityIncentivePlan2014Member" xlink:label="EquityIncentivePlan2014Member" xlink:title="EquityIncentivePlan2014Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityCompensationPlansMember" xlink:to="EquityIncentivePlan2014Member" xlink:title="presentation: EquityCompensationPlansMember to EquityIncentivePlan2014Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_EquityIncentivePlan2018Member" xlink:label="EquityIncentivePlan2018Member" xlink:title="EquityIncentivePlan2018Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityCompensationPlansMember" xlink:to="EquityIncentivePlan2018Member" xlink:title="presentation: EquityCompensationPlansMember to EquityIncentivePlan2018Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_InducementPlan2019Member" xlink:label="InducementPlan2019Member" xlink:title="InducementPlan2019Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityCompensationPlansMember" xlink:to="InducementPlan2019Member" xlink:title="presentation: EquityCompensationPlansMember to InducementPlan2019Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityCompensationPlansMember" xlink:title="presentation: PlanNameDomain to EquityCompensationPlansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeStockOptionMember" xlink:to="IncentiveStockOptionsMember" xlink:title="presentation: EmployeeStockOptionMember to IncentiveStockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_PercentageOfCommonStockOutstanding" xlink:label="PercentageOfCommonStockOutstanding" xlink:title="PercentageOfCommonStockOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="PercentageOfCommonStockOutstanding" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to PercentageOfCommonStockOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to StockIssuedDuringPeriodSharesIssuedForServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LiabilityForUncertainTaxPositions" xlink:label="LiabilityForUncertainTaxPositions" xlink:title="LiabilityForUncertainTaxPositions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="LiabilityForUncertainTaxPositions" xlink:title="presentation: IncomeTaxDisclosureAbstract to LiabilityForUncertainTaxPositions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExaminationPenaltiesAndInterestAccrued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="OtherCommitmentsTable" xlink:title="OtherCommitmentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_MerckKGaALicenseAgreementMember" xlink:label="MerckKGaALicenseAgreementMember" xlink:title="MerckKGaALicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsDomain" xlink:to="MerckKGaALicenseAgreementMember" xlink:title="presentation: OtherCommitmentsDomain to MerckKGaALicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain" xlink:title="presentation: OtherCommitmentsAxis to OtherCommitmentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsAxis" xlink:title="presentation: OtherCommitmentsTable to OtherCommitmentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="RangeAxis" xlink:title="presentation: OtherCommitmentsTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="OtherCommitmentsAbstract" xlink:title="OtherCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: OtherCommitmentsAbstract to OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:label="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="MilestonePaymentsDevelopmentAndFirstCommercialSales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="MilestonePaymentsDevelopmentAndFirstCommercialSales" xlink:title="presentation: OtherCommitmentsAbstract to MilestonePaymentsDevelopmentAndFirstCommercialSales" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:label="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="MilestonePaymentsAchievementOfCertainAggregateSalesLevels" xlink:title="presentation: OtherCommitmentsAbstract to MilestonePaymentsAchievementOfCertainAggregateSalesLevels" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:label="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="RoyaltyPercentagePaidOnNetSalesOfProduct" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="RoyaltyPercentagePaidOnNetSalesOfProduct" xlink:title="presentation: OtherCommitmentsAbstract to RoyaltyPercentagePaidOnNetSalesOfProduct" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_TermOfRoyaltyPayment" xlink:label="TermOfRoyaltyPayment" xlink:title="TermOfRoyaltyPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsAbstract" xlink:to="TermOfRoyaltyPayment" xlink:title="presentation: OtherCommitmentsAbstract to TermOfRoyaltyPayment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsLineItems" xlink:to="OtherCommitmentsAbstract" xlink:title="presentation: OtherCommitmentsLineItems to OtherCommitmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherCommitmentsTable" xlink:to="OtherCommitmentsLineItems" xlink:title="presentation: OtherCommitmentsTable to OtherCommitmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="OtherCommitmentsTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to OtherCommitmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_TermLoansMember" xlink:label="TermLoansMember" xlink:title="TermLoansMember" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanAMember" xlink:label="LoanAMember" xlink:title="LoanAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanAMember" xlink:title="presentation: TermLoansMember to LoanAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanBMember" xlink:label="LoanBMember" xlink:title="LoanBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanBMember" xlink:title="presentation: TermLoansMember to LoanBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanCMember" xlink:label="LoanCMember" xlink:title="LoanCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanCMember" xlink:title="presentation: TermLoansMember to LoanCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanDMember" xlink:label="LoanDMember" xlink:title="LoanDMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanDMember" xlink:title="presentation: TermLoansMember to LoanDMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanEMember" xlink:label="LoanEMember" xlink:title="LoanEMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanEMember" xlink:title="presentation: TermLoansMember to LoanEMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_LoanFMember" xlink:label="LoanFMember" xlink:title="LoanFMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TermLoansMember" xlink:to="LoanFMember" xlink:title="presentation: TermLoansMember to LoanFMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="TermLoansMember" xlink:title="presentation: DebtInstrumentNameDomain to TermLoansMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember" xlink:label="PrimeRateMember" xlink:title="PrimeRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="PrimeRateMember" xlink:title="presentation: VariableRateDomain to PrimeRateMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="presentation: VariableRateAxis to VariableRateDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="presentation: DebtInstrumentTable to VariableRateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="presentation: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="MeasurementInputTypeAxis" xlink:title="presentation: DebtInstrumentTable to MeasurementInputTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentNumberOfIndependentTermLoans" xlink:label="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="DebtInstrumentNumberOfIndependentTermLoans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentNumberOfIndependentTermLoans" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentNumberOfIndependentTermLoans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="DebtInstrumentUnusedBorrowingCapacityAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentUnusedBorrowingCapacityAmount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentUnusedBorrowingCapacityAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTerm" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentBasisSpreadOnVariableRate1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentVariableRate" xlink:label="DebtInstrumentVariableRate" xlink:title="DebtInstrumentVariableRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentVariableRate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentVariableRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:label="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="DebtInstrumentWrittenNoticePeriodForPrepayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentWrittenNoticePeriodForPrepayment" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentWrittenNoticePeriodForPrepayment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod1" xlink:label="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="DebtInstrumentPrepaymentPremiumPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod1" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPrepaymentPremiumPeriod1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentThresholdPeriod" xlink:label="DebtInstrumentThresholdPeriod" xlink:title="DebtInstrumentThresholdPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentThresholdPeriod" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentThresholdPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod2" xlink:label="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="DebtInstrumentPrepaymentPremiumPeriod2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod2" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPrepaymentPremiumPeriod2" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod3" xlink:label="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="DebtInstrumentPrepaymentPremiumPeriod3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod3" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPrepaymentPremiumPeriod3" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_DebtInstrumentPrepaymentPremiumPeriod4" xlink:label="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="DebtInstrumentPrepaymentPremiumPeriod4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPrepaymentPremiumPeriod4" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPrepaymentPremiumPeriod4" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: DebtInstrumentsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: DebtInstrumentsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="presentation: DebtInstrumentsAbstract to WarrantsAndRightsOutstandingTerm" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pdsb-20230630.xsd#pdsb_PercentageOfVotingPowerDisposedOff" xlink:label="PercentageOfVotingPowerDisposedOff" xlink:title="PercentageOfVotingPowerDisposedOff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PercentageOfVotingPowerDisposedOff" xlink:title="presentation: DebtInstrumentsAbstract to PercentageOfVotingPowerDisposedOff" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="WarrantsAndRightsOutstandingMeasurementInput" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="WarrantsAndRightsOutstandingMeasurementInput" xlink:title="presentation: DebtInstrumentsAbstract to WarrantsAndRightsOutstandingMeasurementInput" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="presentation: DebtInstrumentsAbstract to PaymentsOfDebtIssuanceCosts" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentUnamortizedDiscount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="InterestExpenseDebt" xlink:title="InterestExpenseDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="InterestExpenseDebt" xlink:title="presentation: DebtInstrumentsAbstract to InterestExpenseDebt" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: DebtInstrumentsAbstract to AmortizationOfDebtDiscountPremium" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/RetirementPlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" (,!/8# 2(  A$! Q$!_\0
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MO);S1RK')#(DC=%92"?PHT,W.:ZLV/\ A,?$W_0Q:S_X'2__ !5'_"8^)O\
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M  F/B;_H8M9_\#I?_BJPJ*+![2?<W?\ A,?$W_0Q:S_X'2__ !5'_"8^)O\
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M3'Q-_P!#%K/_ ('2_P#Q5>@> O\ DAWC+_KK_P"RI7D5)'17G+EAKT_4W?\
MA,?$W_0Q:S_X'2__ !5'_"8^)O\ H8M9_P# Z7_XJL*BG8Y_:3[F[_PF/B;_
M *&+6?\ P.E_^*H_X3'Q-_T,6L_^!TO_ ,56%118/:3[F[_PF/B;_H8M9_\
M Z7_ .*H_P"$Q\3?]#%K/_@=+_\ %5A446#VD^YN_P#"8^)O^ABUG_P.E_\
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M)4445)W!1110 4444 %%%% !1110 4444 %%%% !7D_[2?\ R(MC_P!A*/\
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M -#A Z83.?\ Q[=^&*:>MCEJ48QASI[VM^OW'$T4451S!1110 4444 %%%%
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MVO(;NUAM)+>Z,)W&,,%_7(_G7,>,]$\!16^JZM8:\;JZF5W@LHW!Q*W0D]<
MG->3T4<H3Q3G=2BG^A]'Z7XG\-V=YHDNEZYI5CHZ0JDEH8AY^_!^\W8=,_2L
M#PAXLT6T^)OB]KR_ACT_4L^5=;OD.#Z^X8_E7A]%'*-XR5T[;?\ #'LL%[X>
MT/X=>,M"L=:@NC)/FU)8!IP8XLD >X8?A5_4KKP3\0+/2-2US61IM_:P+#/
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MU.RTCQW!=ZG=16MLL,BF25L*"1Q7"44,QIS<)*2Z'H'C;XEZ_K$FH:<+Z/\
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M"[#_ ,!T_P *N6MQ%=6T4]NXDAD4.C#H0>E2T!RQ[&=_8>D_] NP_P# =/\
M"C^P])_Z!=A_X#I_A6C10'+'L9W]AZ3_ - NP_\  =/\*/[#TG_H%V'_ (#I
M_A6C10'+'L9W]AZ3_P! NP_\!T_PH_L/2?\ H%V'_@.G^%:-% <L>QG?V'I/
M_0+L/_ =/\*/[#TG_H%V'_@.G^%:-% <L>QG?V'I/_0+L/\ P'3_  H_L/2?
M^@78?^ Z?X5HT4!RQ[&=_8>D_P#0+L/_  '3_"C^P])_Z!=A_P" Z?X5HT4!
MRQ[&=_8>D_\ 0+L/_ =/\*/[#TG_ *!=A_X#I_A6C10'+'L9W]AZ3_T"[#_P
M'3_"C^P])_Z!=A_X#I_A6C10'+'L9W]AZ3_T"[#_ ,!T_P */[#TG_H%V'_@
M.G^%:-% <L>QG?V'I/\ T"[#_P !T_PH_L/2?^@78?\ @.G^%:-% <L>QG?V
M'I/_ $"[#_P'3_"C^P])_P"@78?^ Z?X5HT4!RQ[&=_8>D_] NP_\!T_PJ%M
M$TK[8@_LRQQY;''V=/4>U:]1EE^T*N/FVD@^V10'+'L4O[#TG_H%V'_@.G^%
M']AZ3_T"[#_P'3_"M&B@.6/8SO[#TG_H%V'_ (#I_A1_8>D_] NP_P# =/\
M"M&B@.6/8SO[#TG_ *!=A_X#I_A1_8>D_P#0+L/_  '3_"M&B@.6/8SO[#TG
M_H%V'_@.G^%']AZ3_P! NP_\!T_PK1HH#ECV,C^Q-*^V8_LRQQY><?9T]?I4
MW]AZ3_T"[#_P'3_"KN5^T;<?/MSGVS4E <L>QG?V'I/_ $"[#_P'3_"C^P])
M_P"@78?^ Z?X5HT4!RQ[&=_8>D_] NP_\!T_PH_L/2?^@78?^ Z?X5HT4!RQ
M[&=_8>D_] NP_P# =/\ "C^P])_Z!=A_X#I_A6C10'+'L9W]AZ3_ - NP_\
M =/\*ADT32OM4(_LRQP5;(^SI[>U:]1L5$T8(^8@X/ITH#ECV*7]AZ3_ - N
MP_\  =/\*/[#TG_H%V'_ (#I_A6C10'+'L9W]AZ3_P! NP_\!T_PH_L/2?\
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M_P */[#TG_H%V'_@.G^%:-% <L>QG?V'I/\ T"[#_P !T_PH_L/2?^@78?\
M@.G^%:-% <L>QG?V'I/_ $"[#_P'3_"C^P])_P"@78?^ Z?X5HT4!RQ[&1)H
MFE?:81_9EC@AL_Z.G^%3?V'I/_0+L/\ P'3_  JZ[*)HP1ECG!]*DH#ECV,[
M^P])_P"@78?^ Z?X4?V'I/\ T"[#_P !T_PK1HH#ECV,[^P])_Z!=A_X#I_A
M1_8>D_\ 0+L/_ =/\*T:* Y8]C._L/2?^@78?^ Z?X4?V'I/_0+L/_ =/\*T
M:* Y8]C._L/2?^@78?\ @.G^%']AZ3_T"[#_ ,!T_P *T:* Y8]C._L/2?\
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M4@9MV3G)[=J[;6-/T_\ M2PUW4+G[.=,294=Y%2("4*&+D_[HQR*B\.^&H-
MO-0DL;R\-K>3R7)LI"AABDD<N[)A0PRQ)P6(YX H H>*-6U-O$^E>'=$EAM;
MB[MI[V6[E3S!%%$T:X5/XF+2KU[ USFL^+==T/1_&5K<26UUJNB6UO=07*Q;
M%F28N%#)G 8&-QU[@UV?B3PU;:Y-971NKRPU&R+?9[VS=5E0,!N7YE964X&0
MRD9 /:J#>!=.ET75K"ZN;ZYFU4*+R^E=?/EVXV\A0H [ *!R>.: -O1(-1@M
M7_M>\BNKAY"X,<7EK&I ^0<_-@Y^8]<UR=U?^)=3\8>(=*T>^L[.WTZ"VEB:
M6#S&=Y%<E3ST^7KU%=Y6/H^GZ?\ VI?Z[I]S]H.II"KNDBO$1$&"E"/]XYY-
M ' Z3XR\03:5X+\1WDEH-.\07,%J^GI%S")D8JXDZDY )&.]5-3\>^(KFYUR
MXT*TOY$TV[GM(+*+2)9TNVA8HP,X&$+,I QG'&>]=Q#X'TR+P[X;T99;O[+H
M,T$]JQ==[-""%WG;@CGG 'X4T^";>+5+NZT[5M7T^"\F-Q<V5M+&(99#]YOF
M0NI;J=C+D\^M '*:'%JK_'#7[A]5$5JNE64\D#VH!\HO/B,G/!7!RW?\*I:Q
M\0;_ $\6VJVFJ#4=,DO;>)HXM,?R##+,L99;CH<;@0>A/'<5Z%J'A6UO/$@U
MI;J\M[A[86=S%"4\NZA!8JD@92>"[<J5//6N;N?AQI+:;8^'KWQ'K+V$9B:Q
MT^2X@41B!D90F(PSA0J@[BW!]<$ #I_$^I1_$"73+^^ATJU6ZCBLX+BV.V_C
M9%)99N@?<74*,_=&>M9/@L:C8?$7XD7FHZY#]AM+B!YQ);A%*_8XV5BV?E"@
MC/K@GO79:KX.@U745FOM3U26Q%Q'=?V<9(S;F6-PZMG9YG#*#@/CCICBF:EX
M'T[4-2UBYFN;U;?6;?[/J%DC((;D>68PQRN\,%(&58=!D&@#DM'\9:K=>+M/
MT?\ M+[1#K%K<M;W)TUHD@E10RE&/$JX)/;MZUC_  _O]:\/_!F?51J4=R1J
M$T<,;VP'EDZDZ2$G/S;MQ/M7?Z=X"M;77-(U:ZU?6-0O-*22.V-U+'M5'3:5
M*HB@\#KU]2:(_ -A'I6I:6M_J/\ 9=Y<?:EM-\>RW?SO.;RSLW89\DABW7C%
M $$NI:]KOBG7-.T2\MM-M=&>*%Y)8/.:>5XEEQC(VJ%=.>N<^E=K#O\ *3SM
MOF;1NV],]\>U<K>>&+#4];O-4TG6K_3[R0K!?_V=-&5F9!@+(KH^&"D#(VMC
M'/ KJH8Q%$D:EBJ*%!8DGCU)ZT >1?"%_%@\"PC28-":R^W7_EFZFE60_P"F
M39R%4CKGOTQ7+Z#/=6W@?X0S6UFU[=+K%T1;QR*A<^7=9 9B .YY]*]P\*Z!
M:^&=$CTO3WF>WCEFF#3,"V997E;D #&YSCCIBLG3O 6E6%CX;M(9KPQZ#<R7
M=J6=26=Q("'^7D?O6Z8Z"@#G-2\':GK]AXPO[NVCTW4=4AMC8VZNKM#-;%WB
MD9EXW%V&<=E%..KQ^/;SP1;1*1;-&-=OXB/N&+"QQ-[^><X_Z8FO3JYSPOX.
MTOPUJ>L7VF^=YVIS>;*)&!6,;G?9& !M7?)(V.>7- ',>,-+LK3XK_#^\M[:
M-+JZO[PS2@?,^+&4#)_I599M:N?BSXK?2K*RNKBPM;."%KV4HD<;(SE4P"=S
M,3D]/E&37>:KH%KJ>MZ)JEP\RW&D2RS6ZHP"L9(FB;<,9(VN<8(YQ5/6_"<&
MI:J=2M=2U'2KV2$6\\MB\:F>,$E5<.C#C<V&&&&3S0!2TKQM:S^&-*U-=*U0
MK>*X,-G9O<>2Z-M=6V @?,"!ZX.*ZRWE$]O%*JN@D4.%D4JPR,X(/(/M5;1-
M+M-$TFUTW3H_*M+9!'&I8L<>I)Y)/4D\DFKM !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %1E#]I5_X0A'ZC_"I*A8G[8@
MR<>6QQ^(H FHHHH **** "BBB@ HHHH BV'[5O\ X=FW]:EJ')^V8R<>7G'X
MU-0 4444 %%%% !1110 5&Z$W$;#HH8'\<5)4,A(NH1DX(;(_*@":BBB@ HH
MHH **** "BBB@"-D)N4?^$(P/XD?X5)4+$_;(QDX,;''XK4U !1110 4444
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M]P'>Y ,PD$1&,* !M!!Z#IS0!VMUXLNI-<O]/T31I=233F6.]F$XC".RA]B
M@[V"LI(X^\*K_!E]_P +_#S@$!K<G!&"/F:D&@:_I?B#6;G0+K3_ +!K$ZW,
MRW6[S+>7RDC+( "&!6-3@D<UK> =#G\-^#]+T>[F2>>TB\MY4SASDG//UH S
M_''C";PO'-.=-CN+2WA,\TCWB0MM&<A%(^<\=.*6_P#&3C6;'3-'TQ]0N+W3
MCJ,#><(DV;E7#'!Q]X'//I7/>*_ &JZMJ7B9H)=+G@UF()'->AWELL0B/;&N
M"N,C=G((+'KBN@\.>%;G2]7T6[EGA=+'0ETIU7.6D#(=PX^[\A]^: ((_'\4
MF@VMRFFW!U6XOY-+33=PW?:4+;UW=-H",V['0=*RY]3O[WXG^$(M4TF33IX[
M>_/^M$L;_+%]U@!G'';O5B?P1J,<:W5A>6R:I:Z[<ZO:EPQC995=#&_&1\DC
M<C/-7;?P_K]WXPT;7-9O; 1V,5PAM+96(4R!!D,0"WW,\@8SWH W/&.NQ^&?
M#.H:S- \\=G'YC1H<%AD#C\ZSM/\57#^)K?1]4TB6P-[#)/92F82"58RNX,
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M"BBB@U"BBB@ HHHH *CD*^;$&'S$G;[<5)44JDS0L!PI.?RH EHHHH ****
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M?QQNQ7CE(X\53C%IQ5M_P84444'*%>D_ 3_D<+S_ *\'_P#1D=>;5Z3\!/\
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MS+:AY% $C1L49DY.5W @'C./3% &E1110 4444 %%%% !1110 4444 %%%%
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MM^(UYX*L=/L_#5M:W_B;4+J&WMK.<$@JY<;L!E/5-O4<F@.2/8[_ /L;2_\
MH&V7_?A?\*/[&TO_ *!ME_WX7_"OG75/C=\2?!5[9R?$7P78VNESR!-]KN#>
M^&\QUW8R0#C.*]U\4>.?#?A6R@NO$.K6]A'.H:-9,EV![A%!8CWQ0')'L:O]
MC:7_ - VR_[\+_A43Z)IOVB(C3;/: V?W"^WM56P\8>'[_PU_P )!:ZM:MHV
M"3=LVU!C@@YP0?8\UE:+\2_"6NPZA=:1KEO<6NF1/->N$=?*11G=@J"1@'IF
M@.2/8Z3^QM+_ .@;9?\ ?A?\*/[&TO\ Z!ME_P!^%_PK@?AWXLN+3X?R^)O'
MOBC2[JSN[AY;6Y@A,$20YVB-0RJ['*L>03]>M;>C_$_P=K-UI=MI>N0W-QJ;
M2):1I')F0IRP(V_+@<_-B@.2/8Z/^QM+_P"@;9?]^%_PH_L;2_\ H&V7_?A?
M\*YB^^*G@FP_M3[7X@MHO[-G^S76Y'^27)&T?+\Y&TYVYQWK7;QEX=3PO#XB
MDU>U319AF.[=MJOU&!GDG@\8SP: Y(]C0_L;2_\ H&V7_?A?\*/[&TO_ *!M
ME_WX7_"N=T/XF>#M<TS4]0TK7;>>TTR(S7;['4Q( 26PR@D<'H#7'_#GXW:5
MXQ\9Z_I8EMK>PLPS6,FR0O=1IN+RDXPB@*#@X/S?A0')'L>I?V-I?_0-LO\
MOPO^%26^F6%O*);>RM8I%Z.D2J1^(%>??#7Q5<W7A_6O$_B;Q/I=WH,]X_\
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M %X/_P"C(Z$=>!_WB'J>]T4451]>%%%% !1110 4444 %%%% !1110 4444
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M="@BGTR#3Y8=4L;E83<B0E(KA))&+ 8^Z.!UR#ZBN\HH SO$EI+?^'=4L[<
MS7%K+#&"<#<R$#]37#^*/!5Q?^'_  AG3[34KC1%1)M/G<+'.IB$;@-T#*<,
M#TX([UZ310!YP/!\AT*RCTW0K#1I1K=G?S6T,@;]W%(A9F8<,V%.,=L"M6/0
M-5CO?'DUI.EI/J^PV%P#DQL+5(@Y'LZD_A7944 >,Z?\/=0N]>TZZN=&MM)B
M_LR\L;^=;H3SW$DT:+YK-WY#'GG))/6NW\)R>)K.WT_2=3TBU6*UC$$E_'=
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ML^5/^$ \1_\ 0.DH_P"$ \1_] Z2OJNBBPO['H=V?*G_  @'B/\ Z!TE'_"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH AD!^TPGMAJFJ-W*S1*.C9S^%24 %%%% !1110 4444
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M9U/^[;?F:T** ,_.I_W;;\S1G4_[MM^9K0HH S\ZG_=MOS-,(U'SU;%MN"D
M9/3(K3J%O^/U/^N;?S% %7.I_P!VV_,T9U/^[;?F:T** ,_.I_W;;\S1G4_[
MMM^9K0HH S\ZG_=MOS-&=3_NVWYFM"B@#/SJ?]VV_,T9U/\ NVWYFM"B@#,Q
MJ/G[L6V[;C&3TS3\ZG_=MOS-6O\ E]_[9_UJ:@#/SJ?]VV_,T9U/^[;?F:T*
M* ,_.I_W;;\S1G4_[MM^9K0HH S\ZG_=MOS-&=3_ +MM^9K0HH S\ZG_ ';;
M\S3&&HF9&(MMP!P,GGI6G4,G_'U#_NM_2@"KG4_[MM^9HSJ?]VV_,UH44 9^
M=3_NVWYFC.I_W;;\S6A10!GYU/\ NVWYFC.I_P!VV_,UH44 9^=3_NVWYFC.
MI_W;;\S6A10!F$:CYZ-BVW!2 ,GD9'^ I^=3_NVWYFK3?\?L7_7-_P":U-0!
MGYU/^[;?F:,ZG_=MOS-:%% &?G4_[MM^9HSJ?]VV_,UH44 9^=3_ +MM^9HS
MJ?\ =MOS-:%% &?G4_[MM^9ID@U$RQD_9@5)P,GGBM.H9O\ CXM_JW\J *N=
M3_NVWYFC.I_W;;\S6A10!GYU/^[;?F:,ZG_=MOS-:%% &?G4_P"[;?F:,ZG_
M ';;\S6A10!GYU/^[;?F:,ZG_=MOS-:%% &8XU$S1L1;!AG R>:?G4_[MM^9
MJU+_ ,?4'T:IJ ,_.I_W;;\S1G4_[MM^9INL:U9:.UJ+XS@W4HAB\JWDERYZ
M [%./QQ5"7QEH4<*R&]9PQ"JL<$CL279  JJ3G<C#IV]* -'.I_W;;\S1G4_
M[MM^9J234[6-;1I79/M4ODPAHV!9\,<8(R.%8\^E9<'C+09V58K]2S)%(!Y;
M@E9 Q0].X1OIWQD4 :&=3_NVWYFC.I_W;;\S6=)XRT*.T:Y:]/E*"3B&0G 5
M&S@+GI(G_?0'6GR>+M&BNX[::YEBF>+S@)+>1 J[7;YB5PIQ&YP<'Y>E %[.
MI_W;;\S1G4_[MM^9K/7QCHK6(NUGN#"8I)Q_HDVXQILW,%V[B!YBG..ASV-3
MVGB?2KNXM[>&XD%Q<!&CBD@D1V#*S!MK*#C"MST&,'F@"SG4_P"[;?F:,ZG_
M ';;\S5&Z\6Z+:37<5Q=LAM5D:5O)D*_NP"X5MN&8 C*J2?:IIO$FG0G3Q(;
ML&_;;;_Z',<GDX;Y?DX!/S8X!/2@"QG4_P"[;?F:,ZG_ ';;\S6>GC'1&TV&
M_-U(EI,Q6*22WE02$+NPN5&<CIC[W09-3WOB?2+)[]+F["/8K$UPOEL2GF'"
M< <DG P,GD>M %G.I_W;;\S1G4_[MM^9JS8W45]:17-OO\J1=R[T9&_%6 (^
MA%3T 9^=3_NVWYFC.I_W;;\S6A10!GYU/^[;?F:,ZG_=MOS-:%% &?G4_P"[
M;?F:,ZG_ ';;\S6A10!5M3>>8?M(A"8XV$YS15JB@#YS\5?\C/J__7Y-_P"A
MFLNM3Q5_R,^K_P#7Y-_Z&:RZ@^ K?Q)>K"BBB@S"BBB@ HHHH **** "BBB@
M HHHH *[;X2_\C'<_P#7HW_H:5Q-=M\)?^1CN?\ KT;_ -#2A'9EW^\P]3M?
MB-KUQX7\#:SK=G%%+<6-N9D24'8Q&.N"#7G.D?$SQ=I^M>%(O&FCZ1'IGB5H
MX[.XTZ1RT;N 5#AB?[R]/?FNQ^.*-)\)/%*1JSN;)@%49)Y%<Q\.?AB#%X7U
M_P 0Z[J.L2V5I%-96MR L=HS1KT Z[>V?059]N5M-\;_ !(\1:SXGB\,:5X9
MDL-'U2XTX&[DF21_+8@'@XR1CTYJ[I?QA/\ PBOBNZUO1I+/7?#8'VNP5\AR
MQPA4^A/7K@<]ZY'P!\0M%\$>(/B%9ZXFH"YN?$EY<0K#:/('4O@<@8Y(K4\'
MVES/=>/OB!XET&Y_LW6DBABTLQ[I7MD 0NR?[H!_ T =3X \6>,M7%IJ>OZ5
MHL?AV\@:>.XL;AFD@786'F \>@XZ&N8M_C'X@^S:?XGN]!LXO M]??8HY_,;
M[4H+%1*P^[MR#V_QKE_!,4-U\0TL_AC_ &NOA>[L[B/4X;R)U@@8QMLV[NGS
M%>E9:S7>N?"W0OA8-)U"+Q';Z@L5VK0L(XHEE9C+OZ8P10!ZY\4_B=J'A+6;
M+3M-T.2X66XMX9KZ<$0)YK8"K@@LV ?I6M\2?&FHZ%JNAZ!X9L+>^\0ZPTGD
M+<L5AB1!EG<CG'^!K(_:,BDE\)Z$(D9R->LR0HS@9;FJ?Q:GE\,_$WP;XQN;
M2XGT6TAN+.[>WC+M#O7Y6(')'/Z4 :?A+XEW=[X<\1RZWH[C7O#]Q]FN[*QR
M_FL3A#'GG!YZ]AFKOP?\<:AXXL]>FU73H]-FT_4GLA;J263:HR'.<%@21Q@<
M5B_ NUN+W6O''BR2UGM;/7K]&LTF4JSQ1A@'P>F=_P"E2? F*2/4OB1YB.F[
MQ3>,NX8R,CD>U 'H7BG6[7PWX=U'6;\D6UE"TS@=6P.%'N3@#ZUP<?CS7[?5
M_AS8ZG8V$4GB<7,ERB*^;=417C5<M][#8;/?IBG_ +2EK<7?P7\0I:!BR+#*
MZKW19D9OR S^%<Y\9-)M/&'CSX56Y-P=,O/MKF6U<H50Q1,I##IG H [OQ)X
MNO-*^)W@_P -0P6[VFM)=M-*X/F)Y41==O..2.<@UPFH?$GQX^H^,9M$T?0;
MC1O#=U+%/YKRK.Z("Q(^;!.T>U46\":?X.^//P]_L=M2FBGCOS*]U<-.%(MV
M P3TZU3\-> KSQ=XN^(\<NOZII>F2:Q)'/9VZ@)=*0<DD\]..* .S\#?%.X\
M1>--,TZYLH+;2]8TD:AI\@W>89%.V2)B3@X*N> . *7Q!\0/$)\7^*M+\+:?
M87=MX>T^.YG,RN7EF.&,2D, /W>[''WA5#XP^'HO"GAWPCK_ (=M6 \)7<0$
M48RS6KD)(ON3\OYFM'X&V;6?@?5/%&N)Y-WKUU/JMUY@YCB).Q3[!1G_ (%0
M!WWA_P 06.M^%[/7K:0)87-N+D,YQL7&3N^G(/TK'^%_B6_\7^''UN]M8;6T
MN;F7[ B AVM@V$9\D_,<$\8&,5XMX7FO_P#A0/@SP=:2,FJ>*)Y;=/[T-H97
M>63Z;/\ T.OH[2[&WTS3;6PLHQ';6T2PQ(.BJHP!^0H M5=M_P#4K5*KMO\
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M@*W\27JPHHHH,PHHHH **** "BBB@ HHHH **** "NV^$O\ R,=S_P!>C?\
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M^+9<0>7GZ>9+CZFI/B9J5U8:3IL-G>&P%_J4%E-> #,$3D[B"> 3C:">A;-
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M/[TN\GT0+_Q3T9USQ#_IGB*\_=V]K'SLSTBC'/KRW/7 R3\PO_%/1G7/$/\
MIGB*\_=V]K'SLSTBC'/KRW/7 R3\PG_$F5O$?B?]]K,X\NUM$Y\H'I&@]>>3
M[GU.1/\ B3*WB/Q/^^UF<>7:VB<^4#TC0>O/)]SZG(&WE;77I_>EWD^B!?\
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M+4[B$[9#%NVI$K=5W'J1SBKVM_#K31##=:!OTW5;:>*=+A)F&_:P++)S\RL
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M110 4444 %1R)NEB;(^4G\>*DJ";_CXM_JW\J )Z*** "BBB@ HHHH ****
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MO$.CZ7?6]GJ.IVEK=W! AAEE"M)DX& >O- $OE:C_P _,'_?NCRM1_Y^8/\
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M?V;Z7IUE'KD6L7?V-+C[3N7?<1G@38'8D'D<4 7_ "M1_P"?F#_OW1Y6H_\
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MZ* *'E:C_P _,'_?NHY$U!9(U-Q 2Q.#Y?3BM.HY$+2Q,.BDY_*@"IY6H_\
M/S!_W[H\K4?^?F#_ +]U?HH H>5J/_/S!_W[H\K4?^?F#_OW5^B@"AY6H_\
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M*".!BO7J* /!?BE<:UK.B^-[!H=5AN&5ULK'3]*#K>0B-2DLD[(P+9S\JE7
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M (9XHG5Q;#&[S&4;>>Q)Z\5D>(O#6I^&M!\)6^EW, UJY\[0YW1B%Q=;I'=
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M@[Q4VE_V=_;-J++8$\I<@;?3A<_XT-X.\5-I?]G?VS:BRV!/*7(&WTX7/^-
M?OG\5-N^^VO9;Z1_,OM_Q5<GV&Q_T7PM9G;+(GR?:"O\*^BCU_\ K4-_Q5<G
MV&Q_T7PM9G;+(GR?:"O\*^BCU_\ K50;P=XJ;2_[._MFU%EL">4N0-OIPN?\
M:&\'>*FTO^SO[9M19; GE+D#;Z<+G_&@/WS^*FW??;7LM](_F7V_XJN3[#8_
MZ+X6LSMED3Y/M!7^%?11Z_\ UJ&_XJN3[#8_Z+X6LSMED3Y/M!7^%?11Z_\
MUJSV\'^*VTW^S?[8M18[ GEKD#'IPN?\:5O!WBIM+_L[^V;466P)Y2Y V^G"
MY_QH#]\_BIMWWVU[+?2/YE]O^*KD^PV/^B^%K,[99$^3[05_A7T4>O\ ]:AO
M^*KD^PV/^B^%K,[99$^3[05_A7T4>O\ ]:J#>#O%3:7_ &=_;-J++8$\I<@;
M?3A<_P"-#>#O%3:7_9W]LVHLM@3RER!M].%S_C0'[Y_%3;OOMKV6^D?S+[?\
M57)]AL?]%\+69VRR)\GV@K_"OHH]?_K4DEW=^)&.D^'XOL>@)^ZDO4&-RK]Y
M4]CD#\ZHMX.\5-I?]G?VS:BRV!/*7(&WTX7/^-20^%?%T%B+.'7+6.V5/+")
MD87Z[<_C0/\ ?/XJ<M=]M?):Z+\2W+_Q,F_X1KPQ_HVF6XV7MVG8=T4]V/<T
M2_\ $R;_ (1KPQ_HVF6XV7MVG8=T4]V/<U0L_!WBJRT\V5IK-K#;,&!1,C.>
MO.W.?>BS\'>*K+3S96FLVL-LP8%$R,YZ\[<Y]Z!?OG\5-Z[VMM_*M=%W>[+\
MO_$R;_A&O#'^C:9;C9>W:=AW13W8]S1+_P 3)O\ A&O#'^C:9;C9>W:=AW13
MW8]S5"S\'>*K+3S96FLVL-LP8%$R,YZ\[<Y]Z2S\'^*[&Q-C9ZQ:PVK!@53(
MZ]>=N<^] ?OG\5-Z[VMM_*M=%W>[-"7_ (F3?\(UX8_T;3+<;+V[3L.Z*>['
MN:)?^)DW_"->&/\ 1M,MQLO;M.P[HI[L>YJA9^#O%5EIYLK36;6&V8,"B9&<
M]>=N<^]%GX.\566GFRM-9M8;9@P*)D9SUYVYS[T!^^?Q4WKO:VW\JUT7=[LO
MR_\ $R;_ (1KPQ_HVF6XV7MVG8=T4]V/<T2_\3)O^$:\,?Z-IEN-E[=IV'=%
M/=CW-4+/P=XJLM/-E::S:PVS!@43(SGKSMSGWHL_!WBJRT\V5IK-K#;,&!1,
MC.>O.W.?>@/WS^*F]=[6V_E6NB[O=E7Q-J$%RUKX.\,HH@,BQRR+R"0>1GOC
MJ3[5Z;IUG%I]C!:6XQ%"@1?PKCO G@F70-0EO+^:":79LA\O/RYZGD#GM^)K
MN:$=N!I5%>K55F]$NR6R"BBBF>@1L5^T("/GVL0?;(S_ $J2HF0FZ1\?*$8$
M^Y*_X5+0 4444 %%%% !1110 5'(5$L0898D[3Z<5)44B%IH6 X4G/Y4 2T4
M44 %%%% !1110 4444 1N5$T8(^8YP?2I*BD0F>)@.%SFI: .?OM.N+'6Y-8
MTM/-,\:QW=MG'FA?NNO^T 2/<5R5]:1>(/B!=VR_:;87FFH+GS5VEH%D^9%]
MV)P3Z9]:]-KFO%%A<1:EI^O:=$TUS8AHYH4^]- ^-P'JP(# =\$=ZZ:-5WL]
M[6O^1SU:2M=;7O\ YG0V\$=O"L4"+'&O15& *\W^*>D+:6<EW:LW_$QO[,/;
MJ,[IED ##W*C!^@KOM+U:RU2U,]E.LD:G#=BI]P>1^-8$B_\)1XBL98ANT;2
MY#,)?X;BXP0NWU5<DYZ9QZ&BA*5.IS/IN%=1J0Y5UV)]2MY_$^RUDADM]'#J
M\_F##W&#D(!V7(&?7I73 8&!THHK"4KJW0VC&SOU"BBBI*"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#YS\5?\C/J_\ U^3?^AFLNM3Q5_R,^K_]?DW_
M *&:RZ@^ K?Q)>K"BBB@S"BBB@ HHHH **** "BBB@ HHHH *[;X2_\ (QW/
M_7HW_H:5Q-=M\)?^1CN?^O1O_0TH1V9=_O,/4]9HHHJS[<**** .-\"?#W3?
M!]Y?7\-[J>J:I>*L<M]J=QY\QC7H@; PO^ ]!79444 %%%% !1110 4444 %
M%%% !1110 4444 %7;?_ %*U2J[;_P"I6@"2BBO./$FD>.KCXN^']1TC4TA\
M(0Q$7ML7QN;#YRO\1.5P>QY[4 >CUQ4GQ+T"/XE)X'9KG^V70-O"#R0Q0R!"
MV<ABH)QBNMU&\@T[3[F]O'$=M;1--*YZ*JC)/Y"OC&;5/$%QX:N/&*>$=7-^
MVN_\)&FL8'DK;J,"+UV!<B@#[6HKPEM4UCQM\9EL-$\3W^FZ#+H%MJRK;D'<
M#(IP,\#<& )],BN'U37_ !FO@7QKXPM_%VH1CP[XFFMH++(*2QF6!=CGJ5&\
M87I][UH ^KJY[QMXLLO!^EQWM_;7]V991#%;6%N9II6P2=JCT56)YZ"O-/"=
MYXDT3XV66CZOXAN=7LM:T9]1:&4 );2[^1&!T4<@>QKNOBGXTM_!'A^*\-L+
MO4KJX6TT^V) \V=^!D]@.23Z<=Z +/@#QSI/CBQNKC25NX);28P7-K>1>5-
M_HRY.,_6NDNYUM;6:XDR4B1I&QUP!DUY%X1\%W:>'=7O;_Q:EAXBUJ^BOK^[
MTV5-L) PL /3'4$]Z]4U[_D!:C_U[2?^@F@#F_#OC^RUF32-^EZMIUOJ\8DL
M+F\CC$=QE/,"@H[$,4RP# <*>_%5[3XDV=QIO]J'0]>BT8,P;4&@C:)0K%"Q
M5)#)C(/13Z]*P_ACH>KZOX-^']QK%S8II>FV%I=VL-JK>9*WV8*GF%NF Y/R
M]3[5I_"N\M+#X16EUJ4D<=G$+II6DZ;?/ES_ /JH Z#5O%MI9W%I;6%K>:Q=
MW,'VI(=/5'(A/ E+,RJ%)X'.3V!P<&H>+;:SM].VV&HW-_?JSPZ?#&OV@!<;
MRP9@H"D@$[L9(QG(KB?"'A;5H?"?A?5=%NDL/$-KI<5O+:W2[HY;<OO6*0=5
M(&X CH215SPEKW_"0^/-(U.>'[,UUH5PB1%MP$D=TJ3!3W&0ISW&#0!T<WCW
M0;?PK#K]U/+#:R%XQ"T3&<2INWQ%%R=ZE'![#:3G'-6KSQ78VWA_3-5$5S,-
M3$7V.UB0&:9I%WJ@!(&=N2<D  'FN1TF..3P3\0)T"O ]_J<ENQ&0,(5<K_P
M,2<CU-,TUO+_ .%1-*<0FT:,$]/--E\OXX#X_&@#K++QII,VBWNHWAN-.%C/
M]ENK>ZC_ 'T,O&U"J%MQ8,A7:3D,,<\5H>%M=L_$VA6VKZ:)1:7&_P OS4V-
M\KE3D=N5-<_X7CCG\?\ C>10LD ELD8$9 F6')_$*T?Y"F_!7_DFNE?[]S_Z
M424 =O16?KEW?V=HDFEZ:=1F+A6B\]8=JX/S9;CJ ,>]<M\(]9UK6/">FRZU
M821[K8.+Q[E9#.V>ZCD?C0!TNMZY:Z/<:3#=K*7U.\%C!L4$"0QO)\W/ Q&W
MKSBL74_'VEV%KK=TMO?75II#I%//;HK(\K,J^4A+#<P+#/8=,Y!%<W\?K75;
MW3/"EMX>NEM-6EUL+;3-T1_LEU^1]^W6LC6K[3;WX 7UMHMNVFR63P6ES9N,
MRVEPMQ&'5\]3GG)^]D'O0!WLOC5;2U6YU;0=:TRV-S#;&6Y2$JIE;:&.R1L*
M&V@GMN'OB_KOB2+2M0M["*PO]1OIX7N%@LU0L(T*@L2[*!RX YYY]*KMX;NM
M0T'5=*\1ZL^JV]_"8.;=(3&"""1MZGD'/;%87PA^V:I9WWB#695FU.60Z867
MH$M6:(X]-T@E?_@8]* +^A^/8]8FO%C\/Z[;PV4DL-S/.D 2&2--S*=LI.>@
M& 1DBE\.^/[+69-(WZ7JVG6^KQB2PN;R.,1W&4\P*"CL0Q3+ ,!PI[\5E^#?
M^0/\0_\ L,WW_HI*Y?P(]^^E_"JW\2FUBTH6-O<:;):Y_>7 M=J1S;NAV.[#
M'!*D>E 'KF@ZS;:Y;7,]FLH2WNY[)_,4 [X9&C?')XW*<>U<])\0K%K;09+#
M3-6OY-:CFEMH;>./>%BV[RVYU ^\.YJ+X7S1P:1XB2:1$:WU[4WEW'&P-<R2
M GT&U@?H:X[P*K+=?"4LI7?I>HR $8.UA"P_0B@#O_">IZ1?ZUK!MK.[T[79
M?*EOK2\&V7:%V1N &9"N%QE"1Z\U%IMYH&K_ !#U*.-+J36](A5-TTCF!5<?
M,84+% P^ZS!0><9(K(\4:M::?\2(M6W#R-$T"]EU*1/X5:2%HD)]3Y4I _QK
MF-*_M[P[/X3UG6M$^Q!9Y(-4O/M:2!Q>R GY1R )S%C/09H [Z^^(&DVFO'2
MVBNI&7<7FC\LJH4D,=I<2, 58$JA'!YX-=>I#*"I!!Y!'>O,=2^'>J3^-$U2
MTU6".P\LP['0F2-"9B0H^Z3F=L$\@#%>F0QK%$D:<*BA1]!0 ZBBB@ HHHH
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M_'_(\0HKV_\ X5WHG]V7\Q_A1_PKO1/[LOYC_"BP?V'6_F7X_P"1XA17M_\
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M_H(W?YK_ (4 :%%9_P#9\O\ T$;O\U_PH_L^7_H(W?YK_A0!H45G_P!GR_\
M01N_S7_"C^SY?^@C=_FO^% &A16?_9\O_01N_P U_P */[/E_P"@C=_FO^%
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MR% &U16+Y-S_ ,_LWY"CR;G_ )_9OR% &U16+Y-S_P _LWY"CR;G_G]F_(4
M;5%8ODW/_/[-^0H\FY_Y_9OR% &U16+Y-S_S^S?D*/)N?^?V;\A0!M45B^3<
M_P#/[-^0JQ%9SO&&-]-S["@#2HJA]AG_ .?^?\A1]AG_ .?^?\A0!?HJA]AG
M_P"?^?\ (4?89_\ G_G_ "% %^BJ'V&?_G_G_(4?89_^?^?\A0!?HJA]AG_Y
M_P"?\A1]AG_Y_P"?\A0!?HJA]AG_ .?^?\A1]AG_ .?^?\A0!?HJA]AG_P"?
M^?\ (4?89_\ G_G_ "% %^BJ'V&?_G_G_(4?89_^?^?\A0!?HJA]AG_Y_P"?
M\A1]AG_Y_P"?\A0!?HJA]AG_ .?^?\A1]AG_ .?^?\A0!?HJA]AG_P"?^?\
M(4?89_\ G_G_ "% %^BJ'V&?_G_G_(4?89_^?^?\A0!?HJA]AG_Y_P"?\A1]
MAG_Y_P"?\A0!?HJA]AG_ .?^?\A1]AG_ .?^?\A0!?HJA]AG_P"?^?\ (4?8
M9_\ G_G_ "% %^BJ'V&?_G_G_(4?89_^?^?\A0!?HJA]AG_Y_P"?\A1]AG_Y
M_P"?\A0!?HJA]AG_ .?^?\A1]AG_ .?^?\A0!?HJA]AG_P"?^?\ (4?89_\
MG_G_ "% %^BJ'V&?_G_G_(4?89_^?^?\A0!?HJA]AG_Y_P"?\A1]AG_Y_P"?
M\A0!?HJA]AG_ .?^?\A1]AG_ .?^?\A0!?HJA]AG_P"?^?\ (4?89_\ G_G_
M "% %^BJ'V&?_G_G_(4?89_^?^?\A0!?HJA]AG_Y_P"?\A1]AG_Y_P"?\A0!
M?HJA]AG_ .?^?\A1]AG_ .?^?\A0!?HJA]AG_P"?^?\ (4?89_\ G_G_ "%
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M ,_Y"C[#/_S_ ,_Y"@"_15#[#/\ \_\ /^0H^PS_ //_ #_D* +]%4/L,_\
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M_15#[#/_ ,_\_P"0H^PS_P#/_/\ D* +]%4/L,__ #_S_D*/L,__ #_S_D*
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M!K>^!]O=Z*S:5)X$U#15DB,USJMW=),]S*"/O$#.3DD=AS0!Z_1110 4444
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M9A8M(Q."K2+QWVUS7A?P-=>$_!?A'6]$T6.#Q-86T,>IV<:JKWD; "5&/0R
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M)MP.E 'LTLB11/)(P5$4LS'H .IK"T7Q=HVLZD^GV-Q.+Q8S,(KBTFMS)&"
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M:_JO@&WUO1=1EBU'26$=]"N")$/W9,8_.N*^'>D6OB#Q7::=?;C!*KEMC8/
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MV5(X5B=W;.: /7:*SO#ERMYX>TNY2VGM$FM8I!;SY\R(,@.QL_Q#.#[BM&@
MHHHH ;(BRQM'(JNC JRL,@@]013@,# X%%% &=IVCVNGZCJM[;A_/U.9)[C<
MV066)(A@=AMC7\:T:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH X/XI(S:EX VJ6V^)(2<#.!]FN.:P/B<NA?\+4\+OX
MK>&+3!I=Z-\TC1IYGF08&X$<XW<5ZW10!X'JK&V^&M\Z;T\.V_B>RDTR252/
M]$$\#,W^YO\ -(/IS7;>*M:LO&]A!H/AF9=0^TW4#W-U"-T5O#'*DCDMTW$+
MM ZY/M7HU% !1110 4444 %%%% !41<_:E3^$H3^H_QJ6HR%^T*<_/M( ]LB
M@"2OGSPOJ$7@7Q5XEM]1L9=1\2O*$L&"EFG+D]/3=E23Z<5]!UY5\9;&?1[_
M $CQKI:9N=.E6.X4<;XR>,^W)4_[P]*Z\))7=-_:./&1?*JL?L_EU^X%_P"*
M+A;7/$'_ !-?&VK'R[>VC^8J3TBC Z*,C)'T'N+_ ,47"VN>(/\ B:^-M6/E
MV]M'\Q4GI%&!T49&2/H/?,TO7](T33IO&OB+4K35_$]Y&!!:6TH;[*K#*PJ.
M2F!]YCTY'))WR66M:7X=M+KQAXFU*QUCQ3<+LAM+2=)!; @[8DP3M&,[GY[@
M;B27Z'&757Z>ODNR1S*<>CMU]/-]Y/HB^O\ Q1<+:YX@_P")KXVU8^7;VT?S
M%2>D48'11D9(^@]Q?^*+A;7/$'_$U\;:L?+M[:/YBI/2*,#HHR,D?0>]"RUK
M2_#MI=>,/$VI6.L>*;A=D-I:3I(+8$';$F"=HQG<_/<#<22Y9:UI?AVTNO&'
MB;4K'6/%-PNR&TM)TD%L"#MB3!.T8SN?GN!N))<Y6^E^GKY+LEW#FBMG:VOI
MYOO)]$7U_P"*+A;7/$'_ !-?&VK'R[>VC^8J3TBC Z*,C)'T'OQGB+0;^Z\8
M:'8W=VT_BV^F6[NYD;*V<8^ZB#T4!B?H/J>DLM:TOP[:77C#Q-J5CK'BFX79
M#:6DZ2"V!!VQ)@G:,9W/SW W$DO=^"MA=:M=:IXSUD!KS4',4&!@*@/.W/;@
M*/93ZU2DZ2=1^GJ^R\E^)+BJLHTEZ^B[OS?X'J6\_:MG\.S/ZU+4>%^T;L_/
MMQCVS4E>4>N%%%% !1110 4444 %1.Y%Q$HZ,&)_#%2U&P4S1DGY@#@>O3-
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M^?BZ_P"_G_UJ -"BL_\ LM/^?BZ_[^?_ %J3^S8]VW[5<[L9QYG- &C16?\
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M?\M!YF<\\#YAS7CE:X93UE-:NWY&6*</=C3>BO\ F%>G?L]_\CG>_P#8/?\
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M:Y9KD2(R?.Q]-QK)LOA=XRET;2_!.J7.G-X.T^^%R+M&/VB:(.6$97H.6/-
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M=W$4CX)]D;'X4 ==7-Z[XNMM)UV#1EL-0OM2GMFNHH;2-#O56"D99E //\1
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M $U%%% !1110 4444 %%%% $;*/M"-GY@K #U&1_A4E0M_Q^1_\ 7-_YK4U
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M:C4SK?4H+D<)1?FO*W?OK]YU=%"C"@>G%%4>*%%%% !1110 4444 ?'/CO\
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MOFIN&R3.[ SUXK.\6>-O$%_XXF\'^ +6TDU&SA6>_OKTGR;8, 57 Y)((/\
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ML#[=N<YVLK8]"#2Z1X@T?69[B'2=3L[V6W($R03*YCS_ '@#Q7*Z#I@7Q/\
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M:E:Z>]S#->W=]:O;;8XI%DV(K@,S,5"Y P 2<]*] HH **** "BBB@ HHHH
M*C+D7"IV*%OU'^-25&4'VA7W<A2,?B/\* )&&5(R1GN*^=/#>DZ3X?\ B'K,
M'C.Y/D:?NO81+]R=L_*[?WFPW"]R3]#]%UY+\=M" CTWQ1!;1SR:=*BW$3KN
M62+=D;AW /!]F-=F#G[SIM_$<6-A>*J)7Y=26'_BH6/C+QK_ *%X<LAYNG6$
MW\0[2R#NQXVKWR,<?>(?^*A8^,O&O^A>'+(>;IUA-_$.TL@[L>-J]\C''WN>
MC\9Z#XQ\1"^\6Z@EGHEA)FRTID=_.?'^MFVJ0>O"_ATSO5?&6@>,/$GV[Q7J
M*6FA6$F;'2GC=O/?_GK-M!!]ES[=,[^CV4UT:MVZ+LO-]6<OM8/[2=^_5]WV
M2Z(Z"'_BH6/C+QK_ *%X<LAYNG6$W\0[2R#NQXVKWR,<?>(?^*A8^,O&O^A>
M'+(>;IUA-_$.TL@[L>-J]\C''WN?7QEH'C#Q)]N\5ZBEIH5A)FQTIXW;SW_Y
MZS;00?9<^W3.\7QEH'C#Q)]N\5ZBEIH5A)FQTIXW;SW_ .>LVT$'V7/MTSO/
M9371JW;HNR\WU8>U@_M)W[]7W?9+HCH(?^*A8^,O&O\ H7ARR'FZ=83?Q#M+
M(.['C:O?(QQ][A=>O=8^(7Q"T6 QO90,1+:Q?\M(8,AO-;T9@N1_P''!!.O+
MXUT+Q9KTFH^*+T0Z+IS%K#1RC,;F0#B27 *GT"YQVZ;M_2_!?3I]0FU7QCJJ
M_P"F:I*RPY_@B!YQ[9 'T456M"+G)6:5EY7Z+OYLG3$25.+NF[ON[=7V[)'I
MRL1.(^H"9R>O6I:CV#[1OW<[<8_&I*\D]D**** "BBB@ HHHH *C=R)XT[,"
M?RQ4E1L@,T;;@"H(QZYQ0!)1110 4444 %%%% !1110!&SD7")C@HS?D1_C4
ME1L@-PC[AD*PQZY(_P *DH **** "BBB@ HHHH *CD<K+$HZ,3G\JDJ.1 TL
M3;L%2<#UXH DHHHH **** "BBB@ HHHH C=RLT:]FS^E25&Z S1MN *YP/6I
M* /&?VC/]3HWUD_I6)J6MR^'M&\ 7\8WQBT=)H^TD9.&'Y5M_M%_ZG1O]Z3^
ME>-7-]=75O;P7-Q++#;KMA1FR(QZ#TH ]@\3:?I5M\--7O- E#Z?>74+(H_@
M92%(_3-:JS&V^(^J3JJLT6@*X5AD$A<X->%QZA>1Z>]A'=3+9.V]H WR%O7%
M6&US56N9+@ZC<F>2+R'DW\M'_=/M0!ZC\./'=[K7BVTL9]/TV&.1')>&$*PP
M.QKRU+.;4-?>TM5+S37+(@'J6-5K&\N=/N5N+&>2WG4$+)&<,,UVW@]D\,^'
M=2\8WP#7 S;Z>K_QS-U?\*#6C1G7J1I05VW9"^/+8Z]XH\/>!]*/G/IJB*:X
MZD,>7Y]%%>]ZMH8O?",^B).Z>9:_9UE)R1Q@$UYM^S[X8DBLKGQ1J8+7VH$^
M4S]0F>6_X$?T%>E^,IYK7PGJ\]J[1SQVLC(Z]58*<$5*[L]O,JJC5I8&@]*6
ME_[S>K^\Y"ZT'Q-J/AZ32);;2[!76*V:>!MS&-3\QQ@<' X]S6<GPXU!H;+2
MKN>.;3+2]DN(ID.QT5DXP.Q5^16-K7B3Q+8PZU/#-<36/V>UAROW[:5HU;S!
M['D&M6UU*[E^(+6%WJM_,EV3%&MK-L^SCRP?GC*>O\8/6EH=*ABJ<&X2BEK+
M1=;*_P [,L:3X,\0:2MG?_Z'J&I6UQ<%XIGPLJR$?.#CAN*L7GA?77\4V6K"
MVMN+>*.6.WN!&B,K9/!7D?E69H4FIII^D.^KZG,]WK3VDIEE!Q$N\#'''0'Z
MTQ9-3TVQU2]_M?59H[/6EMG,LF\+;JW)( ]^30*7MG-WE%O;9]7M]YK:#X(U
M2P\366HW4R36T=W<SFWW "$R'Y7!ZGCJ*],KQ[5[V_U32]3U.SU?4HK;^V$@
MM'MWVJ\+%5.,CD=<&I([VZM_B=+IMQJUY]DMW@2)9+T)NRF3E-AWY/N*:=CE
MQ&$JXKWZDE>*>ENUG]_O'KM%%%4>"%%%% !1110 4444 ?'/CO\ Y'CQ#_V$
M;C_T:U8=;GCO_D>/$/\ V$;C_P!&M6'7U=/X$?'U/C?J%%%%60%%%% !1110
M 4444 %%%% !1110 5Z=^SY_R.=[_P!@]_\ T9'7F->E? .%)_&%XDF<?8'/
M!Q_RTCKFQ?\ !D=."_CQ]3Z&.""#@@\$&LCPQX>T[PS82V6D(\5H\[SB$R%E
MC+G)" _=7/8<<U<_LZW_ .FG_?9H_LZW_P"FG_?9KYH^J+>11D54_LZW_P"F
MG_?9H_LZW_Z:?]]F@"WD49%5/[.M_P#II_WV:/[.M_\ II_WV: +>16=XBTB
MT\0:+=Z5J!E^R72>7*(I"C,O<9'.#T/M4W]G6_\ TT_[[-']G6__ $T_[[-
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MI+_W\;_&C^R;7TE_[^-_C0!?R/449'J*H?V3:^DO_?QO\:/[)M?27_OXW^-
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M !H_LFU])?\ OXW^- '#_P#"H?#7_3Q_W\-'_"H?#7_3Q_W\-=Q_9-KZ2_\
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M^#(Z<%_'CZGI_P 9KRYT_P"%OB6[L+B:UNH;1FCFA<HZ'(Y##D&O&M"U/4-
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MXYX[9]S6I^S99SV/P7\.I<[@TBRS*I[(\KLOY@@_C0!Z;1110 4444 %%%%
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MH **** "BBB@ HHHH C9P+A$QR58Y],$?XU)4;(3<(_8(R_F1_A4E !1110
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M#^S9]T?+VX>HKT/X&ZG9:9XLNYM0NHK>)K%T#R-@%O,C./T->O?\*?\ "/\
MSYS?]_C1_P *?\(_\^<W_?XU%7,'4@X-;FE+ U*4U--:&FWB[PZRD-J]B01@
M@R#FL?PM>^#_  QI\ECI&K6\=FTSSK$UQN6(N<E4_NKGH/>I?^%/^$?^?.;_
M +_&C_A3_A'_ )\YO^_QKS[(]+VE?LOQ-/\ X2_P]_T&++_OZ*/^$O\ #W_0
M8LO^_HK,_P"%/^$?^?.;_O\ &C_A3_A'_GSF_P"_QHL@]I7[+\33_P"$O\/?
M]!BR_P"_HH_X2_P]_P!!BR_[^BLS_A3_ (1_Y\YO^_QH_P"%/^$?^?.;_O\
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M\YO^_P :+(/:5^R_$T_^$O\ #W_08LO^_HH_X2_P]_T&++_OZ*S/^%/^$?\
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M\-_]!JQ_[^BN=_X4_P"$?^?.;_O\:/\ A3_A'_GSF_[_ !HL@]I7[+\3HO\
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M?S%S5>R_$V/^$B\'?\_VD?\ CM3P^+?"T";8-6TZ-<YPC@#/X5@?\*?\(_\
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MW_?XT60>TK]E^)T7_"9^&_\ H-6/_?T4?\)GX;_Z#5C_ -_17._\*?\ "/\
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MF?AO_H-6/_?T4?\ "9^&_P#H-6/_ ']%<[_PI_PC_P ^<W_?XT?\*?\ "/\
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M=_X4_P"$?^?.;_O\:/\ A3_A'_GSF_[_ !HL@]I7[+\3HO\ A,_#?_0:L?\
MOZ*/^$S\-_\ 0:L?^_HKG?\ A3_A'_GSF_[_ !H_X4_X1_Y\YO\ O\:+(/:5
M^R_$Z+_A,_#?_0:L?^_HH_X3/PW_ -!JQ_[^BN=_X4_X1_Y\YO\ O\:/^%/^
M$?\ GSF_[_&BR#VE?LOQ.NTOQ!I.JW#0:;J%M<S*N\I$X8A<@9_,C\Z*RO"O
A@/0O"^H27ND6\D=Q)$86+2%OE)!_FHHI,WIN3C>6Y__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" 'Y!.4# 2(  A$! Q$!_\0
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M<$[1CJ?E-/0F+J2=HME3_A+_ !)_T,.L?^!TO_Q5'_"7^)/^AAUC_P #I?\
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MUC_P.E_^*K#HHL'//N;G_"7^)/\ H8=8_P# Z7_XJC_A+_$G_0PZQ_X'2_\
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MUR\-F'B::X=S&=LG*Y/!X'2O+_\ A+O$G_0PZQ_X&R__ !5>@? G_D!>-_\
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M##K'_@=+_P#%4?\ "7^)/^AAUC_P.E_^*K#HHL'//N;G_"7^)/\ H8=8_P#
MZ7_XJC_A+_$G_0PZQ_X'2_\ Q58=%%@YY]S<_P"$O\2?]##K'_@=+_\ %4?\
M)?XD_P"AAUC_ ,#I?_BJPZ*+!SS[FY_PE_B3_H8=8_\  Z7_ .*H_P"$O\2?
M]##K'_@=+_\ %5AT46#GGW-S_A+_ !)_T,.L?^!TO_Q5'_"7^)/^AAUC_P #
MI?\ XJL.BBP<\^YN?\)?XD_Z&'6/_ Z7_P"*H_X2_P 2?]##K'_@;+_\56'0
M>E%@YY]SW_\ 9WU74M6_X2#^U=0O;WROL^SS[AY-F?-SC)XS@454_9A_YF7_
M +=O_:M%9RW/<P:<J,6W_5SW:BBBI.P**** "BBB@ HHHH **** "BBB@#A/
MCC_R2_6O^V/_ */CKYU^&JVS>/M"%]CR/M:=>A;^'_Q[%?17QQ_Y)?K7_;'_
M -'QU\HQNT;J\9*NI!5@<$$<@UI'8\7,'RUXOR7YGI'QS76CXZN!>?:?L1*"
MRZ^7C:/NX_BSGWK3^%J^(].77]3:#3X)E$4<E]KDK1B @9 Z%CE67N.U4]-^
M-&OVUC'!=6UG>N@VB:93O/Y'K699_$_5(WU<7]G8:A;ZG*)IK>XBR@8 *, =
M>%7KZ4[.Q'M*7M/:*3U/6/%D4-UXE^'NJ$VTEY-<E'GMN4E&T'@GJ,YQSWJY
MI/B7[=\3M;\*R:?;"P6(R.^,M(^%R6[$$-C\*\=O_BAJ5]/H<LEC9(=)F\Z)
M4! ;M@C/  ]*J:?\0;^R\;WGB=+2U:[N4*/$=VP#"CCG/\-*S-7BX*5T^J_(
M]!TB]_X0#X5#5]$L([B]N;Z6&6:1=WEJLCJ"V.<80<9 RWYZ7B^\EU&/X87=
MQ:"SEGU.!V@ P$RR<8]*\U\*?%#5_#EK=VT,-M<6T\K3+',"1$S')V\],\X-
M)KGQ,U369M$DN[:V\W2KI;N-EW#S&# @-STX'2BS)^L4^3EOT6ENS/5(+>"'
MXF_$'6VLQ>7FF6MN]M%C)9C;[B%'J=@&?>LX>)[_ ,5_"/Q5?:C8Q6TJCRA)
M$I590"/7G(SC-><VWQ+U>V\:7OB."*!9;Q$2>VY,;!451WS_  @YSW]ZN:[\
M6-6UG1]2TZXL[-+>]4)\@8&,#^[SZ^M%F5]9IV:O;XNF]]F>K>!Y]7TN/0M'
MU$>'["U:U1#9F8M=S';C=M "\D'/7ZU'X&U&73]3\=Z390PQVNF3/<6RJIX9
M][$'G[H*C XKS&'XN:DLUE<RZ7ID^H6J",7;Q'S67N,YX!]JS=%^)&J:3XJU
M76[>"V9]1/[Z!@=F<\8YSQS^='*QK%4X\MGM^5CT?P/=+?\ A/Q%XOO+J'3=
M7N[C8][%9M<?9454'$8R1P22??GI7/?$K^S_ !7%X8CTB\;4=:G?[,]S]BDM
MQ<*<?/\ ,N#@]<$XS6%I/Q4UG3=;U._AAM6BOW$LEHP/EA@H&1SD' _E6OIO
MQ/AO/$#:YK\")<V-J\>G6]O%E!*XPS,2<CC _$T6>Y'MJ<X<C?\ 5]^WX&9\
M9-0@BU&P\,:8V=/T.$09S]^4@;B<<9Z#Z[J\[J6ZN);JYEN+AVDFE<N[,<EF
M)R3^=152T.*I/VDG(****9F]CUWXO_\ ).?AY_UXK_Z)BKR*O7?B_P#\DY^'
MG_7BO_HF*O(JF.QTXK^+\E^2"BBBJ.<**** "BBB@ HHHH **** "BBDH !T
MSGBEKUFV1?\ AG6[?:-_V\8..?OK6@OPGT")](-_KT]L-0A4QQN5WR2L <+Q
MT']12N="PLY6Y>R?WGBU6H-.O9[.:\@L[F6TAXEG2)F2/ZMC KT73_A8T_CK
M5=(N+QHM+T]%GDNB &,;#*X[9ZY/^R:[$:-I&C?"7Q9'H&J?VE92?,9#C<C#
M:". /3-+F'#"R=W+2U_P/"+NPO+*.%[RTN($F3?$TL102+QR">HY[56_6O9/
M'WAC4=5F\":4FHS7<EW;.(_.10(5"1EC\H!/'KZ5B^.O WA_0='NVT[7_M6K
M613SK5RO(+!3C Z@D'\#3NA3PTHW:V1YK2'@9/ KV72_A9X<U&,V5MXD:;61
M )#'&%**2/IT_&MSX:^']&B^&FMQZC=+%.S3PZA*%!-KM)7 ..FT!N_6ES(J
M.$FW9Z'A']GWGV$WWV2X^Q!]AN/*;RPWINZ56KU^^TEXO@U=_P!FZI<W&G_V
MBT4%OL0K(OG[5.<;N< ]>M3P?"G0;/[%8Z_XA-OK=VF4MT*[2Q[#(S^O-',3
M]5FVDNQXS17J'A[X7"\\0>(M(U.[DBFTR-7BDCP%DW D$Y'3 %-\6?#S2;#P
M1+K^A:RVH+;2+'/TV[BP0@8&1AF%.Z%]6J<KE;^D>8T4&BF8!1110 4444 %
M%%% !1110 4444 %>N?";_DF?Q _Z]#_ .BI*\CKUSX3?\DS^('_ %Z'_P!%
M25,MCHPO\3Y/\CR.BD/2O;= _LSX<?#_ $_7KBPCOM9U0[HM_1%(R #V&,9]
MS3;L9TJ?M&[NR6YXGT^GTHKTK6/$<WQ/N-)TA=+M;35FN,"XB'R^7M.0<\\
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M>O3?V>U5O'S!E##['(<$>ZUZ/I^H/XWT/Q-:>)=$AL[6T5UBN-A7. >1N[C
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M1-*TN\&I26*$27N0V_(  W#@],FO+***:5C.I4=23DPKUS]G[IXK_P"O$?\
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MPC_S\7?_ (#FC_A<OA'_ )^+O_P'-'*P^LTOYD>CT5YQ_P +E\(_\_%W_P"
MYH_X7+X1_P"?B[_\!S1RL/K-+^9'H]%><?\ "Y?"/_/Q=_\ @.:/^%R^$?\
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M]G'L8?\ PB7A_P#Z ]A_WX7_  H_X1+P_P#] >P_[\+_ (5N4478>SCV,/\
MX1+P_P#] >P_[\+_ (4?\(EX?_Z ]A_WX7_"MRBB[#V<>QA_\(EX?_Z ]A_W
MX7_"C_A$O#__ $![#_OPO^%;E%%V'LX]C#_X1+P__P! >P_[\+_A1_PB7A__
M * ]A_WX7_"MRBB[#V<>QA_\(EX?_P"@/8?]^%_PJ'_A%- ^U;?['L,;,X\A
M?7Z5T51Y7[1C^/;^F:+L/9P[&/\ \(EX?_Z ]A_WX7_"C_A$O#__ $![#_OP
MO^%;E%%V'LX]C#_X1+P__P! >P_[\+_A1_PB7A__ * ]A_WX7_"MRBB[#V<>
MQA_\(EX?_P"@/8?]^%_PH_X1+P__ - >P_[\+_A6Y11=A[./8P_^$2\/_P#0
M'L/^_"_X4?\ ")>'_P#H#V'_ 'X7_"MRBB[#V<>QSK^%- %S$HT>PP5;_E@O
MM[5-_P (EX?_ .@/8?\ ?A?\*V&*B9 ?OX.VI*+L/9P[&'_PB7A__H#V'_?A
M?\*/^$2\/_\ 0'L/^_"_X5N4478>SCV,/_A$O#__ $![#_OPO^%'_")>'_\
MH#V'_?A?\*W**+L/9Q[&'_PB7A__ * ]A_WX7_"C_A$O#_\ T![#_OPO^%;E
M%%V'LX]C#_X1+P__ - >P_[\+_A4+>%- %U&HT>PP4;CR%]5]JZ*HF*_:$!^
M_M)'TXS1=A[.'8R/^$2\/_\ 0'L/^_"_X4?\(EX?_P"@/8?]^%_PK<HHNP]G
M'L8?_")>'_\ H#V'_?A?\*/^$2\/_P#0'L/^_"_X5N4478>SCV,/_A$O#_\
MT![#_OPO^%'_  B7A_\ Z ]A_P!^%_PK<HHNP]G'L8?_  B7A_\ Z ]A_P!^
M%_PH_P"$2\/_ /0'L/\ OPO^%;E%%V'LX]CG9O">@": #1[  L<_N%YX/M4W
M_")>'_\ H#V'_?A?\*UY"HDB#?>).W\JEHNP]G#L8?\ PB7A_P#Z ]A_WX7_
M  H_X1+P_P#] >P_[\+_ (5N4478>SCV,/\ X1+P_P#] >P_[\+_ (4?\(EX
M?_Z ]A_WX7_"MRBB[#V<>QA_\(EX?_Z ]A_WX7_"C_A$O#__ $![#_OPO^%;
ME%%V'LX]C#_X1+P__P! >P_[\+_A4-QX4T!?+QH]@,R ']PO^%=%4<Q4;-_=
MACZT78>SAV,?_A$O#_\ T![#_OPO^%'_  B7A_\ Z ]A_P!^%_PK<HHNP]G'
ML8?_  B7A_\ Z ]A_P!^%_PH_P"$2\/_ /0'L/\ OPO^%;E%%V'LX]C#_P"$
M2\/_ /0'L/\ OPO^%'_")>'_ /H#V'_?A?\ "MRBB[#V<>QA_P#")>'_ /H#
MV'_?A?\ "C_A$O#_ /T![#_OPO\ A6Y11=A[./8YV?PGH"M#MT>P&7P?W"],
M'VJ;_A$O#_\ T![#_OPO^%;$I7='O_O<?7FI*+A[.'8P_P#A$O#_ /T![#_O
MPO\ A1_PB7A__H#V'_?A?\*W**+L/9Q[&'_PB7A__H#V'_?A?\*/^$2\/_\
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MC\/"3C*6J/0:*\^;XG6B%0VEWH+= 2.:&^)UHA4-I=Z"W0$CFBY/]I8;^?\
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M(.,UJ>#?B)X?\7ZSK.F:+--)=:4^R;?'M5_F9=R'/S+E3S[CUKKFP1ZB@!D
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M@5W7AYK^70=/DUE85U)[>-KI85*HLA4;@H))P#D=>U:!%"C H X37/!-S?\
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MVCYV9Z1(.>F>6YZ\9)^94_XE*OXD\3_O-5E^2UM%Y\H'I&@_O<\GMD^^1/\
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MC)/S8GBW1Y(=%.J:Y=D^(;J5&@AC)(0 _P"J0#T!R3ZX]<G<3_B4J_B3Q/\
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MXHUGQ!;)*-1U98ENF+Y4^6FQ<#MQ6Y110 4444 6[7_5GZU*U16O^K/UJ5J
M.5;Q[X?'CY?!IO<:^T7G"#8<8V[\;NF[:-V/2M_5KV#3--NKZ[<);6L3SRN?
MX54$D_D#62W@[03XN7Q3_9<)U]8O)%YEMP7!'3.,X.,XSCC.*Y_XY:5K^O\
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MH ]20Y4'!&>>>M+2+T]:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AQ_I?\ VS_K
M4U1;S]IV8&-F<_C0!+1110 4444 %%%% !1110!#(/\ 2HCVVM_2IJB9R+B-
M!C#!B?PQ_C4M !1110 4444 %%%% !4+?\?D9_V&'ZK4U0LY%PB<8*,Q^H(_
MQH FHHHH **** "BBB@ HHHH AF&9H".@8Y_(U-44CE98E &&)!_(U+0 444
M4 %%%% !1110 5#<C/EX_O@U-44SE-FT#EPIH EHHHH **** "BBB@ HHHH
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M35VB@"E_:5OZO_WR:/[2M_5_^^35VB@"E_:5OZO_ -\FC^TK?U?_ +Y-7:*
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M S_[7M?63_O@T?VO:^LG_?!K0HH S_[7M?63_O@T?VO:^LG_ 'P:T** ,_\
MM>U]9/\ O@T?VO:^LG_?!K0HH S_ .U[7UD_[X-']KVOK)_WP:T** ,_^U[7
MUD_[X-']KVOK)_WP:T** ,_^U[7UD_[X-']KVOK)_P!\&M"B@#/_ +7M?63_
M +X-1_VI:>?OW/G;C&PUJ5!_R^?]L_ZT 5O[6M?63_O@T?VO:^LG_?!K0HH
MS_[7M?63_O@T?VO:^LG_ 'P:T** ,_\ M>U]9/\ O@T?VO:^LG_?!K0HH S_
M .U[7UD_[X-']KVOK)_WP:T** ,MM4M#,C[GRH(QL/?%2?VO:^LG_?!JS)_Q
M^0_[K?TJ>@#/_M>U]9/^^#1_:]KZR?\ ?!K0HH S_P"U[7UD_P"^#1_:]KZR
M?]\&M"B@#/\ [7M?63_O@T?VO:^LG_?!K0HH S_[7M?63_O@U&=4M#,C[GR%
M(QL/?'^%:E0M_P ?D7_7-_YK0!5_M>U]9/\ O@T?VO:^LG_?!K0HH S_ .U[
M7UD_[X-']KVOK)_WP:T** ,_^U[7UD_[X-']KVOK)_WP:T** ,_^U[7UD_[X
M-']KVOK)_P!\&M"B@#+DU2T:2-BS@J20-AYX-2?VO:^LG_?!JS-_K[?_ 'C_
M .@FIZ ,_P#M>U]9/^^#1_:]KZR?]\&M"B@#/_M>U]9/^^#1_:]KZR?]\&M"
MB@#/_M>U]9/^^#1_:]KZR?\ ?!K0HH S_P"U[7UD_P"^#4<VJ6C[,LXPP/W#
M6I4%U_RR_P"N@H K?VO:^LG_ 'P:/[7M?63_ +X-:%% &?\ VO:^LG_?!H_M
M>U]9/^^#6A10!G_VO:^LG_?!H_M>U]9/^^#6A10!G_VO:^LG_?!H_M:U]9/^
M^#6A10!ER:I:.4RSC:V1\AYZU)_:]KZR?]\&K-Q]Z#_KI_0U/0!G_P!KVOK)
M_P!\&C^U[7UD_P"^#6A10!G_ -KVOK)_WP:/[7M?63_O@UH44 9_]KVOK)_W
MP:/[7M?63_O@UH44 9_]KVOK)_WP:/[7M?63_O@UH44 9_\ :]KZR?\ ?!H_
MM>U]9/\ O@UH44 9_P#:]KZR?]\&C^U[7UD_[X-:%% &?_:]KZR?]\&C^U[7
MUD_[X-:%% &?_:]KZR?]\&C^U[7UD_[X-:%% &?_ &O:^LG_ 'P:/[7M?63_
M +X-:%% &?\ VO:^LG_?!H_M>U]9/^^#6A10!G_VO:^LG_?!H_M:U]9/^^#6
MA10!6M;R*ZW>66^7&<J1UHJS10!\Y^*?^1GU?_K\F_\ 0S676IXI_P"1GU?_
M *_)O_0S674'P%;^)+U84444&84444 %%%% !1110 4444 =)\._^1RT_P#[
M:?\ HMJ]K[5XI\._^1RT_P#[:?\ HMJ]K[52/JLC_P!WEZ_H@HHHIGLA1110
M 4444 %%%% !1110 4444 %%%% !1110!;M?]6?K4U0VO^K/UJ:@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ J/?_I'EXXV;OUJ2HMG^D;\_P;<?C0!+1110 4444 %%
M%% !1110!&SXG1,?>!/Y8_QJ2HF3-PC9^Z",>O2I: "BBB@ HHHH **** "H
MB^+A$Q]Y"V?H1_C4M1,F;A'ST4KCUR1_A0!+1110 4444 %%%% !1110!%(^
MV2)<??)'Z$U+44B;I(FS]TDX]>#4M !1110 4444 %%%% !4<S[-F!G+!:DJ
M*9-^SG&'!^M $M%%% !1110 4444 %%%% $<C[#'@9W/M_G_ (5)44J;FBY^
MZ^?T-2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?.?BG_D9]7_Z_)O_ $,UEUJ>*?\ D9]7_P"OR;_T,UEU!\!6
M_B2]6%%%%!F%%%% !1110 4444 %%%% '2?#O_D<M/\ ^VG_ *+:O:^U>*?#
MO_D<M/\ ^VG_ *+:O6O$5^^E>'=3U&)5=[2UEN%5NC%$+ '\JI'U61_[O+U_
M1&C17@^G_%_Q79Z7X?U[Q/X?TV+PWK$\<$=Q9SLTD9?."5/T/Y5LWOCSQQ?^
M.O%&A^$]"T>\M]#>%97N9GC=O,0L,#."?E;]*9[)Z_17DME\9;8^!?$NL:GI
M<]KJGA]UAO-/S\P=V")@^A8_H:TO!7BWQ;?!+[Q/HFG6FAS6K74=W9W!<QJ%
MW#S >F1Z4 >D45XEIWQAUII-&UG4_#\%MX-UB]^Q6MV)29U))"NZ] #M)_"M
MCXD>/?%?A)[[5(/#MI-X8L'1)KB:<K-+G:"47IC+8Y]#0!ZK17F_C3Q_J5IJ
MVB:'X2TN+4-=U2U-ZL=RY2.&$#JQ'/)! ^E)X9^)RZCX#U36[_2[A=1TF[-A
M>V%L"[>>'5<+[98<^QH ])HK@_@]XVN_'>AZK?:AIZZ?+9ZG+8B $EE"*A^;
M/\67(...*[R@ HHHH **** "BBB@"W:_ZL_6IJAM?]6?K4Q]J "BN=\8>('T
M,:8D"1/)=7(60RG"Q6Z*7FE/^ZBG'N5K:NKNWLXQ)=W$4$9; :5P@SZ9- %B
MBN0\#^()M6N_$4=Y<PN+;5Y;6T"X&Z)8HF&,?>^^3GWKI;B^M;=96GNH(A$0
M)"\@783TSZ9[4 6J*J_;K4PQS"YA,,APD@D&UNO0]#T/Y&EM;VWNH3-;7$,T
M2G!>-PP!QG&10!9HJG#J-G-;/<17EO);QYWRI(I5<#/)S@4Z&]MI[4W$-U#)
M N2TJ2 J,=<D<<4 6J*X^/Q%)=?$FVTJSNX)M+?2)KMO**M^]6:-1\P]G/%6
M_%WB-]!O_#L6V+R-2OFMII)#CRD$$LI8=O\ EF.O;- '2T5RWA3Q#<Z[%>ZH
M\4-KX?SBSFE)629%ZS'/ 0\X[X&>];T6H6DT!G@NK>2 -L,BR J&[#.<9Y'Y
MT 6Z*JVM]:W32):W4$S1G#K'(&*_7'3H?RIL.HV4]PUO!>6\MPA.Z-)5+#!P
M<@<T 7**S[B_1DNHK&>VEO849O),HX8#C=SD#.*719[JYT6PGU!8$O9;>-YT
M@??&LA4%@C=USG!]* +]%<1X?U_7O$$[ZAIT.FKH:7LMH8I"_P!I*QRF)WSG
M:O*LP4C. !WKK'O[1+I;5KN!;D](3(-Y_#.: +=%5OMML;@0"YA,Q)41^8-Q
M(&2,=> 1^=);WUM<M(MM=03-&<2".0,4^N.G0T 6J*J6>HV=Z7%G>6]P4Y81
M2!]OUP::NJ6$C%4OK5F$?FD"920N,[NO3'.: +M%5(]0M);5KE+N!K9<YE60
M%!^.<5):W4%W%YMK/'-&3@/&X9?S% $]% HH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BO/?^$_EC^,<W@VYM8TLS:1R070)W-,RLWEGMRL<A'^[4
MWQ%\=2>%];\+:78VT=U=:MJ$,$X<G]Q;M*D32<=]TB 9XZT =Y152ZO[2T=(
M[J[@A9ONB60*6^F3S3YKJ"%09IXH@5+ NX&0.IH L45!!=07%N)X)XY83DB1
M'#+Q[CBH8=2L[A7:WO+:58AF0I*K;![\\4 7:*\ZU+Q_'J'@74M7T">..YM;
MT6H4LKG"W2PLV/1ADCZUW=O>VUS))';7,,TD9PZQR!BOU Z4 6J*J6]_:7,C
MQVUW!+(GWE20,5^H%$>HV;EE2[MV95\Q@L@.%]3ST]Z +=%5;>_M+F*26WNH
M)8H_OND@95P.Y!XI(]0M);CR(KJ!YL9\M9 6Q],T 6Z*@^U0&V-P)XO( ),F
M\;0!U.>G&*G4Y4&@ JN?^/S_ +9_UJQ7.>-M:&BZ-<3(0+AT\N+UW'@?ER?P
MH(J5%3@YRV1S&HZUX@UKQ7<V'ABY6&VMAL>1U&S<.I)()Z\#'IGUJE#=>,[C
M7)=+M=8@GE@7,\J(OE1'GY2VS[WL ?T.)=#%U9Z;'H.B\:O=CS[VYZBU4CN?
M[V,<=C6G)_H"KX8\*_\ 'XPW7=X>?)!ZLQ_OGMZ<4CPES5%SRG+7>S>_\J7?
MN^GY8\-UXSN-<ETNUUB">6!<SRHB^5$>?E+;/O>P!_0X(;KQG<:Y+I=KK$$\
ML"YGE1%\J(\_*6V?>]@#^AQL2?\ $O5?#'A7_C\8;KN\//D@]68_WSV].*)/
M^)>J^&/"O_'XPW7=X>?)!ZLQ_OGMZ<46'[.2WG+?6S>_\J[ON_Z6/#=>,[C7
M)=+M=8@GE@7,\J(OE1'GY2VS[WL ?T."&Z\9W&N2Z7:ZQ!/+ N9Y41?*B//R
MEMGWO8 _H<;$G_$O5?#'A7_C\8;KN\//D@]68_WSV].*)/\ B7JOACPK_P ?
MC#==WAY\D'JS'^^>WIQ18/9R6\Y;ZV;W_E7=]W_2QX;KQG<:Y+I=KK$$\L"Y
MGE1%\J(\_*6V?>]@#^AP0W7C.XUR72[76()Y8%S/*B+Y41Y^4ML^][ ']#C8
MD_XEZKX8\*_\?C#==WAY\D'JS'^^>WIQ1)_Q+U7PQX5_X_&&Z[O#SY(/5F/]
M\]O3BBP>SDMYRWULWO\ RKN^[_I8L-QXRN=>DTVVU>WGFMUS+,B+Y41_NL=G
MWN.@!_0X=!=^,KC7)=+M=8MYY8%S-*B+Y41Y^4MLZ^P!_0XV)/\ 0%7PQX5_
MX_"-UW>'GR0>K,?[Y[>G%$G_ !+U7PQX4_X_&&Z[O#SY(/5F/]\]O3BBP>SD
MMYR\[-[_ ,J[ON_Z6/#=>,[C7)=+M=8@GE@7,\J(OE1'GY2VS[WL ?T."&Z\
M9W&N2Z7:ZQ!/+ N9Y41?*B//REMGWO8 _H<;$G_$O5?#'A7_ (_&&Z[O#SY(
M/5F/]\]O3BB3_B7JOACPK_Q^,-UW>'GR0>K,?[Y[>G%%@]G);SEOK9O?^5=W
MW?\ 2QX;KQG<:Y+I=KK$$\L"YGE1%\J(\_*6V?>]@#^AP0W7C.XUR72[76()
MY8%S/*B+Y41Y^4ML^][ ']#C8D_XEZKX8\*_\?C#==WAY\D'JS'^^>WIQ1)_
MQ+U7PQX5_P"/QANN[P\^2#U9C_?/;TXHL'LY+><M];-[_P J[ON_Z6/!=>,[
MG7)=+M=8@GEA7,TJ(OE1'GY2=GWO89_0X-)NO&>K7MU!8ZQ!)%;G8]SL7RF;
MCY5.S)Q],>^",[,D<-J%\*>'D+R2#_3[GJ8T/#L3_?(Z>G%)+_Q,V_X1OPU_
MHVEV_P EY=IV'=%/=CW/U_$L'LI7UG)^2;W[+TZLQ])NO&>K7MU!8ZQ!)%;G
M8]SL7RF;CY5.S)Q],>^",II=QXQU6_NH['5[>2.U/EM=;!Y1;C*J=F2?PQ[]
M,[,O_$S;_A&_#7^C:7;_ "7EVG8=T4]V/<_7\5F_XF;?\(WX:_T?2[?Y+R[3
ML.Z*>['N?K^("IRT]^3]&]7V7DNK,;2;KQGJU[=06.L0216YV/<[%\IFX^53
MLR<?3'O@C)I-UXSU:]NH+'6()(K<['N=B^4S<?*IV9./ICWP1G8E_P")FW_"
M-^&O]&TNW^2\NT[#NBGNQ[GZ_B2_\3-O^$;\-?Z-I=O\EY=IV'=%/=CW/U_$
M!4I:>_)^C>K[+R75F/I-UXSU:]NH+'6()(K<['N=B^4S<?*IV9./ICWP1DTF
MZ\9ZM>W4%CK$$D5N=CW.Q?*9N/E4[,G'TQ[X(SL2_P#$S;_A&_#7^C:7;_)>
M7:=AW13W8]S]?Q)?^)FW_"-^&O\ 1M+M_DO+M.P[HI[L>Y^OX@*E+3WY/T;U
M?9>2ZLK>"O%%])XBN-*U;4(KW<,0SQ@!-Z\E0<#.1G\N.*](KR/Q4(F:%?#%
MMB+05WR7*= <CY0?XCD9/XUZ7H.I)JVE6U[$?EE3)&>C="/P.:$=F JN\J,W
M=K5/NOUL]#1HHHIGID$W^OM\=-QS_P!\FIZCD8+)$",EF('MP:DH **** "B
MBB@ HHHH *@N?^67_705/4<S!-F1G+ 4 24444 %%%% !1110 4444 07'WH
M.O\ K!_(U+(VV-FQG )Q396"M'D9RV![<&BX_P"/>3_=/\J /F?6/B1XGFU.
MX:'47@BWD+'&JX49P.HJE_PL+Q5_T&)O^^$_PI_@GP_;^)O&<VG7DKQ0E99"
MR'D%:2T\)-'\0X/#NI,Z1R3;/,3^),$AA0 W_A87BK_H,3?]\)_A1_PL+Q5_
MT&)O^^%_PJQ-X6M8_#FKWXEE,MGJ8LD'&"I8#)]ZSOB#H<'AOQ#+86DCR1)"
MDFZ3J25R: .T^'_CC5]5O+K1]3U259+V(I:W1"@PRX^7MR*W/A%XWU6X\0W_
M (8\63%]1@8^5(X"LQ!Y4XP/<5YMXNT:+PU)H<]C-*9+JT2[+-_"V>U:OC:6
M6ZM=&\?Z/\E[ ZQ7P3^&1>C'V/2I?<]G*%2Q'/@ZJ5Y_"^JDMM?/8^ECT-<1
MJWQ!L-,U+6;":&4W.G1+*%R )P<9"GU&16[X4UR#Q'X?L]3M2"DZ99<_=;N#
M7-^)O"&AZG=7\6IWBQW.H31S(-RAXV10N%]CBGTT.7"TJ,*TJ>+3TTTW3NK_
M (7-&?QK:)XFAT1()GN9;?S5;@+O(RL>?[Q%9]GX^EECE>ZT6XMHX[U+ LTZ
M-^]+8/0]NM,?P)I+ZE)=O>R_VM'.EWY_F -'C&!CIC Q]*O?\(UI\MNT27Q9
M;G4?[44A@=S Y('MZT:G1; Q223>BOOOU:U_JQ!:^.TENH)'TR[31YYS:PWY
M9=K.,C[N<A21@&C0_B'8:PUA'!!,L]S=/:O&S#,14$[CZ@XXQ5:S\-:,DX==
M;,FE6EP;A+(R+Y<4ASR3UP#D@&J__"'^'X/[*NX-66&XM$EBCN5D4>9NR.>Q
M(SQ1J:>SP+NK-/IOV=K^>U[?+J:,/Q$L)[/7IX;>9AI;?=)QYR9V[U]LUVD$
MGG0QR $;U#8],BN!3X9Z0EJR:?/<6XFM3;3,K[O-!(8,<]\\_C77Z#83Z;8K
M;W-]-?,#Q)(H! [#BC7J<>+6$M?#M[[/?9?K<U****9P!1110 4444 %%%%
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MYA7=CRIDDQCWV8_&@#S'5VL-0U>5_A9):RW]OHE^EU)IS*4$C(!;K*1QYOF
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M660^O/ ^G4D9R?\ A(-,\.Z/]GT.\CO-5O'S/>R@\-WD?(R<9.!SW)R<Y/\
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M44 %%%% !1110 4444 %&*** #%%%% !465^T;<?-MSG\:EJ+8?M._MLQ^M
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MBF8+LW#.6 'UJ6HIT+^7CLX;\J ):*** "BBB@ HHHH **** (Y6"F/<,Y;
M_6GL RD$9!&#4<R%FBV_POD_D:EH \BU3X,6MUJ$T]MJ,D4<C%PA3.W-5?\
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M +\-_A0!H45G_P!J)_S[W?\ WX;_  H_M1/^?>[_ ._#?X4 :%%9_P#:B?\
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M!H45G_VHG_/O=_\ ?AO\*/[43_GWN_\ OPW^% &A16?_ &HG_/O=_P#?AO\
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M %9^M38J&U_U9^M34 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444
M&*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,4
M44 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &
M*,444 &*,444 &*,444 &*,444 &*AVG[7NQ\NS&??-35#N/VO;GC9G'XT 3
M48HHH ,48HHH ,48HHH ,48HHH A=2;F)AT56S^E35"[$7,2@\%6)'KC%34
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MGA1MKRHK>A8"F_:H/^>T?_?0KY#UG4;NZU2ZFN+B5W:1LDL?6J7VB7_GJ_\
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MSD\?A75:IXDM;O1=!LXXIEDT\@R,0,-@#IS63JVB7>GZK/8K%-,T;$!EB.&
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M0,,C<J%AGVXKR?X=_P#(Y:?_ -M/_1;5ZAXW1Y?!6OQQ(SR/IUPJJHR6)C;
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MEGP M+BTT[QF+JWF@,GB>]DC$D93<A$>&&>HXZ^U>IT %%%% !1110 4444
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M@_U<-NFQ%/TR:Q?PJ6>9BIPJ57*%[:;G2?#O_D<M/_[:?^BVKVOL*\4^'?\
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MJ1XZP->'N0LXWZWNUT3TV1S3:QIWB?4\7U[;V>@VC@1VTD@1KEAT+#LH]/\
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M/XV7NQQP/\DL]8T[6[\ZSKU[;Q6EL6-IIYD!88_C9>['' _R>E_X0/PY_P!
MT?\ ?V3_ .*J-O _AP7")_9HP59O];)V(_VO>@%A<5UY7U>^K\].G1;'/6>L
M:=K=^=9UZ]MXK2V+&TT]I 6&/XV7NQQP/\DL]8T[6[\ZSKU[;Q6EL6-II[2
ML,?QLO=CC@?Y/2_\('X<_P"@:/\ O[)_\51_P@?AS_H&C_O[)_\ %4 L+BNO
M*^KWU?GITZ+8YJSUC3M;OSK.O7MO%:6Q8VFGM("PQ_&R]V..!_DEGK&G:W?G
M6=>O;>*TMBQM-/:0%AC^-E[L<<#_ ">E_P"$#\.?] T?]_9/_BJ/^$#\.?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%/\ R,^K_P#7Y-_Z&:RZ@^ K?Q)>K"BBB@S"BBB@ HHHH **** "BBB@#H?
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MQH_M%O\ GRN?^^1_C6A10!G_ -HM_P ^5S_WR/\ &C^T6_Y\KG_OD?XUH44
M9_\ :+?\^5S_ -\C_&C^T6_Y\KG_ +Y'^-:%% &?_:+?\^5S_P!\C_&C^T6_
MY\KG_OD?XUH44 9_]HM_SY7/_?(_QH_M%O\ GRN?^^1_C6A10!G_ -HM_P ^
M5S_WR/\ &C^T6_Y\KG_OD?XUH44 9_\ :+?\^5S_ -\C_&C^T6_Y\KG_ +Y'
M^-:%% &?_:+?\^5S_P!\C_&C^T6_Y\KG_OD?XUH44 9_]HM_SY7/_?(_QH_M
M%O\ GRN?^^1_C6A10!G_ -HM_P ^5S_WR/\ &C^T6_Y\KG_OD?XUH44 9_\
M:+?\^5S_ -\C_&C^T6_Y\KG_ +Y'^-:%% &?_:+?\^5S_P!\C_&C^T6_Y\KG
M_OD?XUH44 9_]HM_SY7/_?(_QH_M%O\ GRN?^^1_C6A10!G_ -HM_P ^5S_W
MR/\ &C^T6_Y\KG_OD?XUH44 9_\ :+?\^5S_ -\C_&C^T6_Y\KG_ +Y'^-:%
M% &?_:+?\^5S_P!\C_&C^T6_Y\KG_OD?XUH44 9_]HM_SY7/_?(_QH_M%O\
MGRN?^^1_C6A10!G_ -HM_P ^5S_WR/\ &C^T6_Y\KG_OD?XUH44 9_\ :+?\
M^5S_ -\C_&C^T6_Y\KG_ +Y'^-:%% &?_:+?\^5S_P!\C_&C^T6_Y\KG_OD?
MXUH44 9_]HM_SY7/_?(_QH_M%O\ GRN?^^1_C6A10!G_ -HM_P ^5S_WR/\
M&C^T6_Y\KG_OD?XUH44 9_\ :+?\^5S_ -\C_&C^T6_Y\KG_ +Y'^-:%% &?
M_:+?\^5S_P!\C_&C^T6_Y\KG_OD?XUH44 9_]HM_SY7/_?(_QH_M%O\ GRN?
M^^1_C6A10!G_ -HM_P ^5S_WR/\ &F?VF_F[?L=QC&<;1GK]:TZBV?Z1OS_!
MMQ^- %3^T6_Y\KG_ +Y'^-']HM_SY7/_ 'R/\:T** ,_^T6_Y\KG_OD?XT?V
MBW_/E<_]\C_&M"B@#/\ [1;_ )\KG_OD?XT?VBW_ #Y7/_?(_P :T** ,_\
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M S_[1;_GRN?^^1_C1_:+?\^5S_WR/\:T** ,_P#M%O\ GRN?^^1_C1_:+?\
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M^:U/43,!<(N.2K$'Z$?_ %J ):*** "BBB@ HHHH **** ()O^/BWQ_>.?\
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MV:-D&'8G<P\S=SU*UU%K'JFK^/)]7?1KFQL#H<MI&UQM$C2&56PR@G''3DT
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MG\EQUO+SKY(/5B>[G].,>Q8/9-;SEOK:3W_E7?S?]+'MYO&%UKLVF6FM13O
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M56"2C!7*N&&&P1ACFY9Z5,_COQQ=11-#<7%C:6]O=LI !V2_=;V8@G'H,]J
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M,JK*,9RI/7BG:CXDT73UC-]JME;B1!*ADF5=R$A0PYY!) _$5YKKD4D'CO\
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MB(6EI_Q,?%.I'<SGDD_WCZ(.?K@_AS>C^+]/TJQN[SR[F]\0W0W2SSH%3/\
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MF%%%% !1110 4444 %%%% '2?#O_ )'+3_\ MI_Z+:O:^U>*?#O_ )'+3_\
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M J>B@.5$'V.W_P">$7_? H^QV_\ SPB_[X%3T4!RH@%I &R(8P?4(*FQ2T4
MDEL%%%% R&8D3P '@L<_]\FIJBD*B2+=]XD[?RJ6@ HHHH **** "BBB@ J"
MY8CR\'K(!4]1S%?DW]V&/K0!)1110 4444 %%%% !1110!#<$AH<'&9,'\C4
MU1RE<Q[^[<?6I* .;OO!'AV^NGN+G3(&F<Y9MN,FH/\ A7OA?_H$P?E75T4
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M6[KD[?R-2U#,"9X"!PK'/Y&IJ "BBB@ HHHH **** "HYMIV;_[P(^M25#<
MGRL#.'% $U%%% !1110 4444 %%%% $<NW,>_P#O?+]<&I*AG!+0X'1P3^M3
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M =**** /G/Q3_P C/J__ %^3?^AFLNM3Q3_R,^K_ /7Y-_Z&:RZ@^ K?Q)>K
M"BBB@S"BBB@ HHHH **** "BBB@#I/AW_P CEI__ &T_]%M7M?:O%/AW_P C
MEI__ &T_]%M7M?:J1]5D?^[R]?T04444SV0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH MVO^K/UJ;.*AM?\ 5GZU*: %S1FO.;W5;Z+Q]XKLXK^6!!IF
MG16F[YXX+B>:>,2;#Q][9GU"XKHM'\+KIE[#=KK&LW,X!\X75[)+'-D'/[MC
ML3YL-\H&,8&!Q0!T>12D@5QOP?O;K4OA=X8O-0N);F[GL8WEFF8L[L1R23U-
M<'JUX)+SXBW4OB+5+?5=,O"-,M8=0D RMK"Z*+<-M<&0MD%2#DYH ]NS1FN5
MOO%::8MI:W-C?7VJFV6XN+6PB$C0@\;FR1@%L@>N#Z5R/B;7K+Q!XX\%6W]F
MW>JZ-<VUQ?Q[80T32 PK')@D?ZL2/G(RNX=>P!ZQFC-<CI7CFPU;39]0T^RU
M.:TC&%D6 8EDW^7Y:<\MN_#WI]MXYTE]-U.[NTN[!M-D2&YM[J+;*K.%,8"@
MG.[< ,'DT =7FC->>^*OB#-I6AQ7EMH&JBX:^MK9H+FW *I),B;N'[[F"\_>
M'.!6O?>,[:UFAMH],U:[OC;K<S6MO KRVR'A?,&X $X; R>AH ZO-!('6N/F
M\?Z,L&C26JW=Z=7CEDLX[6+<\GEE0ZX)&&&[D'^Z?2K/_"8Z:/#-SK16Y$-O
M.]K)"8_WWG++Y7EA<\L7P!SSD>M '3YHR*Y7XI7=Q8?#7Q3=V4TEO<PZ9<21
MRQL59&$;$,".A%<EXN^(&ER^"532M5N$U-VM41TBF1LF6,-\Q4=1GO0!ZOD4
MF17D&LSVMQXR\;C5O$NI:;]ACMS91P:E)$$+6^XE8@V'.[!Q@YZ8.:U_AUJ^
ML?VZMIXD>;[1J^D6VKQ12,<0RA%CN8E'8!C&VT="YH ])S1FN1\"W5SJ]QKN
MLRSS/9W-\\%C$6.Q88?W6Y1_MN)&SW!7TJWJWBNRT[Q!%HGV>]N=1D@6Y6*W
MB#_NRY4MG(  (YH Z/-&:Y%?'6EMJ*VWD7WV5[H6*ZCY/^BM-G:$#YS]_P"3
M.,9XS63X*U0:5H6MSM;7=XS>(=0C2&V3S)'/VAS@ D#  )Y/04 >B9HS7G6N
M?$A;?2M,N]*TG4+IKC5!IUQ"T WV[!PK(PW##G/R]0:V-2\<6-@\B/8:I.UO
M MQ>B" .;)67</-YX.T$D#)X]QD ZW(]:*Y:_P#&FG6][%:VD%[JDKP+=2?8
M8A((8F^Z[DD8##)'4X!XK/\ @E*)OAEI,H8L':X8,<\CSY/6@#N<T9%8GB+Q
M%::)-:P217-W?76[R;2TCWRR!>68 D  9&23W%4;SQE9V_V.%+'4;J_N8C-]
MAMX0T\2 [27!(  8;>O)!QD4 =3D49KSC4=;M/$&O?#N^T]G\J35+I'CD7:\
M;K97(9''9@1@BM6Y^(.DV\TKM!?MIL,_V:34UA!M4?<%.7SG ;Y2<8SGMS0!
MV.X4M<;K7C_3=+O=7M6L]3NY=)"O>_9;?>(4,8DW'D9&T]N>#Q766=S#>V<%
MU:R++;SQK+'(O1E89!'U!H FHHHH **** "BBB@ HHHH ***,T %%&0*,T %
M%%)D>M "T449H **,T9H **,BC- !11FC(H ***,T %1;C]IV?P[-WXYJ6HC
ML$Y8GYMN"/;- $N11D5Y9=7FI>(]6U:[LM9ETO2;$!/,#L$.._!'/?\ $"JN
MCV'B"^TVXU&X\17=G81Y:.69V_>*/XL9X'\\TKGF_P!HWE:$&UKK==.OH>N9
M%&17D>CV'B"_TRXU*X\17=G81Y:.69V_>*/XL9X'\\T:/8>(+_3+C4KCQ%=V
M=A'EHY9G;]XH_BQG@?SS1<2S&3M:F]==UM]YZYD49%>1Z/8>(+_3+C4KCQ%=
MV=A'EHY9G;]XH_BQG@?SS1H]AX@O],N-2N/$5W9V$>6CEF=OWBC^+&>!_/-%
MP68R=K4WKKNMOO/7,BC(KR/1[#Q!?Z9<:E<>(KNSL(\M'+,[?O%'\6,\#^>:
M-'L/$%_IEQJ5QXBN[.PCRT<LSM^\4?Q8SP/YYHN"S&3M:F]==UM]YZN[D7,:
MCH58G]*ER*\CT?3]?O\ 3I]3N/$5U9V,>3'+,[9D0?Q8SP/YT:/8>(+_ $RX
MU*X\17=G81Y:.69V'F*/XL9X'^-%P68R=K4WKKNMOO/7,BC(KR/1[#Q!?Z9<
M:E<>(KNSL(\M'+,[?O%'\6,\#^>:-'L/$%_IEQJ5QXBN[.PCRT<LSM^\4?Q8
MSP/YYHN"S&3M:F]==UM]YZYD49%>1Z/8>(+_ $RXU*X\17=G81Y:.69V_>*/
MXL9X'\\T:/8>(+_3+C4KCQ%=V=A'EHY9G;]XH_BQG@?SS1<%F,G:U-ZZ[K;[
MSUS(HR*\ATRR\07>CW>J3^(+VVL(@SQR.S;I5&?F"YXSC '?-.AL/$$?A\ZM
MJOB*[L(\;EC=V9B#TXR.3V'M1<2S&35_9O:^ZV/7,BHF<_:43^$HS'Z@BO*(
M;#Q!'X?.K:KXBN["/&Y8W=F8@].,CD]A[4D.GZ^F@_VQJOB&ZL$VY5'=F<J<
M8XR.3QQ[47'_ &C+_GV]K[K;[]/F>NY%&17D<-AX@C\/G5M5\17=A'C<L;NS
M,0>G&1R>P]J(;#Q!'X?.K:KXBN["/&Y8W=F8@].,CD]A[47#^T9?\^WM?=;?
M?H>N9%&17D<-AX@C\/G5M5\17=A'C<L;NS,0>G&1R>P]J(;#Q!'X?.K:KXBN
M["/&Y8W=F8@].,CD]A[47#^T9?\ /M[7W6WWZ'KF12UY7X+U;5]-URTM_$$U
MPT.I1;H?/<MM;/'7IG^HKU3-,ZL-B5B(\R5O)A1110=)#*Q$L*@\,2#^1J:H
MY IDC)X8$[1Z\5)0 4444 %%%% !1110 5%.[)LV]W -2U%,JG9N;'S@CW-
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MX;S 6#8/F+@J#SGI0!J6_P 0- N+B)(KBX^SS2"&*]-M(+61R=H59L;"2>
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MM(X[D]AWX_$B_P")LW_"2>)/]&TBV_>6=K)W':1QW)[#OQ^(G_%1R?VWKO\
MHWAVU)DMK:7_ ):X_P"6L@[^R]^G3.X3_BHY/[;UW_1O#MJ3);6TO_+7'_+6
M0=_9>_3IG<!OMK?77K_>EVBNB,;Q+;ZAKNDS>(KI_L4%L UA Y ;:6'SD^IX
MP/I^/?>$]676M"MKP$>8R[91_=<=?\?QKSSQ=?W&KZ:=4O5:+3RWEZ;9G@RL
M>#,X]AT'T'0G=WG@G1AHGA^WMV7]^_[V8_[1_P !@?A20\&V\3+EVMJWU?1V
MZ>7D=!1113/8(9N9H".S'_T$U-44KE9(E X8D'VX-2T %%%% !1110 4444
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M/?W*JR9^HJQXR@N[/Q=X>U]+&XU"QLX+JVGAMH_,DC:7RBDBIU/^K*G'0/\
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M %%%% !1110 4444 %13('V9.,,"/>I:@NO^67_704 3T444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^3?_ !='_"6_$?\ Z%*V_)O_ (NO::*+H/83_G?X'BW_  EOQ'_Z%*V_)O\
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M_P#BZ/\ A-OB1_T*5M_WRW_Q=>PT47#V$_\ GX_P/'O^$V^)'_0I6W_?+?\
MQ='_  FWQ(_Z%*V_[Y;_ .+KV&BBX>PG_P _'^!X]_PFWQ(_Z%*V_P"^6_\
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M?_%U[#11</83_P"?C_ \>_X3;XD?]"E;?]\M_P#%T?\ ";?$C_H4K;_OEO\
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M *%*V_[Y;_XNC_A-OB1_T*5M_P!\M_\ %U[#11</83_Y^/\  \>_X3;XD?\
M0I6W_?+?_%T?\)M\2/\ H4K;_OEO_BZ]AHHN'L)_\_'^!XT_C/XCL4)\)6WR
MMG[K>G_72I/^$V^)'_0I6W_?+?\ Q=>P4M%T'L)_\_'^!X]_PFWQ(_Z%*V_[
MY;_XNC_A-OB1_P!"E;?]\M_\77L-%%P]A/\ Y^/\#Q[_ (3;XD?]"E;?]\M_
M\71_PFWQ(_Z%*V_[Y;_XNO8:*+A["?\ S\?X'CW_  FWQ(_Z%*V_[Y;_ .+H
M_P"$V^)'_0I6W_?+?_%U[#11</83_P"?C_ \>_X3;XD?]"E;?]\M_P#%T?\
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(TC%Q5F[G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624541104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PDS Biotechnology Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001472091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-4231384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25B Vreeland Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Florham Park,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">208-3343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00033 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PDSB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,868,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694625464592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 60,624,991<span></span>
</td>
<td class="nump">$ 73,820,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,725,958<span></span>
</td>
<td class="nump">2,660,230<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">63,350,949<span></span>
</td>
<td class="nump">76,480,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">143,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Financing lease right-to-use assets</a></td>
<td class="nump">220,213<span></span>
</td>
<td class="nump">374,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-to-use asset</a></td>
<td class="nump">39,488<span></span>
</td>
<td class="nump">152,645<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">63,754,250<span></span>
</td>
<td class="nump">77,007,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,414,905<span></span>
</td>
<td class="nump">1,219,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,376,325<span></span>
</td>
<td class="nump">8,313,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease obligation-short term</a></td>
<td class="nump">53,309<span></span>
</td>
<td class="nump">56,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation-short term</a></td>
<td class="nump">59,650<span></span>
</td>
<td class="nump">231,429<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,904,189<span></span>
</td>
<td class="nump">9,821,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Note payable, net of debt discount</a></td>
<td class="nump">23,254,367<span></span>
</td>
<td class="nump">23,020,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease obligation-long term</a></td>
<td class="nump">151,505<span></span>
</td>
<td class="nump">164,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">31,310,061<span></span>
</td>
<td class="nump">33,005,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00033 par value, 75,000,000 shares authorized at June 30, 2023 and December 31, 2022, 30,868,188 shares and 30,170,317 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">10,188<span></span>
</td>
<td class="nump">9,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">155,187,231<span></span>
</td>
<td class="nump">145,550,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(122,753,230)<span></span>
</td>
<td class="num">(101,558,417)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">32,444,189<span></span>
</td>
<td class="nump">44,002,030<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 63,754,250<span></span>
</td>
<td class="nump">$ 77,007,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624475040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00033<span></span>
</td>
<td class="nump">$ 0.00033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">30,868,188<span></span>
</td>
<td class="nump">30,170,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in shares)</a></td>
<td class="nump">30,868,188<span></span>
</td>
<td class="nump">30,170,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694622454560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 8,004,852<span></span>
</td>
<td class="nump">$ 3,761,646<span></span>
</td>
<td class="nump">$ 13,848,538<span></span>
</td>
<td class="nump">$ 8,922,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,691,321<span></span>
</td>
<td class="nump">3,331,006<span></span>
</td>
<td class="nump">8,270,049<span></span>
</td>
<td class="nump">6,648,913<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">12,696,173<span></span>
</td>
<td class="nump">7,092,652<span></span>
</td>
<td class="nump">22,118,587<span></span>
</td>
<td class="nump">15,571,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,696,173)<span></span>
</td>
<td class="num">(7,092,652)<span></span>
</td>
<td class="num">(22,118,587)<span></span>
</td>
<td class="num">(15,571,874)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Interest income (expenses), net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">750,654<span></span>
</td>
<td class="nump">74,547<span></span>
</td>
<td class="nump">1,479,995<span></span>
</td>
<td class="nump">80,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(995,397)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,962,242)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expenses), net</a></td>
<td class="num">(244,743)<span></span>
</td>
<td class="nump">74,547<span></span>
</td>
<td class="num">(482,247)<span></span>
</td>
<td class="nump">80,247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(12,940,916)<span></span>
</td>
<td class="num">(7,018,105)<span></span>
</td>
<td class="num">(22,600,834)<span></span>
</td>
<td class="num">(15,491,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="nump">1,406,021<span></span>
</td>
<td class="nump">1,198,905<span></span>
</td>
<td class="nump">1,406,021<span></span>
</td>
<td class="nump">1,198,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,534,895)<span></span>
</td>
<td class="num">(5,819,200)<span></span>
</td>
<td class="num">(21,194,813)<span></span>
</td>
<td class="num">(14,292,722)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (11,534,895)<span></span>
</td>
<td class="num">$ (5,819,200)<span></span>
</td>
<td class="num">$ (21,194,813)<span></span>
</td>
<td class="num">$ (14,292,722)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">30,802,498<span></span>
</td>
<td class="nump">28,451,579<span></span>
</td>
<td class="nump">30,616,310<span></span>
</td>
<td class="nump">28,450,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">30,802,498<span></span>
</td>
<td class="nump">28,451,579<span></span>
</td>
<td class="nump">30,616,310<span></span>
</td>
<td class="nump">28,450,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694618257936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 9,387<span></span>
</td>
<td class="nump">$ 123,904,602<span></span>
</td>
<td class="num">$ (60,703,562)<span></span>
</td>
<td class="nump">$ 63,210,427<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">28,448,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,128,973<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,128,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options (in shares)</a></td>
<td class="nump">2,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,473,522)<span></span>
</td>
<td class="num">(8,473,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 9,388<span></span>
</td>
<td class="nump">125,041,062<span></span>
</td>
<td class="num">(69,177,084)<span></span>
</td>
<td class="nump">55,873,366<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">28,450,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 9,387<span></span>
</td>
<td class="nump">123,904,602<span></span>
</td>
<td class="num">(60,703,562)<span></span>
</td>
<td class="nump">63,210,427<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">28,448,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,292,722)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 9,391<span></span>
</td>
<td class="nump">126,412,089<span></span>
</td>
<td class="num">(74,996,284)<span></span>
</td>
<td class="nump">51,425,196<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">28,458,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 9,387<span></span>
</td>
<td class="nump">123,904,602<span></span>
</td>
<td class="num">(60,703,562)<span></span>
</td>
<td class="nump">$ 63,210,427<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">28,448,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,491<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 9,956<span></span>
</td>
<td class="nump">145,550,491<span></span>
</td>
<td class="num">(101,558,417)<span></span>
</td>
<td class="nump">$ 44,002,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">30,170,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 9,388<span></span>
</td>
<td class="nump">125,041,062<span></span>
</td>
<td class="num">(69,177,084)<span></span>
</td>
<td class="nump">55,873,366<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">28,450,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,348,601<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,348,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">22,426<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options (in shares)</a></td>
<td class="nump">7,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,819,200)<span></span>
</td>
<td class="num">(5,819,200)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 9,391<span></span>
</td>
<td class="nump">126,412,089<span></span>
</td>
<td class="num">(74,996,284)<span></span>
</td>
<td class="nump">51,425,196<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">28,458,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 9,956<span></span>
</td>
<td class="nump">145,550,491<span></span>
</td>
<td class="num">(101,558,417)<span></span>
</td>
<td class="nump">44,002,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">30,170,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,080,319<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,080,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock from the Sales Agreement, net</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">4,588,339<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,588,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="nump">553,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,659,918)<span></span>
</td>
<td class="num">(9,659,918)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 10,139<span></span>
</td>
<td class="nump">152,219,149<span></span>
</td>
<td class="num">(111,218,335)<span></span>
</td>
<td class="nump">41,010,953<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">30,723,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 9,956<span></span>
</td>
<td class="nump">145,550,491<span></span>
</td>
<td class="num">(101,558,417)<span></span>
</td>
<td class="nump">$ 44,002,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">30,170,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for consulting agreement (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,194,813)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 10,188<span></span>
</td>
<td class="nump">155,187,231<span></span>
</td>
<td class="num">(122,753,230)<span></span>
</td>
<td class="nump">32,444,189<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">30,868,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 10,139<span></span>
</td>
<td class="nump">152,219,149<span></span>
</td>
<td class="num">(111,218,335)<span></span>
</td>
<td class="nump">41,010,953<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">30,723,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,105,538<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,105,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,848<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuances of common stock, from exercise of stock options (in shares)</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for consulting agreement</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">609,967<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for consulting agreement (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock from the Sales Agreement, net</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">243,729<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 243,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock from the Sales Agreement, net (in shares)</a></td>
<td class="nump">43,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,534,895)<span></span>
</td>
<td class="num">$ (11,534,895)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 10,188<span></span>
</td>
<td class="nump">$ 155,187,231<span></span>
</td>
<td class="num">$ (122,753,230)<span></span>
</td>
<td class="nump">$ 32,444,189<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">30,868,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694625531712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,534,895)<span></span>
</td>
<td class="num">$ (9,659,918)<span></span>
</td>
<td class="num">$ (5,819,200)<span></span>
</td>
<td class="num">$ (8,473,522)<span></span>
</td>
<td class="num">$ (21,194,813)<span></span>
</td>
<td class="num">$ (14,292,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,185,857<span></span>
</td>
<td class="nump">2,477,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of shares in consulting agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">121,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,523<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,891<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,514<span></span>
</td>
<td class="nump">120,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,627<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,272<span></span>
</td>
<td class="num">(1,160,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,195,618<span></span>
</td>
<td class="nump">568,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,937,383)<span></span>
</td>
<td class="nump">115,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,136)<span></span>
</td>
<td class="num">(116,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,003,030)<span></span>
</td>
<td class="num">(12,287,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,849<span></span>
</td>
<td class="nump">29,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments of finance lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,253)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,832,265<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,807,861<span></span>
</td>
<td class="nump">29,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,195,169)<span></span>
</td>
<td class="num">(12,257,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,820,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,242,622<span></span>
</td>
<td class="nump">73,820,160<span></span>
</td>
<td class="nump">65,242,622<span></span>
</td>
<td class="nump">65,242,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of period</a></td>
<td class="nump">$ 60,624,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,984,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,624,991<span></span>
</td>
<td class="nump">52,984,672<span></span>
</td>
<td class="nump">$ 73,820,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental information of cash and non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,962,241<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694627395808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Note 1 <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211; </span>Nature of Operations</span><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-size: 10pt; font-style: normal; font-weight: bold;"> <br/>
            </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">PDS Biotechnology Corporation, a Delaware
                    corporation (the &#8220;Company&#8221; or &#8220;PDS Biotech&#8221;), is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on its Versamune</span><span style="font-family: 'Times New Roman';"><sup>&#174;</sup><span style="font-size: 10pt;">, Versamune</span><sup>&#174;</sup><span style="font-size: 10pt;"> plus PDS0301 and Infectimune</span><sup>&#174;</sup><span style="font-size: 10pt;"> T cell-activating platforms and
                      PDS0301 tumor targeting immunocytokine. The Company believes its targeted immunotherapies have potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of
                      T cells.&#160; Versamune, and Versamune plus PDS0301 for treatments in oncology and Infectimune, for treatments in infectious disease.&#160; When paired with an antigen, which is a disease-related protein that is recognizable by the immune
                      system, Versamune and Infectimune have both been shown to induce, </span><span style="font-size: 10pt; font-style: italic;">in vivo,</span><span style="font-size: 10pt;"> large quantities of high-quality, highly potent polyfunctional
                      CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies.&#160; Versamune
                      plus PDS0301 enhances the proliferation, potency and longevity of T cells in the tumor microenvironment and works synergistically to overcome tumor immune suppression.</span></span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s immuno-oncology clinical candidates are of potential interest for use as a component of combination
                  clinical candidates (for example, in combination with other leading technologies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or refractory cancers. The Company is also
                  evaluating our immunotherapies as monotherapies in early-stage disease.&#160; PDS Biotech is developing targeted clinical candidates to treat several cancers including Human Papillomavirus (HPV)-positive cancers, melanoma, colorectal, lung,
                  breast and prostate cancers. The Company infectious disease candidates are of potential interest for use in universal influenza vaccines.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694627385360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 2 &#8211; Summary of Significant Accounting
            Policies</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">Unaudited interim financial statements:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The interim balance sheet at June 30, 2023, the statements of operations and comprehensive loss and changes in stockholders&#8217; equity and cash flows for the three and six months ended June 30, 2023 and 2022 are
              unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As
              permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the
              Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations
              for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The balance sheet as of December 31, 2022
              included herein was derived from the audited consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and
              notes thereto as of and for the year ended December 31, 2022, filed by the Company with the SEC in its Annual Report on Form 10-K on March 28, 2023.</span></span><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of condensed consolidated financial
            statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements
            and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates. The most significant estimate relates to the fair value
            of securities underlying stock-based compensation.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its clinical candidates, the ability to preserve its cash resources, the Company&#8217;s review of strategic alternatives, the
                          ability to add clinical candidates to its pipeline, the Company&#8217;s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by
                          other companies, the price of, and demand for, Company products if approved for sale, the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the ability to raise capital, and
                          the effects of health epidemics, pandemics, or outbreaks of infectious diseases.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#8217;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.</div>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a
            maturity weighted average of less than three months to be cash equivalents. The Company&#8217;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <br/>
        </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#8217;s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on
            behalf of the Company.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical trial site activations or information provided by vendors on their actual costs incurred. Payments
            for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation
              (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order
              to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest
              rate and dividend yield. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company
              recognizes forfeitures as they occur.</div>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                  </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"> <span style="font-weight: bold; font-family: 'Times New Roman';">2023</span><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2022</span><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,324,402</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">4,289,943</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">506,229</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">124,604</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Total</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,830,631</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">4,414,547</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(I)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Income taxes:</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div>

<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div>
                          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">(J)</div>
                                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">Fair value of financial instruments:</div>
                                </td>

  </tr>


</table>
                        </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 0px;"><span style="font-family: 'Times New Roman';"><br/>
                        </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three levels of the fair value hierarchy are as follows:</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1 &#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 2 &#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 3 &#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
              <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(K)</span></div>
                        </td>

    <td style="align: left; vertical-align: top; width: auto;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Leases:</span></div>
                        </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#8220;ASC 842&#8221;). Both financing and operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#8217;s consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to
                  make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the
                  lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694627343808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 3 &#8211; Liquidity</div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">As of June 30, 2023, the
              Company had $60.6 million of cash and cash equivalents. The Company&#8217;s primary uses of cash are to fund operating expenses,
              primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change to the Company&#8217;s outstanding accounts payable and accrued
              expenses.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2022, the Company received approximately $1.2 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant the Company&#8217;s participation in the New Jersey Technology
              Business Tax Certificate Transfer NOL program for tax year 2020.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In August 2022, the Company filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC
              for the issuance of common stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $150
              million, $50 million of which covers the offer, issuance and sale by the Company of its common stock under the Sales Agreement (as
              discussed below).&#160; The 2022 Shelf Registration Statement was declared effective on September 2, 2022.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley
              Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock,
              having an aggregate offering price of up to $50 million, or the Placement Shares, through or to the Agents, as sales agents or
              principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in
              Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company&#8217;s common stock. The Agents will use commercially
              reasonable efforts to sell the Placement Shares from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the
              Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under
              the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company is not obligated to make any sales of its common stock under the Sales Agreement.&#160; The offering of Placement
              Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. For the year ended December
              31, 2022, the Company sold 1,238,491 shares of common stock with a net value of $9.9 million pursuant to the Sales Agreement. During the three and six months ended June 30, 2023, we sold 43,169 shares of our common stock with a net value of $0.2
              million and 596,462 share of our common with a net value of $4.8 million, respectively, pursuant to the Sales Agreement.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;">In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with
                Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders.&#160; The Loan and Security Agreement provides for the following 6 separate and independent term loans: (a) a term loan in the amount of $7,500,000,
                or Loan A, (b) a term loan in the amount of $10,000,000, or Loan B, (c) a term loan in the amount of $3,750,000, or Loan C, (d) a term loan in the amount of $3,750,000, or Loan D, (e) a term loan in the amount of $5,000,000, or
                Loan E, and (f) a term loan in the amount of $5,000,000, or Loan F, (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and
                Loan F, individually a Loan and, collectively, the Loans).&#160; Loan A, Loan B, Loan C<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">, and Loan D were delivered to the Company on August 24, 2022.&#160; Loan E and Loan F are uncommitted Loans that could have been advanced by the lenders upon the Parties agreement prior to July 31, 2023 upon the
                  satisfaction of certain conditions. The Parties are in discussion to extend this option, however, there is no guarantee that such an option will be extended on terms favorable to the Company or its existing stockholders, or at all. The
                  Company may only use the proceeds of the Loans for working capital or general corporate purposes.&#160; Each Loan matures on the 48-month
                  anniversary following the applicable funding date unless accelerated pursuant to certain events of default.</span> Payments on the principal balance begin on October 1, 2024 and are paid monthly in the succeeding 24 months. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) </span>the per annum rate of
                interest from time to time published in The Wall Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#8220;prime rate&#8221; then in effect, plus (b) 5.75%; provided that, in the event such rate of interest is less than 4.00%,
                such rate shall be deemed to be 4.00% for purposes of calculating the interest rate. Interest is payable on a monthly basis
                based on each Loan principal amount outstanding the preceding month.&#160; The Company, at its option upon at least ten (10) business
                days&#8217; written notice to the lenders, may prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the
                Loans; plus (ii) an amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date (as defined in the Loan and Security Agreement) applicable to such Loan, 3% of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan, but on or before the date that is 12 months after such Loan Amortization Date, 2%
                of the then outstanding principal balance of such Loan, or (C) if such Loan is prepaid more than 12 months after the Loan
                Amortization Date but prior to the stated maturity date applicable to such Loan, 1% of the then outstanding principal balance of
                such Loan;&#160;plus&#160;(iii) the outstanding principal balance of such Loan;&#160;plus&#160;(iv) all other sums, if any, that shall have become due and payable thereunder.&#160; No prepayment premium will be applied to any outstanding balance of any Loan paid on the stated maturity date.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Loan and Security Agreement contains customary representations, warranties and covenants, including covenants by the
              Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates, and
              fundamental changes.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2023, the Company received approximately $1.4 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company&#8217;s participation in the New Jersey Technology
                Business Tax Certificate Transfer NOL program for tax year 2021.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash
              used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change in its outstanding accounts payable and accrued expenses.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial
              doubt about its ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q.&#160; The Company&#8217;s budgeted cash requirements in 2023 and beyond include expenses related to continuing development and
              clinical trials.&#160; Based on its available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, management believes there are sufficient funds to continue operations and
              research and development programs <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for 12 months following the filing of this Quarterly Report on Form 10-Q</span>.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company plans to continue to fund its operations and capital funding needs through equity and/or debt financings.
              However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders.&#160; The Company may also enter into
              government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to the Company&#8217;s stockholders. Incurring debt financing would
              result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict its operations. If the Company is unable to raise additional capital in sufficient amounts or
              on acceptable terms, we may be required to delay, limit, reduce, or terminate its clinical development or future commercialization efforts or grant rights to third parties to develop and market immunotherapies that the Company would otherwise
              prefer to develop and market itself. Any of these actions could harm its business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect the Company&#8217;s ability to operate as a going concern.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694628158240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 4 &#8211; Fair Value of Financial Instruments</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">There were no transfers among Levels 1, 2, or 3 during the three and six months ended June 30, 2023 or 2022.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of <span style="text-indent: 0pt;">June 30</span>, <span style="text-indent: 0pt;">2023</span>: (unaudited)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">60,624,991</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">60,624,991</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December
                      31, <span style="text-indent: 0pt;">2022</span></span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">73,820,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">73,820,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;">The carrying value of the Note Payable approximated its fair value at June 30,
              2023 due to its variable rate.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624481712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 5 &#8211; Leases</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Operating Lease:</span></div>

<div><span style="font-family: 'Times New Roman';"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effective March 5, 2020, the Company entered into a sublease for approximately 11,200 square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 and will continue for a term of forty
              (40) months with an option to renew through October 31, 2027. As of June 30, 2023 there are two (2) months remaining in the sublease term. Upon inception of the sublease, the Company recognized approximately $0.7 million of a ROU asset and operating lease liabilities. The discount rate used to measure the operating lease liability as of May 1, 2020
              was 9.15%. Throughout the period described above the Company has maintained, and continues to maintain, a month-to-month lease for
              its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Supplemental cash flow information related to operating
            leases is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2023<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2022<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Cash paid for operating lease liabilities</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="font-family: 'Times New Roman';">179,136</div>
                  </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">116,783</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div> <span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Maturity of the Company&#8217;s operating lease liability is as
            follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: &amp;amp;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Year ended December 31,</div>
                </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2023</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">60,333</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2024</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2025</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2026</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2027 and after</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total future minimum lease payments</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">60,333</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Less imputed interest</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(683</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">59,650</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Financing Lease:</span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company has financed certain
              laboratory equipment as follows: </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of June 30,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';">2023<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2022<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for finance lease liabilities</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">43,221</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"> Maturity of the Company&#8217;s financing lease liability is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div> <span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Year ended June 30,</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2023<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">34,924</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2024</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman';">$ <br/>
                    </span> </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">69,850</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2025</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman';">$ <br/>
                    </span> </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">69,850</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2026</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman';">$ <br/>
                    </span> </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">40,108</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2027 and after</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman';">$ <br/>
                    </span> </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">26,724</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total future minimum lease payments</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">241,456</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less imputed interest</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(36,642</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Remaining lease liability</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">204,814</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company entered into four
              financing leases for laboratory equipment with a total cost of $251,959 with <span style="-sec-ix-hidden:Fact_f0c3462c2ee44efcb853f792cd6a38ad">four</span> to five-year terms and a capitalized interest rate of
              9.15%. Each of the lease agreements include a bargain purchase option to acquire the equipment at the end of the lease term. The
              aggregate monthly payments are approximately $6,000. In the six months ended June 30, 2023, the Company exercised a bargain
              purchase option, which resulted in recognition of property and equipment of $151,490.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624423648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 6 &#8211; Accrued Expenses</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Accrued expenses and other liabilities consist of the
          following:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">June 30, 2023</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2022</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="background-color: rgb(204, 238, 255); vertical-align: middle; white-space: nowrap; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div>
                  <div style="font-family: 'Times New Roman';">Accrued research and development</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">874,200</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">5,645,737</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued professional fees</div>
              </td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">941,515</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">550,259</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued compensation</div>
              </td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,268,575</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,837,330</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accrued interest on debt</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">291,667</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">280,382</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">Accrued rent</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="margin-left: 9pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div style="font-family: 'Times New Roman';">3,376,325</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">$</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">8,313,708</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624540704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Note 7 &#8211; Stock-Based Compensation</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">In 2014, the Company&#8217;s stockholders approved the 2014
            Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (&#8220;RSUs&#8221;),
            subject to increases as hereafter described (the &#8220;Plan Limit&#8221;). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive
            Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of
            the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to 826,292 shares.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;">As previously disclosed, on December 8, 2020, the Board of
              Directors of the Company adopted, subject to stockholder approval, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Inventive Plan (the &#8220;Restated Plan&#8221;), which amended and restated the Amended and Restated PDS
              Biotechnology Corporation 2014 Equity Incentive Plan (the &#8220;Current Plan&#8221;). At the annual meeting of stockholders on June 17, 2021 the stockholders voted to approve the Restated Plan at the Annual Meeting. The Restated Plan is identical to the
              Current Plan in all material respects, except as follows: (a) the number of shares of Common Stock authorized for issuance under the Restated Plan will increase from 826,292 shares to 3,339,243 shares, plus the total number of shares that
              remained available for issuance, that are not covered by outstanding awards issued under the Current Plan, immediately prior to December 8, 2020; and (b) the Restated Plan will terminate on December 7, 2030, unless earlier terminated. On July
              14, 2023, the Company&#8217;s stockholders approved an amendment to the Current Plan increasing the number of shares of common stock for issuance from 4,165,535
              to 6,565,535 shares. As of June 30, 2023, there were 178,513 shares available for grant under the Restated Plan. </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">In 2018, the
              Company&#8217;s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i)
              Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards. As of June 30, 2023, there were 190,799 shares available for grant under the Restated Plan.<br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block; font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">Pursuant to the terms of the Plans, ISOs have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a
            four-year period. Unless terminated by the Board, the Plans shall continue to remain effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding.</span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block; font-family: 'Times New Roman';">&#160;</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On June 17, 2019, the Board adopted the 2019 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan was recommended
              for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.<span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> On December 8, 2020, the Company amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under
                the Inducement Plan from 200,000 shares to 500,000 shares.</span> On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from 500,000 shares to 1,100,000
              shares.&#160;The 2019 Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the 2019 Inducement Plan may only be made to an
              employee who has not previously been an employee or member of the Board (or any parent or subsidiary of the Company), or following a bona fide period of non-employment by the Company (or a parent or subsidiary of the Company), if he or she is
              granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such
              subsidiary. As of June 30, 2023, there were 185,315 shares available for grant under the 2019 Inducement Plan. </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The Company&#8217;s stock-based compensation expense related to stock options was recognized in operating expense as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Three Months Ended June 30,<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six months ended June 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Stock-Based Compensation</div>
                </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Research and development</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">806,548</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">487,532</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,607,312</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">856,582</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">General and administrative</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,298,990</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">861,069</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"></div>
                  </div>
                  <br/>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,578,545</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,620,992</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Total</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,105,538</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,348,601</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,185,857</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2,477,574<br/>
                      </span> </div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br class="Apple-interchange-newline"/>
            </span></span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The fair value of options granted during the three and six months ended June 30, 2023 and 2022 was estimated using the Black-Scholes option
            valuation model utilizing the following assumptions. There were 29,900 and 1,154,500 of options granted during the three and six month periods ended June 30, 2023, respectively and 494,000 and 1,439,005 of options granted during the three and six month
            period ended June 30, 2022, respectively.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Three Months Ended June 30</span> </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six Months Ended June 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Volatility</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">143.87</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">100.05</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">142.07</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">99.45</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Risk-Free Interest Rate</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3.59</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2.60</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.05</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">11.62</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Expected Term in Years</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.02</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.43</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Dividend Rate</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Fair Value of Option on Grant Date</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.09</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.01</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">10.64</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.59</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> <br/>
            </span></span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Number</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">of Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercise Price</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Remaining</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Contractual</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Life in Years</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Aggregate</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Intrinsic Value</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,171,311</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.56</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.89</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">10,839,589</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Granted</div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,154,500</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">11.45</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercised</div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(1,409</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                </span> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Forfeited











                      and expired<br/>
                    </span> </div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"></div>
                </div>
                <br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                </span> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">June 30, 2023</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,324,402</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.85</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.86</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,645,635</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Vested and expected to vest at <span style="text-indent: 0pt;">June 30, 2023</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,324,402</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.85</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.86</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,645,635</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">June 30, 2023</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,513,595</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.80</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.83</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,901,233</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br class="Apple-interchange-newline"/>
          </span></span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">At June 30, 2023 there was approximately $20,357,890 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 2.75 years.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company entered into an agreement with DC Consulting for certain consulting services
            and issued 100,000 shares in connection with the agreement.</span><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694627621488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 8 &#8211; Income Taxes</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative
            evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation
            of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for <span style="font-size: 10pt;">2023</span> and there will be <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">no</span>
            current income tax expense.&#160; Additionally, there was a full valuation allowance against the net deferred tax assets as of <span style="font-size: 10pt;">June 30, 2023</span> and December 31, <span style="font-size: 10pt;">2022</span>. As
            such, the Company recorded <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">no</span> income tax benefit due to realization uncertainties.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s U.S. statutory rate is 21%.
                The primary factor impacting the effective tax rate for the three and six months ended <span style="font-size: 10pt;">June 30, 2023</span> is the anticipated full year operating loss which will require full valuation allowances against any
                associated net deferred tax assets.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on
                their income tax returns. The Company has analyzed its tax positions and has concluded that as of <span style="font-size: 10pt;">June 30, 2023</span>, there were no uncertain positions. The Company&#8217;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax
                examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.&#160; The Company did not have any unrecognized tax benefits and has not
                accrued any interest or penalties for the three and six months ended <span style="font-size: 10pt;">June 30, 2023</span> and for the year ended December 31, <span style="font-size: 10pt;">2022.<br/>
                </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">In accordance with the State of New Jersey&#8217;s Technology Business Tax Certificate Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate
                taxpayers, the Company sold New Jersey NOL carryforwards, resulting in the recognition of $1.4 million and $1.2 million of income tax benefit, net of transaction costs in the six months ended June 30, 2023 and 2022, respectively.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694627539456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Note 9 &#8211; Commitments and Contingencies</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Rent</span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> <br/>
      </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and six months ended June 30, 2023 was $126,532 and $253,202 respectively, compared to the three and six months ended
          June 30, 2022 of $55,500 and $111,000.</span>
      </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Exclusive License Agreement</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">In January 2023, we entered into an exclusive global license agreement
              with Merck KGaA, Darmstadt, Germany for the tumor targeting antibody conjugated IL-12, M9241 (the &#8220;Merck KGaA License Agreement&#8221;). Pursuant</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> to the </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">Merck KGaA License Agreement, the Company agreed to make (i) development</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> and </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">first commercial sale milestone payments totaling up to $11 million upon
              the achievement</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> of </span><span style="font-family: 'Times New Roman'; font-size: 10pt;">certain milestones, including the dosing of the fifth patient
              in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up to $105 million upon achieving certain aggregate sales levels of the product.</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company also agreed to pay Merck KGaA, Darmstadt, Germany a royalty of 10% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) ten years after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering
            the compound or product in such country. The royalty rate is subject to reduction in that event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or
            if the Company obtains a license to any intellectual property owned or controlled by a third-party which but for such license would be infringed by making, using or selling the compound.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt;"> </span> <span style="font-size: 10pt;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">Legal Proceedings</span><br/>
      </span> </div>

<div><span style="font-family: 'Times New Roman';"> <br/>
    </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company is currently not a party to,</span><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> and the Company&#8217;s</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> property is not currently the subject of,</span><span style="font-family: 'Times New Roman';"> any <span style="font-size: 10pt;">material </span>pending <span style="font-size: 10pt;">legal proceedings.</span> The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary
          course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694627343152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Venture Loan and Security Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Venture Loan and Security Agreement</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">Note 10 &#8211; Venture Loan and Security Agreement</div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In August&#160; 2022, the Company entered into a Venture Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Horizon
            Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the &#8220;Collateral Agent&#8221;), and the other persons party thereto from time to time as lenders (&#8220;Lenders&#8221;).</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Term Loan Amounts</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement provides for the following six (6) separate and independent term loans: (a) a term loan in the amount of $7,500,000
            (&#8220;Loan A&#8221;), (b) a term loan in the amount of $10,000,000 (&#8220;Loan B&#8221;), (c) a term loan in the amount of $3,750,000 (&#8220;Loan C&#8221;), (d) a term loan in the amount of $3,750,000
            (&#8220;Loan D&#8221;), (e) a term loan in the amount of $5,000,000 (&#8220;Loan E&#8221;), and (f) a term loan in the amount of $5,000,000 (&#8220;Loan F&#8221;) (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and Loan F, individually a &#8220;Loan&#8221; and, collectively, the &#8220;Loans&#8221;). </span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Loan A, Loan B, Loan C, and Loan D were
            delivered to the Company on August 24, 2022. Loan E and Loan F are uncommitted Loans that could have been advanced by the Lenders upon the Parties agreement prior to July 31, 2023 upon the satisfaction by the Company of certain agreed upon
            conditions<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">. The Parties are in
              discussion to extend this option</span>, however, there is no guarantee that such an option will be extended on terms favorable to the Company or its existing stockholders, or at all. The Company may only use the proceeds of the Loans for
            working capital or general corporate purposes.</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-style: italic;">Maturity</span>. Each Loan matures on the 48
                month anniversary following the applicable date on which a Loan is made to or on account of the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>under the Loan and Security Agreement (the &#8220;Maturity Date&#8221;) unless accelerated pursuant to agreed upon events of default. All amounts outstanding under each Loan will be due and payable upon
                the earlier of the Maturity Date or the acceleration of the loans and commitments upon an event of default.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Interest Rate</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) the per annum rate of interest from time to time published in The Wall
            Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#8220;prime rate&#8221; then in effect, plus (b) 5.75%;
            provided that, in the event such rate of interest is less than 4.00%, such rate shall be deemed to be 4.00% for purposes of calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding the
            preceding month.</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Amortization.</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">&#160;Each Loan shall commence amortization upon the date set forth on the promissory note executed in connection with the respective Loan, upon which the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>is required to commence making equal payments of principal plus accrued interest on the outstanding principal amount of the respect Loan
            (the &#8220;Loan Amortization Date&#8221;), and continuing thereafter on the first business day of each calendar month through the Maturity Date.</span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Prepayment Premium.</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">&#160;The <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Company </span>may, at its option upon at least ten (10) business days&#8217; written
            notice to the Lenders, prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each Lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an
            amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date applicable to such Loan, three percent (3%) of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan,
            but on or before the date that is twelve (12) months after such Loan Amortization Date, two percent (2%) of the then outstanding principal balance of
            such Loan, or (C) if such Loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated
            Maturity Date applicable to such Loan, one percent (1%) of the then outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iii) the outstanding principal balance of such Loan;&#160;<span style="font-style: italic;">plus</span>&#160;(iv) all other sums, if any, that shall have become due and payable hereunder.&#160; No prepayment premium will be
            applied to any outstanding balance of any Loan paid on the stated Maturity Date.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Security</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">.</span><span style="font-family: 'Times New Roman';"> The Company&#8217;s obligations are secured by a security interest in all of the assets of the Company, subject
            to limited exceptions and excluding the Company&#8217;s intellectual property. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span></span>
        </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Covenants; Representations and Warranties; Other Provisions</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement contains customary representations, warranties and covenants, including
            covenants by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with
            affiliates, and fundamental changes.</span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"><span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">Default Provisions</span><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;">. The Loan and Security Agreement provides for events of default customary for term loans of this type, including but not limited to non-payment,
            breaches or defaults in the performance of covenants, insolvency, and bankruptcy by and/or of the Company.</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Warrant and Debt Discount.</span><span style="font-family: 'Times New Roman';"> In connection with the Loan and Security Agreement, the Company issued Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP warrants to purchase an aggregate total of 381,625 shares of the Company&#8217;s common stock at an initial exercise price of $3.6685 per share. Each warrant is classified as equity and is exercisable at any time for a period beginning on the date of grant and ending on the earlier of (A) 10 years from the date of grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or
                substantially all of the Company&#8217;s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other
                reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of, in
                each case, for cash or for marketable securities meeting certain requirements as described in the applicable warrants.&#160; The key assumptions used in the Black-Scholes option pricing model were (i) expected term of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">10</span>
                years, (ii) a risk-free rate of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">3.11%</span>, (iii) expected volatility of <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">93.8%</span>, (iv) and <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">no</span> estimated dividend
                yield. In addition, the Company incurred third party and lender fees of $<span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">449,329</span>. These proceeds were allocated on a basis that approximates the relative fair value method. The fair value of the warrant and
                fees incurred were recorded as a debt discount and are being recognized as interest expense over the life of the loan and Security Agreement using the effective interest method. The unamortized debt discount was $<span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">2,683,133</span>
                as of June 30, 2023. The Company recognized interest expense of $961,753 and $1,952,272 for the three and six months ended June 30, 2023 and $121,997
                and $233,523 was related to the amortization of the debt discount for the three and six months ended June 30, 2023.</span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694627535936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Note 11 &#8211; Retirement Plan</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; text-align: justify; font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;">The
                Company has a 401(k) defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $36,863 and $131,769 for the three
                and six months ended June 30, 2023, respectively, compared to the three and six months ended June 30, 2022 of $37,776 and $157,009 respectively<span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span></span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624551200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694622599200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Unaudited Interim Financial Statements</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(A)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman';">Unaudited interim financial statements:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The interim balance sheet at June 30, 2023, the statements of operations and comprehensive loss and changes in stockholders&#8217; equity and cash flows for the three and six months ended June 30, 2023 and 2022 are
              unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As
              permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the
              Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations
              for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The balance sheet as of December 31, 2022
              included herein was derived from the audited consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and
              notes thereto as of and for the year ended December 31, 2022, filed by the Company with the SEC in its Annual Report on Form 10-K on March 28, 2023.</span></span><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of condensed consolidated financial
            statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements
            and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates. The most significant estimate relates to the fair value
            of securities underlying stock-based compensation.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock', window );">Significant Risks and Uncertainties</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(C)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant risks and uncertainties:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its clinical candidates, the ability to preserve its cash resources, the Company&#8217;s review of strategic alternatives, the
                          ability to add clinical candidates to its pipeline, the Company&#8217;s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by
                          other companies, the price of, and demand for, Company products if approved for sale, the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the ability to raise capital, and
                          the effects of health epidemics, pandemics, or outbreaks of infectious diseases.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#8217;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents and Concentration of Cash Balance</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(D)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash equivalents and concentration of cash balance:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company considers all highly liquid securities with a
            maturity weighted average of less than three months to be cash equivalents. The Company&#8217;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(E)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Research and development:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#8217;s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on
            behalf of the Company.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical trial site activations or information provided by vendors on their actual costs incurred. Payments
            for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(F)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Patent costs:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(G)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Stock-based compensation:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#8212;Stock Compensation
              (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order
              to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest
              rate and dividend yield. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company
              recognizes forfeitures as they occur.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(H)</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Net loss per common share:</div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                  </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"> <span style="font-weight: bold; font-family: 'Times New Roman';">2023</span><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2022</span><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,324,402</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">4,289,943</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">506,229</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">124,604</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Total</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,830,631</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">4,414,547</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(I)</td>

    <td style="width: auto; vertical-align: top; text-align: left;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Income taxes:</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div>
                          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">(J)</div>
                                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;">Fair value of financial instruments:</div>
                                </td>

  </tr>


</table>
                        </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 0px;"><span style="font-family: 'Times New Roman';"><br/>
                        </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three levels of the fair value hierarchy are as follows:</div>

<div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 1 &#8212; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 2 &#8212; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.</div>
                    </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
                </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><span style="font-family: 'Times New Roman';"><br/>
                      </span> </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Level 3 &#8212; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</div>
                    </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 36pt;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">(K)</span></div>
                        </td>

    <td style="align: left; vertical-align: top; width: auto;">
                          <div style="text-align: justify; font-family: 'Times New Roman';"><span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Leases:</span></div>
                        </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"> <span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"> The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#8220;ASC 842&#8221;). Both financing and operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#8217;s consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to
                  make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the
                  lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for significant risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694627535936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span>
          <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                  </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"> <span style="font-weight: bold; font-family: 'Times New Roman';">2023</span><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: &amp;amp; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: normal;"><span style="font-weight: bold; font-family: 'Times New Roman';">2022</span><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Stock options to purchase Common Stock</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,324,402</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">4,289,943</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Warrants to purchase Common Stock</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">506,229</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">124,604</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; font-family: &amp;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';">Total</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">5,830,631</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: &amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">4,414,547</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694628979712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Fair Value Measurements at Reporting Date Using</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Active Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 1)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Quoted Prices in</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Inactive Markets</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 2)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Significant</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Unobservable Inputs</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(Level 3)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of <span style="text-indent: 0pt;">June 30</span>, <span style="text-indent: 0pt;">2023</span>: (unaudited)</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">60,624,991</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">60,624,991</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December
                      31, <span style="text-indent: 0pt;">2022</span></span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">73,820,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">73,820,160</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#8211;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624788352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock', window );">Supplemental Cash Flow Information Related to Operating Leases</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
          <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Supplemental cash flow information related to operating
            leases is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';">As of June 30,</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2023<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman';">2022<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">Cash paid for operating lease liabilities</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="font-family: 'Times New Roman';">$</div>
                  </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="font-family: 'Times New Roman';">179,136</div>
                  </div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">$</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">116,783</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Payments for Operating Lease Liabilities</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">Maturity of the Company&#8217;s operating lease liability is as
            follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: &amp;amp;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Year ended December 31,</div>
                </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2023</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">60,333</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2024</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2025</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2026</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2027 and after</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Total future minimum lease payments</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">60,333</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Less imputed interest</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(683</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman';">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">59,650</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock', window );">Supplemental Cash Flow Information Related to Financing Lease</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Company has financed certain
              laboratory equipment as follows: </div>

<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of June 30,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <span style="font-family: 'Times New Roman';">2023<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-family: 'Times New Roman';">2022<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for finance lease liabilities</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">43,221</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Future Payments for Financing Lease Liability</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
            <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"> Maturity of the Company&#8217;s financing lease liability is as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div> <span style="font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Year ended June 30,</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2023<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">34,924</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2024</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman';">$ <br/>
                    </span> </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">69,850</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2025</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman';">$ <br/>
                    </span> </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">69,850</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2026</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman';">$ <br/>
                    </span> </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">40,108</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">2027 and after</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"><span style="font-family: 'Times New Roman';">$ <br/>
                    </span> </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">26,724</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total future minimum lease payments</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">241,456</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Less imputed interest</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(36,642</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                  </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Remaining lease liability</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">204,814</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information related to lessee's operating leases and right-of-use assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694621738768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Liabilities</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;">Accrued expenses and other liabilities consist of the
          following:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">June 30, 2023</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-family: 'Times New Roman';">As of</div>
                <div style="text-align: center; font-family: 'Times New Roman';">December 31, 2022</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="background-color: rgb(204, 238, 255); vertical-align: middle; white-space: nowrap; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div>
                  <div style="font-family: 'Times New Roman';">Accrued research and development</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">874,200</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">5,645,737</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued professional fees</div>
              </td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">941,515</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div style="font-family: 'Times New Roman';">550,259</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">Accrued compensation</div>
              </td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,268,575</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="font-family: 'Times New Roman';">1,837,330</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accrued interest on debt</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">291,667</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">280,382</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">Accrued rent</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">368</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="margin-left: 9pt; font-family: 'Times New Roman';">Total</div>
              </td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div style="font-family: 'Times New Roman';">$</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div style="font-family: 'Times New Roman';">3,376,325</div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">$</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="font-family: 'Times New Roman';">8,313,708</div>
                </div>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624816032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The Company&#8217;s stock-based compensation expense related to stock options was recognized in operating expense as follows:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Three Months Ended June 30,<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six months ended June 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Stock-Based Compensation</div>
                </td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Research and development</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">806,548</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">487,532</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,607,312</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">856,582</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">General and administrative</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,298,990</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">861,069</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"></div>
                  </div>
                  <br/>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,578,545</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,620,992</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Total</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,105,538</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,348,601</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,185,857</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">2,477,574<br/>
                      </span> </div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options Granted</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;">The fair value of options granted during the three and six months ended June 30, 2023 and 2022 was estimated using the Black-Scholes option
            valuation model utilizing the following assumptions. There were 29,900 and 1,154,500 of options granted during the three and six month periods ended June 30, 2023, respectively and 494,000 and 1,439,005 of options granted during the three and six month
            period ended June 30, 2022, respectively.</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Three Months Ended June 30</span> </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Six Months Ended June 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(unaudited)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Volatility</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">143.87</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">100.05</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">142.07</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">99.45</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Risk-Free Interest Rate</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">3.59</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2.60</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.05</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">11.62</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">%</div>
                  </div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Expected Term in Years</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.02</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.08</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.43</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Dividend Rate</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">&#8211;</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Fair Value of Option on Grant Date</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.09</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.01</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">10.64</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div>
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4.59</div>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman';"> </span>
        <span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The following table summarizes the number of options outstanding and the weighted average exercise price:</div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Number</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">of Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Average</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercise Price</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Weighted Average</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Remaining</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Contractual</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Life in Years</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Aggregate</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Intrinsic Value</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at December 31, <span style="text-indent: 0pt;">2022</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,171,311</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.56</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.89</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">10,839,589</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Granted</div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">1,154,500</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">11.45</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercised</div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">(1,409</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                </span> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Forfeited











                      and expired<br/>
                    </span> </div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"></div>
                </div>
                <br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">-</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div><span style="font-family: 'Times New Roman';"><br/>
                  </span> </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
                    </span> </div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"><span style="font-family: 'Times New Roman';"><br/>
                </span> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Options outstanding at <span style="text-indent: 0pt;">June 30, 2023</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,324,402</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.85</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.86</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,645,635</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Vested and expected to vest at <span style="text-indent: 0pt;">June 30, 2023</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5,324,402</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.85</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">7.86</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">4,645,635</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">Exercisable at <span style="text-indent: 0pt;">June 30, 2023</span></div>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,513,595</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">5.80</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">6.83</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">$</div>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">2,901,233</div>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624407392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive impact to EPS (in shares)</a></td>
<td class="nump">5,830,631<span></span>
</td>
<td class="nump">4,414,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive impact to EPS (in shares)</a></td>
<td class="nump">5,324,402<span></span>
</td>
<td class="nump">4,289,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive impact to EPS (in shares)</a></td>
<td class="nump">506,229<span></span>
</td>
<td class="nump">124,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694618049552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>Loan </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>Loan </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,624,991<span></span>
</td>
<td class="nump">$ 60,624,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,820,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards', window );">Proceeds from sale of tax benefits</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ShelfRegistrationStatementAvailableForFutureSale', window );">Registered securities in Shelf Registration Statement available for future sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_PlacementSharesAvailableForFutureSale', window );">Placement Shares included in at-the-market offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_CommissionPercentage', window );">Commission paid on Placement Shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,169<span></span>
</td>
<td class="nump">596,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 4,832,265<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentNumberOfIndependentTermLoans', window );">Number of independent term loans | Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance', window );">Period after October 1, 2024 for making monthly payments on principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod1', window );">Prepayment premium paid if loan is prepaid on or before Loan Amortization date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentThresholdPeriod', window );">Threshold period after Loan Amortization Date used to determine prepayment premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod2', window );">Prepayment premium paid if load is prepaid after Loan Amortization date, but on or before date that is 12 months after such Loan Amortization Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod3', window );">Prepayment premium paid if loan is prepaid more than 12 months after Loan Amortization Date but prior to stated Maturity Date.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod4', window );">Prepayment premium paid if loan is paid on stated maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentVariableRate', window );">Minimum base rate used to compute floating interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment', window );">Written notice period for prepayment of outstanding loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanAMember', window );">Loan A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanBMember', window );">Loan B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanCMember', window );">Loan C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanDMember', window );">Loan D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanEMember', window );">Loan E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Uncommitted loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanFMember', window );">Loan F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Uncommitted loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_CommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_CommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentNumberOfIndependentTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of independent term loans provided for under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentNumberOfIndependentTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after October 1, 2024 for making monthly payments on the principal balance of the debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid on or before the Loan Amortization date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid after the Loan Amortization date, but on or before the date that is twelve (12) months after such Loan Amortization Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated Maturity Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid on the stated maturity date of the loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period after the Loan Amortization Date used to determine prepayment premiums on the outstanding principal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum base rate to be used in computing the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time prior to prepaying all of the outstanding loan that written notice must be provided by the borrower, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_PlacementSharesAvailableForFutureSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_PlacementSharesAvailableForFutureSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ShelfRegistrationStatementAvailableForFutureSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission (the "2020 Shelf Registration Statement") for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the "Shelf Securities") that are available for future sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ShelfRegistrationStatementAvailableForFutureSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694725927984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract', window );"><strong>Fair Value Transfers Between Levels [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers into Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">60,624,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,624,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,820,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">60,624,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,624,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,820,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Quoted Prices in Inactive Markets (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694617110832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Operating Lease (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space under sublease | ft&#178;</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of sublease agreement</a></td>
<td class="text">40 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining sublease term</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 39,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,645<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">59,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate used to measure operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Supplemental Cash Flow Information Related to Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">179,136<span></span>
</td>
<td class="nump">$ 116,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future Payments for Operating Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">60,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter', window );">2027 and after</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">60,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 59,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694625477824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Financing Lease (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract', window );"><strong>Supplemental Cash Flow Information Related to Finance Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_FinanceLeasePrincipalAndInterestPayments', window );">Cash paid for finance lease liabilities</a></td>
<td class="nump">$ 43,221<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future Payments for Finance Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">34,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">69,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">69,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">40,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter', window );">2027 and after</a></td>
<td class="nump">26,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">241,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(36,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Remaining lease liability</a></td>
<td class="nump">$ 204,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeFinanceLeaseNumberOfLeases', window );">Number of financing leases entered into | Lease</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_FinanceLeaseCost', window );">Total cost of financing leases</a></td>
<td class="nump">$ 251,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Finance lease liability capitalized interest rate</a></td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LesseeFinanceLeaseMonthlyRentalExpense', window );">Aggregate monthly rental payments</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Recognition of property and equipment from bargain purchase option</a></td>
<td class="nump">$ 151,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of financing lease</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Financing Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Term of financing lease</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for finance lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_FinanceLeasePrincipalAndInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal and interest payments on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_FinanceLeasePrincipalAndInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeFinanceLeaseMonthlyRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated aggregate monthly rental expense under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeFinanceLeaseMonthlyRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LesseeFinanceLeaseNumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of finance leases entered into by the lessee during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LesseeFinanceLeaseNumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowFinancingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowFinancingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694625469616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 874,200<span></span>
</td>
<td class="nump">$ 5,645,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">941,515<span></span>
</td>
<td class="nump">550,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,268,575<span></span>
</td>
<td class="nump">1,837,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on debt</a></td>
<td class="nump">291,667<span></span>
</td>
<td class="nump">280,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,376,325<span></span>
</td>
<td class="nump">$ 8,313,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694620821728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Equity Compensation Plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jul. 14, 2023</div></th>
<th class="th"><div>May 17, 2022</div></th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Jun. 17, 2021</div></th>
<th class="th"><div>Dec. 08, 2020</div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember', window );">The Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan', window );">Term of plan</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember', window );">The Plans [Member] | Incentive Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember', window );">The Plans [Member] | Incentive Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of option</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member', window );">2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="nump">4,165,535<span></span>
</td>
<td class="nump">91,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,339,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">826,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_PercentageOfCommonStockOutstanding', window );">Percentage of Common Stock outstanding used to determine annual increase in the plan limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">178,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member', window );">2014 Equity Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,565,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2018Member', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">558,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">190,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pdsb_InducementPlan2019Member', window );">2019 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">185,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_PercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_PercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term the Plan shall continue to remain effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_EquityCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pdsb_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pdsb_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_EquityIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pdsb_InducementPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pdsb_InducementPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694624568784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Stock-Based Compensation Expense (Details) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,105,538<span></span>
</td>
<td class="nump">$ 1,348,601<span></span>
</td>
<td class="nump">$ 4,185,857<span></span>
</td>
<td class="nump">$ 2,477,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">806,548<span></span>
</td>
<td class="nump">487,532<span></span>
</td>
<td class="nump">1,607,312<span></span>
</td>
<td class="nump">856,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,298,990<span></span>
</td>
<td class="nump">$ 861,069<span></span>
</td>
<td class="nump">$ 2,578,545<span></span>
</td>
<td class="nump">$ 1,620,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694625477376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions Used in Determining Fair Value of Stock Options and Warrants Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">143.87%<span></span>
</td>
<td class="nump">100.05%<span></span>
</td>
<td class="nump">142.07%<span></span>
</td>
<td class="nump">99.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">11.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of option on grant date (in dollars per share)</a></td>
<td class="nump">$ 5.09<span></span>
</td>
<td class="nump">$ 4.01<span></span>
</td>
<td class="nump">$ 10.64<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">29,900<span></span>
</td>
<td class="nump">494,000<span></span>
</td>
<td class="nump">1,154,500<span></span>
</td>
<td class="nump">1,439,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694617237648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,409)<span></span>
</td>
<td class="num">(7,794)<span></span>
</td>
<td class="num">(2,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unamortized Stock Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for consulting services (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,171,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">29,900<span></span>
</td>
<td class="nump">494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,154,500<span></span>
</td>
<td class="nump">1,439,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,409)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">5,324,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,324,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,171,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">5,324,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,324,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,513,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,513,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 6.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">6.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,839,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 4,645,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,645,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,839,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value</a></td>
<td class="nump">4,645,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,645,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">2,901,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,901,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unamortized Stock Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock compensation expense</a></td>
<td class="nump">$ 20,357,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,357,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694622574016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Income tax benefit due to realization uncertainties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_LiabilityForUncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">$ (1,406,021)<span></span>
</td>
<td class="num">$ (1,198,905)<span></span>
</td>
<td class="num">$ (1,406,021)<span></span>
</td>
<td class="num">$ (1,198,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_LiabilityForUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_LiabilityForUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694618257936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="nump">$ 126,532<span></span>
</td>
<td class="nump">$ 55,500<span></span>
</td>
<td class="nump">$ 253,202<span></span>
</td>
<td class="nump">$ 111,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember', window );">Merck KGaA License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales', window );">Milestone payments for development and first commercial sales</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct', window );">Royalty percentage paid on net sales of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_TermOfRoyaltyPayment', window );">Term of royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember', window );">Merck KGaA License Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels', window );">Milestone payments for aggregate sales levels of product</a></td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to be made for development and first commercial sale milestones detailed in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage paid on net sales of the product detailed in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_TermOfRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_TermOfRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=pdsb_MerckKGaALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694621784096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Venture Loan and Security Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>Loan</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>Loan</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock that can be purchased with warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="nump">$ 2,683,133<span></span>
</td>
<td class="nump">2,683,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">961,753<span></span>
</td>
<td class="nump">1,952,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">$ 121,997<span></span>
</td>
<td class="nump">$ 233,523<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_PercentageOfVotingPowerDisposedOff', window );">Percentage of voting power disposed off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0311<span></span>
</td>
<td class="nump">0.0311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.938<span></span>
</td>
<td class="nump">0.938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Estimated Dividend Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentNumberOfIndependentTermLoans', window );">Number of independent term loans | Loan</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod1', window );">Prepayment premium paid if loan is prepaid on or before Loan Amortization date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentThresholdPeriod', window );">Threshold period after Loan Amortization Date used to determine prepayment premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod2', window );">Prepayment premium paid if load is prepaid after Loan Amortization date, but on or before date that is 12 months after such Loan Amortization Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod3', window );">Prepayment premium paid if loan is prepaid more than 12 months after Loan Amortization Date but prior to stated Maturity Date.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod4', window );">Prepayment premium paid if loan is paid on stated maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentVariableRate', window );">Minimum base rate used to compute floating interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment', window );">Written notice period for prepayment of outstanding loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember', window );">Term Loans [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanAMember', window );">Loan A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanBMember', window );">Loan B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanCMember', window );">Loan C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanDMember', window );">Loan D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanEMember', window );">Loan E [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Uncommitted loan</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pdsb_LoanFMember', window );">Loan F [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Venture Loan and Security Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Uncommitted loan</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentNumberOfIndependentTermLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of independent term loans provided for under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentNumberOfIndependentTermLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid on or before the Loan Amortization date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid after the Loan Amortization date, but on or before the date that is twelve (12) months after such Loan Amortization Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated Maturity Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentPrepaymentPremiumPeriod4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid on the stated maturity date of the loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentPrepaymentPremiumPeriod4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentThresholdPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period after the Loan Amortization Date used to determine prepayment premiums on the outstanding principal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentThresholdPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum base rate to be used in computing the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time prior to prepaying all of the outstanding loan that written notice must be provided by the borrower, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pdsb_PercentageOfVotingPowerDisposedOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting power disposed of in a transaction (including a merger or other reorganization) or series of related transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pdsb_PercentageOfVotingPowerDisposedOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pdsb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pdsb_LoanFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pdsb_LoanFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139694627960976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">401(k) employer contributions</a></td>
<td class="nump">$ 36,863<span></span>
</td>
<td class="nump">$ 37,776<span></span>
</td>
<td class="nump">$ 131,769<span></span>
</td>
<td class="nump">$ 157,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>brhc20057346_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pdsb="http://pdsbiotech.com/20230630"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pdsb-20230630.xsd" xlink:type="simple"/>
    <context id="c20230101to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="c20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220401to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220801to20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230630_DebtInstrumentAxis_TermLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20220831_DebtInstrumentAxis_LoanBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220831_DebtInstrumentAxis_LoanAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220831_DebtInstrumentAxis_LoanDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20220831_DebtInstrumentAxis_LoanCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c20230630_DebtInstrumentAxis_LoanFMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanFMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230630_DebtInstrumentAxis_LoanEMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:LoanEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230101to20230630_DebtInstrumentAxis_TermLoansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_VariableRateAxis_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pdsb:TermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="c20230630_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230630_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230714_PlanNameAxis_EquityIncentivePlan2014Member_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-14</instant>
        </period>
    </context>
    <context id="c20181231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20141231_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="c20230630_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20190331_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c20210617_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-17</instant>
        </period>
    </context>
    <context id="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c20230630_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230630_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230101to20230630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pdsb:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_PlanNameAxis_EquityCompensationPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:EquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220517_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-17</instant>
        </period>
    </context>
    <context id="c20220516_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-16</instant>
        </period>
    </context>
    <context id="c20201207_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="c20201208_PlanNameAxis_InducementPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pdsb:InducementPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-08</instant>
        </period>
    </context>
    <context id="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20221231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230630_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230101to20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">pdsb:MerckKGaALicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230630_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230101to20230630_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230630_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230630_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230630_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <unit id="U001">
        <measure>shares</measure>
    </unit>
    <unit id="U002">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>pure</measure>
    </unit>
    <unit id="U005">
        <measure>pdsb:Loan</measure>
    </unit>
    <unit id="U006">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U007">
        <measure>pdsb:Lease</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20230101to20230630"
      id="Fact_6c009218040741b1b2604e20837dc8c5">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20230101to20230630"
      id="Fact_283688b8bdb44a82b3334f054597cf47">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20230101to20230630"
      id="Fact_fea2677f23654174bd2b716d11f6ca4a">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20230101to20230630"
      id="Fact_bb9b9de8f103407abbefaf2511bcdbe3">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20230101to20230630"
      id="Fact_936c1cad8f4d43548ba0a86bf8099e8a">0001472091</dei:EntityCentralIndexKey>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="c20230630_RangeAxis_MinimumMember"
      id="Fact_f0c3462c2ee44efcb853f792cd6a38ad">P4Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <dei:DocumentType
      contextRef="c20230101to20230630"
      id="Fact_b59d840e3f5d4a04a4b5f41cf1292907">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="c20230101to20230630"
      id="Fact_f6b096a4566e4970b5a0c5c9321a777d">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20230101to20230630"
      id="Fact_2421b349f3234401ac29fb4d54a972fa">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20230101to20230630"
      id="Fact_2bc49b0f278f4090873b0e45d74212ae">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20230101to20230630"
      id="Fact_6576a71ce2c442c1b71d7df756e5c631">001-37568</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20230101to20230630"
      id="Fact_ba517afd436d482596883e64ced60f82">PDS Biotechnology Corp</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230101to20230630"
      id="Fact_5ef9c1b493104b1e99b101bd8333528c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230101to20230630"
      id="Fact_3014b5225e5f4c4da6899b0f3e109287">26-4231384</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230101to20230630"
      id="Fact_bb88bccb436443fba222c0784bf10065">25B Vreeland Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20230101to20230630"
      id="Fact_d172b7d629bf4b61904f0f3ea7cc7e5d">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20230101to20230630"
      id="Fact_71b7850c106b4886a5f25e115c184deb">Florham Park,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230101to20230630"
      id="Fact_70f7652cd5a0452b869e5f3b61b3a9ec">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230101to20230630"
      id="Fact_beb815aa6ad34874bbc2b1bf41fbf4eb">07932</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230101to20230630"
      id="Fact_e6a7652a769e4788bfa45b2529405319">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230101to20230630"
      id="Fact_90bb7f872a414841bd0261b9fe6c1f43">208-3343</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20230101to20230630"
      id="Fact_43fac12d95fd4e9c891e9e2d5b229302">Common Stock, par value $0.00033 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230101to20230630"
      id="Fact_71ab8fb2ef9d4599a7c4c6a0c5aa92d5">PDSB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20230101to20230630"
      id="Fact_b6c44aba72494d699c5aeb7083357610">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="c20230101to20230630"
      id="Fact_b9bf0882257f41c79dbe2c56f775d526">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20230101to20230630"
      id="Fact_bbab0b39097a4452b4e1c436e5236010">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20230101to20230630"
      id="Fact_98e4c1627d4e4d179d64b0ad70359ebd">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20230101to20230630"
      id="Fact_226e12c63dfb45bdbd7999ec2e807254">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230101to20230630"
      id="Fact_b7ca6c4d2ddb42a6a2c955c2860887fd">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="c20230101to20230630"
      id="Fact_5fac3df56a714ca4b442de5ab070ac3d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20230807"
      decimals="INF"
      id="Fact_5c6d9145477c49e49de2765e298fc1e8"
      unitRef="U001">30868188</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20230630"
      decimals="0"
      id="Fact_58cd4bde50064e879484494d9c2b33ff"
      unitRef="U002">60624991</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20221231"
      decimals="0"
      id="Fact_2c5533225ad44d25b51f3b96b8ebdedf"
      unitRef="U002">73820160</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_ba5045bb2b1146809daf8b45a5ff6b4d"
      unitRef="U002">2725958</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_a6f868956f5141c3b6d5dfba703002a3"
      unitRef="U002">2660230</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_8e82065c38b4463cb75c905e217dc8bd"
      unitRef="U002">63350949</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_de9ac827d7464354846d0e8450cfce8f"
      unitRef="U002">76480390</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20230630"
      decimals="0"
      id="Fact_1610703be8d14131b468dd1feb95d5b8"
      unitRef="U002">143600</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20221231"
      decimals="0"
      id="Fact_e3123f90e91241e09fb614e4acf21877"
      unitRef="U002">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="c20230630"
      decimals="0"
      id="Fact_ec51644928f342fab65fffab15c9344e"
      unitRef="U002">220213</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="c20221231"
      decimals="0"
      id="Fact_79bdfa67c2564faea68c946258c3b0f4"
      unitRef="U002">374888</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20230630"
      decimals="0"
      id="Fact_0d29dcc322e949e597a16135417353e1"
      unitRef="U002">39488</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20221231"
      decimals="0"
      id="Fact_ed0f77e865224f6eb3cdfd22d83f3d4e"
      unitRef="U002">152645</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="c20230630"
      decimals="0"
      id="Fact_4281ffb1886b4fcf81a360ce214507dc"
      unitRef="U002">63754250</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20221231"
      decimals="0"
      id="Fact_9e0f5b2a7aae49e0a944cd5525cb1a74"
      unitRef="U002">77007923</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_46d1f113f7064383b9c0a53ae3c621cb"
      unitRef="U002">4414905</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_786bc17e06704462a43e5cc423205c58"
      unitRef="U002">1219287</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_77f4221a3d974b8d89b110b90f8789c8"
      unitRef="U002">3376325</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_f5980f0733194e649c543011e04d0352"
      unitRef="U002">8313708</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_930a97456ab54b1094d86a6ca6b52bbf"
      unitRef="U002">53309</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_9065c4fc58de4480a7013244f7452ecb"
      unitRef="U002">56612</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_0599c00c47a541f4af094db186b378c7"
      unitRef="U002">59650</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_b7093cf420664f3e8d411c52ad0fc2f3"
      unitRef="U002">231429</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_c9c498fc16054a4aa66ae8b81d8ce318"
      unitRef="U002">7904189</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_265b5300de1f4c238f300aa6f6149985"
      unitRef="U002">9821036</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecuredLongTermDebt
      contextRef="c20230630"
      decimals="0"
      id="Fact_e79f4575e7a24f05a2aa0ae73e620e02"
      unitRef="U002">23254367</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="c20221231"
      decimals="0"
      id="Fact_b4272ad0792244358be9eed96e8c20d7"
      unitRef="U002">23020844</us-gaap:SecuredLongTermDebt>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_68f4c5b4c5504fbdad7e92f20176f50c"
      unitRef="U002">151505</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_5099de4cb3a24d3389dd6cb3fde33fbc"
      unitRef="U002">164013</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20230630"
      decimals="0"
      id="Fact_ee4953fdccaa4d9f83a899fd467ecb68"
      unitRef="U002">31310061</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20221231"
      decimals="0"
      id="Fact_d48a783ef7c34207b4346111c6e48cd0"
      unitRef="U002">33005893</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20221231"
      decimals="5"
      id="Fact_b8f1e1cec1554bf39aa91bfb5373ba1e"
      unitRef="U003">0.00033</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20230630"
      decimals="5"
      id="Fact_afe705407fef4fe3b552a6f1f274f4d7"
      unitRef="U003">0.00033</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_431de4d30dd64797aa7083104cd64761"
      unitRef="U001">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20230630"
      decimals="0"
      id="Fact_de047457995d478d92605420094ba417"
      unitRef="U001">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20230630"
      decimals="0"
      id="Fact_d79271ee9a174f7b84c41f5392723335"
      unitRef="U001">30868188</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20230630"
      decimals="0"
      id="Fact_3df64f5fb65b4e51a5b78f5305ebb1e1"
      unitRef="U001">30868188</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20221231"
      decimals="0"
      id="Fact_887dc19dc6b64d18a7175a1a2ae8fd5a"
      unitRef="U001">30170317</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20221231"
      decimals="0"
      id="Fact_f828179e22b349d18d0a45eeef3ba5e7"
      unitRef="U001">30170317</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20230630"
      decimals="0"
      id="Fact_a47bde7256bc458086cdb2556c8d25ed"
      unitRef="U002">10188</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20221231"
      decimals="0"
      id="Fact_b828a76b6b95439bbd99e74407b29be2"
      unitRef="U002">9956</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20230630"
      decimals="0"
      id="Fact_50674871eb3e46a584b9df2dbdafd92d"
      unitRef="U002">155187231</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20221231"
      decimals="0"
      id="Fact_d9f9ca9030864b54a06a464ad811e628"
      unitRef="U002">145550491</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20230630"
      decimals="0"
      id="Fact_7f6e65f53dea4969ada42ab21649e6c6"
      unitRef="U002">-122753230</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20221231"
      decimals="0"
      id="Fact_e5fa26da84dd45efbe0ac5bc5ebaa25f"
      unitRef="U002">-101558417</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20230630"
      decimals="0"
      id="Fact_08b733a4e2414b378a9aed24878392b1"
      unitRef="U002">32444189</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="0"
      id="Fact_89d2a3f6b0aa42899a92a6294c698b6d"
      unitRef="U002">44002030</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20230630"
      decimals="0"
      id="Fact_8b3940b36839447b938cbc07d93e5530"
      unitRef="U002">63754250</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20221231"
      decimals="0"
      id="Fact_3180b1082b314039be709c6632793839"
      unitRef="U002">77007923</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_8bba540a61a4413faccfea9f3ae4f817"
      unitRef="U002">8004852</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_fd5627f320894633aa7860de8ca23890"
      unitRef="U002">3761646</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_60ce88eebee04e13821339f1516a7d49"
      unitRef="U002">13848538</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_eaa294547e034ac8802375de78cd1af6"
      unitRef="U002">8922961</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_5b78f82529644b048abc0c85b43ae6b2"
      unitRef="U002">4691321</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_fc09345edcf749d1b39251e3faa13f32"
      unitRef="U002">3331006</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_e1ac8b1e75134de6be703d1c502e7d8c"
      unitRef="U002">8270049</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_e4d4eca890a84f02bf8319cba6f1edcb"
      unitRef="U002">6648913</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_9aef51dd433c4069aeff637002eb389b"
      unitRef="U002">12696173</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_57b4430b66f74d9fb17fe684467c4354"
      unitRef="U002">7092652</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_96358d707af447a59eed7925afc22495"
      unitRef="U002">22118587</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_dafa5490aa4641598d8f94925b0d5359"
      unitRef="U002">15571874</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_898151dcf1644cd59b775729f9a90292"
      unitRef="U002">-12696173</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_5edb96973b724027b45f9390f263a93e"
      unitRef="U002">-7092652</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_3f8e84babafc444d940c15e80df89a8a"
      unitRef="U002">-22118587</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_55f1ee071a5947a281a65ebef312bba9"
      unitRef="U002">-15571874</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_cfd8d9f4cca14b1f8b89dac2662007fa"
      unitRef="U002">750654</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_f546e4c345224266b4572bc952e24ad7"
      unitRef="U002">74547</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_c72eb3371158441cb3df2babec54eede"
      unitRef="U002">1479995</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_14a025f188e74c01b7d1ec46d20657d3"
      unitRef="U002">80247</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_39b65869a0fc438babeaed2d84f851dd"
      unitRef="U002">995397</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_64688066719f4f7982e9c045fd507b57"
      unitRef="U002">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_8ffbd5c0a9fa4f50a7ff8cfde83aeb44"
      unitRef="U002">1962242</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_db6c0fb8bd79405faf92eace357936b8"
      unitRef="U002">0</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_48abaa1ffa8c41c7ad6a9669ab79c8e0"
      unitRef="U002">-244743</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_c71b680948334f36a50bc3ef78b3b47c"
      unitRef="U002">74547</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_cf42185cfb204234b631c15914d37691"
      unitRef="U002">-482247</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_669db3e4ba764a36b50546bf4b19c450"
      unitRef="U002">80247</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_d0125977f7354c72ab26334dfd6a5ff2"
      unitRef="U002">-12940916</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_1fcabb81db8e481984a93ac606a07e86"
      unitRef="U002">-7018105</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_6abb0fbaac1a460291375d1e75d91d68"
      unitRef="U002">-22600834</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_51565e47403d496ba70b5da85c54d24a"
      unitRef="U002">-15491627</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_b33dc11bd3d2422d94f8d0b9f0259d60"
      unitRef="U002">-1406021</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_582d0cdea4724fd5813585c512e8f1a8"
      unitRef="U002">-1198905</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_1f168ecfd98a491db20df18d14d9e6ab"
      unitRef="U002">-1406021</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_f231c52bc9b241a5b598a08e38540250"
      unitRef="U002">-1198905</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_377ea27d197048f5942f829f477da39b"
      unitRef="U002">-11534895</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_c8e74a3f54754ac39f048f57d5655ce4"
      unitRef="U002">-11534895</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_168c4bd943c74e22990b18bddbaea573"
      unitRef="U002">-5819200</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_26f7a6d1b18248619a757ae546ef3889"
      unitRef="U002">-5819200</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_810abc1986434ae3a3079c95e9cddff9"
      unitRef="U002">-21194813</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_31fde16c696c42ba979f6f8f06f778cd"
      unitRef="U002">-21194813</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_9de7ba64ee8e4fa182f316fcfb74a14d"
      unitRef="U002">-14292722</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_fa688cb517e6427aa1dfb4e6dfc0cdd1"
      unitRef="U002">-14292722</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230401to20230630"
      decimals="2"
      id="Fact_843d6131b1344b5abc58409f48041fad"
      unitRef="U003">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230401to20230630"
      decimals="2"
      id="Fact_524e9b25a74a44b499d2bf8b8b6e73f6"
      unitRef="U003">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220401to20220630"
      decimals="2"
      id="Fact_00d43245b3ca4deba80dcfa6b75e1d6e"
      unitRef="U003">-0.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220401to20220630"
      decimals="2"
      id="Fact_0f2d6c5a0b3f41c2a504bf9a4dd94a10"
      unitRef="U003">-0.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230101to20230630"
      decimals="2"
      id="Fact_01b8a864ef314062b7cb0c77d1e0cff7"
      unitRef="U003">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230101to20230630"
      decimals="2"
      id="Fact_4d64c8a7c73f4f298033d85bb655d9e2"
      unitRef="U003">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220101to20220630"
      decimals="2"
      id="Fact_33ef74912c5b40c697f7297fd319b8ad"
      unitRef="U003">-0.5</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220101to20220630"
      decimals="2"
      id="Fact_d8e5cb42cc494cb89598ace68a4074a5"
      unitRef="U003">-0.5</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_c191ceb8a4e9404c8a7243fc8090441f"
      unitRef="U001">30802498</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_185868c66f3d4f17bf5677657b204c94"
      unitRef="U001">30802498</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_58fa32f85fbf475f99e3641379dcde87"
      unitRef="U001">28451579</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_68db77a33a334551993cf150bb508a98"
      unitRef="U001">28451579</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_7af4ec41069a445bb2fcfd3f8290a668"
      unitRef="U001">30616310</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_89edddddde5a47439dbc98e49215eb5d"
      unitRef="U001">30616310</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_16be6bf8c60f44d19a8ef1f960cd84c3"
      unitRef="U001">28450104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_dfb97dd9234e4da1961c0bbfecef1e66"
      unitRef="U001">28450104</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a17f18e557ee453eb9b345ee86e10817"
      unitRef="U001">28448612</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6c87cf06e4344f1d9211f5c112e479dc"
      unitRef="U002">9387</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_511f41f42528440ea8325a94861d1ca2"
      unitRef="U002">123904602</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_d34bac104ab2426ea302532f79b45316"
      unitRef="U002">-60703562</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="0"
      id="Fact_3a31dea4cc304adab1341e91f0accd27"
      unitRef="U002">63210427</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_8b4457e26a7b4ffebca507e9cdc2c09c"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_b7cc6b9c7ea74b4f994c8650dcaeebdf"
      unitRef="U002">1128973</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_1b297cf17dbf4fbbb2aaaf7d27b7277a"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_690ed19515384e1c9157b25169bb7314"
      unitRef="U002">1128973</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b40f15915a074a118366ae28a34dc4df"
      unitRef="U001">2282</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_85dffa3f4df549eb9ab5c8f4d5f53d95"
      unitRef="U002">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_3663bb5de7dc4d5292a36e5b9fb7132f"
      unitRef="U002">7487</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b5033d45247441a2a56c0d7283db88c8"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_9680e474dfb24de897c9bb3db591ef97"
      unitRef="U002">7488</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ff7cc99dd1814c8bb80dff7a88d65f26"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_8d587fa7eb16423783d2f39dd1e6e0f2"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_426b3e6a049a42128e770a0f1ad0ffa1"
      unitRef="U002">-8473522</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_8f9c7a771886444fae5fbfca75bb2256"
      unitRef="U002">-8473522</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f2b6d1fb9ee8400296441c92c3c97e32"
      unitRef="U001">28450894</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_86cd78018b2e4add888676bb01f5cb1d"
      unitRef="U002">9388</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_d413b1cf114a40af8421545e281be822"
      unitRef="U002">125041062</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_65d0918c4cc84c86a0047b04359965a0"
      unitRef="U002">-69177084</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220331"
      decimals="0"
      id="Fact_c85a1a5e4a554f6a96a46409d5b9e36f"
      unitRef="U002">55873366</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b85c7ec911b3480ebf5444cad3d1d0bd"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_1f3370fc68d14f888eb92a8e8abed6a3"
      unitRef="U002">1348601</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_bb7476561dbe46cd954c1ffa0311a444"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_bee912fdb9e74e2d800f3a005cd60d64"
      unitRef="U002">1348601</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b5e1bccf07d8419b87791f922445e2ab"
      unitRef="U001">7794</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_dc6899b61ec746b4a51cde21f8c57655"
      unitRef="U002">3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_f369d9748bd44041b7ff93f6b3bab9e2"
      unitRef="U002">22426</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_6ade92214ef94d5ca736adc32e0bff2b"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_0086ef5ffd6442fa966e61209177fbf4"
      unitRef="U002">22429</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_7f502060fb224d63aed8d554784d1dd3"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_e41678e80515408c8bbcf24adfb9ab6a"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220401to20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_e786e9af6dc547679a1c10fa8746d577"
      unitRef="U002">-5819200</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_449bf0e5bb824f9584f29a3881304880"
      unitRef="U002">-5819200</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_3ceef7e34b454135a68b80a937afd5ed"
      unitRef="U001">28458688</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_5ba641eef356458187afee7cc0b888d3"
      unitRef="U002">9391</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_db53b31ccb6c419bbba68b32b23752c3"
      unitRef="U002">126412089</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b3b0f61b06724ac68b273da4d2c64a72"
      unitRef="U002">-74996284</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220630"
      decimals="0"
      id="Fact_40e6a6c748d04c0087ac656e02ac8e7d"
      unitRef="U002">51425196</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_072bee52c106457c86537fd1b853f60e"
      unitRef="U001">30170317</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d4b889cfacc346acb1a8e5dfe4b8e3b7"
      unitRef="U002">9956</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_c22de3d64b7d4909a6392c3016acac01"
      unitRef="U002">145550491</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_e6d4f19c24454031acd521ec311b58e8"
      unitRef="U002">-101558417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="0"
      id="Fact_aca96ffd59e9401394bb5c370ade91da"
      unitRef="U002">44002030</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d56e24862104405ba96c470b0c5a507e"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_4d56635128854c1e8cddbd744611499b"
      unitRef="U002">2080319</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_23dba73f6ee84414871e4385d8fb7c7a"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_03688abcd4da4b7aa2305dea2d82322b"
      unitRef="U002">2080319</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_33b829a3541d4a8a86b8158acb78b304"
      unitRef="U001">553293</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4dfa382e0007474085c3b1ad4b320dfb"
      unitRef="U002">183</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_3a02eb81c3994f40bac63d6a55ce06ff"
      unitRef="U002">4588339</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_d8b1ee21a0cb42c98450ef64468ea012"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_f150f45c2e50497788e728e25403d1cd"
      unitRef="U002">4588522</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_94d3fd92b5064269bde0299620830d7c"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_a794180720ef4128b5b6d4fc2446190a"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b8147a09fd0442e78e62f4df4ed9d3b0"
      unitRef="U002">-9659918</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_e157fabb85b745e1932a472cbf7796e5"
      unitRef="U002">-9659918</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_83f27d7992ca4ce38ae96a66f6d63597"
      unitRef="U001">30723610</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4c499ff1726c4752b57aa3059e2d7833"
      unitRef="U002">10139</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_6ba72e7db42744c2af96276ec0f7f0e9"
      unitRef="U002">152219149</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_4821885b92004a529b329ab49377a98f"
      unitRef="U002">-111218335</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331"
      decimals="0"
      id="Fact_6d2558224bab4ed88eefcd02275acf18"
      unitRef="U002">41010953</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_55e84919f4d447e6871c51d747267c5b"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_cb691ab584cd41d9bce0e3d5ed1143a4"
      unitRef="U002">2105538</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_09f20ccd89394565bce47b581e9f910a"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_feba92dd57fa49c381ae4bc87588edd5"
      unitRef="U002">2105538</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_c3f1f5b77eee42b68153f8a9b81f8c9e"
      unitRef="U001">1409</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e3f29555788d42bfbd11cbb5bdc02b5b"
      unitRef="U002">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_5a2b037500f143d7b564c24d36e20e01"
      unitRef="U002">8848</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_46135533ea024d04ac7e5bdf3b86a4b9"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_31b62653268744489ffc96efbb9f8674"
      unitRef="U002">8849</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_3859312f726d48fa9d7eb2e3149062fa"
      unitRef="U001">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b63823edd4c241138d8e0b47a9ba4467"
      unitRef="U002">33</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_700abeb320014369be12e25ac7c52879"
      unitRef="U002">609967</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b8d4b89041b5493085ab451c8f15fd4a"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_d90416ee77fb40cea9aefc58e3e08cf7"
      unitRef="U002">610000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_87750f91fc28447db72e6dd62c898c28"
      unitRef="U001">43169</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_0ecd053706b74eff887b7150b5230f3e"
      unitRef="U002">14</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_788e156232d5498eb554053410b36a0d"
      unitRef="U002">243729</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_b032526ff8e24b7bb493750f7f156ab8"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_ec0b3ceb66244963a46fc53d91258c69"
      unitRef="U002">243743</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f06854d265a5405f98b10984b0e5c414"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_bfd14e1d54624ce1aab7d2dd30f71798"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_25cbc41faaed41c1b338609faac4adbc"
      unitRef="U002">-11534895</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_6403afe5eab345149fe7550a2a19a897"
      unitRef="U002">-11534895</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9cce72280d284a9599dc859108110d3b"
      unitRef="U001">30868188</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fba67b7742be4d77a97121246f69178f"
      unitRef="U002">10188</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_d5a9819ca3984b069f6b69b6182d72e2"
      unitRef="U002">155187231</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_1b2529990feb492a92e7726e8e52c909"
      unitRef="U002">-122753230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230630"
      decimals="0"
      id="Fact_4de60f016f7f4195a01e8f656e3da696"
      unitRef="U002">32444189</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_6a7648533a9b49c098e30c517170a32f"
      unitRef="U002">-21194813</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_cb6a798a79b14c6e981627ce1717c772"
      unitRef="U002">-14292722</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_07c65ca40c024f07a2f5f91505d5a4c2"
      unitRef="U002">4185857</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_30aa9a7d593140658171bf7d8ee9126f"
      unitRef="U002">2477574</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_7467602b1def44c7aeb4a1ad6cb3a675"
      unitRef="U002">267000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_0abef650f456488cb87a9ec119c48d55"
      unitRef="U002">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_717479e0165f408a87718859a9a77e29"
      unitRef="U002">233523</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_89711dc8adb6425ea2d896c833e45a70"
      unitRef="U002">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:Depreciation
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_30ea2e1bfb6c4f538eb1138e594faf49"
      unitRef="U002">7891</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_1effacaa472b43fa8d349155b5fd1ae7"
      unitRef="U002">86</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_3ff6b85afbff44cfaf2abb10e7fb5649"
      unitRef="U002">120514</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_78b26f555f224e5ea15fc0440b10bb7a"
      unitRef="U002">120514</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_6eb39af57a3e46adb7508ef11621af06"
      unitRef="U002">20627</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_44f7150ed1914139b11ee4bf292a22f5"
      unitRef="U002">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_0a2a93bb0b9d40cb9eca4424e3016d06"
      unitRef="U002">-277272</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_7e086e35841945259299d561ac90d96a"
      unitRef="U002">1160341</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_951663059c2e42ad98b5a398d3abc295"
      unitRef="U002">3195618</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_857a09c7db0742afa591ce2ef104490a"
      unitRef="U002">568588</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_d8d80fd486df4ec58334a6ee546780ce"
      unitRef="U002">-4937383</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_41a88b3dbad54194aee151d6640f36fb"
      unitRef="U002">115217</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_8c8853832d0e4eceb56f836bd6187d2c"
      unitRef="U002">-179136</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_74fe5700c4a9478790a22e03f7b08d46"
      unitRef="U002">-116783</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_c5ac124a352a4a83a36cfc1d7c4bc467"
      unitRef="U002">-18003030</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_d0a00e8ec5c54f25b89163ae7be0de7a"
      unitRef="U002">-12287867</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_c59164d4f519492e854a817aa1d03a67"
      unitRef="U002">8849</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_47c472dc02ef4c519412a1d9ebb06985"
      unitRef="U002">29917</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_879b6ec4621043b08f8972eb9f4a1baa"
      unitRef="U002">33253</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_b3468c1344b146828d1e890bbffb8254"
      unitRef="U002">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_7c94403d1f1d49ac94d9819ebc68919a"
      unitRef="U002">4832265</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_776f7d59c34d4a8b94c9e9e591b2f801"
      unitRef="U002">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_b11b937e8275454d937fd48b58de6415"
      unitRef="U002">4807861</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_7c1f96dcfe7346fb8109b9033bd46a71"
      unitRef="U002">29917</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_91e95a87490642d5b6c30068e4fd5c82"
      unitRef="U002">-13195169</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_7ec88691f4db4bf38136fd10e2f3e0a2"
      unitRef="U002">-12257950</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="0"
      id="Fact_86e648fde6a24b3ea45b69f6933221fc"
      unitRef="U002">73820160</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20211231"
      decimals="0"
      id="Fact_d939ad32a82440209ddc0e0a6bf52e7e"
      unitRef="U002">65242622</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20230630"
      decimals="0"
      id="Fact_4853376a58594fbd992a5c84852efa40"
      unitRef="U002">60624991</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20220630"
      decimals="0"
      id="Fact_fcb26aaa34d54959934454a085a3b3fa"
      unitRef="U002">52984672</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_e645b65d62344937a47ca1d8ff1f0e89"
      unitRef="U002">1962241</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_ab2b72c2940341808e49aa4540b0ae6a"
      unitRef="U002">0</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="c20230101to20230630"
      id="Text_f99c036f06914cada08548bd403cf17e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"&gt;Note 1 &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013; &lt;/span&gt;Nature of Operations&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"&gt;&lt;span style="font-size: 10pt; font-style: normal; font-weight: bold;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;PDS Biotechnology Corporation, a Delaware
                    corporation (the &#x201c;Company&#x201d; or &#x201c;PDS Biotech&#x201d;), is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on its Versamune&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;span style="font-size: 10pt;"&gt;, Versamune&lt;/span&gt;&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;span style="font-size: 10pt;"&gt; plus PDS0301 and Infectimune&lt;/span&gt;&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;span style="font-size: 10pt;"&gt; T cell-activating platforms and
                      PDS0301 tumor targeting immunocytokine. The Company believes its targeted immunotherapies have potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of
                      T cells.&#160; Versamune, and Versamune plus PDS0301 for treatments in oncology and Infectimune, for treatments in infectious disease.&#160; When paired with an antigen, which is a disease-related protein that is recognizable by the immune
                      system, Versamune and Infectimune have both been shown to induce, &lt;/span&gt;&lt;span style="font-size: 10pt; font-style: italic;"&gt;in vivo,&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt; large quantities of high-quality, highly potent polyfunctional
                      CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies.&#160; Versamune
                      plus PDS0301 enhances the proliferation, potency and longevity of T cells in the tumor microenvironment and works synergistically to overcome tumor immune suppression.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s immuno-oncology clinical candidates are of potential interest for use as a component of combination
                  clinical candidates (for example, in combination with other leading technologies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or refractory cancers. The Company is also
                  evaluating our immunotherapies as monotherapies in early-stage disease.&#160; PDS Biotech is developing targeted clinical candidates to treat several cancers including Human Papillomavirus (HPV)-positive cancers, melanoma, colorectal, lung,
                  breast and prostate cancers. The Company infectious disease candidates are of potential interest for use in universal influenza vaccines.&lt;/div&gt;
</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="c20230101to20230630"
      id="Text_468c865464894a079c214101bfc6ddb1">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 2 &#x2013; Summary of Significant Accounting
            Policies&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(A)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman';"&gt;Unaudited interim financial statements:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The interim balance sheet at June 30, 2023, the statements of operations and comprehensive loss and changes in stockholders&#x2019; equity and cash flows for the three and six months ended June 30, 2023 and 2022 are
              unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As
              permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the
              Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations
              for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The balance sheet as of December 31, 2022
              included herein was derived from the audited consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and
              notes thereto as of and for the year ended December 31, 2022, filed by the Company with the SEC in its Annual Report on Form 10-K on March 28, 2023.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(B)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Use of estimates:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The preparation of condensed consolidated financial
            statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements
            and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates. The most significant estimate relates to the fair value
            of securities underlying stock-based compensation.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(C)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant risks and uncertainties:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its clinical candidates, the ability to preserve its cash resources, the Company&#x2019;s review of strategic alternatives, the
                          ability to add clinical candidates to its pipeline, the Company&#x2019;s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by
                          other companies, the price of, and demand for, Company products if approved for sale, the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the ability to raise capital, and
                          the effects of health epidemics, pandemics, or outbreaks of infectious diseases.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#x2019;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(D)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash equivalents and concentration of cash balance:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company considers all highly liquid securities with a
            maturity weighted average of less than three months to be cash equivalents. The Company&#x2019;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(E)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#x2019;s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on
            behalf of the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical trial site activations or information provided by vendors on their actual costs incurred. Payments
            for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(F)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Patent costs:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(G)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Stock-based compensation:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#x2014;Stock Compensation
              (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order
              to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest
              rate and dividend yield. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company
              recognizes forfeitures as they occur.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(H)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Net loss per common share:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt; &lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2023&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2022&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: &amp;amp;amp; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';"&gt;Stock options to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,324,402&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;4,289,943&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: &amp;amp;amp; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';"&gt;Warrants to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;506,229&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;124,604&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: &amp;amp;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,830,631&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;4,414,547&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(I)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Income taxes:&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
              &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
                          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;(J)&lt;/div&gt;
                                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;Fair value of financial instruments:&lt;/div&gt;
                                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 1 &#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 2 &#x2014; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 3 &#x2014; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
              &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;(K)&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;Leases:&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"&gt; The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#x201c;ASC 842&#x201d;). Both financing and operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#x2019;s consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to
                  make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the
                  lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.&lt;/div&gt;
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20230101to20230630"
      id="Text_ae15636a958f48f590ed8b2b8efa9524">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(A)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman';"&gt;Unaudited interim financial statements:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The interim balance sheet at June 30, 2023, the statements of operations and comprehensive loss and changes in stockholders&#x2019; equity and cash flows for the three and six months ended June 30, 2023 and 2022 are
              unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP, in accordance with the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As
              permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the
              Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations
              for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The balance sheet as of December 31, 2022
              included herein was derived from the audited consolidated financial statements as of that date. These condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and
              notes thereto as of and for the year ended December 31, 2022, filed by the Company with the SEC in its Annual Report on Form 10-K on March 28, 2023.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20230101to20230630"
      id="Text_8e8f7dfa7f71490682a0f73c10591bb1">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(B)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Use of estimates:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The preparation of condensed consolidated financial
            statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements
            and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates. The most significant estimate relates to the fair value
            of securities underlying stock-based compensation.&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <pdsb:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock
      contextRef="c20230101to20230630"
      id="Text_c545e5abd9404e599145b2e2902aa2a4">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(C)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant risks and uncertainties:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s operations are subject to a number of factors that may affect its operating results and
                          financial condition. Such factors include, but are not limited to: the clinical and regulatory development of its clinical candidates, the ability to preserve its cash resources, the Company&#x2019;s review of strategic alternatives, the
                          ability to add clinical candidates to its pipeline, the Company&#x2019;s intellectual property, the ability to efficiently and effectively conduct its clinical trials, competition from products manufactured and sold or being developed by
                          other companies, the price of, and demand for, Company products if approved for sale, the ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, the ability to raise capital, and
                          the effects of health epidemics, pandemics, or outbreaks of infectious diseases.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;The Company currently has no commercially approved
            products. As such, there can be no assurance that the Company&#x2019;s future research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to
            regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants
            and obtaining and protecting its intellectual property.&lt;/div&gt;
</pdsb:SignificantRisksAndUncertaintiesPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20230101to20230630"
      id="Text_01bbd76af7a6433f8426790f730739da">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(D)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash equivalents and concentration of cash balance:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company considers all highly liquid securities with a
            maturity weighted average of less than three months to be cash equivalents. The Company&#x2019;s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits.&lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20230101to20230630"
      id="Text_17d0a550b2da44a2a4ae7181cf80533c">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(E)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs incurred in connection with research and development
            activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company&#x2019;s research and development projects as well as fees paid to consultants and entities that perform certain research and testing on
            behalf of the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Costs for certain development activities, such as clinical
            trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient enrollment, clinical trial site activations or information provided by vendors on their actual costs incurred. Payments
            for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.&lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="c20230101to20230630"
      id="Text_d55a0bcd06fb41e088a5e0ddd7a36446">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(F)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Patent costs:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company expenses patent costs as incurred and
            classifies such costs as general and administrative expenses in the accompanying statements of operations and comprehensive loss.&lt;/div&gt;
</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20230101to20230630"
      id="Text_b1e49b3b2a11499ea3e20799bd91936b">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(G)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Stock-based compensation:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation&#x2014;Stock Compensation
              (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. In order
              to determine the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest
              rate and dividend yield. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company
              recognizes forfeitures as they occur.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20230101to20230630"
      id="Text_267cafa3f35f467f880e864ab04514b9">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(H)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Net loss per common share:&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Basic and diluted net loss per common share is determined
            by dividing net loss attributable to common stockholders by the weighted average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options and warrants have been excluded from the
            calculation because their effect would be anti-dilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt; &lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2023&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2022&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: &amp;amp;amp; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';"&gt;Stock options to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,324,402&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;4,289,943&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: &amp;amp;amp; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';"&gt;Warrants to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;506,229&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;124,604&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: &amp;amp;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,830,631&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;4,414,547&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20230101to20230630"
      id="Text_bd6c17c1239342398b7bffdd5d70af4d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The potentially dilutive securities excluded from the
            determination of diluted loss per share as their effect is antidilutive, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt; &lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2023&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: normal; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: &amp;amp;amp; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: normal;"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2022&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: &amp;amp;amp; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';"&gt;Stock options to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,324,402&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;4,289,943&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: &amp;amp;amp; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';"&gt;Warrants to purchase Common Stock&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;506,229&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;124,604&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: &amp;amp;amp; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;5,830,631&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: &amp;amp; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;4,414,547&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_58d5e7e358b4478caabeac00efbae576"
      unitRef="U001">5324402</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_c847eb30c65349ceb576505381a14364"
      unitRef="U001">4289943</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_f3286673525f4c7f9fbcdcbfed2a80b1"
      unitRef="U001">506229</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220630_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_85c1740bb69645b58c8ac07c6048ec93"
      unitRef="U001">124604</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_018365f9d7f846cc9ec07e2798542358"
      unitRef="U001">5830631</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_29b4b67038e34d1a85bcebfb7695c8f1"
      unitRef="U001">4414547</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20230101to20230630"
      id="Text_947124b4214a4a51a357f82d9362a009">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;(I)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Income taxes:&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company provides for deferred income taxes under the asset and liability method, which requires deferred tax assets
                and liabilities to be recognized for the future tax consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities.
                Deferred tax assets are reduced if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20230101to20230630"
      id="Text_9d8ae5da59e54622be3ed11c8b60726e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
                          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;(J)&lt;/div&gt;
                                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 0px;"&gt;Fair value of financial instruments:&lt;/div&gt;
                                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs
                        to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to
                        unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 1 &#x2014; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the
                        measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 2 &#x2014; Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g.,
                        quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models
                        or other valuation methodologies.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Level 3 &#x2014; Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using
                        pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="c20230101to20230630"
      id="Text_06d525e453a04cfd9dbad2bf11afc5b7">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 36pt;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;(K)&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                          &lt;div style="text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);"&gt;Leases:&lt;/span&gt;&lt;/div&gt;
                        &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none; text-align: justify;"&gt; The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (&#x201c;ASC 842&#x201d;). Both financing and operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, lease
                  obligation-short term and lease obligation-long term in the Company&#x2019;s consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to
                  make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the
                  lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.&lt;/div&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="c20230101to20230630"
      id="Text_3c4156a7dd5c4ae7a6d201702ce741d3">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 3 &#x2013; Liquidity&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"&gt;As of June 30, 2023, the
              Company had $60.6 million of cash and cash equivalents. The Company&#x2019;s primary uses of cash are to fund operating expenses,
              primarily research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change to the Company&#x2019;s outstanding accounts payable and accrued
              expenses.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In April 2022, the Company received approximately $1.2 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant the Company&#x2019;s participation in the New Jersey Technology
              Business Tax Certificate Transfer NOL program for tax year 2020.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In August 2022, the Company filed a shelf registration statement, or the 2022 Shelf Registration Statement, with the SEC
              for the issuance of common stock, preferred stock, warrants, rights, debt securities, and units, up to an aggregate amount of $150
              million, $50 million of which covers the offer, issuance and sale by the Company of its common stock under the Sales Agreement (as
              discussed below).&#160; The 2022 Shelf Registration Statement was declared effective on September 2, 2022.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"&gt;In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley
              Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock,
              having an aggregate offering price of up to $50 million, or the Placement Shares, through or to the Agents, as sales agents or
              principals.&#160; Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents may sell the Placement Shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d; offering as defined in
              Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company&#x2019;s common stock. The Agents will use commercially
              reasonable efforts to sell the Placement Shares from time to time, based upon the Company&#x2019;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the
              Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under
              the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company is not obligated to make any sales of its common stock under the Sales Agreement.&#160; The offering of Placement
              Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. For the year ended December
              31, 2022, the Company sold 1,238,491 shares of common stock with a net value of $9.9 million pursuant to the Sales Agreement. During the three and six months ended June 30, 2023, we sold 43,169 shares of our common stock with a net value of $0.2
              million and 596,462 share of our common with a net value of $4.8 million, respectively, pursuant to the Sales Agreement.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; text-indent: 36pt;"&gt;In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with
                Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders.&#160; The Loan and Security Agreement provides for the following 6 separate and independent term loans: (a) a term loan in the amount of $7,500,000,
                or Loan A, (b) a term loan in the amount of $10,000,000, or Loan B, (c) a term loan in the amount of $3,750,000, or Loan C, (d) a term loan in the amount of $3,750,000, or Loan D, (e) a term loan in the amount of $5,000,000, or
                Loan E, and (f) a term loan in the amount of $5,000,000, or Loan F, (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and
                Loan F, individually a Loan and, collectively, the Loans).&#160; Loan A, Loan B, Loan C&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;, and Loan D were delivered to the Company on August 24, 2022.&#160; Loan E and Loan F are uncommitted Loans that could have been advanced by the lenders upon the Parties agreement prior to July 31, 2023 upon the
                  satisfaction of certain conditions. The Parties are in discussion to extend this option, however, there is no guarantee that such an option will be extended on terms favorable to the Company or its existing stockholders, or at all. The
                  Company may only use the proceeds of the Loans for working capital or general corporate purposes.&#160; Each Loan matures on the 48-month
                  anniversary following the applicable funding date unless accelerated pursuant to certain events of default.&lt;/span&gt; Payments on the principal balance begin on October 1, 2024 and are paid monthly in the succeeding 24 months. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) &lt;/span&gt;the per annum rate of
                interest from time to time published in The Wall Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#x201c;prime rate&#x201d; then in effect, plus (b) 5.75%; provided that, in the event such rate of interest is less than 4.00%,
                such rate shall be deemed to be 4.00% for purposes of calculating the interest rate. Interest is payable on a monthly basis
                based on each Loan principal amount outstanding the preceding month.&#160; The Company, at its option upon at least ten (10) business
                days&#x2019; written notice to the lenders, may prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the
                Loans; plus (ii) an amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date (as defined in the Loan and Security Agreement) applicable to such Loan, 3% of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan, but on or before the date that is 12 months after such Loan Amortization Date, 2%
                of the then outstanding principal balance of such Loan, or (C) if such Loan is prepaid more than 12 months after the Loan
                Amortization Date but prior to the stated maturity date applicable to such Loan, 1% of the then outstanding principal balance of
                such Loan;&#160;plus&#160;(iii) the outstanding principal balance of such Loan;&#160;plus&#160;(iv) all other sums, if any, that shall have become due and payable thereunder.&#160; No prepayment premium will be applied to any outstanding balance of any Loan paid on the stated maturity date.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Loan and Security Agreement contains customary representations, warranties and covenants, including covenants by the
              Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates, and
              fundamental changes.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In April 2023, the Company received approximately $1.4 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company&#x2019;s participation in the New Jersey Technology
                Business Tax Certificate Transfer NOL program for tax year 2021.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s primary uses of cash are to fund operating expenses, primarily research and development expenditures. Cash
              used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change in its outstanding accounts payable and accrued expenses.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial
              doubt about its ability to continue as a going concern within one year after the filing of this Quarterly Report on Form 10-Q.&#160; The Company&#x2019;s budgeted cash requirements in 2023 and beyond include expenses related to continuing development and
              clinical trials.&#160; Based on its available cash resources and cash flow projections as of the date the consolidated financial statements were available for issuance, management believes there are sufficient funds to continue operations and
              research and development programs &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;for 12 months following the filing of this Quarterly Report on Form 10-Q&lt;/span&gt;.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;The Company plans to continue to fund its operations and capital funding needs through equity and/or debt financings.
              However, the Company cannot be certain that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or its existing stockholders.&#160; The Company may also enter into
              government funding programs and consider selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to the Company&#x2019;s stockholders. Incurring debt financing would
              result in debt service obligations, and the instruments governing such debt could provide for operating and financing covenants that would restrict its operations. If the Company is unable to raise additional capital in sufficient amounts or
              on acceptable terms, we may be required to delay, limit, reduce, or terminate its clinical development or future commercialization efforts or grant rights to third parties to develop and market immunotherapies that the Company would otherwise
              prefer to develop and market itself. Any of these actions could harm its business, results of operations and prospects. Failure to obtain adequate financing also may adversely affect the Company&#x2019;s ability to operate as a going concern.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20230630"
      decimals="-5"
      id="Fact_2e30faa3fe564db48d9db199832dee3a"
      unitRef="U002">60600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
      contextRef="c20220401to20220430"
      decimals="-5"
      id="Fact_3413a4cbc8814a76a2e44d6deed28f43"
      unitRef="U002">1200000</pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards>
    <pdsb:ShelfRegistrationStatementAvailableForFutureSale
      contextRef="c20220831"
      decimals="-6"
      id="Fact_105cc8ccc71344debcd6d892a74a43e5"
      unitRef="U002">150000000</pdsb:ShelfRegistrationStatementAvailableForFutureSale>
    <pdsb:PlacementSharesAvailableForFutureSale
      contextRef="c20220831"
      decimals="-6"
      id="Fact_75a6262766cb4ef48c8902cd6f607eac"
      unitRef="U002">50000000</pdsb:PlacementSharesAvailableForFutureSale>
    <pdsb:PlacementSharesAvailableForFutureSale
      contextRef="c20220831"
      decimals="-6"
      id="Fact_6016895080224eec9eca9aa07b163262"
      unitRef="U002">50000000</pdsb:PlacementSharesAvailableForFutureSale>
    <pdsb:CommissionPercentage
      contextRef="c20220801to20220831"
      decimals="2"
      id="Fact_135376385d954ef28f1d2222f3083b61"
      unitRef="U004">0.03</pdsb:CommissionPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_a0a33ae57ea448f79c2df3deec9dbbb3"
      unitRef="U001">1238491</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20220101to20221231"
      decimals="-5"
      id="Fact_7681cbd4e3014a64892e518a4795921e"
      unitRef="U002">9900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_d1bb121572224748aa92a8d3d5906361"
      unitRef="U001">43169</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20230401to20230630"
      decimals="-5"
      id="Fact_4ee13ea9b1d642b3943438d82756ba2f"
      unitRef="U002">200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_7fb2e6085cd54af88ec3aed56c659c31"
      unitRef="U001">596462</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20230101to20230630"
      decimals="-5"
      id="Fact_be54667a9d9a4d5d8869061dd791c113"
      unitRef="U002">4800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pdsb:DebtInstrumentNumberOfIndependentTermLoans
      contextRef="c20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="0"
      id="Fact_9da00dc5d61a4cb5a63dcb6bdb7340d2"
      unitRef="U005">6</pdsb:DebtInstrumentNumberOfIndependentTermLoans>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanAMember"
      decimals="0"
      id="Fact_bdfca3eec53c4b44bde8bf7634d98706"
      unitRef="U002">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanBMember"
      decimals="0"
      id="Fact_416b5967a00f43b6b8ca575e2e1f6def"
      unitRef="U002">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanCMember"
      decimals="0"
      id="Fact_3191e5336d844fc2b66174f6fe35c0e8"
      unitRef="U002">3750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanDMember"
      decimals="0"
      id="Fact_15bfa2c3a7b743b98524f2323906efb1"
      unitRef="U002">3750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="c20230630_DebtInstrumentAxis_LoanEMember"
      decimals="0"
      id="Fact_63c8257cceb34928ab283d57c602e537"
      unitRef="U002">5000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="c20230630_DebtInstrumentAxis_LoanFMember"
      decimals="0"
      id="Fact_00832118ec6e470f931472aab11b2063"
      unitRef="U002">5000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_7e4ba71e239c46db88f6877256b8aaee">P48M</us-gaap:DebtInstrumentTerm>
    <pdsb:DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_c4ee888719a74e9e8e5dbc1a9aeb4479">P24M</pdsb:DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_VariableRateAxis_PrimeRateMember"
      decimals="4"
      id="Fact_82fb301b3b564f2093d84469268e868f"
      unitRef="U004">0.0575</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <pdsb:DebtInstrumentVariableRate
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_8df8dfa5b9f54f04949187b19d5bbee0"
      unitRef="U004">0.04</pdsb:DebtInstrumentVariableRate>
    <pdsb:DebtInstrumentVariableRate
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_17e304f0160443a49d740ab7dbc8bf2d"
      unitRef="U004">0.04</pdsb:DebtInstrumentVariableRate>
    <pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"
      id="Fact_141edf28094c4f6d964978791c6736b5">P10D</pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod1
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_42a1b3d9dea24d2ba149bb8d1e6dea46"
      unitRef="U004">0.03</pdsb:DebtInstrumentPrepaymentPremiumPeriod1>
    <pdsb:DebtInstrumentThresholdPeriod
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_5c64435ab8ef4933bd367f2547fe71c0">P12M</pdsb:DebtInstrumentThresholdPeriod>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod2
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_3f3ad5e13bf94592a5e3f7e159b39f0d"
      unitRef="U004">0.02</pdsb:DebtInstrumentPrepaymentPremiumPeriod2>
    <pdsb:DebtInstrumentThresholdPeriod
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_58aca750d22448a5870553921968fb0a">P12M</pdsb:DebtInstrumentThresholdPeriod>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod3
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_6e70ffe1a62048feb3e85c934909f4c5"
      unitRef="U004">0.01</pdsb:DebtInstrumentPrepaymentPremiumPeriod3>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod4
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_ffa1443d135e4a668fee34644e47c560"
      unitRef="U004">0</pdsb:DebtInstrumentPrepaymentPremiumPeriod4>
    <pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
      contextRef="c20230401to20230430"
      decimals="-5"
      id="Fact_425cd80196634510b32e4f5e4d321603"
      unitRef="U002">1400000</pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20230101to20230630"
      id="Text_73560b82835844c09425c66d391eb93d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 4 &#x2013; Fair Value of Financial Instruments&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;There were no transfers among Levels 1, 2, or 3 during the three and six months ended June 30, 2023 or 2022.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Fair Value Measurements at Reporting Date Using&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Active Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 1)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Inactive Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Unobservable Inputs&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 3)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of &lt;span style="text-indent: 0pt;"&gt;June 30&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;: (unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash and cash equivalents&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;60,624,991&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;60,624,991&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December
                      31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash and cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;73,820,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;73,820,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"&gt;The carrying value of the Note Payable approximated its fair value at June 30,
              2023 due to its variable rate.&lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_f2ec1a7358a049e2bf5a09df6ab02f8f"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_adfd5be06c3446dba935032647928571"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_84eb7a2944ed492b95c31981cad066ec"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_18ed41f3de8544fc9f1581f5bbf13461"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_0696aef957f34e2c85e2c02531ab255b"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_eb72031be6174b52a99e3c1fa1b02b7b"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_150b98f937de42c680b9ea2bd3c938ba"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_fa16382c96d8465aa7048fb6d86044ed"
      unitRef="U002">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="c20230101to20230630"
      id="Text_b10d17043f62400a903fe724ce9a939b">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Fair Value Measurements at Reporting Date Using&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Active Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 1)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Quoted Prices in&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Inactive Markets&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Significant&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Unobservable Inputs&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(Level 3)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of &lt;span style="text-indent: 0pt;"&gt;June 30&lt;/span&gt;, &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;: (unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash and cash equivalents&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;60,624,991&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;60,624,991&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December
                      31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Cash and cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;73,820,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;73,820,160&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20230630"
      decimals="0"
      id="Fact_3496c4a8cf96434aa781747e6ad072f4"
      unitRef="U002">60624991</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_2e5743260f674b869750998a91e757c6"
      unitRef="U002">60624991</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_a0e30c10954649a78b95ac3146efdeb9"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20230630_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_9a79764b4efd45289e43ac3538ae2202"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20221231"
      decimals="0"
      id="Fact_d8799d0f3c3f42829df75ce79e5c86d0"
      unitRef="U002">73820160</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_94bcf8fe414247699e5246ad40923f27"
      unitRef="U002">73820160</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_a5ce73417c7d4125ab11d4524b6836b4"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_068fc8d640854107acd48fdcdccba068"
      unitRef="U002">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20230101to20230630"
      id="Text_c84c9041eb47400f877f5e85c2adee8d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 5 &#x2013; Leases&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Operating Lease:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Effective March 5, 2020, the Company entered into a sublease for approximately 11,200 square feet of office space located at 25B Vreeland Road, Suite 300, Florham Park, NJ. The sublease commenced on May 1, 2020 and will continue for a term of forty
              (40) months with an option to renew through October 31, 2027. As of June 30, 2023 there are two (2) months remaining in the sublease term. Upon inception of the sublease, the Company recognized approximately $0.7 million of a ROU asset and operating lease liabilities. The discount rate used to measure the operating lease liability as of May 1, 2020
              was 9.15%. Throughout the period described above the Company has maintained, and continues to maintain, a month-to-month lease for
              its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Supplemental cash flow information related to operating
            leases is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2022&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Cash paid for operating lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="font-family: 'Times New Roman';"&gt;179,136&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;116,783&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Maturity of the Company&#x2019;s operating lease liability is as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: &amp;amp;amp;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Year ended December 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;60,333&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2027 and after&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total future minimum lease payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;60,333&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Less imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(683&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;59,650&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="c20230630"
      decimals="0"
      id="Fact_f93aab5277d34383a293644e4fe4f805"
      unitRef="U006">11200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="c20230630"
      id="Fact_35c8b80803024f4091676956b12348bd">P40M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="c20230630"
      id="Fact_01e250fb0808468fa5d0e7d492ff8944">P2M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20200501"
      decimals="-5"
      id="Fact_8a9f9bee0e7045f7af37a9b301fb82f6"
      unitRef="U002">700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20200501"
      decimals="-5"
      id="Fact_51b8c027716642b99666dece125c1d9c"
      unitRef="U002">700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c20200501"
      decimals="4"
      id="Fact_09080085ee1e4a57b6ad4ac0a645ee2d"
      unitRef="U004">0.0915</us-gaap:LesseeOperatingLeaseDiscountRate>
    <pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock
      contextRef="c20230101to20230630"
      id="Text_e53fc6fae7d04841af06125cd44cb1e0">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Supplemental cash flow information related to operating
            leases is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman';"&gt;As of June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2022&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Cash paid for operating lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="font-family: 'Times New Roman';"&gt;179,136&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;116,783&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_cf88223345a1491984df38ae918a6065"
      unitRef="U002">179136</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_996ef5fac0214723bc0cf6bb7b08cf0d"
      unitRef="U002">116783</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20230101to20230630"
      id="Text_ff0e5466c1cc434c827689fab180362e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;Maturity of the Company&#x2019;s operating lease liability is as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: &amp;amp;amp;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Year ended December 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;60,333&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2027 and after&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total future minimum lease payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;60,333&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Less imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(683&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;59,650&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20230630"
      decimals="0"
      id="Fact_bbf32e3e5e5549c988ea60f82ddc78a8"
      unitRef="U002">60333</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20230630"
      decimals="0"
      id="Fact_4896e154fb3746a3bf885db78dee7928"
      unitRef="U002">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20230630"
      decimals="0"
      id="Fact_571d86250b684e14a56bfd24bd5ffc88"
      unitRef="U002">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20230630"
      decimals="0"
      id="Fact_46d43b3014764d29a4504488382fc5bd"
      unitRef="U002">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <pdsb:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter
      contextRef="c20230630"
      decimals="0"
      id="Fact_3b94591683c74ce0b63ca6d133379290"
      unitRef="U002">0</pdsb:LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20230630"
      decimals="0"
      id="Fact_968ab27a93c84955b001ad137e275fd9"
      unitRef="U002">60333</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20230630"
      decimals="0"
      id="Fact_202c5acc5ee1460abf1fca47d939bcc5"
      unitRef="U002">683</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20230630"
      decimals="0"
      id="Fact_34e3d982cc9946f28ef28c15fa8e0e85"
      unitRef="U002">59650</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="c20230101to20230630"
      id="Text_41fd09658afd4ab184eb1cf9960421fd">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Financing Lease:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;The Company has financed certain
              laboratory equipment as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2022&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash paid for finance lease liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;43,221&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"&gt; Maturity of the Company&#x2019;s financing lease liability is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year ended June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;34,924&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$ &lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;69,850&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$ &lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;69,850&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2026&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$ &lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;40,108&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2027 and after&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$ &lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;26,724&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total future minimum lease payments&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;241,456&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Less imputed interest&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(36,642&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining lease liability&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;204,814&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;The Company entered into four
              financing leases for laboratory equipment with a total cost of $251,959 with &lt;span style="-sec-ix-hidden:Fact_f0c3462c2ee44efcb853f792cd6a38ad"&gt;four&lt;/span&gt; to five-year terms and a capitalized interest rate of
              9.15%. Each of the lease agreements include a bargain purchase option to acquire the equipment at the end of the lease term. The
              aggregate monthly payments are approximately $6,000. In the six months ended June 30, 2023, the Company exercised a bargain
              purchase option, which resulted in recognition of property and equipment of $151,490.&lt;/div&gt;
</us-gaap:LesseeFinanceLeasesTextBlock>
    <pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock
      contextRef="c20230101to20230630"
      id="Text_b073d91e77ab4362937f69077b4cbdb8">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;The Company has financed certain
              laboratory equipment as follows: &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2022&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash paid for finance lease liabilities&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;43,221&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</pdsb:LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock>
    <pdsb:FinanceLeasePrincipalAndInterestPayments
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_7d01b18a9f824e2084f83a2e916db4f6"
      unitRef="U002">43221</pdsb:FinanceLeasePrincipalAndInterestPayments>
    <pdsb:FinanceLeasePrincipalAndInterestPayments
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_f95c39f295a642baac30906778ff3b32"
      unitRef="U002">0</pdsb:FinanceLeasePrincipalAndInterestPayments>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="c20230101to20230630"
      id="Text_b058af5d7b1f4beda78c3242f6dbdf5d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-indent: 36pt;"&gt; Maturity of the Company&#x2019;s financing lease liability is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year ended June 30,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2023&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;34,924&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$ &lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;69,850&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$ &lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;69,850&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2026&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$ &lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;40,108&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;2027 and after&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$ &lt;br/&gt;
                    &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;26,724&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total future minimum lease payments&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;241,456&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Less imputed interest&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(36,642&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining lease liability&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;204,814&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20230630"
      decimals="0"
      id="Fact_70c662006c664101a086ed6973968bdf"
      unitRef="U002">34924</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20230630"
      decimals="0"
      id="Fact_545fbe3337a447ee8e6ebfe8a3f2ce7d"
      unitRef="U002">69850</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20230630"
      decimals="0"
      id="Fact_ccff53db136a4d308572775cb96882a9"
      unitRef="U002">69850</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="c20230630"
      decimals="0"
      id="Fact_5c10b8e99d484139a920eae17cbb4e85"
      unitRef="U002">40108</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <pdsb:FinanceLeaseLiabilityToBePaidYearFourAndThereafter
      contextRef="c20230630"
      decimals="0"
      id="Fact_e98b765ad5d2444ab759af34c1b54283"
      unitRef="U002">26724</pdsb:FinanceLeaseLiabilityToBePaidYearFourAndThereafter>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="c20230630"
      decimals="0"
      id="Fact_1056b28874cd43eaaf1343f89aff2004"
      unitRef="U002">241456</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20230630"
      decimals="0"
      id="Fact_4edfc7375bee4715b4070dfe99de80fd"
      unitRef="U002">36642</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="c20230630"
      decimals="0"
      id="Fact_d2c52c7fba30430b938ba5aa72eac6fb"
      unitRef="U002">204814</us-gaap:FinanceLeaseLiability>
    <pdsb:LesseeFinanceLeaseNumberOfLeases
      contextRef="c20230101to20230630"
      decimals="INF"
      id="Fact_18ba008e5ecf4f2c86d5fb6df3621fde"
      unitRef="U007">4</pdsb:LesseeFinanceLeaseNumberOfLeases>
    <pdsb:FinanceLeaseCost
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_9dddca1ca72641fcac27e3217386541a"
      unitRef="U002">251959</pdsb:FinanceLeaseCost>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="c20230630_RangeAxis_MaximumMember"
      id="Fact_5d78b7a795de46e69db72ade6f393217">P5Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="c20230630"
      decimals="4"
      id="Fact_3629cd398f574c9894a6b0d03d957a80"
      unitRef="U004">0.0915</us-gaap:LesseeFinanceLeaseDiscountRate>
    <pdsb:LesseeFinanceLeaseMonthlyRentalExpense
      contextRef="c20230101to20230630"
      decimals="-3"
      id="Fact_133327ee86704d0eac55541f2e7e7e1d"
      unitRef="U002">6000</pdsb:LesseeFinanceLeaseMonthlyRentalExpense>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_c15d648d4c67400288f66079cd3f0614"
      unitRef="U002">151490</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20230101to20230630"
      id="Text_32a268bf225b4809b33cf77488db16a5">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 6 &#x2013; Accrued Expenses&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
        &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;Accrued expenses and other liabilities consist of the
          following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;June 30, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="background-color: rgb(204, 238, 255); vertical-align: middle; white-space: nowrap; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Accrued research and development&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;874,200&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;5,645,737&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued professional fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;941,515&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;550,259&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,268,575&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,837,330&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued interest on debt&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;291,667&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;280,382&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;Accrued rent&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;3,376,325&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;8,313,708&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20230101to20230630"
      id="Text_c8d65d70ec0f4b9390897c4a8e85dfdd">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
        &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify; text-indent: 36pt;"&gt;Accrued expenses and other liabilities consist of the
          following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;June 30, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; text-align: center;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;As of&lt;/div&gt;
                &lt;div style="text-align: center; font-family: 'Times New Roman';"&gt;December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="background-color: rgb(204, 238, 255); vertical-align: middle; white-space: nowrap; width: 76%; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;Accrued research and development&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;874,200&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;5,645,737&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued professional fees&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;941,515&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;550,259&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;Accrued compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,268,575&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;1,837,330&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued interest on debt&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;291,667&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;280,382&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;Accrued rent&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;368&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; font-family: 'Times New Roman';"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman';"&gt;3,376,325&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="font-family: 'Times New Roman';"&gt;8,313,708&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pdsb:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_1d64e1edc81449008d17caa213c53fdf"
      unitRef="U002">874200</pdsb:AccruedResearchAndDevelopmentCostsCurrent>
    <pdsb:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_9e9e93f4bcc1427bb19bc0d1500c450b"
      unitRef="U002">5645737</pdsb:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_44cb1df96fa846d3a0abdba3950b228f"
      unitRef="U002">941515</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_3139c002b71c432d93ba1503f1e55550"
      unitRef="U002">550259</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_d702c3c66b4b4ca4ab7f24ea79f40ad7"
      unitRef="U002">1268575</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_01a019aae3ad4a21a760b7a095135810"
      unitRef="U002">1837330</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_88af646dc144434caec13f271929c325"
      unitRef="U002">291667</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_b1d3b697c4874950af0ea3a5311827ef"
      unitRef="U002">280382</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_1695a70b3b304d8b87e1773a95c5f88a"
      unitRef="U002">368</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_d2780ba71a184a128fc4936c661a855d"
      unitRef="U002">0</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20230630"
      decimals="0"
      id="Fact_c50e555a01e242af907c18e70b9c851e"
      unitRef="U002">3376325</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_b41e80bbb1fd4177b11ede6b415edeb7"
      unitRef="U002">8313708</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20230101to20230630"
      id="Text_c437c32b26e1418682eb12f87af9e911">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Note 7 &#x2013; Stock-Based Compensation&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;In 2014, the Company&#x2019;s stockholders approved the 2014
            Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (&#x201c;RSUs&#x201d;),
            subject to increases as hereafter described (the &#x201c;Plan Limit&#x201d;). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive
            Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of
            the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to 826,292 shares.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-align: justify; text-indent: 36pt; text-transform: none;"&gt;As previously disclosed, on December 8, 2020, the Board of
              Directors of the Company adopted, subject to stockholder approval, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Inventive Plan (the &#x201c;Restated Plan&#x201d;), which amended and restated the Amended and Restated PDS
              Biotechnology Corporation 2014 Equity Incentive Plan (the &#x201c;Current Plan&#x201d;). At the annual meeting of stockholders on June 17, 2021 the stockholders voted to approve the Restated Plan at the Annual Meeting. The Restated Plan is identical to the
              Current Plan in all material respects, except as follows: (a) the number of shares of Common Stock authorized for issuance under the Restated Plan will increase from 826,292 shares to 3,339,243 shares, plus the total number of shares that
              remained available for issuance, that are not covered by outstanding awards issued under the Current Plan, immediately prior to December 8, 2020; and (b) the Restated Plan will terminate on December 7, 2030, unless earlier terminated. On July
              14, 2023, the Company&#x2019;s stockholders approved an amendment to the Current Plan increasing the number of shares of common stock for issuance from 4,165,535
              to 6,565,535 shares. As of June 30, 2023, there were 178,513 shares available for grant under the Restated Plan. &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In 2018, the
              Company&#x2019;s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i)
              Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards. As of June 30, 2023, there were 190,799 shares available for grant under the Restated Plan.&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block; font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Pursuant to the terms of the Plans, ISOs have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a
            four-year period. Unless terminated by the Board, the Plans shall continue to remain effective for a term of ten years or until such time as no further awards may be granted and all awards granted under the Plans are no longer outstanding.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block; font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On June 17, 2019, the Board adopted the 2019 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). The Inducement Plan provides for the grant of non-qualified stock options. The Inducement Plan was recommended
              for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; On December 8, 2020, the Company amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under
                the Inducement Plan from 200,000 shares to 500,000 shares.&lt;/span&gt; On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from 500,000 shares to 1,100,000
              shares.&#160;The 2019 Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, non-qualified stock options under the 2019 Inducement Plan may only be made to an
              employee who has not previously been an employee or member of the Board (or any parent or subsidiary of the Company), or following a bona fide period of non-employment by the Company (or a parent or subsidiary of the Company), if he or she is
              granted such non-qualified stock options in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such
              subsidiary. As of June 30, 2023, there were 185,315 shares available for grant under the 2019 Inducement Plan. &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;The Company&#x2019;s stock-based compensation expense related to stock options was recognized in operating expense as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Three Months Ended June 30,&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Six months ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Stock-Based Compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Research and development&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;806,548&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;487,532&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,607,312&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;856,582&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;General and administrative&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,298,990&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;861,069&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;/div&gt;
                  &lt;/div&gt;
                  &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,578,545&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,620,992&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Total&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,105,538&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,348,601&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,185,857&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2,477,574&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br class="Apple-interchange-newline"/&gt;
            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;The fair value of options granted during the three and six months ended June 30, 2023 and 2022 was estimated using the Black-Scholes option
            valuation model utilizing the following assumptions. There were 29,900 and 1,154,500 of options granted during the three and six month periods ended June 30, 2023, respectively and 494,000 and 1,439,005 of options granted during the three and six month
            period ended June 30, 2022, respectively.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Three Months Ended June 30&lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;143.87&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;100.05&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;142.07&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;99.45&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Risk-Free Interest Rate&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3.59&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2.60&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.05&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;11.62&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Expected Term in Years&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.02&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.43&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Dividend Rate&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Fair Value of Option on Grant Date&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.09&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.01&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;10.64&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.59&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
          &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
        &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Number&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;of Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercise Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Life in Years&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Aggregate&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Intrinsic Value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Options outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,171,311&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.56&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.89&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;10,839,589&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Granted&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,154,500&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;11.45&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(1,409&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;)&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited











                      and expired&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;/div&gt;
                &lt;/div&gt;
                &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Options outstanding at &lt;span style="text-indent: 0pt;"&gt;June 30, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,324,402&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.85&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.86&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,645,635&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;June 30, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,324,402&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.85&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.86&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,645,635&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercisable at &lt;span style="text-indent: 0pt;"&gt;June 30, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,513,595&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.80&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.83&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,901,233&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
        &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br class="Apple-interchange-newline"/&gt;
          &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;At June 30, 2023 there was approximately $20,357,890 of unamortized stock option compensation expense, which is expected to be recognized over a remaining average vesting period of 2.75 years.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company entered into an agreement with DC Consulting for certain consulting services
            and issued 100,000 shares in connection with the agreement.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20141231_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_86067fbc1db34767989387a4d9917487"
      unitRef="U001">91367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <pdsb:PercentageOfCommonStockOutstanding
      contextRef="c20140101to20141231_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="2"
      id="Fact_0fe28907156f4ceca34b436a0913541d"
      unitRef="U004">0.04</pdsb:PercentageOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_39155fcd843941f49dbd475668d4ac08"
      unitRef="U001">826292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20190331_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_9b390e0219254175a84a27bfa763b908"
      unitRef="U001">826292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20210617_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_59026e91d399413699dc4d1c6ac28b9a"
      unitRef="U001">3339243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20230630_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_306d69d7abfd40ee86d5b4525a5b6037"
      unitRef="U001">4165535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20230714_PlanNameAxis_EquityIncentivePlan2014Member_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_6ec023c9f38e450bb2856459de74bb87"
      unitRef="U001">6565535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20230630_PlanNameAxis_EquityIncentivePlan2014Member"
      decimals="0"
      id="Fact_c6ab48f2106b4674be0fc38dbb6e0c40"
      unitRef="U001">178513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20181231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_70af3ccbb8634c8295875d04eef15de0"
      unitRef="U001">558071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20230630_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_8a569881c63d47aa89b0f7d8e27b99cd"
      unitRef="U001">190799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="c20230101to20230630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember_RangeAxis_MaximumMember"
      id="Fact_86ac4e46573f470fb6ec75fee6d76dc4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20230101to20230630_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityCompensationPlansMember"
      id="Fact_b6b57db0dd834813a1d4d372d6c7ebd0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan
      contextRef="c20230101to20230630_PlanNameAxis_EquityCompensationPlansMember"
      id="Fact_316352e38eb5458194e8ef9b0c424377">P10Y</pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201207_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_8615897054bc460e8e028434429c2522"
      unitRef="U001">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201208_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_997004b9313d4dabb7447b6b1030d987"
      unitRef="U001">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20220516_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_747909e818024aa992b02b2fdb244a66"
      unitRef="U001">500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20220517_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_ef1ab83822284fa0999f05ac91f76949"
      unitRef="U001">1100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20230630_PlanNameAxis_InducementPlan2019Member"
      decimals="0"
      id="Fact_9e52194f0bcc4c6a9e3d3c934a0bdc1c"
      unitRef="U001">185315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20230101to20230630"
      id="Text_0d4ff581aa6d4e7f9a24f2a492e60771">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;The Company&#x2019;s stock-based compensation expense related to stock options was recognized in operating expense as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Three Months Ended June 30,&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Six months ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Stock-Based Compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Research and development&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;806,548&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;487,532&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,607,312&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;856,582&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;General and administrative&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,298,990&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;861,069&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;/div&gt;
                  &lt;/div&gt;
                  &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,578,545&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,620,992&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Total&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,105,538&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,348,601&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,185,857&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2,477,574&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_399848f6ab6940d892a4d40dd7df4805"
      unitRef="U002">806548</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_f2b58b9aa88340578243b46a5e6f15db"
      unitRef="U002">487532</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_7838a2cc9c9348478440725247da39cf"
      unitRef="U002">1607312</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_89ccc06ded4e4476add3327b7bc61298"
      unitRef="U002">856582</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_4b80dfb116db4bc88124a3afd2909426"
      unitRef="U002">1298990</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_041c7f7d8adf41bbb0c1a696b34b1ba4"
      unitRef="U002">861069</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_70ba6896ffa04a1fb42263396d4fad55"
      unitRef="U002">2578545</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact_cab63f4df0bc4e18ba7a23c476c0da66"
      unitRef="U002">1620992</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_9e91225df29f4ad8a3f11995f6ab8440"
      unitRef="U002">2105538</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_142cee1c809f41ec9f217180360138d7"
      unitRef="U002">1348601</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_9daee8b5b3fd4e29b5ea90348b15559b"
      unitRef="U002">4185857</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_6fa65a61a1d74e73840cd96696a09c1e"
      unitRef="U002">2477574</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20230101to20230630"
      id="Text_a95acb4203944c9283fabe06595262cd">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; text-indent: 36pt;"&gt;The fair value of options granted during the three and six months ended June 30, 2023 and 2022 was estimated using the Black-Scholes option
            valuation model utilizing the following assumptions. There were 29,900 and 1,154,500 of options granted during the three and six month periods ended June 30, 2023, respectively and 494,000 and 1,439,005 of options granted during the three and six month
            period ended June 30, 2022, respectively.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Three Months Ended June 30&lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Six Months Ended June 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(unaudited)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Volatility&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;143.87&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;100.05&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;142.07&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;99.45&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Risk-Free Interest Rate&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;3.59&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2.60&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.05&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;11.62&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;%&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Expected Term in Years&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.02&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.08&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.43&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Dividend Rate&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&#x2013;&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Fair Value of Option on Grant Date&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.09&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.01&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;10.64&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4.59&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_060c83653b194da79d1fcc16c05614ed"
      unitRef="U001">29900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_6a40040539b845478f28350b0cee9d85"
      unitRef="U001">1154500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220401to20220630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_2c4d291f29cf4bdebeec31f151f2dfea"
      unitRef="U001">494000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220101to20220630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_3ef5ffb9505b487fadf3513acb4482b0"
      unitRef="U001">1439005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230401to20230630"
      decimals="4"
      id="Fact_c542f8af5ffe4e74ad1bc2f46ce48535"
      unitRef="U004">1.4387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220401to20220630"
      decimals="4"
      id="Fact_44d27e0975be4d349e207d0ca197ee35"
      unitRef="U004">1.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20230630"
      decimals="4"
      id="Fact_d5f0ae6c7d094d89abdc1dd86599a510"
      unitRef="U004">1.4207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220101to20220630"
      decimals="4"
      id="Fact_6ab92fa967b14da48fcc7c627ea135c8"
      unitRef="U004">0.9945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230401to20230630"
      decimals="4"
      id="Fact_59d9124c61bc42609d6c4611c95a3e26"
      unitRef="U004">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220401to20220630"
      decimals="4"
      id="Fact_557f9bc308874c248569cc6b28b54bfe"
      unitRef="U004">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230630"
      decimals="4"
      id="Fact_43e2d72d964944c18bd45ebd207c0768"
      unitRef="U004">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220101to20220630"
      decimals="4"
      id="Fact_919ecd621aee4bf3906f4083ce6aebe9"
      unitRef="U004">0.1162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230401to20230630"
      id="Fact_ae0d769dfb7c46c0a2c6fd32d3868da8">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220401to20220630"
      id="Fact_c7ce388f7aa04187a1b5c31b1d942e7f">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230630"
      id="Fact_9795525418994a909b9ff2640a9b1cc1">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220101to20220630"
      id="Fact_05e5e13f0028412c97448795dc42830a">P6Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_0b916db09fdb4bfcb9dfa50aef863d9b"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_9de147e8bc434cbfb98ed0ab852441bf"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20230630"
      decimals="INF"
      id="Fact_1130eb8f73844ad68fb38fb19e2774ad"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220101to20220630"
      decimals="INF"
      id="Fact_e1f396286da3426f9adcce13d005318b"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230401to20230630"
      decimals="2"
      id="Fact_0429d8254a4c43f4bcee8ed117a5f15a"
      unitRef="U003">5.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20220401to20220630"
      decimals="2"
      id="Fact_82974d763d714838b1758a1079ff13b4"
      unitRef="U003">4.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20230630"
      decimals="2"
      id="Fact_1d6a0dfca4d2439681ae8fa9575bd0db"
      unitRef="U003">10.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20220101to20220630"
      decimals="2"
      id="Fact_049480c93340494cb09b96c3a110dae2"
      unitRef="U003">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20230101to20230630"
      id="Text_eb6c618c5c0b416c89868fac25211833">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;
        &lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Number&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;of Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercise Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Life in Years&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Aggregate&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Intrinsic Value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Options outstanding at December 31, &lt;span style="text-indent: 0pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,171,311&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.56&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.89&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;10,839,589&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Granted&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;1,154,500&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;11.45&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;(1,409&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;)&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited











                      and expired&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"&gt;&lt;/div&gt;
                &lt;/div&gt;
                &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;-&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Options outstanding at &lt;span style="text-indent: 0pt;"&gt;June 30, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,324,402&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.85&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.86&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,645,635&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;June 30, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5,324,402&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.85&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;7.86&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;4,645,635&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;Exercisable at &lt;span style="text-indent: 0pt;"&gt;June 30, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,513,595&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;5.80&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;6.83&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;2,901,233&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_3f702781e54d4a21bb4b9874367ddf29"
      unitRef="U001">4171311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_d488481bd4a843319f1915a4bfc5ebfa"
      unitRef="U003">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_916b9188cb9b4f5684af7c22d52b9688">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_12b0af9dfba1472cb7475cf3044db61a"
      unitRef="U002">10839589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_034fb239226c4d6daf54ab757cfcebf8"
      unitRef="U001">1154500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_e128bc68be844aaabdcae176b4735a7d"
      unitRef="U003">11.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_df8be442f7cf4639a635d946128af093"
      unitRef="U001">1409</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_00f23f567714412c9913fd10cc942d94"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_33b492cd5fa245518ead294134745fd4"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_f71db9c488e6410ba97641f6b7c22c7a"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_e57e70350e6341a89552fdb264da75bf"
      unitRef="U001">5324402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_01997bc014a84730a449b915b6ba3e20"
      unitRef="U003">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_7394599f88db4274ac026041c3eb8df3">P7Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_412c709137544361b21b13986331f70f"
      unitRef="U002">4645635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_1a7e92d2784d467f8e6eb0a96de37e73"
      unitRef="U001">5324402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_73c12437374a427d9f419e694aa9c8db"
      unitRef="U003">6.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_b0421126f39f4a61bba4829bf44a02dd">P7Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_b982ed66ba114f7b8b119b7746fc6466"
      unitRef="U002">4645635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_3745190b2eaa466fb1a91b1568ec532d"
      unitRef="U001">2513595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_1f875c86f8e94af48bf98d7c9c2ec890"
      unitRef="U003">5.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_9f9c453b12cc4c7ba884fa4c783fe1a0">P6Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_b0d3f73e56fa488a8400a5b2081a4a6c"
      unitRef="U002">2901233</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20230630_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_d23196f2bf314ef8a3bed445f4c226ea"
      unitRef="U002">20357890</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_715625624e0a4104883daabd8a8e32f8">P2Y9M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20230101to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a08151dd523646558b36ea60af03aa78"
      unitRef="U001">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20230101to20230630"
      id="Text_cf221a3e72a14d25a9d9ea1dbd54aba0">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 8 &#x2013; Income Taxes&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative
            evidence to determine whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation
            of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for &lt;span style="font-size: 10pt;"&gt;2023&lt;/span&gt; and there will be &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;no&lt;/span&gt;
            current income tax expense.&#160; Additionally, there was a full valuation allowance against the net deferred tax assets as of &lt;span style="font-size: 10pt;"&gt;June 30, 2023&lt;/span&gt; and December 31, &lt;span style="font-size: 10pt;"&gt;2022&lt;/span&gt;. As
            such, the Company recorded &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;no&lt;/span&gt; income tax benefit due to realization uncertainties.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s U.S. statutory rate is 21%.
                The primary factor impacting the effective tax rate for the three and six months ended &lt;span style="font-size: 10pt;"&gt;June 30, 2023&lt;/span&gt; is the anticipated full year operating loss which will require full valuation allowances against any
                associated net deferred tax assets.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on
                their income tax returns. The Company has analyzed its tax positions and has concluded that as of &lt;span style="font-size: 10pt;"&gt;June 30, 2023&lt;/span&gt;, there were no uncertain positions. The Company&#x2019;s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax
                examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities.&#160; The Company did not have any unrecognized tax benefits and has not
                accrued any interest or penalties for the three and six months ended &lt;span style="font-size: 10pt;"&gt;June 30, 2023&lt;/span&gt; and for the year ended December 31, &lt;span style="font-size: 10pt;"&gt;2022.&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;In accordance with the State of New Jersey&#x2019;s Technology Business Tax Certificate Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate
                taxpayers, the Company sold New Jersey NOL carryforwards, resulting in the recognition of $1.4 million and $1.2 million of income tax benefit, net of transaction costs in the six months ended June 30, 2023 and 2022, respectively.&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_d8f0b467adf44d90b60abd0faec586a6"
      unitRef="U002">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20230101to20230630"
      decimals="-6"
      id="Fact_e24c1454b0114aa597343a4365f7c27f"
      unitRef="U002">0</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20230401to20230630"
      decimals="2"
      id="Fact_cd88beb9f3384d58ad79709cf420b32d"
      unitRef="U004">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20230101to20230630"
      decimals="2"
      id="Fact_7b581a49b7e4451d82f0da2b95aa113e"
      unitRef="U004">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <pdsb:LiabilityForUncertainTaxPositions
      contextRef="c20230630"
      decimals="0"
      id="Fact_43dba59874964f59a5f7a1e294a278f0"
      unitRef="U002">0</pdsb:LiabilityForUncertainTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20230630"
      decimals="0"
      id="Fact_4940c6399bb94cc5b57470a48b9b6541"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20221231"
      decimals="0"
      id="Fact_1edd5f463b1c4c98823494b409bacc15"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="c20230630"
      decimals="0"
      id="Fact_e376224a377649c3ade1bde193af77ec"
      unitRef="U002">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="c20221231"
      decimals="0"
      id="Fact_04ded47c584a4884a69584f606a92e03"
      unitRef="U002">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230101to20230630"
      decimals="-5"
      id="Fact_f082557fbb42418cbbec70af185140c0"
      unitRef="U002">-1400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220101to20220630"
      decimals="-5"
      id="Fact_40e0398831a442bf8c6acf6cc4bd9fb4"
      unitRef="U002">-1200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20230101to20230630"
      id="Text_52ee43536ad149dfb48cd95e38b71a8a">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 9 &#x2013; Commitments and Contingencies&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
    &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Rent&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and six months ended June 30, 2023 was $126,532 and $253,202 respectively, compared to the three and six months ended
          June 30, 2022 of $55,500 and $111,000.&lt;/span&gt;
      &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Exclusive License Agreement&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;In January 2023, we entered into an exclusive global license agreement
              with Merck KGaA, Darmstadt, Germany for the tumor targeting antibody conjugated IL-12, M9241 (the &#x201c;Merck KGaA License Agreement&#x201d;). Pursuant&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt; to the &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Merck KGaA License Agreement, the Company agreed to make (i) development&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt; and &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;first commercial sale milestone payments totaling up to $11 million upon
              the achievement&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt; of &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;certain milestones, including the dosing of the fifth patient
              in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up to $105 million upon achieving certain aggregate sales levels of the product.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company also agreed to pay Merck KGaA, Darmstadt, Germany a royalty of 10% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) ten years after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering
            the compound or product in such country. The royalty rate is subject to reduction in that event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or
            if the Company obtains a license to any intellectual property owned or controlled by a third-party which but for such license would be infringed by making, using or selling the compound.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt; &lt;span style="font-size: 10pt;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0pt; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;span style="text-decoration: underline;"&gt;Legal Proceedings&lt;/span&gt;&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;br/&gt;
    &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company is currently not a party to,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt; and the Company&#x2019;s&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; property is not currently the subject of,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; any &lt;span style="font-size: 10pt;"&gt;material &lt;/span&gt;pending &lt;span style="font-size: 10pt;"&gt;legal proceedings.&lt;/span&gt; The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary
          course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance.&lt;/span&gt;&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_58c91f5117114a64a70a283d9b3d280f"
      unitRef="U002">126532</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_714b0d4523de43cebaa19885e977dde9"
      unitRef="U002">253202</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_316e144192d5426f9315d1f4c78817ab"
      unitRef="U002">55500</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_fc64744c8f6d4e28b434a63542737b03"
      unitRef="U002">111000</us-gaap:OperatingLeaseCost>
    <pdsb:MilestonePaymentsDevelopmentAndFirstCommercialSales
      contextRef="c20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"
      decimals="-6"
      id="Fact_6c8a153768b04d3aa862d5eb13921d61"
      unitRef="U002">11000000</pdsb:MilestonePaymentsDevelopmentAndFirstCommercialSales>
    <pdsb:MilestonePaymentsAchievementOfCertainAggregateSalesLevels
      contextRef="c20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember_RangeAxis_MaximumMember"
      decimals="-6"
      id="Fact_6647c44b57144fdf8c48b6bd82309b45"
      unitRef="U002">105000000</pdsb:MilestonePaymentsAchievementOfCertainAggregateSalesLevels>
    <pdsb:RoyaltyPercentagePaidOnNetSalesOfProduct
      contextRef="c20230101to20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"
      decimals="2"
      id="Fact_4e625d5bf46f4a52bf9ba598673aac3d"
      unitRef="U004">0.10</pdsb:RoyaltyPercentagePaidOnNetSalesOfProduct>
    <pdsb:TermOfRoyaltyPayment
      contextRef="c20230101to20230630_OtherCommitmentsAxis_MerckKGaALicenseAgreementMember"
      id="Fact_eda6f8dbfe1a4d75a883a54c96f7e92c">P10Y</pdsb:TermOfRoyaltyPayment>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="c20230101to20230630"
      id="Text_1e66b360307945beae775da6db05f15a">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"&gt;Note 10 &#x2013; Venture Loan and Security Agreement&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In August&#160; 2022, the Company entered into a Venture Loan and Security Agreement (the &#x201c;Loan and Security Agreement&#x201d;) with Horizon
            Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the &#x201c;Collateral Agent&#x201d;), and the other persons party thereto from time to time as lenders (&#x201c;Lenders&#x201d;).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Term Loan Amounts&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;. The Loan and Security Agreement provides for the following six (6) separate and independent term loans: (a) a term loan in the amount of $7,500,000
            (&#x201c;Loan A&#x201d;), (b) a term loan in the amount of $10,000,000 (&#x201c;Loan B&#x201d;), (c) a term loan in the amount of $3,750,000 (&#x201c;Loan C&#x201d;), (d) a term loan in the amount of $3,750,000
            (&#x201c;Loan D&#x201d;), (e) a term loan in the amount of $5,000,000 (&#x201c;Loan E&#x201d;), and (f) a term loan in the amount of $5,000,000 (&#x201c;Loan F&#x201d;) (with each of Loan A, Loan B, Loan C, Loan D, Loan E, and Loan F, individually a &#x201c;Loan&#x201d; and, collectively, the &#x201c;Loans&#x201d;). &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Loan A, Loan B, Loan C, and Loan D were
            delivered to the Company on August 24, 2022. Loan E and Loan F are uncommitted Loans that could have been advanced by the Lenders upon the Parties agreement prior to July 31, 2023 upon the satisfaction by the Company of certain agreed upon
            conditions&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;. The Parties are in
              discussion to extend this option&lt;/span&gt;, however, there is no guarantee that such an option will be extended on terms favorable to the Company or its existing stockholders, or at all. The Company may only use the proceeds of the Loans for
            working capital or general corporate purposes.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-style: normal; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: italic;"&gt;Maturity&lt;/span&gt;. Each Loan matures on the 48
                month anniversary following the applicable date on which a Loan is made to or on account of the &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Company &lt;/span&gt;under the Loan and Security Agreement (the &#x201c;Maturity Date&#x201d;) unless accelerated pursuant to agreed upon events of default. All amounts outstanding under each Loan will be due and payable upon
                the earlier of the Maturity Date or the acceleration of the loans and commitments upon an event of default.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Interest Rate&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;. The principal balance of each Loan bears a floating interest. The interest rate is calculated initially and, thereafter, each calendar month as the sum of (a) the per annum rate of interest from time to time published in The Wall
            Street Journal as contemplated by the Loan and Security Agreement, or any successor publication thereto, as the &#x201c;prime rate&#x201d; then in effect, plus (b) 5.75%;
            provided that, in the event such rate of interest is less than 4.00%, such rate shall be deemed to be 4.00% for purposes of calculating the interest rate. Interest is payable on a monthly basis based on each Loan principal amount outstanding the
            preceding month.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Amortization.&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;&#160;Each Loan shall commence amortization upon the date set forth on the promissory note executed in connection with the respective Loan, upon which the &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Company &lt;/span&gt;is required to commence making equal payments of principal plus accrued interest on the outstanding principal amount of the respect Loan
            (the &#x201c;Loan Amortization Date&#x201d;), and continuing thereafter on the first business day of each calendar month through the Maturity Date.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Prepayment Premium.&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;&#160;The &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Company &lt;/span&gt;may, at its option upon at least ten (10) business days&#x2019; written
            notice to the Lenders, prepay all (and not less than all) of the outstanding Loan by simultaneously paying to each Lender an amount equal to (i) any accrued and unpaid interest on the outstanding principal balance of the Loans; plus (ii) an
            amount equal to (A) if such Loan is prepaid on or before the Loan Amortization Date applicable to such Loan, three percent (3%) of the then outstanding principal balance of such Loan, (B) if such Loan is prepaid after the Loan Amortization Date applicable to such Loan,
            but on or before the date that is twelve (12) months after such Loan Amortization Date, two percent (2%) of the then outstanding principal balance of
            such Loan, or (C) if such Loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated
            Maturity Date applicable to such Loan, one percent (1%) of the then outstanding principal balance of such Loan;&#160;&lt;span style="font-style: italic;"&gt;plus&lt;/span&gt;&#160;(iii) the outstanding principal balance of such Loan;&#160;&lt;span style="font-style: italic;"&gt;plus&lt;/span&gt;&#160;(iv) all other sums, if any, that shall have become due and payable hereunder.&#160; No prepayment premium will be
            applied to any outstanding balance of any Loan paid on the stated Maturity Date.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 36pt; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Security&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; The Company&#x2019;s obligations are secured by a security interest in all of the assets of the Company, subject
            to limited exceptions and excluding the Company&#x2019;s intellectual property. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Covenants; Representations and Warranties; Other Provisions&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;. The Loan and Security Agreement contains customary representations, warranties and covenants, including
            covenants by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with
            affiliates, and fundamental changes.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Default Provisions&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;. The Loan and Security Agreement provides for events of default customary for term loans of this type, including but not limited to non-payment,
            breaches or defaults in the performance of covenants, insolvency, and bankruptcy by and/or of the Company.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Warrant and Debt Discount.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; In connection with the Loan and Security Agreement, the Company issued Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP warrants to purchase an aggregate total of 381,625 shares of the Company&#x2019;s common stock at an initial exercise price of $3.6685 per share. Each warrant is classified as equity and is exercisable at any time for a period beginning on the date of grant and ending on the earlier of (A) 10 years from the date of grant, and (B) the closing of (A) (i) the sale, lease, exchange, conveyance or other disposition of all or
                substantially all of the Company&#x2019;s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other
                reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of, in
                each case, for cash or for marketable securities meeting certain requirements as described in the applicable warrants.&#160; The key assumptions used in the Black-Scholes option pricing model were (i) expected term of &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;10&lt;/span&gt;
                years, (ii) a risk-free rate of &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;3.11%&lt;/span&gt;, (iii) expected volatility of &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;93.8%&lt;/span&gt;, (iv) and &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;no&lt;/span&gt; estimated dividend
                yield. In addition, the Company incurred third party and lender fees of $&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;449,329&lt;/span&gt;. These proceeds were allocated on a basis that approximates the relative fair value method. The fair value of the warrant and
                fees incurred were recorded as a debt discount and are being recognized as interest expense over the life of the loan and Security Agreement using the effective interest method. The unamortized debt discount was $&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;2,683,133&lt;/span&gt;
                as of June 30, 2023. The Company recognized interest expense of $961,753 and $1,952,272 for the three and six months ended June 30, 2023 and $121,997
                and $233,523 was related to the amortization of the debt discount for the three and six months ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
    <pdsb:DebtInstrumentNumberOfIndependentTermLoans
      contextRef="c20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_b4288d79394e4b8bbc04e218fed29b4d"
      unitRef="U005">6</pdsb:DebtInstrumentNumberOfIndependentTermLoans>
    <pdsb:DebtInstrumentNumberOfIndependentTermLoans
      contextRef="c20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="0"
      id="Fact_eb479d054ea348f895be6727c535fafe"
      unitRef="U005">6</pdsb:DebtInstrumentNumberOfIndependentTermLoans>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanAMember"
      decimals="0"
      id="Fact_daa9499244cb4090ae838ff6babe3541"
      unitRef="U002">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanBMember"
      decimals="0"
      id="Fact_2b548ee4eede4a879c7c04f7cd5b63a6"
      unitRef="U002">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanCMember"
      decimals="0"
      id="Fact_28a833a97a67442b9e4982bfce4e6742"
      unitRef="U002">3750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20220831_DebtInstrumentAxis_LoanDMember"
      decimals="0"
      id="Fact_cc0e1014ea4d48898293808a00fc26ce"
      unitRef="U002">3750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="c20230630_DebtInstrumentAxis_LoanEMember"
      decimals="0"
      id="Fact_ae27211e10e7485aa206f938854851f6"
      unitRef="U002">5000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="c20230630_DebtInstrumentAxis_LoanFMember"
      decimals="0"
      id="Fact_5f4cb663441948e4933f91c387f06a68"
      unitRef="U002">5000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_cb356b7f9f1e43c9a668191eb3667d49">P48M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_VariableRateAxis_PrimeRateMember"
      decimals="4"
      id="Fact_7bf38196e5c64ccfb3a32e29cbf31a4b"
      unitRef="U004">0.0575</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <pdsb:DebtInstrumentVariableRate
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_28c9de20f6074d78b26a5311a5f14606"
      unitRef="U004">0.04</pdsb:DebtInstrumentVariableRate>
    <pdsb:DebtInstrumentVariableRate
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_5d89cd7c2f9c4c27918c4dcafc3cf6f1"
      unitRef="U004">0.04</pdsb:DebtInstrumentVariableRate>
    <pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember_RangeAxis_MinimumMember"
      id="Fact_19ca51bd48314e528009035770771c23">P10D</pdsb:DebtInstrumentWrittenNoticePeriodForPrepayment>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod1
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_59d21217a3f848f5b1d4ece3294185b4"
      unitRef="U004">0.03</pdsb:DebtInstrumentPrepaymentPremiumPeriod1>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod1
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_0e712b060e2548d2a2df5ec30e5df02f"
      unitRef="U004">0.03</pdsb:DebtInstrumentPrepaymentPremiumPeriod1>
    <pdsb:DebtInstrumentThresholdPeriod
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_175403ef47354e86a6239bb14b4cf8bd">P12M</pdsb:DebtInstrumentThresholdPeriod>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod2
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_7938634d7b654b748686a03d2ec197f4"
      unitRef="U004">0.02</pdsb:DebtInstrumentPrepaymentPremiumPeriod2>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod2
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_5d26db88ee874918958288b7f8e3ea6a"
      unitRef="U004">0.02</pdsb:DebtInstrumentPrepaymentPremiumPeriod2>
    <pdsb:DebtInstrumentThresholdPeriod
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      id="Fact_431ce041343f4208b4002dd64b68ae48">P12M</pdsb:DebtInstrumentThresholdPeriod>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod3
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_2d53c11949b14cbab4cc99b077859e98"
      unitRef="U004">0.01</pdsb:DebtInstrumentPrepaymentPremiumPeriod3>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod3
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="2"
      id="Fact_d3c7f13d9dea4be5b67967164b502bfd"
      unitRef="U004">0.01</pdsb:DebtInstrumentPrepaymentPremiumPeriod3>
    <pdsb:DebtInstrumentPrepaymentPremiumPeriod4
      contextRef="c20230101to20230630_DebtInstrumentAxis_TermLoansMember"
      decimals="INF"
      id="Fact_90b3a702eef249b19e1fc789332ecc3b"
      unitRef="U004">0</pdsb:DebtInstrumentPrepaymentPremiumPeriod4>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220831"
      decimals="0"
      id="Fact_cd92ebbd9e654428bf02a837e4073f77"
      unitRef="U001">381625</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220831"
      decimals="4"
      id="Fact_1bc5fa7e5e6742378239c390a34d79dc"
      unitRef="U003">3.6685</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20230630"
      id="Fact_cd5b4714dbc14475a04329fef277d105">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <pdsb:PercentageOfVotingPowerDisposedOff
      contextRef="c20230101to20230630_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_ad735a00a7d64950b9e3dffe81ff2901"
      unitRef="U004">0.50</pdsb:PercentageOfVotingPowerDisposedOff>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20230630_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_327536ddf17e4a22907d3062ad12cc95">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c20230630_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="Fact_f7e4fb5f4d81402eac7783521bb74843"
      unitRef="U004">0.0311</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c20230630_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="Fact_3ccd525f02074ad2b298115a72513f7d"
      unitRef="U004">0.938</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c20230630_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="0"
      id="Fact_377cccf854e74319970a5a20f38f30dc"
      unitRef="U004">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_9f2ce7ab0b094ac0a804fd0423bf4296"
      unitRef="U002">449329</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20230630"
      decimals="0"
      id="Fact_22e5aeecae90431d8ecdb886b081e229"
      unitRef="U002">2683133</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_aad3cce66c294bc7938d7848aa02c0db"
      unitRef="U002">961753</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_a4010d81c23f4ba28c2921192ccd56ab"
      unitRef="U002">1952272</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_774f658b20d341819303fd70f11a592d"
      unitRef="U002">121997</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_9bf2477ebefe4dc7baddf7127a21ce81"
      unitRef="U002">233523</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="c20230101to20230630"
      id="Text_a6cabaaa720442fdb8bc1481eada5813">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Note 11 &#x2013; Retirement Plan&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; background-color: rgb(255, 255, 255); font-style: normal; font-variant: normal; text-transform: none;"&gt;The
                Company has a 401(k) defined contribution plan for the benefit for all employees and permits voluntary contributions by employees subject to IRS-imposed limitations. The 401(k) employer contributions were $36,863 and $131,769 for the three
                and six months ended June 30, 2023, respectively, compared to the three and six months ended June 30, 2022 of $37,776 and $157,009 respectively&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20230401to20230630"
      decimals="0"
      id="Fact_76fa5ff00efb402bbe9337bbed435d52"
      unitRef="U002">36863</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20230101to20230630"
      decimals="0"
      id="Fact_c9e49b0572964df19e0d469b984eb8e6"
      unitRef="U002">131769</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20220401to20220630"
      decimals="0"
      id="Fact_4bc6ef137f38467f9704d319a210202b"
      unitRef="U002">37776</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20220101to20220630"
      decimals="0"
      id="Fact_22cc143fb9cb45bf82f9e69bf858d188"
      unitRef="U002">157009</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="c20230401to20230630"
      id="Fact_3c223fd2197d4bb48e9b4a2fb383457a">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="c20230401to20230630"
      id="Fact_0c9e33be4c1b4c6e97a6cd5dcc42424f">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="c20230401to20230630"
      id="Fact_3e9cf043c3bf451abee910aed088a622">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="c20230401to20230630"
      id="Fact_27be61a61f9b4920a9793e636adc5f76">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MSWOP>5D<(A<W2B3Y.>Q,*"6B_'+)F<^E?@%^GPNA=C?Z ^51_O _4$L#!!0
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M<N_KI&E;/M!3RH>]%%D?[Y-="+OW%_ZFQ2/9T[5,]J[5W)WFGUS?RM( ]ZQ
M%9_'8$EOKPFW ZLV]4W;0EFKBOIQ+3A =P+P?J6 >G<#=WG77-;._@=02P,$
M%     @ 7&D.5S"9X\.E @  70<  !@   !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6RM56M/VS 4_2M6-FT@L>;5IA5K(XW"!'N(CL*F?33);6/AV)GMM&R_
M?M=)&K4L0)'6#XVO?<_Q.7Y<C]=2W>D,P)#[G L]<3)CBF/7U4D&.=4]68#
MD854.348JJ6K"P4TK4 Y=P//B]R<,N'$XZIOIN*Q+ UG F:*Z#+/J?I] ERN
M)X[O;#JNV#(SML.-QP5=PAS,33%3&+DM2\IR$)I)010L)LX'_W@:V?PJX3N#
MM=YJ$^OD5LH[&URD$\>S@H!#8BP#Q<\*IL"Y)4(9OQI.IYW2 K?;&_:/E7?T
M<DLU3"7_P5*339R10U)8T)*;*[D^A\;/P/(EDNOJGZSKW&CHD*341N8-&!7D
M3-1?>M^LPQ; [S\""!I L"\@; !A9;165MDZI8;&8R771-EL9+.-:FTJ-+IA
MPN[BW"@<98@S\52*%/<$4H(M+3E+J<'@A'(J$B!S2ZS)P8PJ$"8#PQ+*#\D[
M\IJX1&?8J\>N01V6S4V:.4_J.8-'YOQ4BAX)O2,2>$'8 9\^#3^%!.%^!0]V
MX2ZZ;Y<@:)<@J/C"1_CFUY?3S^>77T[/KN9OR=FWFXOKGUVF:I9^-XN];<>Z
MH E,'+Q.&M0*G/C-*S_RWG=9_$]D.X;#UG#X%#ON>9[C#<*SE=P=D8(JLJ*\
M!'+ !$DEYU1I4H"J]_>P:REJ_F'%;^O$*O9ZGN>%N)NK;9?/Y^T8Z+<&^B\P
M4!]#0DN32<7^X.FU1NK>3O4U^6!+U7#@5;\'\O=(W-$_:/4/7JZ?:5T^KWWP
MCZ30&T4C?S1ZH+TKT1]ZH3_LUAZUVJ.]M6^DX^N@#14I$\OG]$?[ZN]*[-3O
M;A4_^_!\I6K)A"8<%@CU>D/D4'4QKP,CBZH>WDJ#U;5J9OC^@;().+Z0TFP"
M6V+;%S7^"U!+ P04    " !<:0Y7K[\$W)<%  "(&0  &    'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;*U9VW+;-A#]%8S:Z20SC@6 X,VU-1-;:IM.TWKB
MIGFF1<CBA"14 I+=O^_R(DH$EXS<R@\6+V?/8L\NP"5X_:R*KWHMI2$O69KK
MF\G:F,W5=*J7:YE%^E)M9 YW5JK((@.GQ=-4;PH9Q951EDXYI=XTBY)\,KNN
MKMT7LVNU-6F2R_N"Z&V61<4_MS)5SS<3-ME?^)0\K4UY83J[WD1/\D&:SYO[
M LZF+4N<9#+7B<I)(5<WD_?L:L%I:5 A_DKDLSXZ)F4HCTI]+4\^Q#<36HY(
MIG)I2HH(?G;R3J9IR03C^+LAG;0^2\/CXSW[3U7P$,QCI.6=2K\DL5G?3(()
MB>4JVJ;FDWK^138!N27?4J6Z^D^>&RR=D.56&Y4UQC""+,GKW^BE$>+( 'AP
M ]X8<-M #!@XC8%SJ@?1&(A3/;B-017ZM(Z]$FX>F6AV7:AG4I1H8"L/*O4K
M:] KR<M">3 %W$W SLSN5!Y#VF5,X$BK-(DC R</!GZ@'HPF:D7^V,@B*O.J
M2927R R*<EU6RTZ2WY36Y!WY_# G;[Y_>STU,*J2>[IL1G!;CX /C, A'U5N
MUIHL8"0Q8C\?M_=&[*>@1BL)WTMRRT<)?]WFE\2A%X13[B#CN3O=G&/A_#_O
MB__LO2.&T]:'4_$Y WQ-ZO,G(E\V9:'H*RS%-8G 2<K%[DIOHJ6\F4#A:%GL
MY&3VPW?,HS]B^IZ3;'Y.LL69R#J9$&TFQ!C[[!,P1L5R74W!6.Y@C=^4,[1-
M#):7FM*K*,MGQFX64"H"%TIC=RQY'^?X'O.$U\7-^SCF!,#G!%W@ G$<<AYZ
MK,5U1'!;$=Q1$7Z6.=1C6FD0Q; >)MJ4]0GKT)@,-:E[-!KAA<SAS)*ACW,<
MA\$SUY*ACPNX#\*&E@I]G.>) #SC*GBM"MZH"G\J QJHWM3$0O=Z0V#<@SSX
MCA5['^C3D'MVJ<S[.,X9"]S MX)'/+NNSP)?X-'[;?3^:/35 V=5J&RO #R7
ML,C]GO]W Z$C2#QV!#@0/.9\-/J@C3X879 _Y$;"XF)(DB]5)LF;??+?7I!<
M&DR(X)R+\SG)YN<D6YR)K).5L,U*.%J35E:P+(3]^>52SQ56+2(PX0JKO.9]
M%!-^&(:N589]7$#Y$5LG6$8/32,]+=RF^-"NC_:G  S0":U8[A @M<+%N%CH
M<2ZL&;H8)>M&>]0BL]<D]Y0IUS!V5PHA?&$O/0@0RS?&)P+.;> " 8YEG!\T
MX-]>=!\EO)G*O0PF>L$?.0V5M?*&@H;,L\-'H#YE :.NK0""Y-RC-'"$K0'F
MWQ7@G0_I<&B'V6B/-[N%!F25& )"?%L'!YFEU*.]M@,#LC (^R*<R+@X@;$K
MP*$+9>-MZ._2D!2* 0U8(,(SUX&6Q[5#1J!NP$).>W,?0<(S-Q0!<^RH,?^"
MA]SG?"#N0^/)QCO/[DOOH )NK^\=5 "!#BB ((<4P/R/*W!H.IDWVGG<RX+H
M=50M /4.%71>Z-L@&VU?7]MQG)5M?E:VQ;G8NBDY=,)LO!7>3T:RV>?FHMPV
M2Y;D39*36*5I5!S=Q'=G:A?!<<G02Z?WE*YA81=F-\@XF1>$G3^[:%'JH97J
MT"BST8X/%2=.TFVYO_4*>8+3Y E.D@<E^Y8\*/60/(>.E8VWK%^J/530(MK!
M6]23)/ PRU1>2Z&)VAIMX#4;WB^/:ZJ^BRO5;S8=6C8?86"+U4?R0+C,]4-;
M,(S38QZ\E-LJX9R4T8$7+G[H=OEXM_L:I8X+;$0KWF]3![1"D -:H9RH5@.<
MB%;3HYWE3!9/U9:^!@&VN:DW$=NK[6>#]]5FN77]EEW=,>3ZG%TMZH\"!_KZ
M&\7'J'A*<DU2N0)7]-*'X1;UMG]]8M2FVM=^5,:HK#I<RRB610F ^RNES/ZD
M=-!^?)G]"U!+ P04    " !<:0Y755XVI2<*  !24@  &    'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;+U<:V_;.!;]*X)WL#L%FEI\Z=%- K2V%ML%9E T
M.[L?!OM!M95$J&QE)+GI_/NE9,<T>2E*<F[2#XT?EX?DX>L>WFM=/I;5M_H^
MRQKOQZ;8UE>S^Z9Y>#^?UZO[;)/6[\J';"N_N2VK3=K(M]7=O'ZHLG3=%=H4
M<^K[P7R3YMO9]67WV>?J^K+<-46^S3Y77KW;;-+JSX]943Y>S<CLZ8,O^=U]
MTWXPO[Y\2.^RFZSY[>%S)=_-CRCK?)-MZ[S<>E5V>S7[0-XG05>@L_A/GCW6
M)Z^]MBM?R_);^^;3^FKFMRW*BFS5M!"I_/,]6V1%T2+)=OQQ )T=ZVP+GKY^
M0O]'UWG9F:]IG2W*XK_YNKF_FD4S;YW=IKNB^5(^_C,[=$BT>*NRJ+O_O<>]
M;1C/O-6N;LK-H;!LP2;?[O^F/PY$G!2@M*< /12@1@$6]!1@AP+,K*&O2?Q0
M@!L%".LI( X%NJ[/]WWOB%NF37I]696/7M5:2[3V1<=^5UKRE6_;B7+35/+;
M7)9KKA?E=BV'/5M[\E5=%ODZ;>2;FT;^D?.AJ;WRUEO<I]N[K/;RK?RB7'V[
M+XMU5M5_\Y(_=GGSIW?A_7:S]'[^Z<WEO)%M:I'GJT/]'_?UT][Z-YOR .O]
M_DNV^9I5_[/ +-PP'];KO)UX:>%]3O/UA6SI(GW(&_G> ;H< %VM=IM=T1&R
MS&[S5=ZXT!(WVK]+V1J]V%P.UG'$Z''$:(?#>W ^ID6Z765>VLA&K=YYC+SU
MJ$^)C?L]4M AM5O&]^N81>'E_/LIL]"(4!;[//"I;KF$EA>!'_I,!(9E BT#
M1HG/J:I<ZSP[=IZ-ZOS/<H#K^[3*ZC>CB-BCBI/VT(CS*"!&PQ?.ZMM=^WW]
MD*ZRJYG<ENNL^I[-KO_Z%Q+X?[=-+TRP! E,HYT?:><=.NNA_=-V)4^A6O(N
MF>Y>O>G=#'[_4A:%)W?QQ[1:V];)1XY(RP(3;(D)EB"!:0,FC@,FG.MDOY^V
M)^C:6Y4;Z5;4:7<P9S_:UYEM6 18L[ZQ. 181830* Z9L4] .P,I&4;2NAT<
MNQTXN_VIKG?M_M"=6JO]T5*W5+SU;JMR(WN?5:M<SF/Y=?>Y5SZTM-0V/@*X
M+QI\!* 7(3>WUR4T,LFPPD1V)L(C$^'+,'&ZM=I8">%.2B-S%W6V;>JBQ 1+
MD,"T,8F.8Q(YQ^17Z?<796V=;-'@XHN&YM$26EQ$/&2"FJ?S"$.M@_&Q@_%8
MU^27M#J>R-36X=CFFD1&GV.X35#A<^*;#L<26EX$,0E#/^)&YZ&E$%'(6!#8
M.T]\Y4K[YS@G@U0<8 WO1/A1;+1]X6[ U(6%BI9@H>GDG^@8@N86'Z &_.*#
ME3[[[(ZQQ;3/,[:8NEUCHH0!&:<,ICK'!]@1WK&[ 9/G'R9:@H6FDZ^$"6&O
MZ"(33.FP0$5;HJ(E6&CZL"EA0YQNN/-,=A>=/ BH2@45+3F@:?L7X32F89]+
M0)02(6XI<K(Q_VNWE3N1[S@)H0:)66RZW<2B'FC "94GIKDQ0].+D,=Q0(%?
M8#$5D@-!XC['0*D2XI8E/1OS,!U0&;2.010 1\G=@,F3"Q,MP4+3R5="B+B5
MT"3'(!SE&$ -U.L80-->QP#6/> 8*-U!W,+C;,< "H4^Q\#9@,GS#Q,MP4+3
MR5>:B,2OZ1@X%=CD,PD3;8F*EF"AZ9?L2LQ1MYCKO4#9WY\T]YEWDQ;RZP]W
M5=:%2MYZ6^E,#%R?N&N=.GZH:$M4M(1"52MWR8B?'.?ZT"BI1\^2>M8CE%JD
M7BP"8_NB%JG'A1 ^-YV/I<7T@OA$B(@3XZ!(+)5S[OO49WX/!R=!H&=K/3L?
M4.LQG\@#R6S\PMV R7,+5>MAH>GD*ZU'QT6AQESN'* &+KHH#%#UW7193/NN
MNBRF[KLNJG03=>NF<^^Z*%0:/7==[@9,GG^H>@D+32=?22HJ7M&EH$[]-OE(
MPD1;HJ(E6&CZL"D92-TR\)R@'(51*#,P0*%*)$PZZ3XXNH9#42.P],XK&49?
M*"!E905J)6:R8@M4<1J8G$ SP(D=*>YA1*DRZE9E+Q:BHU"VA2'<7U$E&RI:
M@H6FCXR2;-0=QW)="E(8N (+$H:8S%"=Q>1"1"2F/IA](RSU5!HE<=BX>-68
MJZ@#U,#-'+/Y_/:;.8MIW\V<Q=1],\>4E&#CI,34FSD&54#/S9R[ 9,SBC#1
M$BPTG7RE8=A9F6QVPBVI;%#',:AN^G2<Q;17QUELW3J.G>2S/3NAS<X'=.U[
M=)R[ 9,G(&Y.VTL$?Y@2,>PUT]H8:K@(%6V)BI9@H>G#IN0/PT]N8\/9;0P&
M@.2Y)5<4.+J&\]M&8.F=5R*"G9GBYKZ7M')BR7"+3#^:044@S[F(,<#*L+KH
MP>K-.V)*7; SU<7S;FL9=/V%8#0&)*$FO*&B)5AH^L@HE</.3WICPUEO;#CM
MS6)R$0<BCDEDSK\1EGHWE61@9Z6^,6NWH820GH>YH!;,DOTFEPJ)"0=KSR(2
M""%4+F<F3!*@+9?5^['H2;[E2E#P9R? 60GAT,%G?DA90,SIX&[ Y'1OU( '
M%II.OI(R'"\JPD=%1?CXJ(C%M->;ME3N]J:Y4A3\9:(B?'14Q-V R1,0-2J"
MA::3KZ0,?\T,.(Z: 8>*MD1%2[#0]&$[^6F/.Y+SY#I!SZFLY ?;>E<T^?;.
M2Y\\IR&GB<,0#_';?^92POWI#NYO=UY"X7"E<+A;X;R0.^NN=?*:0HWTH*(E
MW)+,%P<\Z!$:7,DO[I9?+G?6770RO:@I?:AH"8?*\8(2$O.(]#F12LKQT?EZ
MI]>P=L<1QH&DUP'N8+DE84\($DD7$S@REH0]0FDH51\SY:S%EE'..8EZ5#Y7
MJHF?E;$W3 A4.,R/@LC""6KX!Q4MP4+3R5=:CN-I.3Y.R_'Q6LYBVJOE++9N
M+2>4EA,OH^7$:"WG;L#4&8B*EF"AZ>0K+2?(*[K2 C-HM$!%6Z*B)5AH^K I
M^2G<\O.L7UW#P!98*);?9Q%?"&;LZ4N+(?CA]3"6WGDE_X0[DH6:X"%@UIP9
M:Q8P A9%'% "K0 E5J">(UPH727&Z2KT] YAT5?<-T\<=^LF+U-4=86%IH_,
MR;,1QJFKT8K7.@HPH,3,L(" *B3PXS@P'Q%@L0.3U )%-%&MDZ$$C1@73T*3
M_\*20F:3_^YV39Z@J/H&"TT?$R6!Q(M$LZRC85%(9B:8L"2X<192TS.UV(%I
M"JMKH7B?.ZH$D3@S6>YY-R("ZB7.2  V4U2QA(J6#'9!9URI('%^$IP83H(3
MPTEP%A.I= 3C46P*'4N%T%1_9(Q2.L%9:7!6=1/ -#C;A8/-K.?"P6+:>^%@
ML75?. 1*<03/3H2S$P(#/ST7#NX&3%U#J&@)%MJ>_/G)X_C:IRU*S7R72[^N
MR&XEO/\NE&Q5^P<8[M\TY4/WA+ZO9=.4F^[E?99*E=<:R.]OR[)Y>M,^]._X
M&,GK_P-02P,$%     @ 7&D.5YP\O"HW"   5SX  !@   !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6RUFW^/H[86AK\*2J^J5NILL/D]G8DT$R#92MN..NJ]
M?SO@)'0)3H',[/;3UP8F!.-XD]LS6FF'D',>&_SFV+S W2LK/U=;2FOCRRXO
MJOO)MJ[WM]-IE6SICE0?V)X6_)LU*W>DYA_+S;3:EY2D3=(NGV+3=*<[DA63
MV5VS[ZF<W;%#G6<%?2J-ZK#;D?+K(\W9Z_T$3=YV_)YMMK78,9W=[<F&/M/Z
MC_U3R3]-CY0TV]&BREAAE'1]/WE MTOLB80FXK\9?:U.M@UQ*"O&/HL/']/[
MB2EZ1'.:U )!^)\7.J=Y+DB\'W]UT,FQ39%XNOU&CYN#YP>S(A6=L_Q_65IO
M[R?^Q$CIFASR^G?VNJ3= 3F"E["\:OXW7MM8SYT8R:&JV:Y+YCW8947[EWSI
M3L1) N>H$W"7@.4$^TR"U258ER;878)]:8+3)3B7'H/;);B7MN!U"9Z<<.ZT
M^EV"WXQN.QS-6(:D)K.[DKT:I8CF-+'1"*+)YD.8%4*[SW7)O\UX7CV;LR+E
M2J2IP;<JEF<IJ?F'YYK_X1*M*X.MC3FIMD;,95X9-\8?SZ'QPW]^O)O6O'D!
MF29=4X]M4_A,4Y;QB17UMC(BWF2JR(_U^>ZW\I?Z?(0U@"D_;\>3A]].WB/6
M$G\Y%!\,R_S)P":V%!V:Z],_D9*GH[/IX>6M8T5Z='GKJO3XWQW[XM]U?JE/
M#VERKO.#D;2./P.KX5GG?@9"X>M&X>N2[0P^-Y2DSHI-6URS.J/5K4KR+=96
M8\7$<UOM24+O)WQFJ6CY0B>S[[]#KOFS2BZ0L! 2%D'"8DC8 A*V!((-)&@?
M)6CKZ+-?^4(E9U6E4EF;Z3:98C7R,KM!R+%L/W#NIB^G$E)$!JX3!,@?!H:*
M0,=' 5_S# ,C1:!O>Y8C?G>G@;$B$",4V#ZRAI$+U>'8.,">S%QJ3]G_.2#.
M<4 <;4UX2/_D\V\["=:,+]025B193HVB&RFQ5VPGHG@<Q!R:%9=7#@>R<D#"
M0DA8! F+(6$+2-@2"#80JGL4JJNM',\U2S[?B!5\:B1LQR]K*M)<&- O8INJ
MU*<E7JL^2%@("8L@87$+<T[*EHU\QW<\J;R-X[#M>8YG2\4-J',#S7A'S7A:
MS7RLJ@,I$BJ6]]66\ 9$\>(5KN(7?4WUVI2TN0)0J4?+OE8]D+ 0$A9!PF)O
MK K7,^7I=C$.DR*60+T:R,8_RL;7RN9AQ\HZ^[LM+UPZ*5W51II5"3NHE>*/
M#@=A% 323V:N;?5:#4#"(DA8/#X;V.(K*7E]- Z3-0#4JX$&@J,& JT&0LJA
M2?;-*49+N;9(0,)"2%@$"8N#T<A[?H D>8R#?%?2!U"G!OI 9N\IF5J%_'9<
M ^>4KTIT(M&3KE4)*"T$I46@M+BC#0NKZ2!IC;&X,&X)U;NA8DY<2*153)P5
MS6JDU4MZ88710Z\6#R0M!*5%H+2XHPWF(=/%\CI6$2;/0U#]&LH&][+!>MMN
M2XI-NW0E547YA3HI4B//R"K+SU]Y=U HV4#20E!:!$J+06D+4-H2BC848F\?
M(ZTU.'LJZ9YDZ5NQ:G7(ZBTM.V$J=0AJ'H/20E!:!$J+.]J@?'D>]K!<O\9Q
M-XA#+1O)9>P]C%_4.[](;_T^),WU4V7LR5>RRM5S'9 5VHD%DA:"TB)06MS1
M3D5@H<!Q94-\H0AT7-_Q?5DK[^%)H]Z41EHK46BE/-"^TBBU NHM@])"4%H$
M2HL[VJ!@V('E6;Y\A:Z(1,C!R)/%\AZ^,.J-8:1WAN4+L9.5D5(WH*XP*"T$
MI46@M!B-'=\;Y 7(<F79J *1Z\GZ6D+U;ZB;WAQ&>G?XUTON:BD5!.H,@])"
M4%H$2HO1V/:]0;YI6OR?K"%5*,:^Y[NCZO,>5C'JO6+D7_50Q;JYR+_@UBB"
M-%WGH+00E!:!TF)0V@*4MH2B#;78>]9(;UH_E2RA-.V42+_0,LFJ]NZ7N'O*
M"YPPF]0U#=3(!J6%H+0(E!8CA4_MVX%<SL91. C&"ZGW<+1Q[VACO:/]1+X>
MGX9<#[Q*MLJS#3DK'CWW6O& TD)06@1*B_'8M[ZQ+.S("W%%G.Q10G5L*)W>
MVL9Z:WM8>;*3^^X)V^U8T1:@GYHGB?C.8T#"*K5MA%7NK3FZDSS7]^MJL8#Z
MV:"T6'%&;-_"V'5DM7S;T>Y"3A]."X+AZ1T*H3>KL=:#[!?5^Y*]9"E?6*^^
M*M=$RD$']:Q!:2$H+0*EQ1UM* V3KY7EFZJ*0-4\!-6[H89ZGQGK?6:AH:Q(
MRF;J$0_L"#T)K[G9H'\=LA>2BXE*J2%0OQF4%H+2(E!:C%4^LC 1D2NO9I2A
M&#M>X(P*S7MXSKCWG+'><YZ?4XY!:F-%-UE1B*K$9R1^Z9\QU?L6C_HFKA:4
M/:J\GN5CD\=+SRZ#MALIVG4=;&-W](0S'EO$ZAXN%)%JYO*2R.$0]U8QUEO%
MVB&NM]2@XB:5=H"=\:DQ76P'\C,I<WU7KJX&XW8='/BV*]_CB4#;C?'8UE4?
M[T(1J>[A4G$L(]$,![BW=[&K-5B>#_M]WCRD27(^&[1O,G9/YAUGAH(5-\V'
MNB1%19I7!M6V"P:U?T%I(2@M J7%H+0%*&T)11LJM#>2L=Y(;DI0<V><BY-+
MM*:\%>6#HGK0U>(#=8Y!:1$H+>YHI^4%!7SRD.]Q+Q2!HR4)J%\\/7DK=4?+
M3?.&<F4TM[K;-_..>X]O03\T[_Y*^Q_1;804^V-TNVC?<>[Q[2O7GTC)%S"5
MD=,U;\K\X/$:7+9O,;<?:K9OWHE=L;IFNV9S2TE*2Q' OU\S5K]]$ T<WR6?
M_0-02P,$%     @ 7&D.5^!;:>">!0  R P  !@   !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6R55]MN%#D0?9^OL 8)@33W!(A(,A))=@5([$; PL-J'SS=
M-=U6W'9CNV=HOGY/N2_I24)V><FT+W5<=>I4V3G;6W?C<Z(@OA?:^/-Q'D+Y
M>C[W24Z%]#-;DL'*UKI"!@Q=-O>E(YE&HT+/5XO%RWDAE1FOS^+<M5N?V2IH
M9>C:"5\5A73U!6F[/Q\OQ]W$1Y7E@2?FZ[-29O2)PE_EM<-HWJ.DJB#CE37"
MT?9\_&;Y^N*8]\<-7Q3M_>!;<"0;:V]X\"X]'R_8(=*4!$:0^-G1)6G-0'#C
M6XLY[H]DP^%WA_Y[C!VQ;*2G2ZN_JC3DY^.3L4AI*RL=/MK]6VKC><%XB=4^
M_A7[9N_1:BR2R@=;M,;PH%"F^97?6QX&!B>+GQBL6H-5]+LY*'IY)8-<GSF[
M%XYW XT_8JC1&LXIPTGY%!Q6%>S"^@\9*D?";L6?)3G)3/FS>0 RK\^3%N6B
M05G]!.6E^&!-R+WXS:24'MK/X5'OUJISZV+U*.#[RLS$T6(B5HO5T2-X1WV8
M1Q'OZ!?"%'^_V?C@H(M_'HJX 3Q^&)!KY;4O94+G8Q2#)[>C\?KID^7+Q>DC
M[A[W[AX_AOZ_L_(?*#:06(JG3TY6R^6IN+[Z)"X4YI+<6&VS6EQ:5]H&?B*D
MN"(M]]+1*+F=%\]"3A%BM3B]M$4I31U' +2N6QA MXO/)T)Y8"9P2B523WU
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MKS1P8FZZ5L(R^N[8*)+(I >#?DW]8!M7QQ33@.'8ID6N"[,F0($%W3K ;JE
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M.H,2XI.5M2N4%>___H[T65E9"708UOP&.4#>F ;GM"N@X![O%+HDUPA@7UG
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MKJ$D-^T2&+^DJ0%I+I>H . (02, 1-<@QG0-%"L3P  8: -YQAFFCC</1JY
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MC<=%@5^N%8RWM "?%\;X[@T=T/\&Z.P_4$L#!!0    ( %QI#E<,%0D!*@,
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M$K]A7+B+61>[4XN9W)J:"[A31&^;AJG?*ZCE;NZ&[CYPSS>5L0%_,6O9!A[
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MP0'2F15.;% V ==+B2]B<.P&XW_ X@]02P,$%     @ 7&D.5WRP'$2W"@
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MF:8:J KI<**2F&R5Q*P#(8U8QX+RQHN*(VP;!@0A+%5Q.;6-T0>AP/)2 3^
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MX^K>4O3*S-ZJ8DH@5[*JJ=B_?;.(POE'_:H0^TY89Q#V3Z"*@+UIY!-D4&U
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M2F6R(I]L YI\X&S-!;<<S"G59WE/JSX4@^-BJB\F[HN14N$H&DM43?#,JY7
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MKO4A#L( ]/.2<_4T,>?$^+<@^P=02P,$%     @ 7&D.5Z0:C%RX!P  HUL
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MLCW.8&X(T6- CV L?GUC!]9O8_G629;H)$LUD?4JXW65\:;8V\JL566R\\I
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M0K:3Y>T&2 Q,&<CO*TK%X4$-T/R78OHO4$L#!!0    ( %QI#E<K9%E@/P@
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MY^,T^8&+Y)V3")C<UXE(@'=YJ16YULLAR0+WHI=#RH4#D;6\]&HO/:V7(<3
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M3C567D*4!4$/Q:%Y0X4\@A>/>\ R1:L&\OV64G$N*('Z*LC_#U!+ P04
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MXP9H"D(WP/<KSM6QH ,T-X33_P!02P,$%     @ 7&D.5\T1U:,-"@  _EP
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MZ\VVZP\RVU6[22\S*;.D^G4CPDCD^@#U]W66R?T'?8+#EN>+_P-02P,$%
M  @ 7&D.5[QFAGF* @  MP<  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&ULK55M;]HP$/XK5C9-K;0UKX2.0:1"F+9)E5"K;A^F?3#)0:PZ=F8[T/[[
MV4Y(H4L1VOJ%V.?G><YW9^[&6R[N90&@T$-)F9PXA5+5R'5E5D")Y06O@.F3
M%1<E5GHKUJZL!.#<DDKJ!IX7NR4FS$G&UK80R9C7BA(&"X%D7998/$Z!\NW$
M\9V=X8:L"V4,;C*N\!IN0=U5"Z%W;J>2DQ*8))PA :N)<^6/YI'!6\!W ENY
MMT8FDB7G]V;S-9\XGKD04,B44<#ZLX$94&J$]#5^MYI.Y](0]]<[]<\V=AW+
M$DN8<?J#Y*J8.)<.RF&%:ZIN^/8+M/$,C%[&J;2_:-M@P]A!62T5+UNROD%)
M6//%#VT>]@A:IY\0M(3@.2%Z@1"VA/!4#U%+B$[U,&@)-G2WB=TF+L4*)V/!
MMT@8M%8S"YM]R];Y(LR\DULE]"G1/)7<@"("=.$56E#,T%D*"A,JS]$'='>;
MHK.WYV-7:4<&[F:MZ+01#5X0#=$U9ZJ0:,YRR'OXZ7%^?(3OZ@"[*(-=E-/@
MJ."WFEV@T'N/ B\(>^XS.YT>](7S?][G_^S](!EA5_+0ZH4GEOSGU5(JH?^Q
MO_HJW6A%_5JFBXUDA3.8.+I-21 ;<))W;_S8^]27YM<42U]3;/Y*8@<%B;J"
M1,?4D\CSS^[/$905Y8\@4*8?OR#+VG12V5>31BZV<F80;)(POHSUT]KL)[L'
M-1P.XT-4^C?*#_UA_/$0-N^!#8:>]P1K(G?W.E$)8FU'@-01U4PU+[2S=E/F
MRC;79_:I/YKY/?943Z5FB#S)-R/M&HLU81)16&E7WL50-TK1C(EFHWAE^^"2
M*]U5[;+0DQ6$ >CS%>=JMS$.NEF=_ %02P,$%     @ 7&D.5U;Y6'I< P
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M!.Y&',$<@ <,B6/['-QY'H6KYU2X_F_U\#=02P,$%     @ 7&D.5Y>*NQS
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M>@OJ+>_4VX=[Y?S4\UCC^>^D.@S?NNGX<?G81 GG(\X6;L9WOU!+ P04
M" !<:0Y78]:*%)L!  "4%P  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-F,UN
MPC 0A%\ERA418[NE/P(N;:\MA[Z FVQ(1!);MJ'P]G7"C]2*1B J=2ZQ$N_.
MC+W2=\CD?6O(19NZ:MPT+KPWCXRYM*!:N40;:L).KFVM?'BU"V94NE0+8F(T
M&K-4-YX:/_2M1CR;/%.N5I6/7C;ALRMU,XTM52Z.GG:%K=<T5L949:I\V&?K
M)OOA,MP[)*&SJW%%:=P@%,3LI$.[\[O!ON]M3=:6&45S9?VKJD,5VU3,^6U%
M+NF7.)%1YWF94J;351U:$F<LJ<P51+ZNDIWHH-_9AQNFW9-?[=_)]!F&RKG5
MQH6)6;K<[C"2MGMH@A!97_8?\>@8I*\^'[73SB@[TSM<[Z>VRVX>CG7+]7?\
M?<9'_0MS") <$B3'#4B.6Y <8Y <=R Y[D%R/(#DX".4("A$Y2A(Y2A,Y2A0
MY2A4Y2A8Y2A<Y2A@Y2AD%2AD%2AD%2AD%2AD%2AD%2AD%2AD%2AD%2AD%2AD
ME2ADE2ADE2ADE2ADE2ADE2ADE2ADE2ADE?])U@^MEW_]G[A=DUJ5S<&?=3_C
M9U]02P$"% ,4    " !<:0Y7!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %QI#E<2MML-[P   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( %QI#E>97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ 7&D.5W*]][WS!0  UA\  !@
M         ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( %QI#E=UX;4 F04  +@5   8              " @3<.  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !<:0Y7,)GCPZ4"  !=!P
M&               @($&%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ 7&D.5Z^_!-R7!0  B!D  !@              ("!X18  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( %QI#E=57C:E)PH
M %)2   8              " @:X<  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " !<:0Y7G#R\*C<(  !7/@  &               @($+
M)P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 7&D.5^!;
M:>">!0  R P  !@              ("!>"\  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( %QI#E<\@.C_Z@\  !DL   8
M  " @4PU  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !<
M:0Y7:U[5ND$-   /)   &               @(%L10  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ 7&D.5PP5"0$J P  0 <  !D
M         ("!XU(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " !<:0Y7+M5PD"\%   M#   &0              @(%$5@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %QI#E=VT]EIR (   \&
M   9              " @:I;  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ 7&D.5WRP'$2W"@  MQL  !D              ("!J5X
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !<:0Y7B5,X
MO8T$   ""@  &0              @(&7:0  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( %QI#E?3X1&#< 4  '8,   9
M  " @5MN  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M7&D.5SK!*OP/"0  7Q8  !D              ("! G0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " !<:0Y7M]%Z$L("   K!@  &0
M            @(%(?0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( %QI#E>EQT:&0P(  ) &   9              " @4&   !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 7&D.5Y6UJB7D$
MF3$  !D              ("!NX(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " !<:0Y7I7>=I,4"   1!@  &0              @('6
MDP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( %QI#E>I
MK$5'N (  %$&   9              " @=*6  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ 7&D.5W0JM&6W P  , H  !D
M     ("!P9D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %QI#E?9P0HP6@0  '@=   9              "
M@2RT  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 7&D.
M5\P5^@X8!0  I1X  !D              ("!O;@  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " !<:0Y7+.E?<_$$  !"&   &0
M        @($,O@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( %QI#E?=<YZ)Q (  "((   9              " @33#  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 7&D.5Z0:C%RX!P  HUL
M !D              ("!+\8  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " !<:0Y7DDB:NHP#  !\$   &0              @($>S@
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %QI#E>KQ$C9
M&@0  +$0   9              " @>'1  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ 7&D.5RMD66 _"   PDH  !D
M ("!,M8  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !<
M:0Y7GNBZ**X#   6$@  &0              @(&HW@  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( %QI#E<^KF<]\ ,  "T4   9
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M  !X;"]S='EL97,N>&UL4$L! A0#%     @ 7&D.5Y>*NQS     $P(   L
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64$L%!@     N "X >0P  &O_      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>111</ContextCount>
  <ElementCount>238</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/NatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Venture Loan and Security Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement</Role>
      <ShortName>Venture Loan and Security Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>070200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>080200 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/AccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/StockbasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/Liquidity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Leases, Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LeasesOperatingLeaseDetails</Role>
      <ShortName>Leases, Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>090510 - Disclosure - Leases, Financing Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/LeasesFinancingLeaseDetails</Role>
      <ShortName>Leases, Financing Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/AccruedExpensesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails</Role>
      <ShortName>Stock-Based Compensation, Equity Compensation Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation, Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation, Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Venture Loan and Security Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails</Role>
      <ShortName>Venture Loan and Security Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="brhc20057346_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/RetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pdsbiotech.com/role/RetirementPlan</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="brhc20057346_10q.htm">brhc20057346_10q.htm</File>
    <File>brhc20057346_ex31-1.htm</File>
    <File>brhc20057346_ex31-2.htm</File>
    <File>brhc20057346_ex32-1.htm</File>
    <File>brhc20057346_ex32-2.htm</File>
    <File>pdsb-20230630.xsd</File>
    <File>pdsb-20230630_cal.xml</File>
    <File>pdsb-20230630_def.xml</File>
    <File>pdsb-20230630_lab.xml</File>
    <File>pdsb-20230630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image00001.jpg</File>
    <File>image00002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="459">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc20057346_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 459,
    "http://xbrl.sec.gov/dei/2023": 30,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "contextCount": 111,
   "dts": {
    "calculationLink": {
     "local": [
      "pdsb-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pdsb-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "brhc20057346_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pdsb-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pdsb-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pdsb-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 361,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 1,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 6
   },
   "keyCustom": 31,
   "keyStandard": 207,
   "memberCustom": 13,
   "memberStandard": 18,
   "nsprefix": "pdsb",
   "nsuri": "http://pdsbiotech.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060400 - Disclosure - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060500 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://pdsbiotech.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060600 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://pdsbiotech.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060700 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://pdsbiotech.com/role/StockbasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060800 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://pdsbiotech.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060900 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://pdsbiotech.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061000 - Disclosure - Venture Loan and Security Agreement",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement",
     "shortName": "Venture Loan and Security Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061100 - Disclosure - Retirement Plan",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://pdsbiotech.com/role/RetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061200 - Disclosure - Insider Trading Arrangements",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://pdsbiotech.com/role/InsiderTradingArrangements",
     "shortName": "Insider Trading Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010000 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080200 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080400 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080500 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://pdsbiotech.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pdsb:LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080600 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://pdsbiotech.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080700 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://pdsbiotech.com/role/StockbasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090200 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090300 - Disclosure - Liquidity (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://pdsbiotech.com/role/LiquidityDetails",
     "shortName": "Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230430",
      "decimals": "-5",
      "lang": null,
      "name": "pdsb:ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090400 - Disclosure - Fair Value of Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090500 - Disclosure - Leases, Operating Lease (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails",
     "shortName": "Leases, Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pdsb:FinanceLeasePrincipalAndInterestPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090510 - Disclosure - Leases, Financing Lease (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
     "shortName": "Leases, Financing Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pdsb:FinanceLeasePrincipalAndInterestPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230630",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010100 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230630",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pdsb:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090600 - Disclosure - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://pdsbiotech.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "pdsb:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630_PlanNameAxis_EquityCompensationPlansMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090700 - Disclosure - Stock-Based Compensation, Equity Compensation Plans (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
     "shortName": "Stock-Based Compensation, Equity Compensation Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630_PlanNameAxis_EquityCompensationPlansMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pdsb:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090702 - Disclosure - Stock-Based Compensation, Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation, Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090704 - Disclosure - Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
     "shortName": "Stock-Based Compensation, Assumptions Used to Value Stock Options and Warrants Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090706 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation, Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090800 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://pdsbiotech.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090900 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20220831",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091000 - Disclosure - Venture Loan and Security Agreement (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails",
     "shortName": "Venture Loan and Security Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20220831",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091100 - Disclosure - Retirement Plan (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://pdsbiotech.com/role/RetirementPlanDetails",
     "shortName": "Retirement Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "020000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20211231_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "030000 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNetOfTax",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230401to20230630",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "040000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060100 - Disclosure - Nature of Operations",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://pdsbiotech.com/role/NatureOfOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060200 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060300 - Disclosure - Liquidity",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://pdsbiotech.com/role/Liquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20057346_10q.htm",
      "contextRef": "c20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 32,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ecd_InsiderTradingArrLineItems": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "localname": "InsiderTradingArrLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "NonRule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "NonRule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "Rule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "Rule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://pdsbiotech.com/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "pdsb_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_CommissionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals.",
        "label": "Commission Percentage",
        "terseLabel": "Commission paid on Placement Shares sold"
       }
      }
     },
     "localname": "CommissionPercentage",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pdsb_DebtInstrumentNumberOfIndependentTermLoans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of independent term loans provided for under the debt instrument.",
        "label": "Debt Instrument, Number of Independent Term Loans",
        "terseLabel": "Number of independent term loans"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfIndependentTermLoans",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pdsb_DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period after October 1, 2024 for making monthly payments on the principal balance of the debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Period for making monthly payments on principal balance",
        "terseLabel": "Period after October 1, 2024 for making monthly payments on principal balance"
       }
      }
     },
     "localname": "DebtInstrumentPeriodForMakingMonthlyPaymentsOnPrincipalBalance",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pdsb_DebtInstrumentPrepaymentPremiumPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid on or before the Loan Amortization date.",
        "label": "Debt Instrument, Prepayment Premium, Period 1",
        "terseLabel": "Prepayment premium paid if loan is prepaid on or before Loan Amortization date"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPeriod1",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pdsb_DebtInstrumentPrepaymentPremiumPeriod2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid after the Loan Amortization date, but on or before the date that is twelve (12) months after such Loan Amortization Date.",
        "label": "Debt Instrument, Prepayment Premium, Period 2",
        "terseLabel": "Prepayment premium paid if load is prepaid after Loan Amortization date, but on or before date that is 12 months after such Loan Amortization Date"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPeriod2",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pdsb_DebtInstrumentPrepaymentPremiumPeriod3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid if the loan is prepaid more than twelve (12) months after the Loan Amortization Date but prior to the stated Maturity Date.",
        "label": "Debt Instrument, Prepayment Premium, Period 3",
        "terseLabel": "Prepayment premium paid if loan is prepaid more than 12 months after Loan Amortization Date but prior to stated Maturity Date."
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPeriod3",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pdsb_DebtInstrumentPrepaymentPremiumPeriod4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The prepayment premium, calculated as a percentage of the then outstanding principal, to be paid on the stated maturity date of the loan.",
        "label": "Debt Instrument, Prepayment Premium, Period 4",
        "terseLabel": "Prepayment premium paid if loan is paid on stated maturity date"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPeriod4",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pdsb_DebtInstrumentThresholdPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period after the Loan Amortization Date used to determine prepayment premiums on the outstanding principal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Threshold Period",
        "terseLabel": "Threshold period after Loan Amortization Date used to determine prepayment premiums"
       }
      }
     },
     "localname": "DebtInstrumentThresholdPeriod",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pdsb_DebtInstrumentVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum base rate to be used in computing the variable rate on the debt instrument.",
        "label": "Debt Instrument, Variable Rate",
        "terseLabel": "Minimum base rate used to compute floating interest rate"
       }
      }
     },
     "localname": "DebtInstrumentVariableRate",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pdsb_DebtInstrumentWrittenNoticePeriodForPrepayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time prior to prepaying all of the outstanding loan that written notice must be provided by the borrower, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Written Notice Period for Prepayment",
        "terseLabel": "Written notice period for prepayment of outstanding loan"
       }
      }
     },
     "localname": "DebtInstrumentWrittenNoticePeriodForPrepayment",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pdsb_EquityCompensationPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans).",
        "label": "Equity Compensation Plans [Member]",
        "terseLabel": "The Plans [Member]"
       }
      }
     },
     "localname": "EquityCompensationPlansMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_EquityIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In 2014, the Company's stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units (\"RSUs\"), subject to increases (the \"Plan Limit\"). In addition, on January 1, 2015 and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the 2014 Equity Incentive Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Plan was amended and restated which removed the annual increase component and was limited to 826,292 shares.",
        "label": "Equity Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2014Member",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_EquityIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In 2018, the Company's stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards.",
        "label": "Equity Incentive Plan 2018 [Member]",
        "terseLabel": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2018Member",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_FinanceLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for finance lease contract.",
        "label": "Finance Lease, Cost",
        "terseLabel": "Total cost of financing leases"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_FinanceLeaseLiabilityToBePaidYearFourAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four and Thereafter",
        "verboseLabel": "2027 and after"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidYearFourAndThereafter",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_FinanceLeasePrincipalAndInterestPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal and interest payments on finance lease.",
        "label": "Finance Lease, Principal and Interest Payments",
        "terseLabel": "Cash paid for finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeasePrincipalAndInterestPayments",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options (ISOs) under the equity compensation plans that may be granted only to employees.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options [Member]"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_InducementPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2019 Inducement Plan provides for the grant of non-qualified stock options.",
        "label": "Inducement Plan 2019 [Member]",
        "terseLabel": "2019 Inducement Plan [Member]"
       }
      }
     },
     "localname": "InducementPlan2019Member",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_LesseeFinanceLeaseMonthlyRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated aggregate monthly rental expense under finance lease.",
        "label": "Lessee, Finance Lease, Monthly Rental Expense",
        "terseLabel": "Aggregate monthly rental payments"
       }
      }
     },
     "localname": "LesseeFinanceLeaseMonthlyRentalExpense",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_LesseeFinanceLeaseNumberOfLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of finance leases entered into by the lessee during the period.",
        "label": "Lessee, Finance Lease, Number of Leases",
        "terseLabel": "Number of financing leases entered into"
       }
      }
     },
     "localname": "LesseeFinanceLeaseNumberOfLeases",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pdsb_LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities.",
        "label": "Lessee, Finance Lease, Supplemental Cash Flow Information Related to Finance Lease [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Related to Financing Lease"
       }
      }
     },
     "localname": "LesseeFinanceLeaseSupplementalCashFlowInformationRelatedToFinanceLeaseTableTextBlock",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pdsb_LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four and Thereafter",
        "terseLabel": "2027 and after"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information related to lessee's operating leases and right-of-use assets and lease liabilities.",
        "label": "Lessee, Operating Lease, Supplemental Cash Flow Information Related to Operating Lease [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Related to Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationRelatedToOperatingLeaseTableTextBlock",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pdsb_LiabilityForUncertainTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date.",
        "label": "Liability for Uncertain Tax Positions",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositions",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_LiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity [Abstract]"
       }
      }
     },
     "localname": "LiquidityAbstract",
     "nsuri": "http://pdsbiotech.com/20230630",
     "xbrltype": "stringItemType"
    },
    "pdsb_LoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $7,500,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan A [Member]",
        "terseLabel": "Loan A [Member]"
       }
      }
     },
     "localname": "LoanAMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_LoanBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $10,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan B [Member]",
        "terseLabel": "Loan B [Member]"
       }
      }
     },
     "localname": "LoanBMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_LoanCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $3,750,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan C [Member]",
        "terseLabel": "Loan C [Member]"
       }
      }
     },
     "localname": "LoanCMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_LoanDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $3,750,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan D [Member]",
        "terseLabel": "Loan D [Member]"
       }
      }
     },
     "localname": "LoanDMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_LoanEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $5,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan E [Member]",
        "terseLabel": "Loan E [Member]"
       }
      }
     },
     "localname": "LoanEMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_LoanFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of six separate and independent term loans in the amount of $5,000,000 under a Loan and Security Agreement entered into on August 24, 2022 with Horizon Technology Finance Corporation, as a lender and collateral agent for itself and other Lenders.",
        "label": "Loan F [Member]",
        "terseLabel": "Loan F [Member]"
       }
      }
     },
     "localname": "LoanFMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_MerckKGaALicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements with each of the Company's executives that generally provide for product.",
        "label": "Merck KGaA License Agreement [Member]",
        "terseLabel": "Merck KGaA License Agreement [Member]"
       }
      }
     },
     "localname": "MerckKGaALicenseAgreementMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_MilestonePaymentsAchievementOfCertainAggregateSalesLevels": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement.",
        "label": "Milestone payments, Achievement of Certain Aggregate Sales Levels",
        "terseLabel": "Milestone payments for aggregate sales levels of product"
       }
      }
     },
     "localname": "MilestonePaymentsAchievementOfCertainAggregateSalesLevels",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_MilestonePaymentsDevelopmentAndFirstCommercialSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to be made for development and first commercial sale milestones detailed in the license agreement.",
        "label": "Milestone payments, Development and first commercial sales",
        "terseLabel": "Milestone payments for development and first commercial sales"
       }
      }
     },
     "localname": "MilestonePaymentsDevelopmentAndFirstCommercialSales",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_PercentageOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options.",
        "label": "Percentage of Common Stock outstanding",
        "terseLabel": "Percentage of Common Stock outstanding used to determine annual increase in the plan limit"
       }
      }
     },
     "localname": "PercentageOfCommonStockOutstanding",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pdsb_PercentageOfVotingPowerDisposedOff": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting power disposed of in a transaction (including a merger or other reorganization) or series of related transactions.",
        "label": "Percentage of Voting Power Disposed off",
        "terseLabel": "Percentage of voting power disposed off"
       }
      }
     },
     "localname": "PercentageOfVotingPowerDisposedOff",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pdsb_PlacementSharesAvailableForFutureSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals.",
        "label": "Placement Shares, Available for future sale",
        "terseLabel": "Placement Shares included in at-the-market offering program"
       }
      }
     },
     "localname": "PlacementSharesAvailableForFutureSale",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers.",
        "label": "Proceeds from Sale of Unused Net Operating Loss Carryforwards",
        "terseLabel": "Proceeds from sale of tax benefits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_RoyaltyPercentagePaidOnNetSalesOfProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage paid on net sales of the product detailed in the license agreement.",
        "label": "Royalty Percentage Paid on Net Sales of Product",
        "terseLabel": "Royalty percentage paid on net sales of product"
       }
      }
     },
     "localname": "RoyaltyPercentagePaidOnNetSalesOfProduct",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pdsb_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term the Plan shall continue to remain effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Term of Plan",
        "terseLabel": "Term of plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfPlan",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pdsb_ShelfRegistrationStatementAvailableForFutureSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission (the \"2020 Shelf Registration Statement\") for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the \"Shelf Securities\") that are available for future sale.",
        "label": "Shelf Registration Statement, Available for future sale",
        "terseLabel": "Registered securities in Shelf Registration Statement available for future sale"
       }
      }
     },
     "localname": "ShelfRegistrationStatementAvailableForFutureSale",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pdsb_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for significant risks and uncertainties.",
        "label": "Significant Risks and Uncertainties, Policy [Policy Text Block]",
        "terseLabel": "Significant Risks and Uncertainties"
       }
      }
     },
     "localname": "SignificantRisksAndUncertaintiesPolicyPolicyTextBlock",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pdsb_TermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On August 24, 2022, the Company, as borrower (the \"Borrower\"), entered into a Venture Loan and Security Agreement (the \"Loan and Security Agreement\") by and among Borrower, PDS Operating Corporation, as guarantor (\"Guarantor\", including the Borrower and any subsidiary of the Borrower party thereto from time to time, collectively, the \"Loan Parties\" and each individually a \"Loan Party\") , the persons party thereto from time to time as lenders (collectively, the \"Lenders\"), and Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the \"Collateral Agent\"). The Loan and Security Agreement provides for six separate and independent term loans.",
        "label": "Term Loans [Member]",
        "terseLabel": "Term Loans [Member]"
       }
      }
     },
     "localname": "TermLoansMember",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pdsb_TermOfRoyaltyPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term of Royalty Payment",
        "terseLabel": "Term of royalty payment"
       }
      }
     },
     "localname": "TermOfRoyaltyPayment",
     "nsuri": "http://pdsbiotech.com/20230630",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r219",
      "r340",
      "r356",
      "r369",
      "r370",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r434",
      "r440",
      "r444",
      "r451",
      "r486",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r219",
      "r340",
      "r356",
      "r369",
      "r370",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r434",
      "r440",
      "r444",
      "r451",
      "r486",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r202",
      "r219",
      "r250",
      "r251",
      "r252",
      "r339",
      "r340",
      "r356",
      "r369",
      "r370",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r434",
      "r440",
      "r444",
      "r451",
      "r454",
      "r482",
      "r486",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r202",
      "r219",
      "r250",
      "r251",
      "r252",
      "r339",
      "r340",
      "r356",
      "r369",
      "r370",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r434",
      "r440",
      "r444",
      "r451",
      "r454",
      "r482",
      "r486",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails",
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails",
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r450"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails",
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRentCurrent": {
     "auth_ref": [
      "r17",
      "r430"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rent"
       }
      }
     },
     "localname": "AccruedRentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r53",
      "r450",
      "r536"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r367",
      "r478",
      "r479",
      "r480",
      "r517",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r38",
      "r39",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r254",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r4",
      "r42",
      "r63",
      "r193"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive impact to EPS (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of office space under sublease"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r97",
      "r116",
      "r142",
      "r147",
      "r149",
      "r151",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r292",
      "r294",
      "r312",
      "r346",
      "r390",
      "r450",
      "r462",
      "r484",
      "r485",
      "r526"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r94",
      "r98",
      "r116",
      "r151",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r292",
      "r294",
      "r312",
      "r450",
      "r484",
      "r485",
      "r526"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Unaudited Interim Financial Statements"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]",
        "verboseLabel": "Liquidity [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r25",
      "r96",
      "r429"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents and Concentration of Cash Balance"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r25",
      "r64",
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r64"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information Related to Finance Lease [Abstract]"
       }
      }
     },
     "localname": "CashFlowFinancingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information Related to Operating Leases [Abstract]"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares of common stock that can be purchased with warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r156",
      "r157",
      "r426",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r478",
      "r479",
      "r517",
      "r535",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r52",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r52",
      "r378",
      "r396",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r52",
      "r347",
      "r450"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.00033 par value, 75,000,000 shares authorized at June 30, 2023 and December 31, 2022, 30,868,188 shares and 30,170,317 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r23",
      "r100",
      "r102",
      "r108",
      "r342",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r76",
      "r282",
      "r287",
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current income tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Venture Loan and Security Agreement [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r115",
      "r171",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r187",
      "r194",
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Venture Loan and Security Agreement"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r49",
      "r50",
      "r78",
      "r79",
      "r118",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r321",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Margin on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r43",
      "r45",
      "r172",
      "r321",
      "r436",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [
      "r118",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r321",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r118",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r321",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r20",
      "r33",
      "r34",
      "r42",
      "r43",
      "r45",
      "r46",
      "r71",
      "r72",
      "r118",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r321",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r42",
      "r45",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.",
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "terseLabel": "Uncommitted loan"
       }
      }
     },
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]",
        "terseLabel": "Venture Loan and Security Agreement [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "401(k) employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r4",
      "r32"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r220",
      "r224",
      "r255",
      "r256",
      "r258",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r109",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r132",
      "r134",
      "r136",
      "r137",
      "r138",
      "r140",
      "r303",
      "r304",
      "r343",
      "r354",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r109",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r134",
      "r136",
      "r137",
      "r138",
      "r140",
      "r303",
      "r304",
      "r343",
      "r354",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]",
        "verboseLabel": "Net Loss per Common Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r117",
      "r274",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]",
        "terseLabel": "Stock Options [Abstract]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Stock Compensation Expense [Abstract]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized stock compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options [Member]",
        "verboseLabel": "Stock Options to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r8",
      "r92",
      "r104",
      "r105",
      "r106",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r141",
      "r152",
      "r153",
      "r200",
      "r259",
      "r260",
      "r261",
      "r283",
      "r284",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r334",
      "r357",
      "r358",
      "r359",
      "r367",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r306",
      "r307",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r306",
      "r307",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r40",
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r307",
      "r336",
      "r337",
      "r338",
      "r436",
      "r437",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r185",
      "r204",
      "r209",
      "r307",
      "r336",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Quoted Prices in Active Markets (Level 1) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r185",
      "r204",
      "r209",
      "r307",
      "r337",
      "r436",
      "r437",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Quoted Prices in Inactive Markets (Level 2) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r307",
      "r338",
      "r436",
      "r437",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Significant Unobservable Inputs (Level 3) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Transfers into Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Transfers Between Levels [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r185",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r336",
      "r337",
      "r338",
      "r436",
      "r437",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability) [Abstract]",
        "terseLabel": "Fair Value of Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FairValueNetAssetLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/FairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r6",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future Payments for Finance Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r324",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Remaining lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Financing lease obligation-short term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Future Payments for Financing Lease Liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Financing lease obligation-long term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r326",
      "r332"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments of finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Financing lease right-to-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r325",
      "r330",
      "r449"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance lease depreciation expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61",
      "r400"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r58",
      "r81",
      "r142",
      "r146",
      "r148",
      "r150",
      "r344",
      "r351",
      "r433"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r154",
      "r155",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r155",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r269",
      "r275",
      "r277",
      "r280",
      "r285",
      "r289",
      "r290",
      "r291",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Accrued interest and penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r90",
      "r130",
      "r131",
      "r145",
      "r273",
      "r286",
      "r355"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit for income taxes",
        "terseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r271",
      "r272",
      "r277",
      "r278",
      "r279",
      "r281",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Income tax benefit due to realization uncertainties"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r471",
      "r473"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r44",
      "r83",
      "r107",
      "r144",
      "r320",
      "r402",
      "r460",
      "r537"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r63",
      "r191",
      "r198",
      "r438",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "totalLabel": "Interest income (expenses), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r110",
      "r112",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued interest on debt"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r62",
      "r143"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of shares in consulting agreement"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Description [Abstract]",
        "terseLabel": "Financing Lease [Abstract]"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments.",
        "label": "Finance lease liability capitalized interest rate"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Term of financing lease"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Operating Lease [Abstract]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate used to measure operating lease liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Future Payments for Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Remaining sublease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Term of sublease agreement"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r116",
      "r151",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r293",
      "r294",
      "r295",
      "r312",
      "r377",
      "r432",
      "r462",
      "r484",
      "r526",
      "r527"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r57",
      "r80",
      "r349",
      "r450",
      "r476",
      "r481",
      "r520"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r95",
      "r116",
      "r151",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r293",
      "r294",
      "r295",
      "r312",
      "r450",
      "r484",
      "r526",
      "r527"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Estimated Dividend Yield [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Expected Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk-free Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r85",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/NatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r59",
      "r66",
      "r82",
      "r93",
      "r99",
      "r101",
      "r106",
      "r116",
      "r122",
      "r124",
      "r125",
      "r126",
      "r127",
      "r130",
      "r131",
      "r135",
      "r142",
      "r146",
      "r148",
      "r150",
      "r151",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r304",
      "r312",
      "r352",
      "r398",
      "r415",
      "r416",
      "r433",
      "r460",
      "r484"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Interest income (expenses), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r142",
      "r146",
      "r148",
      "r150",
      "r433"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r331",
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future Payments for Operating Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease obligation-short term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r327",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-to-use asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Abstract]",
        "terseLabel": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "OtherCommitmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/RetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock, net of issuance costs",
        "terseLabel": "Proceeds from issuance of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pdsbiotech.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r11"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Recognition of property and equipment from bargain purchase option"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LeasesFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r345",
      "r350",
      "r450"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r47",
      "r268",
      "r534"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r54",
      "r73",
      "r348",
      "r360",
      "r361",
      "r365",
      "r379",
      "r450"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r92",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r152",
      "r153",
      "r259",
      "r260",
      "r261",
      "r283",
      "r284",
      "r296",
      "r298",
      "r299",
      "r301",
      "r302",
      "r357",
      "r359",
      "r367",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Antidilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r221",
      "r223",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r9",
      "r10",
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Value Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Note payable, net of debt discount"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumptions Used in Determining Fair Value of Stock Options and Warrants Granted [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r221",
      "r223",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited and expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited and expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value of option on grant date (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Options outstanding, aggregate intrinsic value",
        "periodStartLabel": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of Shares [Roll Forward]",
        "terseLabel": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://pdsbiotech.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r220",
      "r228",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r262",
      "r263",
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term of option"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationAssumptionsUsedToValueStockOptionsAndWarrantsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r8",
      "r22",
      "r92",
      "r104",
      "r105",
      "r106",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r141",
      "r152",
      "r153",
      "r200",
      "r259",
      "r260",
      "r261",
      "r283",
      "r284",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r334",
      "r357",
      "r358",
      "r359",
      "r367",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r141",
      "r341",
      "r362",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r141",
      "r341",
      "r362",
      "r368",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r399",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for consulting agreement (in shares)",
        "verboseLabel": "Shares issued for consulting services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r73",
      "r364",
      "r417",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock (in shares)",
        "terseLabel": "Issuances of common stock from the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/LiquidityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r73",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Issuances of common stock, from exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://pdsbiotech.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for consulting agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r8",
      "r51",
      "r52",
      "r73",
      "r367",
      "r417",
      "r425",
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuances of common stock from the Sales Agreement, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r22",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Issuances of common stock, from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r68",
      "r380",
      "r396",
      "r418",
      "r419",
      "r450",
      "r462",
      "r476",
      "r481",
      "r520",
      "r538"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheets",
      "http://pdsbiotech.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r319",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r319",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r319",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/StockbasedCompensationEquityCompensationPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/Liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental information of cash and non-cash transactions:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r270",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r86",
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/LiquidityDetails",
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r452",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/VentureLoanAndSecurityAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r133",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r132",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://pdsbiotech.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation"
       }
      }
     },
     "localname": "WorkersCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://pdsbiotech.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org//715/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r464": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r465": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r466": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r467": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r468": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r469": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205-40/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001140361-23-039544-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-039544-xbrl.zip
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M8C/ _.\QO>$]R?[;=Y(3]E-VTAG\)#]5@&>W9:/FJF0PLF/@Q*MF+Z;;<ZW
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M#_063#2@*$L4_P1WS< :2Z&M$-P:**UAFA$+A>*04P454DYX2U6%T.,!;;U
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MYV_O22B64*SR9E4PGB3SWE+I) $02Z(U-9B#6&4*VK+$P!'$EF(:$=((SS8
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M@>,0Z@GA$L\/;";.C"224>CX(R?8O1_*TT8@!H7P-!3"V?0!030((H='E+N
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MDFAUH&_&J+*0$-OA*$:<A%1^XF& Y/F=>4&(PC/9@F04.'B$/;>?JMAD+5T
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MC+0!%!/!X] F4> 3RB+JQ)0['F:.<+$;B$&K7(16.0,<B8V<1YALLV:[I<]
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MPBJ_6%1ZA6H5S='-RM VU::BJG@ZLKB\6/<# 9A.TOYJ40Y5UZ)H!/S1O((
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MZ+SK05T&!Y#8S#> #_(-M-L#G7<=VS?PT(:GF5\ 'Q;4:>07P.<,ZSPFB<T
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M#.;RBA<6D!K>R+>\!>",1(Y5H1G1O4(PBN06+I'#K (G%VVKZ+U"77*Q&"<
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M%1^EZ,/=$'UG*=0>>M'MY$,O!.9"X.U4?30/_W:GAM_5;XGM1E@1 9C04($
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M)A KZ!.L"6)041!*CG5XFC'(& T@!#M-03XI03X:%M1SW9[K]ESWP;FNIH%
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M$<:0"AB4%9%5%=('T%]*DIJON7 =TP.ZCJ'O#_R:Z?);YYCM QYJ0.-C3A%
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MLC8U8D,@H"6C!_YEB'M.WW/ZGM/WG/[,CZ*KG-['%!-?4(2P_5%P6S(2"L0
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M,Z?!(JAPYKMX5_H'/EO_0,].>G9R;AA<LA/O<1#D%W7+C"X_NC[S?;PQG]@
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M^5 >LLWS$XD\]"SOP6!_[NSC3+3:QPCZAU9AKZZO4W7-)FIM!(!3 I4,0\X
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M/,43QL(R\M'B<_EQE@NZ;-&ZL?72L1MO[>TQ"#O_W,B\0II6M1AFK.( 2!E
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MV<U[:@&(%=5\01WER5 VR\E.$?''9*(\XOV?GP@$X!<O1TG/X*3*MK%R]CD
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M*/9%B"CEG&(A AY$./(9)MSPH@"#(V+4ODL'2LI XQ!Q(+"@A$!D=L.Q3XU
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MSYR>>4>Q7]U-F?=\%FQFEKU-\KE.Y>K?S)]W=5U9\F#I:6/S*-MJN/#>VO;
M!EHKCD&[WF'YXA) ^>^S'-KCAE:;<;8%HA^[2+&7S%V4S-M41S1C3@MT:QM!
MVZ<VXG 45EOEU.C..OZ<BH.2&+I$YH]%Q@>C,R,F;@P!O?3@X6DNELE=_N0:
M\C/+XW_$YEGV@=DD3?Y0"]V\VI'GY"86?]@HT 82?1 2KB\7:[QKI5SL)$'?
MNNCM^L9C1QQBT41'VZJW-DTQU\6N;FV:V?H8[MEL*4_WVZ1?NM$1LM)=6R>V
M":V+\*[/Q[41E0\C0Y!3^Y"\ ^$G;=O"%?-I+2SM:ZLI_!Q#0F1$$<4*<\*Y
M\+&"@&@E(>6X-B/79G<NOLSE=LX>7Y=U&U2S;C]\?+]MX_(L_K&:F/_\T%!0
M'$=4^@%6#&&B"0VX"B,8B0 %FNG:L5U[0V'[XN5P!00OO$P97;RL*(GGV_/L
M^&1OF#C1\)R]L/F2Y2=E.)XY4MJB;'UQ?P94*J?"Z@1<QBBF%&(L[  #GRF"
MB-8A9URAVC$,T"<(U('.@NVJL:IC>[!%MJ"]MNI[T0A[7C7EKN8FT'-^=.A!
M'F"B%%9**LQ(1$5D"%!'0@8\1'7S@S="[_4!H0<<Z&K!MPBQUQ6(B>-#C#""
M$*,1"R/;<9DJ3 GD6A@@FD_@CA![<T"(H4$4; .P-Q6 R:,#3 A? 1\8UH8E
M)L0 BR+B$^;[6L!0U/"VC0![>Q* ;2#0MQ7HJ4-"[Q^N2_OK)$V=J'U3^$M6
M ,H4C"  !J@JPB1@#/JV9P<AAI0#H&MG?J\1%G9#[PX(T&!+DGVWZ.=YKA\"
MCH$V(B,,D>U\8I@@I@AI&P,ED?9#%I(=X?C^ >#X?N;B>^Y\?,8<N+'PRB7)
M(/_W=?'OF^+?M\6_[W+@YP\:N,I.H_5-[>QU<QJ5UQ0OL5</G =PWKUFR1$Y
M][+5%LJ>_VB.=8"= ?*MFUJVR#ZD&L9Y24Q1[#(K2"F=PQ[$>2N?R^)H*B?C
M$@NGMFW^;3RQ+00<H//:FWP$EYN6Q)4R^KS\;GVXLYY3I1/659#:#S[;JADW
MA'2NZ]NI6V9A?Y^:<[=S;5R+J=D=F3%7,UV07?'8V?IUI1C55?BM%FC;JN%\
MP-DC0X7<C)H!-+49J\NEV79*WS2S0_C<4+\?$^6\VK$=<&9A,AMX=Y/<*8,B
MY>0[E]CK74^-AFTXD,H/VWG1#02+-F)NW"Q7Q5-MI=+(L5!CM;'O2>KR3Y?Q
MS?GJS1UQYAI49)-$_'&3#*4;YF$+OB=VW,CE2CIN,C*X40YT*U)N9Y7&.3[J
MY>(K8T+]X<J5\T;B]O'7:N1<_;/A(MYX:G[*5+93F7)[5TJKK+5UO6*Z@<*'
M"UH>S@5;WYNF\:Y3)F_M>"Q[@[T/Q3SU4$Q] X3&N]8T0#@OYM.-R%!]VX7&
MNTZ9NO5$V%(?OCJ+\-4>I-8J.0SLE1W6%6;W$.EA2WE8RZUJ]N*:K7*SP,F2
MLP[:ZG(KW>DHZ-BJ_WI-?/79J]\LOXPG]P4:7GKOK%?(.1-N<U9:]M-H+)":
MN[EL6*GJU.4H"'FDJ0:VQ3)E84@ !8JC,(PD;FZQO%7HJJ89BVN(_.P5)NM*
MFN9_BK[<HY%UOF2V+^0\C.G<B^.Q 9BSDUUK-&M3YQ,W<V 9(_R626=$&]LU
MR8=]%@Y)![W3B_=]_!6E/5^@A:OGG-GOVV0:EGCEO370FCD>IZ.A'6)J8*.&
MM@NS;4I3-*ET[57F?J&\:8QS&TBEV70XN?2NAL/"S9O92MILPO)"XGQU:H:X
MI;-#3O. XYC=NX.K:PB8][U1+!W&KA-1WO*HNOBRR<QLT=76.LZ;D><ZSD?0
MY"W8BBU4=[#C3-X]V'"KS,$]&F><F WO6JQ<.U-NEPYOV\R-.Z#MT2H3;X]F
M%KU>W^OU1W5GM,JSA"O=Y/NTM#8Y7!]<T4 V\;X8<?984M+&:3P2\9@92<^&
MKA;!"-JY#L!MZSW;D]8.$,Z;>^1 R.\N?YLUL!-L:/O#35QMA4/]X7T>PW1!
M%M>S;Y _WT9E1Y*EI<Z8%9U4;NT*;!*3BWNX&HB1^3 M!KS/7KE:B#">\F&<
MW>0]%^WR_L>\?E%<?9T8U6CB_3V9IB-;3Y'E.O/M.%]S&<);KYWE(1L[>GUJ
M%)DLLQW^[&N+_KQ%E<2@W$ZAQADHF_6E<QW.?NEB[DIK)<Q3Q\-IYI*/=HFZ
MO[9](+^.#5SEI]$_[;D;_<QB)ZA.9N$:&3LA5($(L1":(X:@@E28SP'#-9-&
M=C<;?J^^W%WPV>[8_M;8CA-OWXXSN(Q66_;^_,OB$1>)E-(%\ 9E7D.N1+IP
MW@HFQ;: )7/AW='VR9;5+2_D*@DJ%?1UZ$=81H3#D 4( !9H@$._-E-D9W!7
M^B(;,EO3%[DME/%E30[$SX,*\+(;5I@&EBA<B)VKO2$72$*%C 345& !(PJ(
MP%(P+9#0H:YMFWX.D',9O670U<7O"R99&L4+7/32^U#!R]+F<@UB':,<ENU?
MS=]Y 'K.K>?,O$SCJ9AWYDW+A**$Z^*4/_@TX6#8*K,>KFG*\MB<E(>S?6"[
M9C%M1[3T<9<^'-S]<#!LE2,!U^1(G!?SZ48X&+8*R,/V0Y%[MM2[C1Z)VZAZ
M^D-CE]LF8I.;7VR']NO8O#X9EWA8?&*^GB2WI;?7MNG,C#[[^LOG]Y_9M7IM
MS,8_KLQ?JW',Y4O?)\G$ZLC%VPM0 =__V3*6%8]N_4/RLBSWPCKWDG ]&?9H
M14LV.\:7*;H&ZY^] D%M9\/5 QB;#5UP"\$+Y]-XZ;'A';O/UH!Y$<3F43?I
MC"D9]#3$446_FM,UE#3^D7];A;YW4^P*NON6.F?4M.$N6S]6_'U-Y_8WQ>3:
MPU_:UFH,O&8:\WHG(*EKO5WDLIH+:KB$9:/,NTFMX?;3AX]OW_VO]=-)]>,O
M?V:O5KZI#V!8^<9JP5$7KM@FA+&7A&R5, 4?9D[-H_/Q7MTFZ23^CSNSR_/W
M\>8-<.:Y"+GCQDU*L:Y>5MGMO/K !>8SY?K,3&[*O(5QFMS&UM_IFGK;%'@E
MIKF?U^+K2(DB0][<8J^?3UQVKQ[DS\^#_><?R8\SL\%_3^.BP&0&T7S2B&>^
MLGVRR\F#;C10Z9IQGEXF1#K-&Q#EOIX"RE6'S:HW1U<AZ\"Z5#.WW*.HBLX+
M*02#(MKN^$SA'2K<\^52\JDZ99]N@Q7WL]# DNM^<F..[OIF->:_O4OI@!9&
MJRPXN"8+KK<P>L?'8W!\M,HGA&M&Y/2.CQ8GT"J5"+;O0M:SI=[Q\4@<'^V)
MKE4"&&P_N^<1R<Q-IN!9R,U'9IE^3E5A3WCFQ]MX>OMH[--O9V\.WK+[@2WD
MMI7>1:EXGKT\,;3&,MN@:33K8%4SF'4Q<>%_4MMT8/0QF<1"?3;7)O)]DLX1
MH)(S :A@ > 2$P2P"B#Q?>JC((K\*)I'6XZ5,U%3*V#,Q.K8W+)2X,6"(9D5
MP[F\NWRGBU;LR.V[K*,OVBD,;+J"'61L'1C/K?%JYS[-TW;,QR]* [EJ1.=9
M;/=>9M8]-!^J9)H-[ZUI[JS>I,B>*+OMEJ9V;L";K^U 73<@N3#8[9NGHS&+
MM[7=*VEUL\+]7XITK]@]?''W*PNX>F%GJKKDF[)$PH$B=LD?2>IQ9<Y!S1/7
M5HS^:M6%>>+L48/M4W;FR%<PGQPMJWEF 97P_V?O39@;-[)UP;^"5VUW2-,4
MB_MBMQVADE2VNFO1E62[;TQ,3(! 4D07"+"Q2,7^]>\LF8G$0I&B2"UEW(EY
M[:)(()>SG^^<TX9;M;O346\T[4_:;D\XHML9]]JC_J2WF_*4E3 =L[]< :A3
M:C"7S"(!(J>(U%GP5.L'M)K;X%A:8MCN3%J#ENCT>R.W8W?<:5\XW9;HNV"(
M3/=\+ \8=MTM0Y<T2Q%<<2V!&Y1U\&XUV6:3FQ](KWE.P0' )0Z@X"6U[H 7
M)G?"OQ6;"]YKH(L8>W/P-9IR=MCOM;IBVAMV^STQ&MB#3G<\F;1[DYXS'4TV
M&&+^N-JK=J<L4>E/L3S-[*!+Q_EX-N^8<-)Q=S3H]MSA9-#O38:]T0!.H]5U
M.\)ICX?3%\7F=^$>F;R3@RYV!NYD-!)B-.R-VZ-Q?]09C2;#Z4ATA3U8/[;L
MR9B\\U@FS_.@P?' AP<GJYE^SAP*'^Z.*WO=MB-:/7#<NM->IS6:@'?3<=U!
M;S(8V:)7V4WL2;GR'AF'TDOW@2+D>X(0]/SQYBOH]J;&NR9^V>UWG79[W!N#
M=',F-@@X9SR>@#TYZH_%>$=GNA/^!E-\C_QM'HK;=8;3=M<=N\+N341_,AB.
M!\,V$%J_U9E,=R3^=\'?[=TI\1_9.UM?_(S&K'2$^"=@V'J'F]G$.WG;[2&Y
M!3RV(D[GX"UX.!N#FN5A%R]*>\J6;3@YME33BMDOJG]MRIDACZ6>GD$]X]:D
M:P];'2&F'62KL6A/G>%HW.V"TG2Z.ZG V)"EUG1>_A26FQ\NLL##@G>H*H,+
MC@M*)TZ'4M\SX^:-^\8_,59=.C"9Z-LV=_BH".%6%77=[2OJOOD(X>M)K+V0
M .'F:9-5B:S]LDAWJXJ-[O:S$+YY%JF#Z,\5;U;UG*\_<KXZ^']O6MAH,BIC
ML+$53H@5L%TLM52-\9"X&-;F?Z!.SJHE S:VV*:TXU@DNBVI?#36"D[^+9PD
M;R& 9>![<P]5O?CJB(5\94#_]%-5I59:(+Z:&B 3J"H*P<1/ELW7D.*6_U-&
MBCX%Y*"[50E8=_L2L!IE].=&&76W&Q]>EU?MCN6W*J_JUN55.Q=+-<KH3X,R
MZFY5L='=OF+CL1-R5Y-DD2\W]&6^.3_A)+P5 7PQ_M&Z% M@3=BKG9FK?]@1
M#@GP!/S],P4=+[#I2$P3%UZ_:[%V5AU2N^W!83A $_"*:&E%^6-J6'?ZC&2I
M@3Q1[,@BC?WBT KYC>+$"_(9T#>P79YJ 5X DM\$' F4!PWXA@C,!V-<L=)I
M:*CY#K"LAC47T0U.ZI"E$''H>ZY:/C@P&+Y$,<$^CA7;OJ"7W((7Q'4=^$/J
M7=C0,SFR,0O.#&$S\"<Z88ZFQE0?4XB;3J>>[\$O8B[*F )5V/A\'-K SWB.
M.HKN5G44W;J.HO9POF$/9ZLZBFY=1[$[L;15'46WKJ/X%CV<-;)I_'K"[-OS
MPU8E#MT5/6Y?ET1ZHOS75BGBWJ-3Q+5[MS</YY0;B?_)O+;<A/%27WC#EZ,)
MY'JB-.=V$$V[7 C3R4($&X'P94XG"7$M1Q(L4@3K1@BTQ_Z'D7ICK'IS@FM&
MH!0)$<FYBN"4P;^<)?M&$SOX$J6+Q%E2=BIPWX91(??T(-S([MI@;"U>>ENE
MUWLK&B*N-6@>!2+8\923WE8)JE[GJ5J=;"V!-QIPLO9Y!=R;##H1'R >S#KU
M8IJ-L64J^+RZ;\>]O8_-L(P7QU@0\VL8>?^%!UP+9Q; N=TLK?=>0+Q\(F,A
M7LA/O CO1(1KCA)X>Q9&^=>_?F]8'RY4R"A&2;)((V=FQX)J<FY@!3<$[ ]I
MJN5T39?D$^Q@]'DJ3^QS=(G"F/M/?9[*?7DB/K%]7[COEO)[L?QB;,Y<<<<=
M,9FX8S'H]WJ=T02(TQYUAZ+7&G:GP^&*0=IY-%Y[RTG9HW9CT"DW/$8X8R2*
M.7>=+<=>)&' <T9IN&B@#$WLV1(Y7DQ=OUG6KAGR7'F09_(I%_@0_4=]>F;Q
M2WOB]*?V4/1I3'MW..ITQV!0M6PL(!B[SD;'UZWNQKOV^)J#P:CB]+"E.)V@
M'-(CJ8ZZE^-VO2FB&.T82["0_)%RO5B=':%%Z527W'0<E:6-#_5"T$_BQ@L"
M&8'4Y2APSC>:=47@&G\W)J9@H=>]PX'401\'+I_TYPQB61P5Y/8GO6&[YTZ<
M=J\W[-NM7K<SGHII9SATVZW^BC';E5CW):RQJJ3/6E)O>&[#7MRJG#'^CE'
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MD B)M1:"JQ7T1I5"D(VE9(H!WBAB)_(FW&JK,$1+J4P%6T<?X(M88LHBG4N
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M+! I> M 5IPH3[Q)Z,*YE(B3J-'<OR),$<PXKD <%X4XJD8I-47T-$LI#&[
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M=4KA*0$BP1HDQ,P3P$X;.9QSMG!)DA^.-[,\7[CM5O5SLLC\Y:I;,1&<>!C
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M/ >#320%]A0%#JR#P1#^3C%_^ ;/."FP(N+O,+NN6+$FRYHLJ\6^BC5KR^H
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M<6'H278R@0!%\N_T%J,"Q@@K);3UM"",?5/2E) <POKBH9C5X0565#P\"I4
M_KD2A]Q0H>Y[U8%",E>VLZHP+/&?12>OU"59Y6*SS:\'[BFE7-8,=*GBZ\+'
M6[R;B1Q4B=X'>\/_!=.DPC##5<_)N95QH]P('@,UI%N/-S+$C*]:A;'&+@Y=
M;Y#KS( ?8V8,GYPK^(4&#>#I>9%#]@*ZUO2TTT_'UH&3P/\<[F48RD9.!I]G
MY[EL>OEZ0H8%)LZ+D)4,JU+N3IIX(.KT^1WEQB:Y>0P6&I&<;]5S?QRQ0'SI
MC3V?V\ ;;%V2J^CRC"M[3NW=@ 3@N@ZNCR\O#A6JAYJ%*9[M&/<:2XRH$BO
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MQB1T$5D6_#N](:OMX/SF%YJ"3>$K#I=P?!$8$X- 'DTZ/*#W'$J_\$B?(T6
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M=' \0<WD)"JKWQUVNZ,N^"JF0M:(+</: 2O,\20D_.3SN\MC\ C Q[S!&K#
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MV5//9>SQS?%!\P14\E%:\@^MNGRDU5NP<#=OOG@I<92P_,\:J+,B?+"-0-D
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M:'9L\!U0;#M,8W!:X\-]T\<S,/;3/;ZS#Q%1G]B3G=B3B)NU#*LB6$?#9L<
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M4'9\LF/7_H\V 20;P760*PNG#J^/+/$5I HN$T0+^<62;E$V%VF*'2-YIG=
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M3+D\C\!]-(C_.J1R/EDK<DL-)&6/GH1:0F!SBA T>P*B]U8$J2  KQO2%[^
M;4H@8L)F>E-Z#.&$U2.JGI!=&ZK1._TT+K5"L:U_'<.!4%D/-TXSGZ+;^%#7
MBL3#HB^)3<96V-@0)8R67-AT*^>!F#A0094 "B\HP?H:.ZK?YF!E"!Z1[+$9
MR$HED8% <;\F^ENO'@VE3--EV\9&#K$0LC,1OJZACD*=P4S_&AZH;2F;>J!F
M[\)B3!/Y.FW(WGGB2]49T%(:M.%;L%Z\0!C;XY]R[R*"LYM'16U"Z"G"K?BM
M;C]JU#8819I88F<TPL9F":[(^CKFMP!Z_4Z=OEP4 H1%0-86*.TTD.<7&&4^
MKH>(X]3G%M)H5ZH>/_A'1!.;=ET:(.6"(0[V2!A)/"^^I82^I9UEA.DAJ#L'
M>J;9,B"20S@J*H3!:E+#ZD9P*G<<R@[ D?679$6N("A$Y><*8$QLO\3'>^5:
M:JY&)OH@TS@#<;]2 ?6L549/5V/$E7>3U+T1N%$RH7/UL_!4[11.Q#*D_I#H
MS1B#HG1]<&C20*$6(@/-QPGX0I)Y9=D1G4NV_\KRH\UJCE@:F/5&^MP*(/:5
M]8*Z_&.G_?]6E"*I[BLY0;W;%Q,%&)/4=MS6<-/:*>LWI2U!@%>J6D-2$8X>
M"X#S)2$-4U>MKWWB$GM55*3\07+/Y>@3BFK$E7\BP2RKG<#8_4_*O1F NF)2
M]H5BE6HY=_\ )^5//$G!&/?MX?)![E[P;^'H;OEF)5XYA$$U-$9)O%9<I)IE
MESB0"R&8,TZBC K\ C9KE"J9Y)F^C.PUZKSC$.17Q)T$[@QNX/MN6N^$8Z>Q
M;OL5I& HA&G,:E[:8[(LC1M?%K2C8OA&6325ZG3@'0M4RK8C4HJR&J9!J21)
ME=US1XNOMI,8W5V+98[EPV49+.T_J6.SW>>N@50T=^?%*YFC&I+&1&XB /:U
MHF9N6,A$DGF/Y272-3R]NGC_ 63V-=5^;%UTDO-RUU:@;%MCDO=;53"VPAN\
M-S)?\'[)6RV&Y9-P4;'JO_YE/!B.[T_LY)]NITFXXNGKILJ6Y4AI/1PZQ=8Q
MW N6="!5@7&PLZ$LSL#-U86A(/'M ,LRM7[GN:$_[B'X7]/CGXD>N><IT=E,
MV#XVPUZ 83WW'.S[8 ?J/ZGL-Z'86LRM3FG.$:H&%PQMFQPU.2U$M\PT;8I,
M^6N3_K[JQZS(KZ;QFL8?1^- N-A(48E9:8W$9#FHOD9&1"5G#(#98:M.QC+[
M]5OS"N>%A-Q4]31*;W+3A^4@I_>GQ]SU_2S%%E9@;GT4+K8QH@R$")PE?>WL
MXW'#"%X8,T4Q$ ([-U96W+B%9S<+N4-3S28UFSR.311+L"]+Y@DV $OH'ZZ8
MRJ9RW%\.J).2?MSB*4$C'^C FYN1.&PT3#,04C;MN9$;%^/7Y%J3ZV[(-:/,
M18ATZ%&;BBK*PWYX*47#,ZR I%TP9["=![?I44T;)M2Z)6&Y[T4N]S*CT1(V
MMNW =BB8),'T" <AV;^L:;NF[5U8Y1+8L& +)5'=\<C_,WJ/&(&66JS6I+<C
ML:H-7VI'A,"9AB0X902X:/"J486.O> TBL? *QQ83-%ARN9@/'H6AK$H9Q]E
MF)3"?LJ!#.^"'_$5-3'7Q+RW:%M5F*TR1IUK1F7FU+&9FLR;RXZZ^N?$,<UG
MA^9NG<JXH'[."#9@F)U,0R=>@E/)Y22=2R_^8KWGR+B:I2/\6##/2Y.HE+;"
M8S\.@I0P-O0)=;?.,N RU5!,NV^2"=I[3ZP+U4S\A(:I/2,Z*$LW!3C]%8X8
MR8Z1N '(,Y)SNO>YDRV7CU/UI)-0SBB6^!-ZHISCY5/Z/8FX,RO-X\F>W<@>
M3B@Y'M%30RI?'J02ZQAK2&4-J=PEI++8*A!CD*@>CQDWC^KU(O01'\(!H3.9
MO7TV88G9WZP3KYSC%9L#&QFP9?M+G#0FU7Y%TJ)D-F1Y"W-"6?[7-$='UBEP
MLV ]))-+%"20J3B@&D/-V:W]<GQ\P7EL.SOFA3YFT+DT)6":HN3.->3_!(+.
MZBA,7C8B ?Y:M4B%/I+@JDW;)A_'56]MJ#%L-/TV&]"= X08[Y;A=QP)H :;
M9T>@4 "R2J.(EK#9;^9B EPGPEQ5D]*I+/F@G_I>YJZH5JQ(#'X8IY$L*: #
MIH#0BM\EN9$9C 2KNG)2K;ZO!A'JI2FTJXG)-0I1") 8F>,)W&P@.#^$*(";
M7C)E& <4B3PYPCV"I49LBJ^(/(%T9C/*X=:.*)G'D=L<=O(N0Y#A,Q&M&C(L
MX_^V=ZW/B1M)_%_1N7)5=H(Q$@\;5^(J#'B7K-<X@*^23RDA":.+D(@0MKF_
M_J:[9T8CD&S ^!5K]PL8/69ZIGOZ\>ONN*.\Y8;6? )0.PLT8QJ@Y!':\B %
M\1=JYD>])C"AY[]S^Y9WDD!0'C[1#,-% J0A^XIG+ ?M@)!@SFR4-B0\,07=
M1/0O 9VHZY: );43Q(+'SH!>6%&4-UM!Q,O4%M [7FY>8HI=<(1/>+'A!OD;
MQ<0!F0/05: G;[, U>OE.XEZ= 7?97(WJVTYU)ZS2V@^N6VY#..(J0T$'=.[
MP2B"Q#&X$8Q_2PCS%"FCUCJ/QFC0"ZKCO>X$=J72UQV^AN;"]+82J3$1Z!*4
M#&G3PY=+G'!!8)7=.T=@CZ:>\Q!OM%="S&)=V]!1I+VJK(L\-5YB^C&ZDV"0
M6T>1 T^D6/&=!RO%Q1O/'60O3%IABD3_)A.X .BJ2%]\0<NQ'-!Z10MEXT6(
MN8[:T1V-#L]Y"[O^&#K+-J#3S.U;9FV@76:[U.<3UUU9+%&?> HP.1_;J233
M)+A<\19X:X%:%[%9BD9],YREJ<RRH*TVR@SGGB-@1!@\%@!$^+'?;KY&-F.?
M&1\>VR0]>4[QSD1OM2R\BXK)]GRXX&V;=4IJ<?#0T+S OZ5NJMS!X4 ')Q@Z
MLT'NF3K&L?T%X>Q8I?RO3(*S4Y"Q$QS&LHM-'_XTG\[@B(!1&"7=H)+G<$_W
MO \_)+L A,X$FX^+L<R(GC$SQ@K X\/JL<V@Z<;PT%#.ZW[<V:G-6W:)L>GU
M<@4WE3E!?L=#A_)@T"=$.%13XP-:'0?XQ80GP42/!%/+V"%-_< A6X):6&-+
MJ@?+X0G'1C695FV2=.(ZTBQQ=4R%'YCMIF03AYN\\5B]U7:H_#SW=/CB_>36
M -WVD2E+O.H4GA$)30["D#[7&[P%-BY^<,01CY)9='A05,\$_$2>KHGVJ/'T
M2:'A<Z3!K*A"6:,6Z0$K.4X14[F98G#'CG%VSF*_4^A#"L2-\WYBD'$\IZWD
MBJFY]B][G4'[>YD9MO\Z/&SXUC@(#P_/P)[]=([[:N4IE_LC?B N>X&86OET
M)Z[XC;SNJ:/Y[:9Q->@,&H/.?]I:XZJEL3]<BN^M3K]YV>W?]-A/Y]V;@?:]
MT?O6'FB]3O_;F[G/E_V&ZSN-E5;F/9 ^X"+/Z@NW1=K">IZ;C.%G'Y+)'94>
M>^%)@,QR#'@[+QY^)G<]/_^"D+$BG*\6=L002K]$A()4),&7K/:0Z&0O#%;L
M?S(,PA"3>&0:2>*]*'1%BV8F8SD87]TAF-JG/G[DS<%2XR95:G<UV6="387"
MI+,9^L)'[%SP_X(L >AG2?-B6KBS$*.3!21$RRB<#!A<:&JC,$N.*FX$D^S4
MAA2?4X<V9>K8-4T\ +)")A"F\:&[YIT;+0HJ!<AF@Y>C?X2@C$LKP'W^3+3=
M.2CD$>:8&"*M@!Q8($TLOLJN[,2JUH)PJ0LK:+SAG;)8W'YG]+6Q%\_8]6!M
M']@"_H\2('%.X <#GX"2PL26F6?-(G*3$4/-6T:7NSI[[$#D*EUBT;@)36J1
M&FI0?@65Y#L,F,#^9C-M*44FV'$4'6*32=^,N'MH:<)PM(Z8L1;P3#>VV&:B
MR2T?G?2D^-!XQK%11P$=AIPBT\#UDS7LDBO N])PW4I:D@(OPE%(IIL@ -\U
MTG^"(7<Q7K1 "MSSR"CB+0JK:=O)_!IIJB=ZL9!>*(8$KA=ELT$3%YM)'J4]
MGVB_D]QA6\BW'4G2K63]B(RK?Y"<C^<41P%-GB0PG\%:*KQ',7,"C#!E$!OB
MVK)=*W>B0OQPIG)HPH/ERO>-F<T!+2U3]W6R:Y)T(JG;7,DK",(,%[UBBT=C
MZ N;[3K9=1^Z--5(6<!8#:ZDJL$?3 %.JL!92O KJ,&5-#5X-XKP%G&R[M6@
MU[WLHQI\W>LVVRVF^?;3PWGQ=EK^:ZI:GUKO57Q:480WW*C:SO;Y\HRV<P1N
M770@=5G:<8=/)BY:L2W>!/$5>*3%74,]*AL:W#X=4,V8:$K@=MUGI9)7QO@W
MHN@K5'9H^&K;5*CS!?$<%].BF3X4.Z)F\RD@46:B);S/X3[H+4VTCN:*2^S\
M5V#<26Z RYICUQEI[0=,8&!G31=" TXHU7'Z_4(&(_CO!>'>H).'W>ES;Q'J
M\/'.L-2=,94[0]M?=;[--+UL'NK5?>< K]:K-ONFL:\'FWCDN+=0_;' JS,D
MZAK /TQ=5EOB:= 3,A0Y3.Z,.X.*<:M;G+1<LL)SB$CJ*93-H""R[':[!OW0
MQA2TQ[QOGXP?$>U2(FYJ5\GD_(=JM&,("?+2-8[S1JC3" P.T/_G0V8S*DN1
MH/\]-ID&Y9@W/[<P2%C@70G9IK>YIYT'=7F9$%[#,/;Y@YG!#)C85]QO-V7\
M*O;8P^Q6U>#-(!LO(,&;L;6('@X ZG'IJ,'64G:!]/COOFUDNLHZX!AC\N(K
M=BW9:'RTECI:M12%\(H"ZV+?5;3TW!0G.K'QZ"!CKQQH6/I(+O)R_9XDBRD7
M*V'.82 4X\"BZ+^JL_Y-,(S42!_>A)R78H.1:UR-WH.KY"_P2D?!Z@V%S4B7
MH_[>(>I/SU%_.>IOLR.$;-#NX&N[U[FZZ/:^-P:=[M4_P1Q]VWC,=:,WT#J=
MXHX",MK*%MC0#,45UI0E?IM("VVWR_:7QB7:PNU6Y^I+/]]N._%[Z.]FM^$"
M:\H*?]RTF,&2 2) KG41*F JL0W@31L^Q2#;6#GNQT!7T*I,H6!> V:D4] Z
M[%=-SRPEF,#=4@B(F2;L%WP-Z,'L64.H88&@0LM1X,,#65B10&@19'U0: @B
M6Y$;S:-8>=2F/*O:<VXIB1J*<4,<#N9*MW'0@XF6^H*#$;"T&"'.$H/#, Q.
MRH4YJH.DD&!,2;0M-Z"D0*NEJ\<Q!5!/3I!]#7#S]I@&B&%?-)J#;B\7:CL2
M:HUW(]5@<36^NA]:H#T)3Y4E(C'L+*#AV%;"N0/0N+>(O1^;04LS$:4Q% X!
M97&<U?5C\B60!>R:P+L#)XHV9@O%C'<(OX(@I0#QN0,%=03B'#M?R(?:CH4>
MR(*V".80[H48J\5$&Z52B&*S*_ZG>T?6:5U+EJB%)V#P<]]D7[AP9$2?8 R+
MI%YZDD8\>25C0C2L0"@:/-L/,#]U!PN!3C+T#W[',J[&B4!()&>2FLE!;C$J
M6XM#4F1O1&=5029?* F@2R<LXDK@^GCRRUX\Z5Y1O*B8=B2\,YBNB?!W@2(A
M^ A@]"E22"%IOO6Q5#0_B!+8E8T1[$6MPW<&EBZFU @>^H8X:5RE7.U@@:D#
M#B0=$WZ=;<MX\A9N3_!MXKFKX/(625!",:4([5($6[2^0D]!8SD'5Z1_Q*AD
M-1'$G4AZP7A-;Q8 _M]TPZPJ<*(0\DH8=[G,<URG'7OCR!2=F @"OY%-0R+3
MT,'%!"<MB :^UAAI6,2)2#C=U)-^8\#_6IK!S56O_:73'[1[[5:_<=GN=R_:
MO]UT!G_D>L).] 3CW:@)ZDIKN-1:]T*CQ88(P$VO,^BT*2!\TV_#C]Q2^L!:
M!1-Y#<:8'C\JR# B;#BZ1H4U8.(I!X7]X4@6<"F2YJTF*O[\Q\O+)F"S9G.>
M6D3VQ^HUB&7F.>V)]^(S!=HZCB$J U".5LJ-YW WC ;P8%KJ<+'J@V_1,4GS
M!G2_K.B.8R)P.0<W=ID*!:>L+J F/(&RXTM=@TX_V4>)CXB#K$(XK8&*2@)>
MRLB2E,<_(W!SRJ3U*NGFTT08#8#U!;:<B3ZJ[ B%5EFK-_.+^3SF/I1_F=%*
MSYC\=63V"1^-#'PE1#;30W$"B&!3\OV@R,8#ICZQ(^B'6K6. ^-!2Y%^"6.#
M')EG&&RM]D7CYG+0O[GN7O7;5QVFVA.'YF)Y-Y#T=R.6Q4IKL-0:K;4BCM^'
MZ'VJ'5O@/V>S?^]<M?N-B_;@CQB#G_LI=@0Z>S<;'599HV56<BT^R@:/E+RG
M9R8758MY=M$.=WAU5SO\'Q++VH7:W%H+Z%& !$<GAJ1!,Q!PR$&%=L)?I:+0
M-+UF'NH 7A%YP(\#S@ZTG]V'4_:J*V@!XEJ:;T[8Y!S+/H7'Z:5A56^$8<,.
MII%C7WCF[1[R&M0#^[-L&49Y9!MZ_=BN#(>5$Z<^K)C&:%@^*5>JQ^8>>H(8
M27H0W[9@6J5*28\"_%0K,UXC%] O>^Y#=#IR'QR;\98W<Q@39PV+G8=/CZQD
MU9UR>>A4+'U8L6I._=BL67;5MJR*P?Z/GC,RD][X\U%BA&?+WPOK47803OQH
MA;!.W1J5*F6K/!Q5JKHY=)RZ7C(=NW1R8M8,XS4(FSHPXWCHU'2SIH_82M>-
MDED_KI>=6KEFVE9U=%Q[SL"D[?0D:8$))H&]#*KB#,#&?ZA+SY&21 ^W0=;P
M4Y<E$&*$552X#$-WE=()<%!/YMUK_<-O!\\XN]J_?^V<=P:Y9K:;<ZOV;C0S
ML;!O=U[EZ+N70]\9.?HN1]]M@[[C8D&\---BR5 X^>Y?JWP.?Y6&[WJYUF6T
M_?#C3HX<OIW9##US.F/7B$^O=AK5B\;QOS..(SXZ(13YBX'5-(SG/F'RI*UE
MZMH]C-VA&V5DB&WQ0)*J:QU&C]2++E:,#,+$L<:UGU8OI3R+"+M"9TG?I,C>
M*;&U%E8WQ%HGVY[:.]QJ6U#T%=;GT6>]+$%2CB[8#$:IPBSG,B 7JM5-MD2<
M82(/@W$436>G1T?W]_?%F6,5;X.[HT9HC=T[9W;DV+=F>&2;D7FD5XZ-4ET_
M8JROZY52N:8S*Z=<.3%J1\-PS,R?4K5Z4B_]Z3SHI4.].(XF>V=ZJ:C_I)XG
MC^ZMK19Y70KM;BN\U)H(Y3,D1JT4J[S<'O1I:5#E*@Q9]1Q$I-C:=:NOG;N!
M;*.QT)H<G A6FE'2*UK[[SF4HNCX( P@_^S:8QKD?@+&F, M<M1G#Z-=3.N(
M"Q(V>8'()>#-">!N$%*3 5E9IH.6AF&!Q_TZ]Q::?DP^H8.M2\WG\NA#RR,A
M3([+E1H3)F5=").R7M1_S(7)>@3-$"9-& *4G!'YQ]>R=LUJ3NRU@DY0LGXK
M^Z:2]8O?-JS"1T[%!/JAS[,*RR5#>G/-<&CZSNRP^^ Y*9T"9>'!DI'+BEQ6
MD*PPI*PP<EFQ)D$WEQ6K^?&YK,AEQ3,(\@:RPI!ZA5'4M5Q8K$G172L6^@F6
MY6L6)5OKY6KI2=ZOEVKIO*^RNK8_FH<^=3H&<#X8*+E=D?,_YW]#\K^1\_^Z
M%-VULI#S?\[_+\G_>DDO=J[Z/^:\O35O_W[>N]0Z/K7"T5J!-2?H".4.\C_;
MXL]VX,RP)J8YG4(:'D]WPQ)+)M7 :IF1R<2"!QF:ECF'M.IHIN%K(O.65\R:
M#!W;3A:?ZOB8/H87BO<=Y.S\V=BYW_R:L_,:U'J,G0?F0^ 'DP73SB,HL0VH
M+FOL3$S)WSE??3:^:C8N<[Y:@UH;\E73]"R!G+QT_;^@@UW.99^6RUKMBYS+
MUJ#6AES6 M2RFS-9SF3 9)>-\YS)UJ#6ADQV:0X=+^>OG+^N>^V<O]:@UH;\
M=4U--'-=,6<SQF:5G,.VCT=@86_(U<CP/.Y3;EY$991<Q;-(W965BHH"*\T$
MW];>1O%IN]2FSY(3IY\\E1,7OP];P]8VV9O9N6\95?@?VXLKX[E #*P(,VG[
M<]_#4F%0YNW>G6'C4MIL0P>R,%-"4R^PN?*=L_J^G][-GNGX-H1,G5FR?M-D
MRO0!,PK"A38%N#8V.I YNUL',)\G@_+TRI=-KRSGZ95Y>N79%NF5_<Z7J\8@
ML]31*EG6S1&+'_P"#>[WSE04"/4Q4KJ$<VQ'LC4472424["[H@TY(QA#MM4N
M4+RJ''18I2)V$& >.F/3&U&_*(=PJ/P"+-TZA_I]^#PF]!D%H0_25E4./FL.
M:75CVRSE6:GWPWA!./ZR9Z2?L&>/ID*]EN&\$P+P9Y5W]ZC*QM;\R])B#15I
M*>.U,;]E8D/3*Y0;]DR[.)NTJ5OK?''ZS!=F+L"S4G[/CF9'VD4(3;O/'7M^
MV+#M(-_I&RUM3KWG4 ^\E=CQ#5TF&9T5L]/YS_8?P8B_&JSKXZW%F\CLG!;Y
M^?42Y]?CK>2_FQ%3S>^UKZ[G+9G'CT[E4_+"&MLRB[(Y23?@IXP6P3D5-Z+B
M?EJ"".@1#<L*F"D.+O+GZ@+BT]8.SW4NB5_W85V/E0S7XU/SC=V)V_H'TUQ1
M=*:<8DU8Z3(&MX7PQB<C?OBW5=^B^HVV!GW_^6@8V O\,(XF'OOP?U!+ P04
M    " !<:0Y7HZ8D?W0(  "K+P  %P   &)R:&,R,# U-S,T-E]E>#,Q+3$N
M:'1M[5IM4^,X$OZ^5?<?=)G:':A*0A*&F2&\5 4(MUQ1P$)F:^^C8LFQ%MGR
M2G)"[M=?MV0GS@N0,.S"U29%%7YIM5KR\ZB?EGT8V5@>_^,'0@XC3ID[@F,K
MK.3'ASO^?W[QG[4:N10!3PQGQ*HV.=&*,BW8@'L+]SM301;SQ)) <VK!,C,B
M&91LR<WM=2@D)ZW=^I=ZL[[7_-PJM3]5Z5B+061)<W]_C]1(J]':+3>OU7R\
M.WG AWW%QJ0_")14^JCR(72_"C%V+/E1)52)K84T%G+<)A][(N:&7/$1N54Q
M33X>$'??B/_R-FDV4GM +'^P-2K%(&D3R4.XXCRWR8>&^QU4\OG2)%$FH@PZ
MR0\JQ+4[JL D6:XG,40<!]0FG]*'!6^D3X/[@599PFKSM\JA>)<')*9Z()(:
M1M8F-+-J<DG[3ORUOM*,@Z]$);R(F(EA\2SAL BNW(ESL1BBFZ-1/HB^D@P\
M=A\BT1>6[#;KS<.=6=?'AWU=G.X\WVLQM%6Z/>W>]B[.+TX[O8OK*W)]#FBZ
MN#J]N.E<DNYOW=-OO8M?NZ1S=4;.+ZXZ< .N7Y^#???VM2.Y^79[]ZUSU2.]
M:^CZ].?.U;^@Y],>N?UVV27-75IK?MJBVSO-/>:/7CN SAWIG%W?]+IGI!S+
M7??4S<UNH_7:/<)T]W[NDKO.[4GGJGM7N_[MLOL?-V:XTVHL=O@$$(X/L8<B
MH@6*752A!5H<GVN:W),3SK):AS'U=+,JC$=;$8Z)C:AMYRY6#<O2/JQ+ 9?2
MI#2 9>NHTJBX\Y0R5IR_=&$9"68C/&G\N,HJ0P))C3FJG-W=G%\*8WL87.6X
M6"JG2^:AU<>E!13.61%CT>57['^(,Q-0671K5;ID;6O68=EGSSCT:\Q2A^6!
M_9X9?!8'E1EWLUC, ]"#_E:C2O!O&Q\_B>B0$\V'@H\PW43"D%\RJ@&K<DQN
M>:JT)2HAYTK',*6U7X@*R<W9'3D1RO(@2L#M8 S91(,EM0),0Z7!#R<IUT(Q
MPA,&CO^=)1RH4G5IYJ",ACS4V<F 4SWW". 2/ID-O%:"5^MMX#4-X(2B? $X
MQ&-RGZB1Y" JJAY@VL.**9CK1(&$@3FF(B$T&9,LL3KCX!9$C=,W@#<*J1<
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MSY917)T=XS?H]B+_GOYO4$L#!!0    ( %UI#E>%@+HLEP0  ',3   7
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MPGP!R*Y>(KI\A(O# EPBP\$EP\&T \P @',%Y]<%_-N%<PD7BQ?_ZC4"0NR
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MC0KLJO)U\I';X<  +#RQYZ]S,,"0SDC,NNR=*D5U)DH,<"TVO'G#:AP,E[1
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M8SUY_+-"@E%3=>]O".EM,&$-+9YQF>]T&P-\SO.A9/,P2*NUA&B._C-<I,>
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MOC>0-(M%XQ8@=1.]YL]5!QDJ?NB@VX;!&]26&.#5)IH";+DI=T!8C@&^>&
M@LAV<];A!BE*:$K_]VJ3#]+O%3O=61>J 2V-%]=07.JDIB.>TS[LPV5)BZQ.
M,:*)-HZV1+F7Q \I\._Z$9Z'84O[0=XV#( S@H7_FT4H<Q1P>IDZO8^8$C#
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MJ]BZWKR%-E?:-<F7) #61?CP[7W/PZ+X?N[DC'@RZM!;6SN7E0WV.YHMQ7T
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M]CLD?DWG2X05]ULP$IN_1LF!=,;\'=URM";1FXGKKM;QR>JIS6);OAN$-+5
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MEN4G7(2?3QO61KY^<>,F6AH>B)((LJ7PHR3LM:JXGYZZV<ZFV[80,_/$Q#N
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MC!N*]GK_),6,X[%%;1L1HS#KKQ:H&7DD?7J6@',,'AT1H;/*..2XG=;A?,T
M'5ALQ*+>LS?9=-/VC(*!7%O\777QD^X'I/&S#RD]\76)O^X8WMIQESEUT\O/
M&D]MNOKM%%^\:#DW7Q)PBFN OJ9$Z;,\*.5FHI+HSB1<5JB2NIG_8O2!T=B&
MY(G/PL6(!_5GE$GWD-XFU< U60J)]L:Z<)UWTKU2K,0/&<,:2$8O8E#AY1DM
MPDH35."5\\8UAK5K9D^])"\G)S)]JOU)VV,)5YS9Q@K[+$S.O:?6:H,FK+FF
M29'VW[AWZ< PRE^-LO+=LBYPUM&NNJ;-UH^JYX-N('-#"U;M'_XHN!B*M5)"
M]LOL'<0=I2G<$#P>'](/M6;PZK*!&G%.V_Q&4Y\X\45[*:7'*YC[IU'L]#W<
MB>=0TF8]O/GDE\<=+PVX@H4J9Y<G_/A$:"WK4]B"D',%DL\;KETB*<*#+^F:
M@_G(0([E7?,\U8664->4\?)<B(7YA$\':)#<[JL\S]"-MGA\AY>B#/! F'T%
M^[3=+V6K9R8LWWVR!P)+R7OCU;ANA<&:NQ2G>8E?*'G2^RY VW_TN9\P[]KN
M$G2NW-8LG,*%(K**7P5UECZ\U"6=W6(-L<O[YD?THXYT[^H[P(,1IOZ#@_S)
M&Z$5C19Y.\?_0=Y;1L6Y;(NB30@A 0+!78('#QH(&H*%H FNP26X-6[!'0($
M=Z?QQBVX-]HXA,8A2*,--/!8^]ZS[]UKKW7..V.\.\8=X_WMFCV]JN;\JN8L
M7G*=LGD.NN]$+_)XTB2Y]H,B_2&2D="L<+Y;!AV9$-D81?#X$4-CXKG@P:5X
M?&ZVFEK?I('#S]T3JC.4642';A*T_UW3Q&$NL))/1\<L7J2&M><H&' B2-DK
MT.7QNR&U(9S]G+78#PQ5B$JMGW[K,_RX!?TR6@_B%/-%WWCMM>,=?D.P!%T^
MU1L57"YW@Y;3Q!I\A+1FNNNHC?XNL<:U6P]FVM/%FT\*<+(]5\J&0<*"D@61
M'^A*"-QL')U3V(U,W%;_]N]3X;9NUZ7U-_N1ER6LP0AK(6"XS:>^EYI2I=P_
MC5L-(V0=">X!G>D#]X!WX*7QOWQFX)4++&TX0_H$TBTD<Y&G)9;HP-L@9AYD
M0O'].3B"ZZ@/_>-Y$6?HD>\:\_%ALDCX0I3TT G,.?80F$GL__G1&YJK<@\/
MYZWJ=J*5Q9UKV[SLO=J"=I!I\8H\5TI BJI.&$.T2F9V7K2W!&4I-:&.%C &
M)A.H/+JM*5=D%?1-*>@[>AV:'&4MLAAUDKD2;9K3KBZ*N*>9/\W1: HDK&)G
MOJ7[X88&G$22GN.0]'EE#I(W<S/*<@^0.C;O>674/KE><P_XYN-8[^'24_/4
M%/?#^^P.%MGU0.2#8U2$GU@_1"3:B\"$GU4_119DRN@GK"3'C"\ZJ]P#?47<
MF'>CGQ%&SG+OUK?33N2U--:/_X,@??BV2UM^;,_OG.8@CCF(X9:?R%#XJ0W_
M0K\,(JQ@'JAH<":?AIEBERWW,8YCBCKQI> ;^EH<AZP/U>ON7C+4W09D<B!?
M,ZE:J18+_2XY@> 7'4SV)$AFU'&+2L[9[*DS&SK)2>-: 0'MC;2">-AF7K2,
M; 3/A_FC':&L H=F#I 3=8A+!H?USR<)..%KU:DZ<BGQF!K1_"8:MN^N0BS%
M#E(!%^1MMEN<E',[*OVX >OR3>T<\TM4@H92E X!#(+K52 %7##Z)#NYMKS%
M.1V)P+.O<I%B]OFG,2#WOA#C/,L.LG(;9U*9^';J%O,@!HY0A=Z*IX/"F?<
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MKVT/HX]^^T/55([8NMCT\1/*&.%P /A_OP\UYL-R#XC+TK@'5 YVG/%HN93
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M1*&6I-H;<.$,]LA!\"J]&7_O+XS'UE$YDD0K94['=).SZ=HNXLNEGX1M0ZA
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M7'C[?$.,92[_@A^U?WT;</,J&/SU6C_T*AM!0A,B^@R^_2^YZKT+O ,6JCL
M\HX'ZV843-?GR5G8Z>^"B.'R&?&: C<X7NYV>?+O6O\I=B/69O@_C+Y7#C-9
M'S3I2C[OBMCP9UJOL^I@U V6C(*#)E10U5-U<VIDQGM&"^D?MF@=$*ISQCG=
MN__5/E)1#%L(L#D\T)$J:)(H;&/A#C"\OQR=W==P!X#,MCV5H'CW7V4!0#7-
M5J5A.&+P"E,D!7)UF_*3$*E6QOA*0/ST1F"#Z:<=>.O"OE<5[=^JL1A?:^@D
M2&#<:9\)^55HY@79'>!>6:_:/PE5U&N6X)G[[@>YN@,\E?N=DB#9+J(Q@B#
M6_# ?WX##+(*O(/ ]VS(3\+?"22?_ZWV_\]JB?!KZDDP(78IJ%C.5"%W '+
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M0,OE<_QGGX^5&3EE/+C!&ZZ5;>@7SZ?K%M!/T7O5GM](U3446.=BW@I/2.P
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MZ/\0W,.%1/#N2_^Q=[()T)/ON KQ%HQ3)LQ"PLH5BA6?=)^%%05V%%G,.-P
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MV*$XK+\+],\;![\4+=)*S1"W;?PV!VO63QXS07[KN_N2G%SQ5N"H;G3VIV*
MW&+P_/>_VTCE2&KW!D,)(LL%\QGIZ;8C;Y,3ON]@(!2,07H70?_6OFC?C-VU
M!) KDB[UO=A62F*!FT75Q!I:E\'_?L,V2[DM2-!M)4(@21R+QV'R;/P\ALI6
MO2DR>DKC[TR,N.J_L;' _QWST#,Q$:W[V#@HO&)-.O/;0^[W_\\]9(-Q;8>#
M+-K-5"',"]4T^?H*(YYF&CEC\2Z[L^#8KMCF==$C9Q_6;@U6C6)SD[ZOC@:C
MF]\&[B<S]U"GN\SU>B]&KG=/)*DH*/W<[)P*D1@8[$]_+S/!_UC@)!E]6Y]!
MWC@:7C2$DT)>?"^:P*D"*$"WH3)"=4VY)-.#S7K--Y][FI(RYCWZ['%N_*WX
M^%:Y3LH-T)WM;AKM]WS5H[J#IY@3#O<N\&"5-6EK WN3"32\46TO/H_Q6M5T
MHNSQHN&;H)X??:[5'CRU?B#)1K3Y]O8O.#$9SSY_5)EYF^N@ Y2L#67@_1V3
M:!"L4!FT"J-&< BKL"<P$A%(W&;M1_>XI^IGPJ$DI4Y\ M:>&I0]3.*N_*O
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MBC5]/Z?-NT<RXKV>=4_S>K.@!8[&:C_U8]Y_.Z&D:,^]XR'8=/RX 1]_C<E
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MH,$4]"P0@D^*WU3&=0L.O2WO65T3.T2&7YRP.8\4#GGZ$Z&IL-SEF1=F##<
ME;HCL6<I/RB,# #[#X3K$A3)\ES;JG8H[=ON[I%6W(;+ZIW,#O-;"R:IK>RQ
MQ7Y>_QU/0VB[/;'\![$II3,Q%>8OFO/=*@(?#6*><!S M@YO #.U\X;^E)M'
M+TNC/%Q=W2@D.@P1^LCS6"C#"=&_G4[]Z,^#AO7^.-IB]/;3S!R[O)F6^3P/
MDKQ*OTW;MY%MVHY)!1''4D/BE\^G#<I3^X8,_4<3"]5V.O3<TFT2 "RY!E)H
M4NXPLX/6,@]KT=/$@A%AT[Z[BK81"&DE\61)YX*WBQ3B*T3]3SEE1:>E=:1I
MZL1\Q/)R>ZQ<N$*^>I=2K[Q^H(@3^"J?+L MMC- AF59LZJV,12!6J,KY59*
MD)AKM]/M/<1_*R2\&:][;$&^@5BIZLMQK#48-TE_67OT.!182D:]YDG+PC4I
MHN;58^ C=NTSJ&[&#?^!>ES<N%1J0]SQQDL"%_@DW&?B/<\I,BLJ5>_*;>L,
M3O)M%MDR!/]<&W__Z#6[*(MQ>2_A>15VX'(29];1_/[820QP<+Q9[PV(O:6D
M%\*M),6B^ZO%-4+H'LLE!F:FT]W(G>A+DEE0;(@P&XKCIU_7M1MY=<N[3&CB
MV#<*/+/=>4KN<-3G698[(%H?\B&R\_#.Q\IE#@"%VRCNIJ[_0]-MAHRXV.,!
MJTF^6>0 =4Q^5EY)&SBJ_[9T8N63X<,N^T?M H/);*/XL*UYSC%WSW@/9_W>
MH1SY^.ZC1]0&CZEC-9YK!0!WLEYFPDF>GFZ1.$XJB(R 5Q7<8^I%'K^P).^X
M'0"*/!C.>-Q&/IP#M;OONA1%('\H_XST3;T0OVO,;*F2N1+,X8JS*J&K0Q Q
M!.9J2X%^OQTQ6FB(G1'[B7LEY;F,I$,%B(NVD6\T$H:#C&%)@9]1P.J?%?L7
M-D?:CL9[2?F/G;]OB247<ZH]I<_3FV/8G>V2>3;_!;A+9GPTPF+AF B),YC(
MI85[QEA%V)XR6,T.^!N*81 &2O* 14"'$N?*:<&B'_^>D3^%2N&O8?.NKFF5
M^ZD4TA&>B$>A_><F.!69$-E/.%LTC?,I'KE01Z0C3>5FDZI?(=<=:=("KY>K
MU3< :I-M"_+C)C]*_:!+Y43EYE0Y9_;^4-W,&=T5KUN*K >/5FKXV-=XH>1M
MI[IG#$XL3T*Q(/EP+/:7"3+%YD57X'W^9UMZ3?"]1#?2"G3DH/Y$]6!_R0V@
MW.6K[PR,!8?C_+1',Q2G$N!D<_<H>G$4_]NL&G6S@&AW!)6RN'!#N]:6FHT#
M]O'!:0[(V^TUS&'ZB5%V DJYE#J9&I>S C\ 7QINT*-*OW\E2)MH>W9@LF \
M9V94P(TB6-5W!QS,WMV5<8T<"ET3H(!<=B&2(ZR]J%NS\'[,S6DXGLXHZ1$2
MD!:9K'6]?2+FL18@E(M) J,T0E,N:D/\P'?R\,85T2^$^M%*IPL/C<(L-X2/
M77A'C\ON;5RTS V5IA3.F)LBF=2H*'FK_5HMR:A7DD]UQ#M:+#J/?LW7YH&^
M#ZQWG#H ("N3J0HV3LYO-==7>7!+>8O0GBGO9#D@MFH,DQU-RI.[+*@'M27>
M]^B2/I.EK-T.W'%]QNQ1%N&NVF*LQC^M7Y&F'2>UJ^TAQ/]TU2V5L1O!8*YD
MCZ@);TQP<XJGGW9[2<@(&)GOYV"96L'BC"YG3G<B;/.^8TIYK]F5\YUEU9[.
M2["EBG;Y7SOWKK@HRH=\%I=.--/HO&:;@:3U&E09J=R=%C^D3I;G\#F?(*_.
M_(6 ;/< ?#@K.;6J$RIS'<6%!=MQX975"Y3V/GFPJ>&TXE]S)HAT#4[AXL<6
MO_W%$G#DA1\\;W'F=76-[U3L%L(W35X"E 995TJ^O]U '4IFGK'-VYW)06O.
MT-!XT!HGDM![.JK!-9R\_".@'S<I(J@Z5'00CYX>EW[S&;-S6*0(WPNUILG'
M'E'$48RB=O7UD1XV(<\&'LNU VYY%_S"1"E.BDI6;S-K_T!AJ>>XFG5XE8,G
MOTLR@WK ?#52R+((BH[KJN_(!8C<MU#4MH8A2?=74T!X% .%XL[KT#WH_]7>
M=0<UM6W](ZB@*"B(]*Y(CU*D$Q0!$>E2!&D7D"8@4J3'1B^1KJB (!U$>B=*
MJ"(U% DU@/1 :"%"2+[HF_'B??J<^]XWK\S<F9Q_<L[>Z_=;:Y>U]]EKG9KR
MFEV]RR>WM^ JQ47649V3=M-V4U)!8E:21U05;YPQPZTHLMT8X^FQ&+#JY>V_
M%7LM=ME8_/UI9[R(F\:SQNI3,@WV8@X#_#E5^YR,/6B?;WQV2YKT(W=U2K_
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MI2QJ88XXH'T6P O<"LOY]HPJU@.V*TX$ZCL D]9T[MP?57-RC>]+P-( $=A
M$';$OSW2?: V3%0@ZUL-'-\>V>?"'?$S(7GET]Z"K?F0I47(MCT1\$\J.QA_
MJX?,KVL'9T>NQ=.G$[T@$(S5*'P%VUJ%-4.7GIFK05:F()& >>OF"6N?L)>[
ML8[SH%V\RVKZ#N]@K_D.;GQ*D6%-7IF)/2T;8HW<5B<"$!:\':&M;".10)#$
M=1_ 0W545+-S.8;.U\<0@?%F(L ,+G;R/TT$8)$$\7V0OX3^)?2_6JCV.5)'
MTMJ>&?^@#_E6I8I[N\[MG'+-:^5^S21/5Y'9FSWM96UY15U9 G)9/&E,GV^U
MLM7"][@^['>(>R0<_9""N^#'3P04V60)^# PZ@ F:Q=P7]E9$S3Y!DWU&Y52
M; GAINT2J<<*[$3\J9)01_",Y8\*CI>45Q27A2%[Q8/&3E-&I[[5EMWW8[ .
M-M+JDS8JQZ$-^49=VR[FGVUW'?R@.M=3AA)@=D/E6C4U"E8^?2E[S!(3_ID]
M+0*J<PW\0_)D!-7L=)X^?9IOVMQK4P 6O<#7NDFO] ,V]T#3/F$/+BKTTX ;
MQGOSB,#O(,\CA"_U9 XI6&CZ-4\QIAZ5^T^TEB >=-$Z$1 :_UR@%;T@>*Z4
MU$A"RS7UGRE8>?+@';3^/=W@&AW'QM>7SH7?:L^>1@@;&"7>"G:5^QS9<F)?
MUB]T+"JOK/U-9L^W:E*I_A7#%I$:WY6'R1UZ) $?_$7[;T9ZMJW;IIRK;%+[
M7<+A9'[,V+.O$38\8]G#T7&HN!WF:1A*&^=(2 :O?+K[,^)P(M#P$C.X*P<9
MAZOB!3B.0A MNWB)D1]JD8*&Y/<'P\TW5DEWCMHO@JE+A<VZKI;47*]OR7K-
M'6C-I96C\&I0_0?FN5# W,_7H?FL9-FX[ &+NET!NL<JZ#1E2"U X1#]H#C^
MUC$OSJU<\(]1,I4/UPA_/AMOH2LGJ7._DW__V5"_=ZR_7;7R/ B1R?M18S!-
M:-0!@$L &_S^N\WT]G!'D49DB]"YP47]']N JOACV''&B%.6%%RWS_(7N#A_
MB:A1^1)10_#XT0!Q;\;F'[<HRE_UQY^WE;0\XX]P)RZOBF4>UBIQ;8I6LW][
M>JSY+]^?%G$G H'UIVO>5"8-++"HV,T$OI=AC5*BOE#(W%TFKZ2X:@B'+=&P
M.A!X$F_8#5Y#%((")QLB<DV#M\XO6RVN;1;>QJ6GC7F%H[ UK^S#(KV];_5<
M8BM_T!B556:(@TR8,C14&R1CJ^4C,_/+BUK<Q/DDQ0+W$9P_2W]Q-M=6#N"L
M]+Z$)M2$PUAP<*T=BA"1)32JJ&^(^W)_<;H]Q?WG%A86>J4P.MS4502!!W=Y
MK+QPDHV,<@:QXI=J$R,-R$$G+5X=?_Y\VJW)K+O4)=2,=@!OLAN89C?H:5Q?
MY):M+-$T,Z ?76\>Y_LE.(%C G(,!]%<9:_<&J@PDQPPY8U1-1_A5&I4]'%J
M[4+TWI-V>5C]HG1^MX C"G\A>Z$<&Z.>.Y>47W//XE$T\['#3LX3R5)2KVTV
M8?3SR4 /0<#4*TLW87(!SQ+)UT9X))RDHA'.?I:%:JMNU_OUX%4,1RA>=?4D
MO#%9Z$UOJ=U2P4R%W<:\9%EW-%. %;IR0",%SL&L]7+>[&#_*437(_>=53?L
MM%^7W)5/C3:R=UJ2@$'<EO<4F^CZE=HW P9P.#H;:>)]LDIMQO,W$]^HBZL1
MU%4S9?4"8PO(0J@<_T2!H'Y-#[I,/'D!N]R!U?K47$49B9>6GIW?D 4SR9W+
M\<J#;YMF/HZN'=@N*!MYH'IXOYWF2DMRO-;DW<"R19*2[S8%'-L1KZY_?#JT
MP-GDEEL3YSN6FJ^A"><4&'#E_H?![/;L0@.\]>68@O=+L&HGA!PU8[857F-M
MJB\6>B4'XV:ZREZX:M*4@HGN<F.],S0\.CS?)<B(IM74N1A[;_C\,B>UFV81
M#ISMZ,-><":TS%Y\U]&P/[U?A$4++A1@_"9**#F5X8Q"0X$7.2H3AAH/0R97
M93MN(8.2L3G,&G)A9G/HYB%@CJ&B]YY\U!_W O\6E)!AZ$0$^@H -65OVY8"
MDT9F_8H@EH8*VA:?[5C9B\%DGW@>7+^JVB>9&.$[,!@A=PV!.]RY M==A@T^
M,D!:%>I[!Y,&0,"T$S*:2CT3MKY"CBMSJF? 7=PQ3EK8TNT3^DT@^F6"[]/S
M!W\#II-GTE=50YP\ZL0N/M/TGK*K5;9U<3V2:Q5S9NR0JEG+$6IYRE0:Y;2J
M K=F8^=0GVYSN%\1SZL[HP55=MR@R)KQU!WX>N;"F 3"':VYI75V?-1LZ-6=
MCJ,%5?'QK+0L4>/\'8#[AJ&LQY0P^U$>C3ZK%\MI?7$2<9ZMUC%3GT;7LJ=7
M!UX2@4>SJJ9T1GVS._K5]L>9"IUF'N6OBAS:GV6F*+79!'B<,.0.X+1;],:J
M1.TZ6RN=SE<9>FC&QTE'25!(7\]#0L+%AW</3NF7,PC3UV8>LES3>AX3=-B*
M?]#S\M38/9G#@@SP@%/%@\@U6:-EBZH2#_5PW^P(W68CFSM916R"#G\JM],/
M+\$/"KSV@R>3!H-.EPQ*M%OF.48/C2@?7<^E3#KT)- <-2,Q?TW.T>U@X)36
M$;OMQ%")9\)L&SMMUG%F4C'7+T7?&IF*O;=$40;X;-)/,6P/%( :O)QY^@O%
MSM<<S:A;4"N^6^K8'^',\[CI$'MEDWLR=SD,HU%77V*5MV!8?GQ4B?Y3QD:S
M?T\;=_-UQK7#RT=7'BJR!W]WDC*NHZ%>]; AARZXX56V"0&L1ZBJ6#^Q3^(V
MC+%6<XP9$P&SB6O)-N/@/J@7I+4BM4V]&TH_:OB>-+S*D6:>0PP1MD8<'O%1
M3JAW$X\#;N*UY@YX3&3O&.?N\(1SF'_L]1R=LR!-T.:3YMN,'E#\T40B$)9.
MH"4"I%\W/!\R<0N&U[?L,;^PA/KXN<M>86F$9')8(VSC["('C@5$!.C-*C ,
MS7?O;B4FB93XRO?UTB@@U4/5*\B//)66/ZN(E4#10R[TG^GQ")=7Z9YTM-\?
MOA*5NG.\R<J<ACEN1+=OF";TA4"8QIQ_EK)>CP>CA#\O0KO4J?M&<S&H7%4K
M>]Y0< 9I/Y2BF^0P![7=5L%#JRHX(M6TB4#[RFX)H4R"Z_MLJ_-/T_V@<<>A
M-R9?95M_.;X'&7695Z3[NUU'7N?C:U(&-_R_[C.^=,'MAA.J8.O&27_8<KPT
M*J3Q^'QL2R']:25)O)_)KLF/4JV2A-Z")LKYS.PY,OAG/FGVG\A/N9R$S7%*
MLTO<SEAW*BNYOWQ:'IM]:FH\;$W8O'&<C@&UX-70AI=TL;Z5HA/3.\ET-8>I
MG?L!]:&ABE-3L::%S8LLD:HHR3#A)3A39*P45?^#QXT!7)?SNXYK2G0-+:^9
M"IO-HHTIEF,DA#Y<!;OO&Y>S&JBWVTX+OB\!"S%.#'JYREOABFKN?2W$O"95
MD!9W58Q.]&&R G9D'2'1-(37Q=VW1$&HO0JO0^&#/B*%[N7M]K>*5=W:1;=.
M00[-)_?/CU&4509/>,8[BM.VW*GFC$RSYH)[&[UC<T.;G4&M!,?@S%&DANH'
M>3F'4)L45M"2U7F3=/YN)?2#P)5T6ZOL=P<4EWVZ*;)P\"9VR93)TGHZC-6<
MJY#QE86KR A=5L*Z)9"S9396B\ S3:70>W6]W2JVVPYX01.ZY'$2X:S<&+PT
M=XW,FG$Z2A$I_=K-"-/?$A4@)3S",,;5(SY?*\&:Y_V;\=#'I\'+IB$;M^(7
MX]GC2Z;F;N+T,/5'0:C=2%1E=<UQB<:S+$^M1@[%>'(T?M0^Z#7M_C:5LI3D
MBJ"&FXWI/]5#0:&EE-RU4>K:S51QEI4M#RX8"+X]4S5OEHYB\QEN)# A//)8
MPWWG3MKH]:LM9(VP/MPHE,"!(*@"0;6! U$O)EGLT\+1U0D9!<@GT]4\TK]-
M/Y]*EK4=&<A:&K*5A[Z#4&=T3O0*E0@DMZ[5@&8HP9& C].O<U9^\G-,-W<(
MX,;8],=Q7Q9':RR+F'B91C_SUF:EZ_JP<%9LH*CV]$0>&M0\*&;&V!6\@1";
MBQ:T?EG)E=&*?A.D3 1L.GSD3^R;XI_0T 4=QLLY=HBH+T92:?G*CLI0C7/K
MS9Q2++[\.O?*D^J30)#<JHDCZ@RS03+2+%#DF9AC0L66=I?O['NKB&R1)=/[
M7(J,!G+[PC:J^<CA =Q>ZDW5A.C)&KK,,?/QD0Z>^4$EG<M.,4<>LOJ2!XT!
MA-/OY&;IYY-X8ST<IPKI'-PNGAS LH@_T'B;N#:@"&=3H:*N+T/H*++KI^-L
M3;M+4_:/PS,+1K'A3A[V;EGY/7EQ3UZ.1%S6>&]E=HC\B#=:-10O]AH'O;S:
MF>J^4C3NL"UJ[^GCV\'T>&G]B7A$OC;MS;?P8V2;A?II]Z0C72Y75:]V!6XR
M6AB4O@E;M8GE]+ZIK%C)YHWT,>20#/;3L;>?U+,\DFJ&2T&CCS <?U5AH$(9
M'\_XG.>DUJ3 ;9JK#\T*E0%O&)R#VL%'-1QOF&UFCS"RWWYT_F+_F5H&VIOG
MSOI/BUG6V\RYMKZ3DIC_D2'_Y,4*A98ZHHUW&FB-+I[6 -^(6IM>H2KFVO_>
M)+9+))T\V2$X_-9F."0$25V7.5<A4Y!1GG+7472XXX@SE*?!,-14]&QD;PV2
MC[QETYQR<<U+R2"!39QEAP@<0R[,9S3)6;6&27.-U(0>J@T)9V6UJ4XN0S@D
M(,<C MJL(*_4T^;F7>D[!I&V86I9:R,RS6F\-D#Q:S7GAXRS40M_?+,YA3[\
M9#I'&O_E'1+316?ZG0."GZ,))_:=]HM<%8-'HJ ,8]<%HAVYUM%M*RSN'/=;
M\8*+2>L@J (SX2/F35\!0M+'7N2VM!UTC".8 B,Q?*]@:6%HJ?-(<W!9AD=U
MW^?<,+["EPJW!!Q9KA<6<I:5*9U:;RUJ?IAW3HKL9>&-W62\!!;M['_GD]B!
MD"%JU8,&;) #NY?S\_2OI<YTV.EZY/*)9%7B]%2@< +;FUZ4; *2,P-6VY(
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MO,+VGPS_[()4L-7$R[@Z8Z9 >@44@\]#=@IU:Y[WVQ<9',J<+F PKW#_QRG
M[S! ?UM10. T/P:@-O+0?N*S-G,\'^8[5_AT@1]WQG@S<?SD.LWCU5CN4(.8
M".U8HZ">'ID Q[[?C -":&TQ0=:.L=9H(EK" *BXTM",HZ66L]M<^US:)DSB
M!7U3=F?\/0P9OPB;CP%>M[1G'-[=8D$R_;ZR;AD4*KNZAF)'LV& CZ%&&.#K
M!@3Y&?3733!@HC*26)N9^76\TJ_CVK+"B:3/4_Z%A;4?K66X_SNF^>OFD(7Q
M,![L.O^3&'@\I!"4'C#P3X.P2)+SBSNTKNZ?AD.H @V9SXD8Z#]WQ2_K6=_^
MK_'^>XQGD0WO,QUSD65&SBWMZ36G+\U-5 KV/=\=8N$=U(N+Z2:*5D5P'4%?
MS^\_1-^ P#YB@"$='<?[V21W)).;H_>E4>#?IG/\C_<B+2KP_[K O^0"38KJ
M+OH8()@P.?0X[60Z<K7-_3CTP'65,G)R4,""W:(> ^P["V  V EZ5#BIZ7+?
M7,,Z5/8/E?ZS+8CX;S2:G^WKHR8#R*M CN84W>;8,^ZTLAF9MB2*)WP1&DJZ
M%I9_,\*C/XR ]RUC7PYEB@$L(<-<^Y(J3-1K?$:.(T?_W(7RK#+^"P+0,-\.
MFU[XOSH%HM4U3O>R&R\S]9E)Q!"N*^*MW7#S.Q%9\MQ*9\$ <>X(E@M(*3J4
MX+;'XS7NWKUL:0SPSTWF)7'ZW[A7+FWF+OJ-2-=ETY0FC3._%##)?9Y$,BCE
M_L0/H]0HQ;\ESC\9(Q/%A0%B39?WSDY 9[Q;W05L'@:I=3=+-4?_%1W^*[ !
MBW @T[$J%J0*I%)$:JN4JU\X,*"MN>W 31 L[4F]I+^547&B20V!O<$ DP5J
M5MDD$I(%HC[8<N"?KK?M?O!?!N3TT+^K:?8SJKZEN>B/"KO0]N0[>,/XKWP
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M/<B>W\#@W[H,'3-8GIZ$HT\+A;6];/O/XYO;'#& + (R+QP0 D,'8'EYL\,
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M%<&P8<C_CGV^L1$TS[[ VZ=E&T%[7? 9W3/7"4,E1W31A>,@FJTZ,X.R$?
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M;IY*;E5_*SOXD?\/K5M<:QP2CS0<U-6ZO&*:,VBBG:?2!G:2YSO#!1\0- 3
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M$_KW;Z\E YPY4.$Z;-DOI&@'9,7]_<\P(>QU'9L7-&%"*LF 2:C]N<&V?X-
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MT,R%0X:^(R7NW>8</MI2$BA$^%E7/I)G2J=+UOXV?A7P]H/EUI(]9_DQ$#O
MS;?W&K ]Y,'6[JVA=PM(=H\P,9RR[&75RV!'&Z/FV#L<-&,5[>A^D=\NX_7\
MW7 [0DV6=R7*C6PSWKV<B!^)/V?F)]\? +55:9RD8V]KR]<76Q,2=@M)J;-S
M[>5)VG)VYZKXV[TB/KGC*SAR5C!6O1O]Z1):)I2C;*4>VX%-A)D0J;]#T>9A
M3K!X S#=(=* DK> IW.K*JH_)8=CA&K9G#_#JH]FJBTC '7I4TX(JF7,;S7
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M>*56GT#"ZB4E6/EF+LM5W3@XZE;5)1]5*_*Z0##=NDOM_BFD#_1N$+05!F6
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M%G[NMMG-C[.RY8$L_[[=?6?"^YN.46R, WL=.W4* S78T0>+?1'QX_PM0J_
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M3)2Y,5!%Q3N-^T;BGZH4.TYVFL9,Q9\H7RY%:WS5]WZ@NWKJJ,7@<=8R:4P
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MMPHC9>=8K>F)=T@>?YWSZ)44),?B&UV&#VFZSL\$VA_9)UE?+NZZ7)[VXN2
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M>+ V%"IOFX$(UO>H%!ZJ^:OVLP]V&!??Y&O(UVT@E<R3D*!XNMDDW:W4$>>
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M698LVT(-Q&C6JBE<@2^W2ND=XAR@W'N9?V%[B&P(NS#&< :W/,=Y"9>_%ZV
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M+<F:U4VA6Y85,C8C_'1^NE*H@J2:+VC]FAZ7!$Z*WVB$.#//1G!NS#4G' ]
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M!^&S2&.-<V$=GJS4)J_SPYH[H,6#SX=3">NH9$A>X6F( =$EX;N_'Z2:#Z5
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M-D[,AX(^DS3KB5$7J,#62;XI@\M"NANUP6OV@*(!)9TU8GIP\#5-YQ5_N[>
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M6=^23ZNS)TG8K@]IV&(O^G:EJ/YO3XYM"ZJ2-"=X^E-$:W-#"Y-"*[-!P]-
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MF=]++0#?'8VL^"Z*Q:+4 06)42 !(JY]EK$' \(I57:SX<8MZRO,?424@EQ
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MV";-X./6#'Q9=@3.2W-*P(, !R>7^W?X@M/$\MU\XX3OR3"NMVZ* )S,91<
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MS"6(+U^7*,G$J/,J,=&'*PW1"B3$U[8&N W7)W_N4DPFB/G;71PD^20):>+
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M/!0KZ*D&)<L0MU%:B^J-[%+6LFV/_+6(5HLU)_Q>0%0)M YVI:%8A:382M;
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M>$9>(,EGXU!%0',[<R;#.W4+]A>\E_9+0#M0D!%UUB:BD7J3C!;^PB'D->T
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MX>>J@.ZY,=V.DE2@OBJ@+S#ZJH"N2?"3!*0NU/<%")7*LP2RUN%'F#_W?6>
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MXM10RX9=HJ0."3TE-W&@XP:^#VSC=@#M18:&-O$!K8JR Y*>ZHIJ-N)W1]^
MU$*/DV$8KBMKY1(&P$=[!/< _$U!5'7<J2.,AM6-+ HX(C$U,&#2#$V:FBI<
M3I";ZKT/)KF+[/1  L+85-40$Q9Q8FBRJBV)%U) '^DTO!3P[& '"-85] +W
M@>VB([P?Z'K+JUV>Y5&RI*]Y0];K#R1E#X$74JJ= *V0E#GQO-A'7*S@UC0J
MB^ERA8["<;'A5;3R)I0+.!T3 W"-BQZ&L&M7Q/X@%Z6HWBA8S@>S<D]=1#^$
MI_G-QQW?:TN3^Z*Y19^9#"J%7M@.!\#G0_<#S;SV9X IKFH&2L",? 'E81I?
MGD.SLG3!964FI749J_7^Y[VERC>8G6I$:4I3MH0+[J(UNHQ7N%AF='^?\FXW
MNJ!/XR2+%_PX^W!N59^&;(#1WAC3L#%?Z18R]!N\7^A1)9B\SZBD7D,*\(Z+
MQN&D#8<OP<8]U)]KM#G0?/,WG+$=&GS_!E[0O]X2]E,CKYYP:S5,88 RUK&%
M\=SXC"M^<#DOR.NX;,$ "C@O;%2;J[D5%L,>Z<_/<I<U$-\!VS$XUL"V<^/*
M!=D00GRA@P^-P23N,*\2=EP$3OT;0?:\$639SU1J7ZQGOM_Z.<9>1YV,YQ1\
MGVTWI1Y!K <0^?CAY#T433DFZYQ(RQ%\XRLI^0%V2=1OXK?5595-U1&9H:@>
MJX_KL?I'IOO<&T0=M2=M"PU8,G4K*"G2M V@\KL<<NP[H#Z'YBV"#7S>>AK2
MZ<^7D!H*,EYBJNS#/,_^1+'F;/+N0]OM9+V%RFWP#611T /L"[0*[K<%;!1%
M.^7 IQF\;R:9FG:3-CM]2$_=R)3K:R=M4YIO?4!1YX"R\':A0PDYWG+LH@@O
M@6Q2EGQ;D>S0DN$/49SR3/XDRW:;<J%3LOP%YP]D2=;D_@EZY;F]Q[$IL(U'
M7^V0>1E!=_A/5EPG;8]E*>8-,?0K:U)H=GN&:<]@4ZQ+9_;*->=LHU'K5DW6
MO/PC8F7*,_0S^X/J'_QBT0%DA&A/AJ$=J"4Q=P[2B-B^JX_FX_TNBQ.<9?35
M[N*$O]DI+6:\Q,5YWK?T+;,53E/:#(J;@Q$6RFH=9&%DN![@TS;\&MP-/+P4
MJJ@ZU.K\,O[7+EZR^]E#"6]CP$7 :KL=?@88:X:3P67Q@WBP/N\(_P[ 3GNB
ME29JJ,Y02QDUM%\XH=K+X8<4GOI<EY@V];*-N>*'Y=?J/AS)Z;8YR/Z!T+**
MAP*%>?%;,,21U PQ^9YMM+?EFD 66? !T9/E_]YE.4M%LUMR@]E7B=?X(\XO
MD@79X$N2T=]/H^SA.B6/E&;+]T^L7W217&TYY9+[DT4>/\9Y+ 6Z2Q?EYW;C
M8B3I7!0*?$[+82%54<"9VWG#,N-;6MGFA].NJ5WV*_O[@EJG="SZ^*0RBZ+:
M[M_]1B&GM"'3P;0=$5UX:\95=V\3:#0 R[M=%M!'*#CJQ8+:.*+646$>O68.
MWK#'S >JG+"II=?E". ;5+M">U_!I"N''B@D/85#C12>^AH?(W;)WM6J+!WM
M%'4"D5R@_.XB@9%!KV\2LN\AM:X*-Q*E>?$[&]7?/_'+:T6%$=-/W*947[9)
M")DE+]V2Q8+L*#.OHZ?H;HU/=[1'G_0Z%DJAJFL@$1K;G O-0J);Z4'9H,H5
MY]4SM"T>>FZYU!5(;#YWI_$0RK?"O\*B)\2G.[R\C*.[>,T;%2GHU7)[W,OD
MQD-?;-FZ<TKR:*WLG&H\:5B@T)W?,M_>T:^I26+YT7L<$*MT:*"RZQ(J5CT7
M_4"&SM5@L!SQL,F>\]6O[.[$YP(<6>H]&CG])!@4.L> C:S:RV#4'.]1TQ"8
MH5+DN2#HV!6"CKTVP[3/M\)9%K.SO#Y@35NL$6XWR%)A&+Y(S,./&YNX,R"/
MRD!-H&U#"*UP(/%75^U]"AE4CI!&$CT!EY0>G",,;BS2R-4X>#6:]:848F)A
MA6E0H*F;?!"D>1H!*PMV0TNA#-<"@7:(;@G D*9A$GB,0&S=@!I=I9H-P>!>
M5%%]K$L^K1#>#5D!I'N6?*#X(J%M+\YRY<B76JA\=9G02$2+S4*B6NE!A6R%
M8HWNN)1!)$%+?.<9Z9J*)#:?O8UXL7P3]2J+/I#_#Y+^3M/.YN+IJFOP)*:!
MA4;Y<8PT1A+$P <D6\S=J:AC:J7FT:(AZ9=#-B@@@ZNIS2X#Y2;5C'UY7P*V
M/\+Z.HJ7%\EIM(WS:,TW+MQU]S;<X'_MXBS.\2></L8+7-QVQ^92[Q-N172Z
MVE3N1$O#G+B#7!CBH(!NEXRY*[#QFA%712CND$/<1"O<5</  2W[<,DCV1(0
MQUA5K 9QX%FZ,L396QY V'"SMLQA87W'##:F='UQ.A.?2K#?"3ACJ\]2M@0<
MK4B*3@GMCS3LO006IVA^WI'%T^C;?M7<!XHB=G]7G.SBY'Z_FN@]IEC'A=QM
M]!5GYU_S-"+I,DZB].DBQYOL(T4EN_F+K&G1[JL.:F_PP[FG>@3%H:?1PS#.
MR@:^CL-]6=6C0FZ]SYEI=,=MH+A859PS*[Z'EMS3A$R.Q^X@ES.G[9$RQ^\6
M=BP 2P,G**?'0$"3O_:> L9#M'?36%A<18M2GKN:H;;I>@3W)8PX@/)SC".>
M,K_K%&]I GM>#(J<),NK_ &G)UF&<\FZ&0N-LIZ,-$9&40,?X&-IYCY5@<W4
MRKP4K-<Q\C.+"!-&$9?V&VML<$$&5UR;^@;*30H;^YH&C&!-LX4_ "0>[:%8
MBG(D<F%42 >R!,<M)"7-D1M,>FH>ZM.M?L$1NQ"5CW[4/_Y[3)N^=/'P=$;8
MW=\=-@S2+;^EI>Y(OEIY@YS^'>)8Q6![>_/&H7CU<\[GCR>_H<^%I.<]LL.
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M3@N(UL(*@$#!7^L3))@;OEG0S/>?21L7TQ_M83)=YJK8BH@:SF;[;/> $]8
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M&85"&@4RX)!QY:C&AA0\,K#O&EY6(_?Z+78F[D:A[.C5G/_ZEJR>+ZQD.Z7
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M%\1$T%42Q/"AJDZ)Q><7H5^@TL:^U*8_Y!\;(O_8$/G'3I!_[!KYQP.1?VR
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M@Z4>*A2K/)#Q9:_[C8';*$ETB&[0I-'$H;/DT=0Y(,9I,OF/=L.QW4.Z,2S
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M?S =B=3>S 1?Y*N$/9+P[2PQVFT)2W>8&+;M)RY99XFU.7OWF)AC6TPQ1W0
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MRM:D5_HUPU^+)WJ7,$KY+5I*V7&Z@-)7YT,4 X% P*@!@\\K8S6*GU"2R##
M(^BV]PZ!KQZ7J %K[9WRC7]]7C>KAZ)XLZESV-T_$>/E\VU!4QW3*2E_@ \H
MT!WF2POXB@<--6%#?BF_!B]#5^3^_KYGQFORPVCW>@%WGP?B>!7ECZ7&V_S[
M=10]5V!&29$WO^Q17?_PQ^Y>?"O9QBVN#BL+K@'K%&F6+T!%AK9C$_UG>4XL
M+]"4_['6B?WH3OIZ!B150D#3T:5'XT(EFEF#IF4@_Z.Y)UZB!-&D1L59E&5O
M) "4F6'8W2>=,LVV%*R,LY@K=QLV4[H;?KE5E!M;,-;.+YF;X.LV0\]1W.1<
M(EK.BR?2";5-P:!+HT1M9E )?Y&EKS 05R#&YI?>BUX*?X?16!:%9='79V!8
M@ #?V0;+^D7O50QG%E.:2M#K\DPFM-6>AWG8==U ;C/\C++BC:9Y+//;D,[E
MF0X+;U _Z*I)=]%61NHA-C1T4T%$SBK<4%K-$E"9G? N7C^1B<,7TF-0_1F@
M "AK6THI/80)7#,52J2<G"<;,<%'-P.['"$@VMJ2"EH/4:*CG0HG"E[.$Y68
M#\JXHS'N,,Q+)W/EA0T?AJ08\6*,I;7<A!6+-EV;05CO+7D(([#K.'J,$Z(@
MHKDO^XD^!6M(NL6: Z/@8JYMH59;K:$ORLB7 ]6$?=6\6!BL\QGGM]$;?1U
M,,V6$C6!7D#D+,0!?(*!NG4#G)AQ&=8$#(-<UZMSJ?<U[B-$3K<'B8C.?YR
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M!;=10M_U..$YT(T$0Q^Y&2)!>(%>J\$,>??&FF/MCC^DB@]Z"F>(PH$_K3?
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M YE'Z,96M_.NZ[AJAGL^9#0#57<P+W%6_T3IV!F#F\K'#B>"RH]Q9727'E*
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M)5ZB= D.=NJ"BGZ55S PX(%M8*.?Y542;GYFY3";8V[A8%5MWF;R)V-YL)-
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M2P$"% ,4    " !=:0Y7A8"Z+)<$  !S$P  %P              @ $GJ@$
M8G)H8S(P,#4W,S0V7V5X,S(M,2YH=&U02P$"% ,4    " !=:0Y7=]C\:XH$
M   4$P  %P              @ 'SK@$ 8G)H8S(P,#4W,S0V7V5X,S(M,BYH
M=&U02P$"% ,4    " !=:0Y7_;&Y]FYE 0#TP0$ #@              @ &R
MLP$ :6UA9V4P,# P,2YJ<&=02P$"% ,4    " !=:0Y7V6>W[N87 0#C;@$
M#@              @ %,&0, :6UA9V4P,# P,BYJ<&=02P$"% ,4    " !=
M:0Y7>?D2FR$,    ?@  $0              @ %>,00 <&1S8BTR,#(S,#8S
M,"YX<V102P$"% ,4    " !=:0Y7<,A.!C@+  !HD@  %0
M@ &N/00 <&1S8BTR,#(S,#8S,%]C86PN>&UL4$L! A0#%     @ 76D.5QS0
M22),(P  K%0" !4              ( !&4D$ '!D<V(M,C R,S V,S!?9&5F
M+GAM;%!+ 0(4 Q0    ( %UI#E>P'6BMU(L  'Q-"  5              "
M 9AL! !P9'-B+3(P,C,P-C,P7VQA8BYX;6Q02P$"% ,4    " !=:0Y7+"=-
MQP)"  "\C@0 %0              @ &?^ 0 <&1S8BTR,#(S,#8S,%]P<F4N
9>&UL4$L%!@     ,  P &0,  -0Z!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
